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ABSTRACT	  This	  thesis	  examines	  the	  productive	  application	  of	  networks	  towards	  proteomics,	  with	   a	   specific	   biological	   focus	   on	   liver	   cancer.	   Contempory	   proteomics	   (shot-­‐gun)	   is	  plagued	  by	   coverage	  and	   consistency	   issues.	  These	   can	  be	   resolved	  via	  network-­‐based	  approaches.	  	  	  The	   application	   of	   3	   classes	   of	   network-­‐based	   approaches	   are	   examined:	   A	  traditional	   cluster	   based	   approach	   termed	   Proteomics	   Expansion	   Pipeline),	   a	  generalization	   of	   PEP	   termed	   Maxlink	   and	   a	   feature-­‐based	   approach	   termed	  Proteomics	  Signature	  Profiling.	  	  PEP	  is	  an	   improvement	  on	  prevailing	  cluster-­‐based	  approaches.	   It	  uses	  a	  state-­‐of-­‐the-­‐art	   cluster	   identification	   algorithm	   as	   well	   as	   network-­‐cleaning	  approaches	  to	  identify	  the	  critical	  network	  regions	  indicated	  by	  the	  liver	  cancer	  data	   set.	   The	   top	   PARP1	   associated-­‐cluster	   was	   identified	   and	   independently	  validated.	  	  Maxlink	   allows	   identification	   of	   undetected	   proteins	   based	   on	   the	   number	   of	  links	  to	  identified	  differential	  proteins.	  It	  is	  more	  sensitive	  than	  PEP	  due	  to	  more	  relaxed	  requirements.	  Here,	  the	  novel	  roles	  of	  ARRB1/2	  and	  ACTB	  are	  identified	  and	  discussed	  in	  the	  context	  of	  liver	  cancer.	  	  Both	  PEP	  and	  Maxlink	  are	  unable	  to	  deal	  with	  consistency	  issues,	  PSP	  is	  the	  first	  method	  able	  to	  deal	  with	  both,	  and	   is	   termed	  feature-­‐based	  since	  the	  network-­‐based	  clusters	  it	  uses	  are	  predicted	  independently	  of	  the	  data.	  It	  is	  also	  capable	  of	  using	  real	  complexes	  or	  predicted	  pathway	  subnets.	  By	  combining	  pathways	  and	  complexes,	  a	  novel	  basis	  of	   liver	  cancer	  progression	   implicating	  nucleotide	  pool	   imbalance	   aggravated	   by	   mutations	   of	   key	   DNA	   repair	   complexes	   was	  identified.	  	  Finally,	   comparative	   evaluations	   suggested	   that	   pure	   network-­‐based	   methods	  are	   vastly	   outperformed	   by	   feature-­‐based	   network	   methods	   utilizing	   real	  complexes.	  This	  is	  indicative	  that	  the	  quality	  of	  current	  networks	  are	  insufficient	  to	   provide	   strong	   biological	   rigor	   for	   data	   analysis,	   and	   should	   be	   carefully	  evaluated	  before	  further	  validations.	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1 TWO	  ISSUES	  IN	  PROTEOMICS	  PROFILE	  ANALYSIS	  1.1 INTRODUCTION	  	  Proteomics	   provides	   important	   information	   -­‐-­‐-­‐	   that	   cannot	   be	   inferred	   from	  indirect	  sources	  such	  as	  RNA	  or	  DNA	  -­‐-­‐-­‐	  on	  key	  players	  in	  biological	  systems	  or	  disease	   states.	   However,	   the	   technology	   and	   its	   resultant	   output	   suffer	   from	  coverage	  and	  consistency	  issues.	  The	  advent	  of	  network-­‐based	  analysis	  methods	  can	   help	   in	   overcoming	   these	   problems	   but	   requires	   careful	   application	   and	  interpretation.	  	  This	   chapter	   first	   reviews	   and	   considers	   briefly	   current	   trends	   in	   proteomics	  technologies	   and	   understands	   the	   causes	   of	   critical	   issues	   that	   need	   to	   be	  addressed-­‐-­‐-­‐i.e.,	   incomplete	   data	   coverage	   and	   inter-­‐sample	   inconsistency.	   On	  the	  coverage	  issue,	  we	  argue	  that	  holistic	  analysis	  based	  on	  biological	  networks	  provides	   a	   suitable	   background	   on	   which	   more	   robust	   models	   and	  interpretations	   can	   be	   built;	   and	   we	   introduce	   some	   recently	   developed	  approaches.	   On	   consistency,	   group-­‐based	   approaches	   based	   on	   identified	  clusters,	   as	  well	   as	   on	  properly	   integrated	  pathway	  databases,	   are	   particularly	  useful.	   In	   spite	   of	   the	   fact	   that	   protein	   interactions	   and	  pathway	  networks	   are	  still	  largely	  incomplete,	  given	  proper	  quality	  checks,	  applications	  and	  reasonably	  sized	   datasets,	   they	   yield	   valuable	   insights	   that	   greatly	   complement	   data	  generated	  from	  quantitative	  proteomics.	  Mass	  spectrometry	  (MS)-­‐based	  proteomics	  is	  a	  widely	  used	  and	  powerful	  tool	  for	  profiling	  systems-­‐wide	  protein	  expression	  changes	  1.	  It	  can	  be	  applied	  for	  various	  purposes,	   e.g.,	   biomarker	   discovery	   in	   diseases	   and	   study	   of	   drug	   responses.	  	  Although	   RNA-­‐based	   high-­‐throughput	   methods	   have	   been	   useful	   in	   providing	  glimpses	  into	  the	  underlying	  molecular	  processes,	  the	  evidences	  they	  provide	  are	  indirect.	  Furthermore,	  RNA	  and	  corresponding	  protein	  levels	  have	  been	  known	  to	  have	  poor	  correlations	  2.	  On	   the	  other	  hand,	  MS-­‐based	  proteomics	   tend	   to	  have	  consistency	   issues	   (poor	   reproducibility	   and	   inter-­‐sample	   agreement)	   3,	   and	  coverage	   issues	   4	   (inability	   to	   detect	   the	   entire	   proteome)	   that	   need	   to	   be	  urgently	  addressed.	  	  Proteomics	  captures	  valuable	  information	  on	  the	  level	  and	  existence	  of	  individual	  proteins	   but	   the	   data	   can	   be	   noisy	   and	   incomplete.	   Two	   exigent	   issues	   in	  proteomics	   are	   particularly	   poignant:	   data	   coverage	   and	   consistency.	  Experimental	   methods	   to	   overcome	   these	   issues	   are	   technically	   challenging,	  resource	  heavy	  or	  place	  an	  unreasonably	  heavy	  dependency	  on	  the	  quality	  of	  the	  initial	  data	  set.	  These	  include	  exhaustive	  fractionation	  of	  samples	  5,	  6,	  repeated	  MS	  runs	   of	   the	   same	   sample	   to	   reach	   saturation	   7,	   8	   and	   compilation	   of	   MS	   data	  specific	  to	  a	  sample	  type	  generated	  and	  archived	  from	  different	  laboratories	  9-­‐11.	  	  	  The	  problems	  are	  particularly	  exemplified	   in	  a	   large-­‐scale	  collaborative	  study	  3	  to	  assess	   the	  extent	  of	  reproducibility	  across	  different	   laboratories.	  The	  results	  were	  striking	  -­‐-­‐-­‐	  only	  7	  out	  of	  	  27	  laboratories	  correctly	  reported	  all	  20	  proteins,	  and	  only	  1	  laboratory	  successfully	  reported	  all	  22	  unique	  peptides.	  	  	  Therefore	  alternative	  analytical	  approaches	  are	  needed	  to	  complement	  existing	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experimental	   approaches	   to	   circumvent	   the	   stochastic	   sampling	  of	  peptides	  by	  MS	   and	   increase	   the	   comprehensiveness	   of	   proteome	   coverage.	   Networks	  provide	   an	   informative	   background	   or	   scaffold	   on	   which	   higher	   confidence	  assertions	  can	  be	  founded.	  	  A	  biological	  network	  is	  a	  set	  of	  molecules,	  e.g.,	  proteins	  or	  genes,	  that	  are	  linked	  together	   via	   defined	   functional	   relationships.	   The	   inter-­‐connections	   between	  molecules	   contain	   a	  wealth	   of	   information	   that	   has	   yet	   to	   be	   fully	   exploited	   in	  network-­‐based	  analysis.	  Deciphering	  the	  patterns	  of	  wiring	  in	  a	  system	  allows	  us	  to	  penetrate	  the	  apparent	  complexity,	  and	  understand	  how	  these	  wirings	  could	  result	  in	  coordinated	  function.	  Early	  discoveries	  suggest	  that	  biological	  networks	  share	  common	  properties	  with	  many	  other	  natural	  and	  man-­‐made	  systems.	  For	  example,	   it	  was	   reported	   that	  protein-­‐protein	   interaction	  networks	   (PPINs)	   are	  scale-­‐free	  12,	  small-­‐world	  13	  and	  disassorted	  14.	  It	  was	  also	  suggested	  that	  highly	  connected	  proteins	  (hubs),	  were	  more	  likely	  to	  be	  essential	  for	  cellular	  survival	  15,	  and	  that	  there	  were	  two	  kinds	  of	  hubs	  -­‐-­‐-­‐	  date	  and	  party	  16.	  	  As	   our	   ability	   to	   exploit	   network	   information	   improves,	   some	   of	   these	   early	  observations	   are	   beginning	   to	   come	   under	   intense	   scrutiny	   and	   revision	   -­‐-­‐-­‐	  especially	   since	   they	   were	   performed	   by	   relatively	   crude	  methods	   that	   do	   not	  capture	  enough	  of	   the	  complexity	  underlying	  biological	  processes.	  For	  example,	  the	  existence	  of	  date	  and	  party	  hubs	   17,	   or	   that	  hubs	  are	  also	  more	   likely	   to	  be	  essential	   genes	   18,	   is	   increasingly	   disputed.	   The	   Barabasi-­‐Albert	   model,	   while	  elegant,	   does	   not	   capture	   the	   notion	   that	   biological	  molecules	   tend	   to	  work	   in	  complexes	  or	  clusters	  19.	  	  	  Given	   that	   network-­‐based	   analysis	   methods	   are	   still	   evolving,	   they	   must	   be	  applied	   appropriately	   in	   order	   to	   gain	   confident	   biological	   insight.	   Network-­‐based	  analysis	   in	  biology	   is	  mostly	   limited	   to	  areas	  where	  data	   is	  more	  readily	  accessible	  or	  interpretable.	  Hence,	  protein-­‐protein	  interactions,	  gene-­‐regulation	  and	  metabolic	   systems	  are	  more	  widely	   studied	   even	   though,	   strictly,	   they	   are	  not	   distinct	   systems	   in	   themselves.	   A	   fortunate	   development	   is	   that	   recent	  experimental	   initiatives	   have	   increased	   tremendously	   the	   amount	   of	   biological	  network	  information	  available	  on	  which	  to	  perform	  analysis.	  For	  example,	  groups	  such	   as	   Marc	   Vidal’s	   20	   have	   been	   generating	   large-­‐scale	   Y2H	   data	   in	   order	   to	  build	  extensive	  PPINs	  for	  model	  organisms.	  Also	  noteworthy	  are	  the	  ascension	  of	  large	  pathway	  and	  metabolic	  databases,	  as	  well	  as	  integrative	  platforms.	  	  	  Currently,	   not	  much	   is	   known	   about	   the	   true	   topology	   of	   biological	   networks.	  And	  even	   less	   is	  known	  about	  how	  errors	  such	  as	   false	  positives	  can	  adversely	  affect	   analysis.	   Combining	   networks	   to	   include	   several	   different	   types	   of	  molecules	   (e.g.,	   proteins,	   RNA	   and	   metabolites)	   and	   interactions	   (e.g.,	   protein	  interaction,	   gene	   interaction,	   and	   signaling)	   to	   capture	   various	   levels	   of	  biological	  complexity	  is	  an	  even	  taller	  order.	  	  Despite	  these	  difficulties,	  the	  theory	  of	  networks	  is	  an	  essential	  next	  stage	  in	  the	  study	  of	  biology.	  Traditional	  reductionist	  methods,	  while	  excellent	  in	  the	  study	  of	  the	   individual	   components	   of	   the	   system,	   cannot	   yield	   its	   emergent	   qualities.	  And	  it	  is	  at	  the	  systems	  level	  where	  knowledge	  on	  coordination,	  regulation	  and	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control	   of	   biological	   processes	   can	   be	   obtained.	   Currently,	   it	   is	   increasingly	  recognized	   that	   the	   understanding	   of	   properties	   that	   arise	   from	   whole-­‐cell	  function	   require	   integrated,	   theoretical	   descriptions	   of	   the	   relationships	  between	  different	  cellular	  components	  12.	  	  1.2 BRIEF	  OVERVIEW	  OF	  QUANTITATIVE	  PROTEOMICS	  	  Proteomics	   can	   be	   pursued	   in	   many	   different	   flavors	   (broadly	   divided	   into	  untargeted	  and	  targeted	  proteomics)	  and	  forms	  (e.g.,	  protein	  structures,	  activities,	  expressions	   and	   interactions).	   2D	   gels	   were	   traditionally	   favored	   but	   lack	  reproducibility	  and	  are	  resource	  heavy	  21.	  	  	  Recent	  developments	   in	  MS	  technology	  have	   led	   to	  higher	  sensitivity,	   increased	  throughput	  and	  greater	  automation.	  	  	  For	   identification,	   the	  most	   common	  set-­‐up	   currently	   is	  LC-­‐MS/MS.	  This	  begins	  with	  tryptic	  digestion	  of	  proteins	  into	  peptides	  which	  are	  subsequently	  separated	  via	  LC	  22.	  The	  separated	  peptides	  are	  then	  ionized	  and	  further	  separated	  via	  MS	  based	  on	  their	  different	  mass-­‐to-­‐charge	  (m/z)	  and	  subsequently	  detected	  over	  a	  period	  of	  detection	  time	  giving	  rise	  to	  a	  preliminary	  set	  of	  MS	  peaks.	  The	  peptides	  corresponding	   to	   these	   MS	   peaks	   can	   be	   further	   fragmented	   giving	   rise	   to	   a	  secondary	   MS/MS	   spectrum.	   This	   allows	   sequence	   identification	   and	  quantification	  of	  the	  peptides.	  	  	  While	   this	   method	   can	   potentially	   identify	   a	   large	   number	   of	   peptides,	   the	  complexities	   in	   unraveling	   a	   complex	   peptide	   mixture	   can	   be	   daunting.	   Other	  issues	   involve	   large	   dynamic	   range	   differences	   between	   instrument	   detection	  limit,	   and	  masking	   of	   lower	   abundance	   proteins	   by	   high	   abundance	   ones.	   This	  results	   in	   limited	   sampling	   of	   the	   complete	   proteome.	   The	   second	  major	   issue	  that	  must	  be	  considered	  is	  that	  selection	  of	  peaks	  for	  fragmentation	  in	  the	  second	  MS	   chamber	   is	   based	   on	   a	   variety	   of	   parameters	   thereby	   giving	   rise	   a	   form	   of	  stochaism	  in	  the	  set	  of	  identified	  peptides.	  This	  consequently	  results	  in	  different	  proteins	  lists	  giving	  rise	  to	  the	  consistency	  problem.	  	  There	   are	   experimental	  methods	   of	   overcoming	   coverage	   issues.	   These	   include	  extensive	   fractionation	   6,	   23,	   repeated	   MS	   runs	   of	   the	   same	   sample	   to	   reach	  saturation	   24,	  25	   and	  compilation	  of	  MS	  data	   specific	   to	  a	   sample	   type	  generated	  and	  archived	  from	  different	  laboratories	  26.	  But	  these	  methods	  are	  tedious,	  time-­‐consuming,	  expensive	  and	   inefficient	   -­‐-­‐-­‐	  A	   lot	  of	   the	   information	  derived	   is	  also	  probably	  uninteresting	  or	  non-­‐useful	  given	  the	  effort.	  	  An	  alternative	  proteomic	  screen	  option	  is	  possible.	  This	  is	  commonly	  referred	  to	  as	   SRM/MRM	  (and	  also	  popularly	   referred	   to	   as	   targeted	  proteomics)27.	   In	   this	  workflow,	  a	  set	  of	  proteins	  of	   interest	  and	  their	  mass	  fragments	  are	  predefined.	  This	  method	  is	  far	  more	  sensitive	  and	  reproducibly	  stable.	  It	  has	  less	  consistency	  issues	  as	  well.	  On	  the	  downside,	  protein	  measurements	  are	  limited	  to	  only	  a	  few	  hundreds.	  It	  also	  requires	  a	  priori	  knowledge.	  Hence,	  this	  is	  not	  a	  discovery	  but	  a	  validation	  platform.	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A	  third	  possibility,	  which	  is	  mentioned	  briefly	  as	  it	  has	  yet	  to	  hit	  mainstream,	  is	  the	  up-­‐and-­‐coming	  SWATH	  platform28.	  This	  proteomic	  strategy,	  also	  referred	  to	  as	   Data	   Independent	   Acquisition	   (DIA),	   complements	   traditional	   shotgun	   and	  targeted	  methods.	  It	  theoretically	  allows	  a	  complete	  and	  permanent	  acquisition	  of	  all	  fragment	  ions	  corresponding	  to	  their	  peptide	  precursors	  in	  a	  biological	  sample	  -­‐-­‐-­‐	   thus	   combining	   the	   strengths	   of	   shotgun	   (high	   throughput)	  with	   SRM	   (high	  reproducibility	  and	  sensitivity).	  In	  SWATH,	  the	  MS	  cycles	  through	  an	  exhaustive	  precursor	   acquisition	   range	   (400-­‐1200	   m/z),	   with	   a	   defined	   window	   size	  (typically	   25	   m/z)	   within	   2-­‐4	   seconds.	   In	   each	   cycle,	   the	   MS	   fragments	   all	  precursors	  within	  the	  window	  and	  records	  the	  complete,	  high	  accuracy	  fragment	  ion	   spectrum.	   The	   same	   range	   will	   be	   sampled	   against	   in	   the	   next	   cycle,	   thus	  providing	   a	   time-­‐resolved	   recording	  of	   all	   eluted	   fragments.	  Having	   a	   complete	  time-­‐resolved	  library	  within	  a	  large	  acquisition	  range	  should	  mean	  that	  coverage	  can	  be	  greatly	  enhanced.	  In	  reality,	  exhaustive	  search	  through	  the	  library	  is	  time-­‐consuming,	   and	   the	   method	   is	   still	   less	   sensitive	   than	   SRM.	   However,	   with	  improved	  technical	  and	  algorithmic	  solutions,	  the	  SWATH	  platform	  is	  extremely	  promising	  as	  a	  future	  standard.	  	  	  Quantitation,	   that	   is,	   measuring	   the	   levels	   of	   proteins	   via	   proteomics,	   can	   be	  achieved	  by	   various	  means.	  Broadly,	   these	   can	  be	  divided	   into	   labeled	   relative	  and	  unlabeled	  absolute.	  	  Examples	  of	  labeled	  relative	  include	  familiar	  workflows	  such	  as	  SILAC	  and	  iTRAQ.	  In	  this	  scenario,	  a	  tag	  such	  as	  stable	  isotopes	  (SILAC)	  or	   a	   chemical	  marker	   (iTRAQ)	   	   is	   incorporated	   into	   the	  peptides	  derived	   from	  different	  samples.	  These	  samples	  can	  be	  combined	  and	  analyzed.	  Corresponding	  peptides	  should	  result	  in	  similar	  peak	  patterns	  but	  because	  of	  the	  tags,	  would	  be	  shifted	   	   by	   a	   consistent	   mass.	   But	   since	   these	   peak	   shifts	   are	   measured,	   the	  quantitation	  achieved	  is	  relative.	  	  In	   unlabeled	   absolute	   quantitation,	   a	   common	   strategy	   is	   to	   spike	   known	  concentrations	   of	   synthetic	   peptides	   into	   sample.	   The	   sample	   is	   then	   analyzed	  via	   LC-­‐MS/MS	   similar	   to	   relative	   quantitation.	   The	   abundance	   of	   the	   target	  peptide	   is	   determined	   using	   a	   pre-­‐determined	   standard	   curve	   to	   yield	   its	  absolute	  quantity.	  Ideally,	  absolute	  quantitation	  should	  be	  preferred	  over	  relative	   for	  analysis.	  An	  obvious	  strength	   is	   that	  relative	  quantity	  can	  be	  determined	   from	  dividing	   two	  absolute	   values,	   but	   not	   vice	   versa.	   The	   other	   is	   applicability	   towards	   novel	  network-­‐based	   analysis:	   Knowledge	   of	   the	   absolute	   expression	   values	   of	   the	  reference	   condition	   is	   critical	   for	   identifying	   the	   highly	   relevant	   reference-­‐condition	   specific	   subnets	   (e.g.	   parts	   of	   pathways).	   The	   perturbations	   of	   these	  subnets	  can	  then	  be	  analyzed	   in	   the	  test	  condition	  with	  high	  efficacy	  29.	  On	  the	  other	  hand,	   absolute	  quantitation	   is	   subject	   to	   greater	   risk	  of	   sample	  variation	  and	  bias.	  In	  practice,	  relative	  proteomic	  quantitation	  is	  much	  more	  commonly	  used	  due	  to	  it	   being	   cheaper	   and	   less	   time-­‐consuming.	   It	   is	   also	   important	   that	   relative	  quantitation	  involving	  complex	  tagging	  procedures	  can	  result	  in	  inaccuracy	  and	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inconsistency	  of	  measurements.	  	  Further	  details	  and	  other	  recent	  advances	  in	  MS	  technologies	  can	  be	  found	  in,	  e.g.,	  the	  review	  by	  Mann	  and	  Kelleher	  30.	  	  1.3 OVERVIEW	  ON	  ALGORITHMS	  FOR	  PEPTIDE	  AND	  PROTEIN	  IDENTIFICATION	  The	  detection	  of	  a	  peptide	  and	  determination	  of	   its	  amino	  acid	  sequence	  can	  be	  done	  using	  two	  types	  of	  algorithms.	  The	  first	  type	  is	  database	  search	  algorithms	  that	  work	  by	  matching	  the	  mass	  spectrum	  of	  the	  peptide	  to	  a	  database	  of	  known	  peptide	   sequences.	   Examples	   of	   these	   algorithms	   include	   MASCOT	   31,	   Protein	  Prospector	   32,	   SEQUEST	   33,	   and	   Paragon	   34.	   	   We	   describe	   Mascot	   and	   Paragon	  since	  these	  are	  used	  in	  our	  analyses.	  For	  further	  details	  on	  the	  other	  algorithms,	  Eng	  et	  al	  offers	  an	  informative	  and	  current	  description	  35.	  	  Mascot31	   integrates	   three	   types	   of	   peptide	   search	   strategies	   -­‐-­‐-­‐	   1/	   peptide	  molecular	  weights	  post	  tryptic	  digestion,	  2/	  	  using	  MS/MS	  data	  from	  one	  or	  more	  peptides,	  and	  3/	  combining	  mass	  data	  with	  amino	  acid	  sequence	  data.	  Also,	   the	  Mascot	   scoring	   algorithm	   is	   probability	   based,	   and	   incorporates	   the	   number	   of	  fragment	   ions	  sought	   in	   the	  MS/MS,	   the	  number	  matched,	   the	  number	  of	  peaks	  observed	   within	   the	   spectrum	   above	   a	   threshold	   intensity,	   and	   the	   number	   of	  peptide	  sequences	  compared	  with	  the	  spectrum	  35.	  	  	  Paragon34	  is	  based	  on	  Sequence	  Temperature	  Values	  (STVs),	  which	  are	  computed	  using	   a	   sequence	   tag	   algorithm,	   which	   determines	   extent	   of	   implication	   by	   an	  MS/MS	  spectrum	  to	  a	  given	  region	  of	  a	  database.	  The	  advantage	  of	  using	  STVs	  in	  conjunction	  with	   feature	  probabilities	   allows	   for	   a	   larger	   effective	   search	   space	  with	   only	   a	   small	   increase	   in	   the	   number	   of	  matches	   that	   needs	   to	   be	   actually	  scored.	  	  For	  any	  given	  algorithm,	   identifying	  the	  optimal	  search	  parameters	   that	  can	  be	  deployed	  across	  all	  search	  engines	  or	  all	  analysis	  is	  near	  impossible.	  	  Aside	  from	  opinion	  differences,	  the	  nature	  of	  the	  data	  set,	  the	  underlying	  hypothesis,	  desired	  outcome	   and	   tools/equipment	   utilized,	   all	   influence	   search	   parameters.	   Over-­‐reliance	   on	   recommended	   manual	   settings	   or	   blindly	   based	   on	   previous	  publications,	   without	   properly	   matched	   contexts,	   hence	   is	   ill-­‐advised.	   Highly	  stringent	   parameters,	  while	   able	   to	   improve	  precision,	   simultaneously	   reduces	  sensitivity,	   resulting	   in	   few	   reported	   proteins.	   This	   in	   turn,	   limits	   analytical	  resolution.	  Important	  parameters	  which	  must	  be	  considered	  prior	  to	  peptide	  identification	  include	   appropriate	   mass	   tolerances	   (which	   defines	   a	   detection	   range	   for	   the	  peptide	   of	   interest)	   that	   are	   handled	   differently	   by	   various	   search	   engines,	  understanding	   enzymatic	   constraints	   (imperfect	   cleavage	   resulting	   in	  uncontrolled	  variability	  or	  different	  cleavage	  patterns	  of	  different	  enzymes)	  that	  need	   to	   be	   configured	   appropriately	   in	   the	   search	   algorithm,	   whether	   post-­‐translational	   modifications	   (PTMs)	   are	   of	   interest,	   and	   sufficient	   search	   space	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(whether	   the	   analyzed	   set	   of	   peptides	   is	   large	   enough	   to	   determine	   if	   the	  assigned	  match	  scores	  are	  indeed	  significant).	  The	  MS	   spectra	   are	  usually	   compared	   to	   a	   reference	  protein	   library	  which	  has	  undergone	  in	  silico	  digestion.	  In	  most	  cases,	  especially	  for	  discovery	  proteomics,	  	  the	   library	   used	   is	   a	   general	   database	   (instead	   of	   a	   specific	   database).	   Several	  databases	   exist	   and	   these	   do	   not	   produce	   similar	   identification	   outcomes.	   The	  major	   databases	   are	   IPI	   (deprecated),	   Uniprotkb	   (of	   which	   there	   are	   two	  versions,	  Swissprot	  and	  Trembl),	  and	  NCBI.	  	  Protein	  databases	  have	  different	  coverage.	  For	  example,	  between	  UniProtKB	  and	  IPI,	  21%	  of	  human	  and	  10%	  of	  mouse	  identifiers	  in	  the	  former	  do	  not	  map	  to	  the	  latter	   36.	   These	   non-­‐overlapping	   segments	   are	   significant	   even	   though	   it	   is	  possible	  these	  represent	  low-­‐quality	  protein	  hits	  in	  MS	  searches.	  Even	   within	   the	   same	   database,	   different	   builds	   can	   have	   strongly	   different	  identification	   results.	   Sirota	   et	   al	   37	   demonstrated	   this	   using	   data	   taken	   from	  NCBI	  over	  30	  years.	  Similar	  results	  were	  obtained	  when	  IPI	  data	  was	  used.	  Depending	   on	   the	   database	   used,	   the	   specific	   accessions	   or	   identifiers	   present	  another	   problem:	   They	   are	   not	   stable	   and	   can	   be	   deprecated	   in	   subsequent	  builds.	  While	   this	  was	  more	   of	   a	   problem	   in	   IPI,	   UniProtKB	   and	  NCBI	   are	   not	  spared	  either37,	  38.	  But	  comparing	  against	  all	  current	  protein	  libraries,	  	  Griss	  et	  al	  concluded	  that	  overall,	  UniProtKB	  is	  the	  best	  database	  for	  applications	  that	  rely	  on	  the	  long-­‐term	  storage	  of	  proteomics	  data	  38.	  For	  comparing	  older	  proteomics	  datasets	  to	  newer	  ones,	  EBI’s	  Protein	  Identifier	  Cross	   Referencing	   (PICR)	   service	   is	   one	   potential	   solution	   that	   saves	   time	   and	  effort	   in	   having	   to	   re-­‐scan	   the	   older	   dataset	   against	   a	   current	   build	  (http://www.ebi.ac.uk/Tools/picr/).	  A	   second	   type	   performs	   de	   novo	   sequencing	   of	   peptides	   from	   mass	   spectra.	  Examples	  of	  these	  algorithms	  include	  PEAKS	  39,	  ADEPTS	  40,	  Lutefisk	  41,	  PepNovo	  42	   and	   GST-­‐SPC*	   43.	   These	   have	   the	   advantage	   of	   being	   able	   to	   detect	   novel	  proteins.	   Moreover,	   de	   novo	   methods	   are	   becoming	   more	   sophisticated	   and	  rapid-­‐-­‐-­‐a	  subset	  of	  unmatched	  spectra	  could	  be	  reanalyzed	  selectively	  to	  bolster	  coverage.	  This	   is	  particularly	   important	   if	   the	   sample	   is	  highly	  mutative	  or	  not	  well	  characterized	  (low-­‐quality	  reference	  library).	  Since	  the	  work	  described	  here	  does	  not	  use	  any	  of	  these	  algorithms,	  we	  describe	  the	  general	  principles	  below.	  	  	  In	   MS/MS,	   peptides	   are	   produced	   from	   proteins	   via	   fragmentation	   along	   the	  peptide	   backbone.	   This	   generates	   the	   MS	   spectrum.	   Different	   fragmentation	  methods	   (e.g.	   Collision-­‐Induced	   Dissociation,	   CID	   and	   Electron-­‐Transfer	  Dissociation,	   ETD,	  which	   produces	   b	   and	   y-­‐ions,	   and	   c	   and	   z-­‐ions	   respectively)	  however,	   produce	   fragment	   ion	   types.	  De	   novo	   sequencing	   takes	   advantage	   of	  specific	   mass	   differences	   between	   fragment	   ions	   to	   determine	   the	   identity	   of	  amino	  acid	  residues.	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1.4 TWO	  ISSUES	  IN	  PROTEOMIC	  PROFILE	  ANALYSIS	  In	   this	   chapter,	  we	  highlight	   two	   important	   issues	   in	  proteomic	  profile	  analysis	  that	  need	  to	  be	  addressed	  and	  suggest	  a	  more	  holistic	  proteomic	  profile	  analysis	  utilizing	  biological	  networks	  and	  pathways.	  	  	  The	  first	  issue	  concerns	  the	  coverage	  of	  the	  proteome	  at	  the	  level	  of	  an	  individual	  sample.	   In	   particular,	   even	   as	   the	   advancement	   of	   MS	   technologies	   continues,	  certain	   limitations	   to	   current	   proteomics	   approaches	   remain	   that	   hamper	   the	  complete	   mapping	   of	   the	   proteome	   in	   a	   sample.	   Like	   many	   high-­‐throughput	  methods,	  proteomics	  data	  is	  noisy.	  Furthermore,	  due	  to	  demanding	  technological	  and	  manpower	   requirements,	   as	  well	   as	   limited	   sample	  availability,	   often	   there	  are	  few	  repeats	  to	  guarantee	  that	  the	  results	  are	  not	  false	  positives	  due	  to	  chance.	  Consequently,	   stringent	   score	   thresholding	   is	  generally	  used	   in	  various	  steps	  of	  peptide	   detection	   and	   identification	   to	   reduce	   noise.	   However,	   more	   stringent	  thresholds	  also	  reduce	  coverage	  of	  the	  proteome.	  For	  example,	  a	  relevant	  protein	  may	   escape	   reporting	   because	   it	   does	   not	   meet	   a	   required	   threshold	   on	   its	  dynamic	  range.	  A	  relevant	  protein	  may	  also	  escape	  detection	  because	  it	  does	  not	  meet	   a	   required	   threshold	   on	   its	   signal	   intensity,	   perhaps	   due	   to	   imperfect	  prediction	  of	  MS-­‐amendable	  transitions44,	  45.	  	  The	  second	  issue	  concerns	  the	  consistency	  of	  proteomic	  profiles	  at	  the	  phenotype	  level	  across	  samples.	  To	  understand	  proteome	  biology	  and/or	   for	   the	  discovery	  of	   biomarkers,	   quantitative	   comparisons-­‐-­‐-­‐e.g.,	   of	   cancerous	   and	  non-­‐cancerous	  samples-­‐-­‐-­‐are	   an	   important	   aspect	   of	   proteomics46.	   Analogous	   to	   DNA/RNA	  microarrays	  and	  common	  to	  proteomic	   labeling	  methods,	  protein	  quantification	  is	   usually	   expressed	   as	   fold	   change	   ratio.	   The	   traditional	   post-­‐MS	   analysis	  approach	   is	   therefore	   to	   select	   and	   study	  only	   those	  proteins	   that	   are	   found	   in	  most	  of	   the	  samples	  of	   the	  phenotype	   in	  question	  and	  have	  a	  consistently	  over-­‐expressed	   or	   under-­‐expressed	   ratio.	  However,	   proteins	  with	   noticeably	   high	   or	  low	   expression	   are	   not	   necessarily	   causal	   or	   important.	   At	   the	   same	   time,	   a	  mutated	  protein	   that	  drives	  other	  proteins	   to	   change	   their	   levels	  may	  not	   itself	  report	   any	   change	   in	   expression	   or	  may	  miss	   being	   detected.	   Moreover,	   many	  relevant	   proteins	   report	   “swing”	   ratios,	   that	   is,	   a	  mixture	   of	   both	   high	   and	   low	  ratios	   across	   samples.	   These	   factors	   are	   further	   compounded	   by	   the	   noise	   and	  coverage	  of	  the	  proteome	  at	  the	  level	  of	  individual	  samples.	  Hence	  one	  often	  fails	  to	  find	  key	  proteins,	  much	  less	  biomarkers	  that	  are	  consistent	  and	  reproducible	  across	  different	  batches	  of	  samples.	  1.5 CALL	  FOR	  A	  MORE	  HOLISTIC	  PROTEOMIC	  PROFILE	  BASED	  ON	  BIOLOGICAL	  NETWORKS	  The	  set	  of	  proteins	  detected	  for	  every	  sample,	  while	  incomplete	  and	  inconsistent,	  does	   contain	   valuable	   information.	   The	   challenge	   is	   to	   find	   novel	   ways	   to	  overcome	  these	  coverage	  and	  consistency	  problems.	  One	  possibility	  is	  to	  identify	  conserved	  patterns	  or	  contexts	  in	  which	  these	  reported	  proteins	  tend	  to	  localize.	  	  In	   biology,	   all	   proteins	   interact	  with	   one	   another	   to	   achieve	   functionality.	   The	  sum	   of	   all	   these	   interactions	   results	   in	   a	   complex	   system	   termed	   a	   biological	  network.	   	  While	   difficult	   to	   analyze	   and	   deploy	   effectively,	   the	   network	   could	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somehow	  provide	  a	  suitable	  context	   for	  resolving	   these	  proteomics	   issues.	  The	  underlying	  theme	  of	  this	  dissertation	  is	  to	  build	  more	  holistic	  proteome	  profiles	  based	  on	  biological	  networks	  in	  order	  to	  achieve	  higher	  analytical	  resolution.	  We	  explain	  in	  the	  next	  chapter	  why	  this	  is	  likely	  to	  be	  a	  successful	  approach.	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2 ADVANCEMENT	  IN	  BIOLOGICAL	  NETWORK	  ANALYSIS	  METHODS	  EMPOWERS	  PROTEOMICS	  2.1 TYPES	  OF	  BIOLOGICAL	  NETWORKS	  A	  biological	  network	  is	  a	  simplified	  model	  that	  describes	  the	   inter-­‐relationships	  between	   a	   set	   of	   functional	   entities	   such	   as	   genes,	   proteins	   or	  metabolites.	   To	  generalize,	  we	  broadly	  regard	  the	   following	  as	   instances	  of	  biological	  networks:	  metabolic	   pathways	   (MNs),	   regulatory	   pathways	   (RNs),	   protein-­‐protein	  interactions	  (PPINs),	  genetic	  interactions	  (GINs),	  protein	  complexes,	  and	  proteins	  annotated	  to	  the	  same	  Gene	  Ontology	  (GO)	  terms.	  	  MNs	   link	   two	   proteins	   in	   a	   directed	   relationship	   if	   the	   product	   of	   one	   is	   the	  substrate	  of	  the	  other.	  RNs	  refer	  to	  transcriptional	  relationships	  or	  other	  indirect	  relationships	   where	   one	   protein	   controls	   the	   expression	   or	   repression	   of	   the	  other.	  MNs	  and	  RNs	  are	   thus	  natural	  biological	  pathways.	  Popular	  databases	  of	  MNs	  and	  RNs	  include	  KEGG	  47,	  BioCyc	  48,	  WikiPathways	  49,	  Reactome	  50,	  Ingenuity	  ®	   Knowledge	   Base	   (http://www.ingenuity.com),	   NetPro™	  (http://www.molecularconnections.com),	  Pathway	  Commons	  51	  and	  PathwayAPI	  52.	  	  In	  PPINs,	   a	   relationship	  between	   two	  proteins	   exists	   if	   they	   are	   experimentally	  verified	  to	  interact	  physically.	  In	  GINs,	  a	  gene	  interacts	  with	  another	  if	  a	  combined	  mutation	   between	   them	   results	   in	   a	   more	   severe	   phenotype	   as	   opposed	   to	   a	  single	   mutation	   in	   either	   of	   them.	   A	   genetic	   interaction	   may	   imply	   a	   physical	  interaction	  (as	  part	  of	  a	  complex)	  or	  a	  complete	  ablation	  of	  functions	  across	  two	  compensatory	   pathways.	   GINs	   are	   only	   beginning	   to	   be	   better	   understood	   but	  remain	  difficult	  to	  study	  empirically;	  see	  Dixon	  et	  al.	  53	  for	  an	  excellent	  review	  on	  GINs.	   Unlike	   MNs	   and	   RNs,	   PPINs	   and	   GINs	   are	   purely	   pairwise	   interaction	  information	  and	  cannot	  yet	  be	  put	  into	  the	  context	  of	  a	  natural	  biological	  pathway.	  Important	  databases	  of	  PPINs	  and	  GINs	  include	  BioGRID	  54,	  DIP	  55,	  HPRD	  56,	  IntAct	  57,	  MINT	  58,	  and	  STRING	  59.	  	  The	  Gene	  Ontology	  (GO)	  was	  established	  by	  the	  Gene	  Ontology	  Consortium	  as	  an	  important	   reference	   terminology	   for	   annotating	   the	   function	   and	   cellular	  localization	  of	  proteins	  60.	  GO	  terms	  are	  organized	  into	  three	  separate	  hierarchical	  ontologies	  —	  viz.,	  cellular	  component	  terms	  (CC),	  molecular	  function	  terms	  (MF),	  and	  biological	  process	  terms	  (BP).	  A	  protein	  that	  is	  annotated	  by	  a	  particular	  GO	  term	   is	  considered	   to	  be	  annotated	  by	  all	  ancestor	   terms	  (in	   the	  corresponding	  hierarchical	  ontology)	  of	  that	  GO	  term;	  that	  is,	  the	  so-­‐called	  “through-­‐path”	  rule	  is	  applied.	  Associated	  with	  the	  GO	  is	  a	  large	  and	  well-­‐organized	  database	  of	  proteins	  annotated	  to	  GO	  terms.	  In	  particular,	  when	  a	  group	  of	  proteins	  are	  annotated	  to	  a	  CC,	  BP,	  or	  MF	  term,	  it	  means	  this	  group	  of	  proteins	  are	  localized	  to	  that	  cellular	  compartment	   (corresponding	   to	   the	   CC	   term),	   participate	   in	   that	   biological	  process	  (corresponding	  to	  the	  BP	  term),	  or	  participate	  in	  that	  molecular	  function	  (corresponding	  to	  the	  MF	  term),	  respectively.	  	  Protein	  complexes	  and	  proteins	  annotated	  to	  the	  same	  GO	  terms	  are	  not	  actually	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networks.	  Nevertheless,	   proteins	   that	   are	   in	   the	   same	   complex	   or	   annotated	   to	  the	   same	   GO	   terms	   are	   functionally	   linked	   and	   can	   be	   considered	   to	   form	  functional	   linkage	  networks.	  The	   larger	  databases	  of	  protein	   complexes	   include	  CORUM	  61,	  MIPS	  62	  	  and	  CYC2008	  catalogue	  63.	  	  Proteins	  usually	  function	  as	  combinatorial	  units.	  At	  a	  fine	  granularity,	  these	  units	  are	   protein	   complexes;	   at	   a	   coarser	   granularity,	   these	   units	   are	   biological	  pathways.	  We	  shall	  generically	   refer	   to	   these	  combinatorial	  units	  of	  proteins	  as	  “biological	  networks”.	  	  	  Biological	   networks	   are	   critical	   for	   understanding	   the	   function	   of	   genes	   and	  proteins	   in	   a	  more	   holistic	  way.	   Thus,	   the	   appearance	   in	   recent	   years	   of	  many	  databases	   containing	   information	   on	   biological	   networks	   may	   offer	   innovative	  solution	  to	  the	  two	  issues	  above;	  see	  Tables	  1	  and	  2.	  	  As	   proteins	   in	   the	   same	   functional	   unit—e.g.,	   a	   protein	   complex—interact	  with	  each	   other	   in	   some	  manner,	   these	   proteins	   are	   expected	   to	   be	   expressed	   in	   a	  correlated	   or	   coordinated	  manner.	   Therefore,	   it	   is	   reasonable	   to	   postulate	   that	  detected	   proteins	   in	   a	   proteomic	   screen	   that	   form	   a	   known	   functional	   unit	   are	  likely	  to	  be	  involved	  in	  biological	  function,	  while	  isolated	  proteins	  are	  noise.	  This	  postulate	  can	  be	  applied	  to	  improve	  coverage	  of	  a	  proteomic	  screen	  and	  remove	  noise.	  	  	  For	  illustration,	  let	  A,	  B,	  C,	  D,	  and	  E	  be	  5	  proteins	  that	  function	  as	  a	  group	  and	  thus	  are	   normally	   correlated	   in	   their	   expression.	   Suppose	   only	   A	   is	   detected	   in	   a	  proteomics	   screen	   and	   B–E	   are	   not	   detected.	   Suppose	   also	   that	   the	   screen	   has	  50%	  reliability.	  Then	  A’s	  chance	  of	  being	  false	  positive	  is	  50%	  while	  the	  chance	  of	  B–E	  being	  all	   false	  negatives	   is	   (50%)4	  =	  6%.	  Hence,	   it	   is	  almost	  10	   times	  more	  likely	  that	  A	  is	  noise	  than	  B–E	  all	  being	  missed.	  Conversely,	  suppose	  only	  A	  is	  not	  detected	  and	  all	   of	  B–E	  are	  detected.	  Then	  A’s	   chance	  of	  being	   false	  negative	   is	  50%	  while	  the	  chance	  of	  B–E	  all	  being	  false	  positives	  is	  (50%)4	  =	  6%.	  Hence,	  it	  is	  almost	   10	   times	   more	   likely	   that	   A	   is	   false	   negative	   than	   B–E	   all	   being	   false	  positives.	  	  Each	   biological	   state—e.g.,	   in	   disease—generally	   has	   some	   underlying	   causes.	  Thus	   it	   is	   reasonable	   to	  postulate	   that	   there	  should	  be	  some	  unifying	  biological	  themes—certain	   biological	   networks	   or	   subnetworks—for	   genes	   and	   proteins	  that	   are	   truly	   associated	   with	   the	   state64-­‐66.	   Hence	   the	   uncertainty	   in	   the	  reliability	  of	  the	  selected	  proteins	  from	  quantitative	  comparisons	  of	  disease	  and	  non-­‐disease	  samples	  can	  be	  reduced	  by	  considering	  the	  molecular	  functions	  and	  the	  biological	  processes	  associated	  with	  the	  genes	  and	  proteins	  67.	  Such	  a	  unifying	  biological	   theme	  is	  also	  a	  basis	   for	   inferring	  the	  underlying	  cause	  of	  the	  disease	  phenotype.	  	  	  For	   illustration,	   let	   there	   be	   3	   disease	   samples	   and	   3	   controls.	   Assuming	   the	  chance	   of	   an	   arbitrary	   protein	   found	   to	   be	   highly	   expressed	   in	   an	   arbitrary	  sample	   is	   50%.	  Then	   a	   group	   of	   5	   functionally	   linked	  proteins	   that	   is	   perfectly	  correlated	  to	  these	  two	  groups	  of	  samples—e.g.,	  they	  are	  all	  highly	  expressed	  in	  the	  3	  disease	  samples	  and	  not	  in	  the	  3	  controls—has	  ((50%)3	  ×	  (1	  -­‐	  50%)3)5	  =	  9.3	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×	   10-­‐8%	   	   chance	   of	   being	   a	   false	   positive	   group.	  On	   the	   other	   hand,	   if	   just	   1	   of	  these	   5	   functionally	   linked	   proteins	   was	   perfectly	   correlated	   to	   the	   two	  phenotypes,	   its	  chance	  of	  being	  a	  false	  positive	  would	  be	  (50%)3	  ×	  (1	  -­‐	  50%)3	  =	  1.6%,	  which	   is	  many	   orders	   of	  magnitude	   higher	   than	  when	   all	   5	   proteins	   are	  simultaneously	  correlated	  with	  the	  two	  phenotypes.	  	  Furthermore,	  network-­‐based	  approaches	  to	  proteomic	  profiles	  analysis	  are	  able	  to	  significantly	  reduce	   the	  number	  of	  samples	  needed	   in	  a	  proteomic	  study.	  To	  appreciate	   this,	   let	   us	   illustrate	  with	   the	   following	   simplified	   scenario.	  Assume	  again	  that	  an	  arbitrary	  protein	  has	  equal	  chance	  to	  be	  up	  or	  down-­‐regulated	  in	  a	  sample.	   Suppose	   that	   there	   are	  2n	   samples,	  with	  n	   samples	   in	   each	  of	   the	   two	  phenotypes.	   Suppose	   also	   that	   there	   are	   1000	   proteins	   being	   tested	   in	   each	  sample.	   Then,	   for	   a	   simple	   method	   that	   tests	   each	   protein	   individually,	   the	  random	  chance	  of	  a	  protein	  that	  is	  perfectly	  correlated	  with	  the	  two	  phenotypes	  is	   (1/2)n×	   (1/2)n.	   Thus,	   the	   expected	   number	   of	   false	   positive	   genes	   that	   are	  perfectly	   correlated	   with	   the	   phenotypes	   is	   1000×	   (1/2)2n.	   	   In	   contrast,	   for	   a	  method	  that	  tests	  a	  group	  of	  proteins	  at	  a	  time,	  the	  random	  chance	  of	  a	  group	  of	  k	  genes	  that	  are	  perfectly	  correlated	  with	  the	  phenotypes	  is	  ((1/2)n	  ×	  (1/2)n)k.	  In	  theory,	  there	  are	  1000Ck	  possible	  groups	  of	  k	  genes,	  and	  so	  the	  expected	  number	  of	   false-­‐positive	   groups	   of	   k	   genes	   is	   (1/2)2nk	   ×	   1000!/(k!	   ×	   (1000	   –	   k)!).	   In	  practice,	  the	  group-­‐based	  methods	  that	  we	  will	  describe	  (e.g.,	  FCS,	  GSEA)	  do	  not	  test	  all	  possible	  groups.	  Instead,	  they	  define	  each	  pathway	  in	  a	  database	  to	  be	  a	  group;	  and	  they	  only	  test	  these	  groups.	  As	  a	  typical	  pathway	  database	  has	  <1000	  pathways,	   the	   expected	   number	   of	   false-­‐positive	   groups	   of	   k	   genes	   is	   reduced	  significantly	  to	  1000	  ×	  (1/2)2nk.	  Since	  1000	  ×	  (1/2)2nk	  /	  1000×	  (1/2)2n	  =	  (1/2)k,	  we	   can	   estimate	   that,	   given	   the	   same	   number	   of	   samples,	   the	   group-­‐based	  methods	  achieve	  (1/2)k	  times	  less	  false	  positives	  than	  individual-­‐gene	  methods.	  Conversely,	   to	   achieve	   the	   same	   number	   of	   false	   positives,	   the	   number	   of	  samples	  needed	  by	  group-­‐based	  methods	   is	   (1/2)k	   times	   less	   than	   that	  needed	  by	   individual-­‐protein	  methods.	   For	   example,	   at	   k	   =	   5,	   the	   number	   of	   samples	  needed	   by	   group-­‐based	   methods	   is	   (1/2)5	   =	   ~3%	   that	   of	   individual-­‐protein	  methods,	  while	  delivering	  a	  comparable	  level	  of	  sensitivity	  and	  specificity.	  	  Clearly,	   leveraging	  on	   these	  network-­‐based	  paradigms	  can	  aid	   in	  circumventing	  some	  of	  the	  shortcomings	  of	  current	  proteomics	  approaches	  mentioned.	  	  	  2.2 IMPROVING	  COVERAGE	  USING	  BIOLOGICAL	  NETWORKS	  There	  are	   cases	  where	   the	  mass	   spectra	  may	   identify	   some	  particular	  proteins,	  but,	   because	   their	   scores	   are	   below	   the	   defined	   cutoff	   threshold,	   may	   not	   be	  reported	  initially	  in	  the	  first	  round	  of	  data	  analysis.	  This	  occurs	  frequently	  in	  the	  tradeoff	   between	   sensitivity	   and	   specificity	   in	   precursor	   ion	   selection	   for	  fragmentation.	   Other	   potential	   reasons	   why	   these	   proteins	   are	   unreported	  include:	   (i)	   not	   satisfying	   the	   minimum	   two	   unique	   peptides	   requirement	   for	  confident	   protein	   identification-­‐-­‐-­‐that	   is,	   the	   protein	   is	   identified	   by	   a	   single	  peptide;	  (ii)	   the	  proteins	  are	  short	   in	  amino	  acid	  composition	  and	  subsequently	  are	  identified	  only	  by	  short	  peptides;	  and/or	  (iii)	  they	  are	  not	  consistently	  found	  in	  patient	  samples.	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  Network-­‐based	  analysis	  can	  allow	  expansion	  of	  the	  detected	  proteome	  to	  uncover	  and/or	  discover	  novel	  proteins.	  This	  is	  critical	   in	  recovering	  missing	  proteins	  in	  known	   pathways	   or	   complexes.	   It	   is	   even	   more	   important	   in	   uncovering	   less	  abundant	  proteins	  commonly	  shrouded	  in	  shotgun	  proteomics.	  	  	  A	   simple	  network-­‐based	  method	   is	   to	  use	  a	  database	  of	  protein	   complexes	  and	  identify	  those	  complexes	  that	  have	  a	  large	  overlap	  with	  the	  initial	  list	  of	  detected	  proteins.	  A	  significance	  value	  can	   then	  be	  calculated	  via	  generating	  randomized	  clusters	  of	  equal	  size	  to	  the	  cluster.	  	  If	  significant,	  then	  the	  rest	  of	  the	  proteins	  in	  the	  complex	  are	  postulated	  as	  likely	  to	  be	  present.	  This	  method	  is	  also	  referred	  to	  as	  functional	  class	  scoring	  (FCS)	  68.	  	  	  More	   sophisticated	   methods	   that	   build	   on	   this	   principle	   include	   PEP	   (refer	   to	  chapter	  4)69,	  CEA	  70,	  Maxlink	  (refer	  to	  chapter	  5)	  71	  and	  shortest-­‐path	  analysis	  72.	  Regardless	   of	   the	   methods	   used,	   they	   are	   all	   a	   form	   of	   “guilt	   by	   association”.	  Hence	   the	   list	   of	   recovered	  proteins	   should	   be	   validated	  using	   some	   additional	  evidence.	  The	  most	  direct	  evidence	  is	  by	  returning	  to	  the	  original	  mass	  spectra	  to	  verify	  the	  quality	  of	  the	  corresponding	  y-­‐	  and	  b-­‐ion	  assignments	  69.	  Proteins	  with	  low	   copy	  numbers	   and	  high	   cellular	   turnover	   such	   as	   transcription	   factors	   and	  some	  protein	  kinases	  may	  still	  be	  untraceable	  through	  retrospective	  assessment	  of	   the	   original	   MS/MS	   data.	   Therefore,	   other	   validation	   methods	   such	   as	  immunological	  assays	  may	  be	  used	  on	  interesting	  targets.	  A	  less	  direct	  evidence	  is	  to	   check	  whether	   these	   recovered	   proteins	   are	   annotated	   to	   a	   list	   of	   GO	   terms	  that	  are	  enriched	  in	  the	  initial	  list	  of	  high-­‐confidence	  proteins	  71.	  Another	  way	  is	  using	  databases	  of	  gene	  expression	  profiles	  —	  e.g.,	  Human	  Protein	  Atlas	  73	  —to	  check	  whether	  these	  recovered	  proteins	  show	  a	  pattern	  of	  differential	  expression	  between	   relevant	   disease	   samples	   and	   normal	   samples	   that	   is	   similar	   to	   that	  shown	  by	  the	  initial	  list	  of	  high-­‐confidence	  proteins	  71.	  	  	  2.2.1 CLIQUE	  ENRICHMENT	  ANALYSIS	  (CEA)	  The	   simple	   network-­‐based	   method	   suggested	   earlier	   is	   to	   shortlist	   non-­‐confidence	   proteins	   in	   protein	   complexes	   that	   contain	   many	   high-­‐confidence	  proteins.	  However,	  the	  number	  of	  known	  protein	  complexes	  available	  in	  protein	  complex	   databases	   such	   as	   CORUM	   61	   is	   still	   small.	   So,	   one	   should	   supplement	  them	  with	  predicted	  protein	  complexes	  and	  functional	  modules.	  	  An	   example	   that	   follows	   this	   route	   is	   the	   Clique	   Enrichment	   Analysis	   (CEA)	  proposed	   by	   Li	   et	   al.	   70.	   CEA	   generates	   cliques—that	   is,	   fully	   connected	  subnetworks—from	  a	  PPIN.	  Those	  cliques	  that	  are	  enriched	  with	  high-­‐confidence	  proteins	   are	   considered	   detected.	   Non-­‐confident	   proteins	   in	   these	   cliques	   are	  thus	   rescued.	   The	  use	   of	   cliques	   from	  PPINs	   is	   reasonable	   because	   cliques	   in	   a	  PPIN	  often	  correspond	  to	  proteins	  at	  the	  core	  of	  complexes	  74.	  	  2.2.2 SHORTEST-­‐PATH	  NETWORK	  ANALYSIS	  In	   a	   related	   approach,	   Managbanag	   et	   al.	   72	   propose	   using	   shortest	   paths	   to	  recover	   genes	   that	   lie	   between	   two	   high-­‐confidence	   seeds.	   In	   their	   study,	   they	  first	  define	  a	  set	  of	  seeds	  previously	  reported	  to	  be	  associated	  with	  the	  disease	  in	  question.	  They	  then	  extract	  a	  shortest-­‐path	  composite	  network	  from	  PATHWAY	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  5.0,	  a	  commercial	  PPIN	  database	  and	  software	  suite	  75.	  This	  approach	  is	  based	  on	  the	  hypothesis	  that	  proteins	  connecting	  pairs	  of	  other	  proteins	  with	  a	  well-­‐defined	  biological	  function	  have	  a	  higher	  probability	  to	  share	  that	   function	   than	   randomly	   selected	   proteins	   76.	   This	   hypothesis	   is	   partially	  justified	  by	   the	  observation	   that	  most	  proteins	   share	  at	   least	  one	   function	  with	  their	  interaction	  partners	  77	   in	  a	  PPIN	  and	  thus	  transitively	  with	  the	  partners	  of	  these	  partners	  78.	  However,	  intuitively,	  the	  longer	  a	  (shortest)	  path	  gets,	  the	  more	  false	  positives	  it	  inevitably	  contains	  79.	  	  2.3 IMPROVING	  CONSISTENCY	  USING	  BIOLOGICAL	  NETWORKS	  Quantitative	   comparison	   of	   samples	   is	   central	   to	   proteomics.	   However,	  biomarkers	   identified	   in	   one	   batch	   are	   quite	   often	   not	   consistent	   and	   not	  reproducible	   in	  another	  batch	  of	  samples.	  This	   is	   likely	  due	   to	  (i)	   the	  noise	  and	  coverage	  of	  the	  proteome	  at	  the	  level	  of	  individual	  samples	  and	  (ii)	  limitation	  of	  current	  statistical	  techniques	  as	  a	  result	  of	  insufficient	  sample	  size.	  	  In	   order	   to	   quantitatively	   improve	   the	   statistical	   power	   of	   proteomic	   analysis	  methods	   and	   the	   reliability	   of	   the	   results,	   additional	   dimensions	  present	   in	   the	  problem	  have	  to	  be	  brought	  into	  consideration.	  In	  particular,	  current	  paradigms	  suggest	  protein	  interactions	  constitute	  a	  major	  part	  of	  all	  cellular	  processes.	  The	  extent	  of	  interactions	  between	  proteins	  denotes	  shared	  functionality	  80,	  complex	  or	  sub-­‐module	  participation	  81	  and/or	  co-­‐expression	  82.	   In	  the	  case	  of	  metabolic	  and	  biochemical	  relationships,	  extensive	  validation	  studies	  have	  established	  with	  higher	   confidence	   relationships	   between	   proteins	   in	   a	   pathway;	   and	   it	   is	  reasonable	   to	   postulate	   shared	   functionalities	   between	   such	   proteins	   even	  though,	   in	   pathways,	   an	   edge	   can	   mean	   different	   things	   such	   as	   regulation	   or	  signaling.	  Thus	  a	  comparative	  proteomic	  profile	  analysis	   that	   incorporates	  such	  information	  from	  biological	  networks,	  as	  suggested	  earlier,	  is	  useful	  in	  identifying	  results	   that	   are	   more	   consistent,	   more	   reproducible,	   and	   more	   biologically	  coherent.	  	  An	   analogous	   situation	   exists	   in	   gene	   expression	   profile	   analysis.	   Many	  approaches	   83-­‐85	   have	   been	   proposed	   for	   identifying	   differentially	   expressed	  genes	   useful	   for	   diagnosis	   of	   diseases	   and	   prognosis	   of	   treatment	   response.	  However,	  these	  methods	  often	  produce	  gene	  lists	  that	  are	  inconsistent	  when	  they	  are	  applied	  to	  different	  data	  sets	  of	  the	  same	  disease	  phenotypes	  86.	  For	  example,	  given	  a	  pair	  of	  datasets	   involving	  prostate	  cancer	  87,	  88,	  Zhang	  et	  al.	   89	  show	  that	  the	  two	  lists	  of	  significant	  genes	   identified	  by	  running	  SAM	  85	   independently	  on	  the	   two	  datasets	  have	  a	   low	  overlap	  of	  30%	   in	   their	   top	  10	  genes	  and	  an	  even	  lower	  15%	  overlap	  in	  their	  top	  100	  genes.	  In	  order	  to	  overcome	  the	  uncertainty	  in	   the	   reliability	   of	   the	   selected	   genes,	   over	   the	   years,	   the	   gene	   expression	  analysis	   community	   has	   developed	   powerful	   methods	   that	   analyze	   gene	  expression	  profiles	  with	  respect	  to	  biological	  networks.	  Although	  gene	  expression	  (DNA	   and	   RNA)	   does	   not	   always	   directly	   correlate	   with	   protein	   expression	   90,	  gene	   co-­‐expression	   is	   something	  proven	  at	   the	  protein	   level,	   especially	  when	   it	  comes	  to	  an	  induction	  of	  a	  particular	  function	  91.	  So,	  some	  of	  these	  methods	  from	  the	  gene	  expression	  community	  can	  be	  adapted	  for	  proteomic	  profile	  analysis.	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In	   the	   following	  subchapters,	  we	  briefly	   introduce	  three	  types	  of	  approaches	  —	  
viz.,	   overlap	   analysis,	   direct	   group	   analysis,	   and	   network-­‐based	   analysis—for	  identifying	   significant	   pathways	   from	   the	   gene	   expression	   analysis	   community.	  We	  also	  briefly	  describe	  approaches	  for	  identifying	  and	  characterizing	  significant	  novel	  protein	  clusters.	  	  	  2.3.1 OVERLAP	  ANALYSIS	  Overlap	  analysis	  methods	  are	  well	  known.	  A	  list	  of	  differentially	  expressed	  genes	  or	  proteins	   is	   first	  determined.	  This	   list	   is	   then	   intersected	  with	  each	  biological	  pathway	   (usually	   a	   protein	   complex,	   MN,	   or	   RN)	   in	   a	   database.	   The	   statistical	  significance	  of	   the	  overlap	   is	  computed	  using,	  e.g.,	   the	  hypergeometric	   test.	  The	  subsets	   of	   differentially	   expressed	   genes	   that	   have	   a	   statistically	   significant	  intersection	   with	   a	   pathway	   are	   declared	   candidate	   biomarkers.	   ORA	   92	   is	   a	  representative	  of	  overlap	  analysis	  methods.	  	  These	  methods	  have	   a	   shortcoming	   in	   that	   they	   are	   sensitive	   to	   the	   thresholds	  used	  in	  determining	  the	  differentially	  expressed	  genes	  or	  proteins.	  	  2.3.2 DIRECT	  GROUP	  ANALYSIS	  Direct	   group	   analysis	   methods	   work	   on	   a	   different	   principle	   to	   avoid	   the	  shortcoming	   above.	   In	   direct	   group	   analysis,	   each	   reference	   biological	   pathway	  (usually	   a	   MN,	   RN,	   or	   protein	   complex)	   is	   checked	   to	   establish	   whether	   the	  pathway	  is	  differentially	  expressed	  as	  a	  whole.	  This	  is	  achieved	  by	  comparing	  the	  distributions	  of	  expression	  values	  of	  genes	  and	  proteins	  on	  the	  pathway	  with	  the	  distributions	  of	   expression	   values	   of	   all	   the	   other	   genes	   and	  proteins,	  e.g.,	   by	   a	  weighted	  Kolmogorov-­‐Smirnov	  test.	  FCS	  93	  and	  GSEA	  94	  are	  examples	  of	  the	  direct	  group	  analysis	  methods.	  	  These	   methods	   are	   able	   to	   detect	   more	   subtle	   changes	   in	   gene	   and	   protein	  expression	   profiles.	   For	   example,	   if	   the	   majority	   of	   genes	   and	   proteins	   on	   the	  biological	  pathway	  have	  small	  but	  correlated	  expression	  level	  changes,	   they	  can	  still	  result	  in	  a	  high	  statistical	  significance	  of	  the	  biological	  pathway	  under	  a	  direct	  group	  analysis	  method.	  Nevertheless,	  direct	  group	  analysis	  methods	  have	  a	  key	  shortcoming	  in	  that	  they	  work	  on	  a	  whole-­‐pathway	  basis.	  Thus,	  they	  are	  unable	  to	  declare	  a	  large	  pathway	  to	  be	  significant	  when	  only	  a	  small	  subnet	  within	  that	  pathway	  is	  truly	  responsible	  for	  the	  disease	  phenotype.	  	  2.3.3 NETWORK-­‐BASED	  ANALYSIS	  Network-­‐based	   analysis	   methods64-­‐67,	   95	   are	   newer	   developments	   in	   gene	  expression	   analysis.	   The	   advantage	   of	   these	  methods	   is	   that,	   rather	   than	   using	  pathways	   as	   a	   whole,	   they	   identify	   subnets	   that	   are	   significantly	   differentially	  expressed.	  Although	  gene	  expression	  (DNA	  and	  RNA)	   is	  known	  not	   to	  correlate	  directly	   with	   protein	   expression,	   the	   concepts	   behind	   these	   network-­‐based	  techniques	  are	  applicable	  to	  proteomics	  profile	  analysis.	  	  An	  early	  example	  of	  these	  network-­‐based	  methods	  is	  NEA	  67.	  NEA	  extracts	  from	  each	  biological	  pathway	  (usually	  a	  MN,	  RN,	  or	  PPIN)	  a	  set	  of	  subnets,	  by	  treating	  each	  regulator	  in	  a	  pathway	  and	  all	  its	  direct	  targets	  in	  the	  pathway	  as	  a	  separate	  group.	  Each	  such	  subnet	   is	   then	   tested	  —	  using	  a	  direct	  group	  analysis	  method	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such	  as	  FCS	  or	  GSEA	  —	  to	   test	   if	   the	  genes	  and	  proteins	   in	   the	  subnetwork	  are	  differentially	   expressed	   as	   a	   whole.	   A	   significant	   subnet	   potentially	   provides	   a	  more	   precise	   hypothesis	   that	   explains	   the	   disease	   phenotype	   than	   an	   entire	  pathway.	  A	  shortcoming	  of	  NEA	  is	  that	  it	  tends	  to	  produce	  small	  subnets	  as	  each	  subnet	  comprises	  only	  a	  regulator	  and	  its	  immediate	  regulatees.	  	  The	  latest	  addition	  to	  this	  family	  of	  methods	  is	  SNet	  95,	  which	  is	  able	  to	  find	  larger	  subnets	  than	  NEA.	  SNet	  first	  maps	  the	  genes	  or	  proteins	  that	  are	  highly	  expressed	  in	   most	   samples	   of	   the	   disease	   phenotype	   in	   question	   to	   biological	   pathways	  (usually	  MNs,	  RNs,	  or	  PPINs).	  It	  then	  discards	  other	  genes	  and	  proteins	  in	  these	  pathways	   and	   networks,	   causing	   these	   pathways	   to	   fragment	   into	   separate	  subnets.	   The	   subnets	   are	   scored	   against	   the	   disease	   cases	   and	   the	   controls	  whereby	   those	   exhibiting	   significant	   score	   differences	   are	   declared	   significant.	  Experiments	  have	  shown	  that	  SNet	  produces	  subnets	  that	  are	  more	  substantial	  in	  size	  and	  much	  more	  consistent	  cross	   independent	  data	  sets	  of	  the	  same	  disease	  phenotypes	   than	   other	   methods	   95.	   A	   disadvantage	   of	   SNet	   in	   the	   proteomics	  context—compared	  to	  NEA,	  FCS,	  GSEA,	  etc.	  —	  is	  that	  it	  requires	  the	  subnets	  to	  be	  scored	   against	   individual	   samples;	   thus	   it	  may	   not	   be	   straightforward	   to	   adapt	  SNet	  for	  situations	  where	  samples	  are	  pooled.	  	  2.4 IDENTIFYING	  AND	  CHARACTERIZING	  NOVEL	  PROTEIN	  CLUSTERS	  The	  methods	  mentioned	   earlier	  —	   viz.,	   ORA,	   FCS,	   GSEA,	   NEA,	   SNet,	   etc.	  —	   are	  dependent	  on	  both	  the	  quality	  and	  comprehensiveness	  of	  the	  reference	  pathway	  databases.	   Hence	   they	   cannot	   yield	   good	   results	   if	   the	   underlying	   cause	   of	   the	  disease	  phenotype	   is	  a	  novel	   functional	  module	  or	  pathway.	  So	   they	  need	   to	  be	  complemented	   by	   methods	   for	   identifying	   and	   characterizing	   novel	   functional	  modules.	  	  A	   simple	   approach	   for	   identifying	   novel	   functional	  modules	   is	   to	   first	  map	   the	  differentially	   expressed	   proteins	   to	   a	   PPIN.	   Then	   a	   protein	   complex	   prediction	  method	  is	  run	  on	  the	  mapped	  portion	  of	  the	  PPIN	  to	  produce	  a	   list	  of	  predicted	  protein	   clusters,	   each	   comprising	   some	   subsets	   of	   the	   differentially	   expressed	  proteins.	   These	   protein	   clusters	   are	   potentially	   novel	   protein	   complexes	   and	  functional	  modules.	  After	  that,	  these	  predicted	  protein	  clusters	  are	  characterized	  using	  some	  form	  of	  GO	  term	  analysis.	  	  For	  the	  protein	  complex	  prediction	  step,	  there	  is	  no	  dearth	  of	  methods.	  A	  detailed	  review	  covering	  newer	  methods	  can	  be	  found	  in	  Wang	  et	  al96.	  So	  we	  just	  briefly	  describe	   a	   few	   easily	   accessible	   methods	   here.	   CFinder	   is	   based	   on	   the	   clique	  percolation	  method	  described	  by	  Palla	  et	  al.	  97.	  It	  relaxes	  the	  constraint	  on	  cluster	  definition	  by	  first	  identifying	  cliques	  and	  then	  scoring	  those	  that	  overlap	  using	  a	  standard	   component	   analysis	   procedure.	   MoNet	   is	   an	   implementation	   of	   the	  Girvan-­‐Newman	  method	  based	  on	  betweenness	  centrality	  98.	  MCL	  is	  based	  on	  the	  Markov	  clustering	  method	  99.	  CMC	  works	  by	  generating	  maximal	  cliques	  from	  the	  cleansed	  network	  and	  then	  merges	  or	  removes	  highly	  overlapping	  cliques	  based	  on	  their	  interconnectivity	  100.	  	  For	   the	   GO	   term	   analysis	   step,	   that	   is	   often	   done	   using	   tools	   based	   on	   the	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hypergeometric	  test.	  Examples	  include	  GO	  East	  101	  and	  GO	  Term	  Finder	  102.	  These	  tools	  essentially	  test	  predicted	  protein	  clusters	  against	  the	  reference	  protein	  sets	  defined	  by	  GO	  terms.	  If	  a	  predicted	  protein	  cluster	  is	  enriched	  in	  some	  GO	  terms,	  the	   proteins	   in	   the	   cluster	   can	   be	   considered	   to	   consistently	   show	   a	   function	  described	  by	  these	  GO	  terms.	  However,	  many	  times,	  given	  the	  incompleteness	  of	  GO	  annotations	  and	  the	  complexity	  of	  the	  GO	  tree	  structure,	  the	  returned	  GO	  term	  lists	   can	   be	   perplexing	   and	   difficult	   to	   analyze.	  Many	   significant	   GO	   terms	  may	  also	   be	   returned;	   this	   creates	   a	   misleading	   picture	   that	   the	   cluster	   is	  heterogeneous	   when,	   in	   fact,	   many	   of	   the	   returned	   GO	   terms	   could	   be	   closely	  related.	  	  	  There	  are	  other	  methods	  that	  can	  improve	  the	  resolution	  of	  GO	  analysis.	  The	  two	  simplest	  are	  the	  parent-­‐child	  method	  103	  and	  the	  intuitive	  “informative	  GO	  term”	  method	  104.	  	  The	   parent-­‐child	   method	   proposed	   by	   Grossmann	   et	   al	   103	   modifies	   the	  hypergeometric	   test	   statistics.	   Instead	   of	   the	   standard	   hypergeometric	  distribution,	  they	  propose	  using:	  	   	  	  Here,	  t	  is	  the	  GO	  term	  for	  which	  we	  want	  to	  establish	  whether	  it	  is	  enriched	  in	  the	  predicted	  protein	  cluster;	  m	  	  	  	  	  is	  the	  number	  of	  proteins	  in	  the	  GO	  database	  that	  are	  annotated	   to	   t;	  mpa(t)	   is	   the	  number	  of	  proteins	   in	   the	  GO	  database	   that	  are	  annotated	   to	   the	   parent	   terms	   of	   t;	   and	   npa(t)	   is	   the	   number	   of	   proteins	   in	   the	  predicted	   protein	   cluster	   that	   are	   annotated	   to	   the	   parent	   terms	   of	   t.	   This	  approach	   reduces	   the	   dependencies	   between	   individual	   terms’	   measurements	  and	   avoids	   producing	   false	   positives	   due	   to	   inheritance	   problems	   103,	   thereby	  increasing	  the	  stringency	  for	  significance	  reporting.	  	  The	  “informative	  GO	  terms”	  method	  decreases	  the	  number	  of	  terms	  reported	  by	  introducing	  a	  threshold	  on	  the	  GO	  tree	  itself.	  Only	  terms	  that	  are	  annotated	  to	  at	  least	   30	   genes,	   and	   each	   of	  whose	  direct	   child	   has	   no	  more	   than	  30	   genes,	   are	  considered	   informative.	   This	   way,	   each	   GO	   term	   considered	   is	   at	   the	   finest	  resolution	   possible	   while	   being	   annotated	   to	   a	   sufficiently	   large	   number	   of	  proteins	  for	  a	  valid	  analysis	  105.	  This	  also	  has	  the	  effect	  of	  reducing	  redundancy	  on	  GO	  terms	  reported	  as	  a	  whole	  104.	  	  2.5 WHAT	  TO	  WATCH	  OUT	  FOR	  USING	  BIOLOGICAL	  NETWORKS	  The	   use	   of	   biological	   network	   databases	   for	   improving	   proteomics	   analysis	   is	  very	   promising.	   Nevertheless,	   we	   should	   be	   aware	   of	   a	   number	   of	   caveats,	  especially	  with	  respect	  to	  the	  reliability	  and	  completeness	  of	  these	  databases.	  	  2.5.1 RELIABILITY	  OF	  PPINS	  The	  databases	  of	  PPINs	  and	  GINs	  have	  grown	  rapidly	  in	  size	  over	  the	  years,	  with	  improved	   methodologies	   in	   testing	   protein	   interactions;	   see	   Figure	   1.	   The	  prominent	  PPIN	  and	  GIN	  databases	  include	  HPRD,	  BioGRID,	  MINT,	  IntAct,	  STRING,	  and	   DIP;	   see	   Table	   1	   (It	   should	   be	   noted	   that	   STRING	   corresponds	   more	   to	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protein	  functional	  associations	  than	  to	  physical	  protein	  interactions).	  	  In	  spite	  of	  the	  growth	  of	  PPIN	  databases,	  it	  is	  difficult	  to	  ascertain	  quality.	  In	  fact,	  given	   high	   false	   positive	   rates	   in	   Yeast	   2	   Hybrid	   (Y2H)	   and	   other	   binding	  experiments,	  up	  to	  70%	  of	  the	  reported	  edges	  may	  be	  false	  106.	  Marc	  Vidal	  and	  co-­‐workers	  tried	  producing	  higher	  quality	  all-­‐against-­‐all	  experimental	  data107,	  108,	  by	  testing	   all	   possible	   protein	   pairs	   in	   their	   data	   set	   using	   Y2H.	   However,	   these	  datasets	  are	  a	  select	  subset	  of	  the	  entire	  proteome,	  and	  are	  not	  reflective	  of	  the	  whole	  PPIN.	  It	  also	  does	  not	  eliminate	  false	  positives	  reported	  by	  Y2H.	  	  
	  
FIGURE	  1	  GROWTH	  OF	  BIOGRID	  FROM	  2006	  TO	  CURRENT.	  	  
ALL	   DATA	   POINTS	   ARE	   TAKEN	   IN	   JULY	   EXCEPT	   IN	   2011	   (TAKEN	   IN	   APRIL).	  WHILE	   THE	   GROWTH	   IN	   HUMAN	  
PROTEIN	  INTERACTION	  HAS	  BEEN	  STEADY,	  IT	  DOES	  NOT	  SIGNIFICANTLY	  CONTRIBUTE	  TO	  THE	  LARGE	  GROWTH	  
IN	  RECENT	  YEARS.	   THIS	   IS	   IN	  PART	  DUE	  TO	  THE	   INCORPORATION	  OF	  NEW	  SPECIES	  AND	  DATA	  FROM	  OTHER	  
MODEL	  ORGANISMS.	  
TABLE	  1	  DATABASES	  OF	  PROTEIN-­‐PROTEIN	  INTERACTION	  NETWORKS.	  
Database	   #	  nodes,	  #	  edges	   URL	   Build	  Focus	   Reference	  BioGRID	   10k,	  40k	   http://thebiogrid.org	   Literature	   54	  DIP	   2.6k,	  3.3k	   http://dip.doe-­‐mbi.ucla.edu	   Literature	   55	  HPRD	   30k,	  40k	   http://www.hprd.org	   Literature	   56	  IntAct	   56k,	  267k	   http://www.ebi.ac.uk/intact	   Literature	   57	  MINT	   30k,	  90k	   http://mint.bio.uniroma2.it/mint	   Literature	   58	  STRING	   5200k,	  ?	   http://string-­‐db.org	   Literature,	  Prediction	   59	  	  Using	  a	  poor-­‐quality	  PPIN	  is	  likely	  to	  skew	  analytical	  outcome.	  Network	  coverage	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needs	  to	  be	  sufficiently	  extensive	  in	  order	  to	  enhance	  resolution.	  In	  recent	  works,	  it	   is	   common	   to	   merge	   datasets	   across	   various	   sources70,	   109.	   However,	   simple	  integration	  may	   lead	   to	  compounded	  errors	   for	  which	  confidence	   is	  not	   certain	  due	  to	  different	  or	  poorly-­‐defined	  study	  parameters.	  	  A	   roundabout	   for	   this	   problem,	   as	   demonstrated	   by	  Bossi	   and	   Lehner	   109,	   is	   to	  repeat	   the	   analysis	   on	   two	   networks	   and	   check	   for	   consistency.	   The	   first	   is	   a	  lower	   confidence	   construct	   using	   edges	   supported	   by	   at	   least	   one	   publication	  source.	  The	  second	  is	  a	  higher	  confidence	  construct	  using	  edges	  supported	  by	  at	  least	   two	   publications.	   However,	   experiment-­‐based	   filtering	   is	   biased,	   and	   two	  papers	   utilizing	   the	   same	   flawed	   technique	   may	   also	   give	   rise	   to	   the	   same	  erroneous	  result.	  Hence	  more	  robust	  methods	  for	  evaluating	  the	  network	  quality	  are	  needed.	  	  A	   good	  way	   to	   assess	   the	   reliability	   of	   an	   edge	   in	   a	   PPIN	   is	   based	   on	  GO	   term	  coherence.	  That	  is,	  we	  check	  whether	  the	  two	  proteins	  connected	  by	  that	  edge	  are	  annotated	   to	  an	   informative	  GO	   term	   in	  common	  110.	  The	  overall	   reliability	  of	  a	  PPIN	  can	  in	  turn	  be	  assessed	  based	  on	  the	  fraction	  of	  its	  edges	  that	  have	  coherent	  GO	   term	   annotations.	   This	   approach	   is	   reasonable	   because	   two	   interacting	  proteins	  should	  be	  in	  the	  same	  cellular	  compartment	  (i.e.,	  share	  an	  informative	  CC	  term)	   and	   participate	   in	   the	   same	   biological	   function	   or	   process	   (i.e.,	   share	   an	  informative	  MF	  or	  BP	  term)78,	  111.	  Limitations	  of	  this	  method	  include	  incomplete	  GO	   term	   annotation,	   unresolved	   bona	   fide	   localization	   of	   proteins,	   and	   the	  dynamic	  distribution	  of	  proteins	  in	  different	  physiological	  states.	  	  Another	   way	   to	   assess	   the	   reliability	   of	   an	   edge	   in	   a	   PPIN	   is	   based	   on	   the	  hypothesis	  that	   if	   two	  proteins	  interact,	   it	   is	  also	  likely	  that	  they	  share	  common	  neighbors	   in	   the	   PPIN.	   This	   hypothesis	   follows	   naturally	   from	   the	   more	  fundamental	   postulate	   that	   proteins	   usually	   function	   as	   a	   group.	   One	   early	  example	   of	   this	   “topological”	   approach	   is	   given	   by	   the	   CD-­‐distance,	   which	   is	  calculated	   as	   the	   number	   of	   interaction	   partners	   shared	   between	   two	   proteins	  divided	  by	  the	  set	  of	  interaction	  partners	  of	  both	  proteins	  100.	  Other	  examples	  are	  surveyed	  in	  Chua	  and	  Wong,	  2008	  110.	  Since	  topological	  cleaning	  approaches	  rely	  on	  network	  intra-­‐connectivity,	  they	  do	  not	  perform	  well	  on	  sparse	  networks.	  It	  is	  possible	   that	   improvements	   could	   be	   achieved	   via	   manifold	   embedding	   112,	   or	  homologous	  transfer	  of	  edges	  113.	  	  A	  harder	  problem	  to	  resolve	  is	  the	  false	  negative	  problem	  —	  viz.,	  true	  interactions	  that	   are	   not	   reported.	   Chua	   and	   Wong	   110	   and	   Shoemaker	   and	   Pachenko	   114	  provided	   detailed	   reviews	   on	   approaches	   for	   predicting	   novel	   protein-­‐protein	  interactions,	   including	   protein	   primary	   structures	   and	   associated	  physicochemical	   properties	   115,	   interacting	   domains	   116,	   interacting	   motifs	   117,	  gene-­‐fusion	  events	  118,	  coevolution	  of	  proteins	  or	  residues	  119,	  and	  the	  topology	  of	  PPINs	  120.	  	  2.5.2 COMPLETENESS	  OF	  BIOLOGICAL	  PATHWAY	  DATABASES	  The	  databases	  of	  MNs	  and	  RNs	  can	  be	  considered	  as	  more	  reliable	  than	  PPIN	  and	  GIN	   datasets	   due	   to	   higher	   levels	   of	   curation	   and	   experimental	   evidence.	   In	  today’s	   research	   landscape,	   the	   major	   ones	   include	   single-­‐lab	   curation	   efforts	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(KEGG,	  BioCyc),	  collaborating	  labs	  (WikiPathways,	  Reactome),	  and	  commercially	  compiled	  databases	  (Ingenuity®,	  NetPro™),	  as	  well	  as	  integrative	  databases	  that	  merge	  information	  from	  other	  databases;	  details	  in	  Table	  2.	  	  
TABLE	  2	  DATABASES	  OF	  BIOLOGICAL	  PATHWAYS.	  
Database	   Remarks	  KEGG	   KEGG	   (http://www.genome.jp/kegg)	   is	   one	   of	   the	   best	   known	  pathway	  databases.	  It	  consists	  of	  16	  main	  databases,	  comprising	  different	   levels	   of	   biological	   information	   such	   as	   systems,	  genomic,	  etc.	  The	  data	  files	  are	  down-­‐loadable	  in	  XML	  format.	  At	  time	  of	  writing	  it	  has	  392	  pathways.	  BioCyc	   BioCyc	   ver	   15	   (http://http://biocyc.org)	   comprises	   over	   1,129	  species-­‐based	   databases.	   An	   interesting	   feature	   of	   the	   BioCyc	  databases	   is	   that	   they	   are	   divided	   into	   3	   tiers,	  where	   tier	   1	   is	  high-­‐confidence	  manually	  curated,	  tier	  2	  is	  computer	  generated	  with	  moderate	  curation,	  and	  tier	  3	  has	  minimal	  curation.	  BioCyc	  can	  be	  downloaded	  via	  BIOPax,	  SBML	  among	  other	  formats.	  WikiPathways	   WikiPathways	   (http://www.wikipathways.org)	   is	   a	  Wikipedia-­‐based	   collaborative	   effort	   among	   various	   labs.	   It	   has	   1,627	  pathways	  of	  which	  369	  are	  human.	  The	  content	  is	  downloadable	  in	  GPML	  format.	  Reactome	   Reactome	   (http:://www.reactome.org)	   is	   also	   a	   collaborative	  effort	   like	  WikiPathways.	   It	   is	   one	  of	   the	   largest	  datasets,	  with	  over	  4,166	  human	  reactions	  organized	   into	  1,131	  pathways	  by	  December	   2010.	   Reactome	   can	   be	   down-­‐loaded	   in	   BioPax	   and	  SBML	  among	  other	  formats.	  Ingenuity	  ®	  	   Ingenuity	  ®	  Knowledge	   Base	   (http://www.ingenuity.com)	   is	   a	  repository	   of	   biological	   interactions	   accessible	   via	   its	  proprietary	  interface.	  Information	  is	  returned	  as	  an	  image	  file.	  NetPro	  ™	   Molecular	   Connections'	   	   NetPro	   ™	  	  (http://www.molecularconnections.com)	   is	   a	   commercial	  manually	   curated	   database.	   It	   contains	   more	   than	   320,000	  protein-­‐protein	   interactions	   and	   small	   molecule-­‐protein	  interactions	   across	   20	   organisms.	   Data	   can	   be	   downloaded	   in	  XML-­‐format	  files	  or	  via	  SQL	  queries.	  Pathway	  Commons	   Pathway	   Commons	   (http://www.pathwaycommons.com)	  collects	   information	   from	  various	  databases	  but	  does	  not	  unify	  the	   data	   51.	   It	   contains	   1,573	   pathways	   across	   564	   organisms.	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The	  data	  is	  returned	  in	  BioPax	  format.	  PathwayAPI	   PathwayAPI	   (http://www.pathwayapi.com)	   contains	   over	   450	  unified	   human	   pathways	   obtained	   from	   a	   merge	   of	   KEGG,	  WikiPathways	   and	   Ingenuity	   R	   Knowledge	   Base.	   Data	   is	  downloadable	   as	   a	   SQL	   dump	   or	   as	   a	   csv	   file,	   and	   is	   also	  interfaceable	  in	  JSON	  format.	  	  	  It	   was	   startling	   that	   none	   of	   the	   pathway	   databases	   proved	   comprehensive	   in	  terms	   of	   coverage.	   For	   example,	   comparison	   of	   human	   apoptosis	   pathway	   in	  humans	  between	  Ingenuity®	  Knowledge	  Base,	  KEGG	  and	  WikiPathways	  showed	  only	   a	   small	   32–46%	   gene	   overlap	   and	   an	   even	   more	   alarming	   11–16%	   edge	  overlap.	  	  	  Soh	   et	   al.	   52	   demonstrated	   the	   difficulties	   associated	   with	   integrating	   pathway	  databases.	  Merging	  pathways	  via	  gene	  or	  reaction	  overlap	  proved	  inefficacious:	  A	  low	   threshold	   resulted	   in	   many	   false	   positives	   while	   too	   high	   produced	   many	  false	   negatives.	   Combining	   pathways	   via	   longest	   common	   substring	   match	   in	  pathway	  names	  (LCS)	  turned	  out	  to	  be	  a	  good	  compromise.	  However,	  later	  work	  by	  us	  69	  found	  that	  some	  redundancies	  still	  persist	  within	  and	  between	  databases	  during	  functional	  analyses.	  This	  suggests	  limitations	  in	  LCS	  that	  could	  be	  further	  improved	  and	  built	  upon	  in	  future	  works,	  as	  explored	  in	  a	  very	  recent	  paper	  by	  Zhou	  et	  al	  121.	  Since	  pathway	  edges	  have	  been	  verified	  by	  expert	  knowledge	  and	  experimental	   verification,	   they	   likely	   have	   low	   false	   positive	   rates.	   Hence,	   in	  combining	   same	  pathways	  across	  different	  databases,	   it	   is	   acceptable	   to	   simply	  take	  the	  union	  of	  their	  genes,	  proteins,	  and	  reactions.	  	  Integration	  problems	  aside,	  there	  are	  specific	  problems	  associated	  with	  different	  pathway	   databases	   that	   still	   prove	   a	   challenge	   to	   resolve	   fully.	   For	   example,	  WikiPathways	  lack	  a	  stable	  and	  useful	  API.	  Extracting	  data	  from	  the	  coordinate-­‐based	   XML	   file	   is	   also	   rather	   challenging.	   In	   Ingenuity®	  Knowledge	   Base,	   only	  image-­‐based	  maps	  can	  be	  retrieved.	  In	  previous	  efforts,	  we	  used	  manual	  curation	  to	  extract	  the	  data.	  But	  this	   is	   inefficient	  and	  non-­‐scalable	   if	  we	  want	  to	  expand	  coverage	  to	  other	  species.	  	  2.6 SCIENTIFIC	  CONTRIBUTIONS	  This	   thesis	   describes	   contributions	   towards	   the	   further	   development	   of	  computational	   network	   proteomics,	   i.e.,	   the	   development	   and	   application	   of	  novel	  network-­‐based	  analysis	  in	  improving	  the	  analysis	  of	  proteomics	  data.	  The	  major	  contributions	  are	  the	  developed	  methods	  (PEP,	  PSP	  and	  Maxlink),	  as	  well	  as	  the	  comparative	  performances	  evaluation	  of	  various	  classes	  of	  network-­‐based	  methods.	  These	  are	  described	   in	  Chapters	  4	  to	  8.	  To	  allow	  the	  reader	  to	  better	  understand	  the	  nature	  of	   the	  experiments,	   the	  data,	  and	  the	  biology,	  Chapter	  3	  describes	   the	   key	   points	   regarding	   liver	   cancer,	   and	   how	   the	   proteomics	  experiment	  was	  performed.	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3 A	  PROTEOMIC	  DATASET	  ON	  LIVER	  CANCER	  
Brief	  summary	  and	  key	  points	  
• Liver	   cancer	   is	   one	  of	   the	  deadliest	   cancers	   characterized	  by	   aggressive	  progression	   and	   poor	   survival	   outcome.	   Despite	   biomedical	   research	  advances,	   incidence	   rates	   are	   increasing	   especially	   in	   the	   developed	  world.	  	  
• Etiologies	  for	  liver	  cancer	  are	  complex	  and	  are	  commonly	  associated	  with	  excessive	   alcohol	   consumption,	   and	   Hepatitis	   virus	   infection,	   amongst	  other	  factors.	  	  
• Several	   forms	   of	   liver	   cancer	   exist.	   However	   the	  most	   common	   form	   is	  Hepatocellular	  carcinoma	  or	  HCC.	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  3.1 ON	  LIVER	  CANCER	  Liver	  cancer	  is	  one	  of	  the	  deadliest	  cancers.	  It	  is	  the	  sixth	  most	  common	  cancer	  worldwide	  and	  the	  third	  most	  common	  cause	  of	  cancer-­‐associated	  death	  due	  to	  low	   survival	   rates122.	   It	   is	   also	   an	   increasing	   health	   concern:	   A	   global	   study	  revealed	   rising	   liver	   cancer	   rates	   in	   8	   out	   of	   32	   cancer	   registries	   analyzed	   123.	  Moreover,	  while	  liver	  cancer	  incidence	  rates	  are	  normally	  high	  in	  the	  developing	  world,	   in	   the	   developed	  world	   (comprising	   US,	  Western	   Europe	   and	   Oceania),	  where	  incidence	  has	  been	  low	  previously,	  both	  incidence	  and	  mortality	  rates	  are	  rising,	  especially	  among	  middle-­‐aged	  black,	  Hispanic,	  and	  white	  men122.	  Hepatocellular	  carcinoma	  or	  HCC	  is	  the	  dominant	  form	  of	  liver	  cancer.	  In	  the	  US	  alone,	   approximately	   90%	   of	   primary	   liver	   cancers	   are	   classified	   under	   HCC,	  while	  most	  of	  the	  remaining	  10%	  are	  intrahepatic	  cholangiocarcinomas.	  Hence,	  for	  comprehensiveness,	  this	  work	  focuses	  on	  HCC	  and	  its	  associated	  studies.	  HCC	  has	   a	   complex	   etiology,	   and	   is	   commonly	   associated	   with	   Hepatitis	   infection	  (Hepatitis-­‐B	   virus,	   HBV,	   and	   Hepatitis-­‐C	   virus,	   HCV)124.	   HCV	   affects	   mostly	  Caucasians,	  while	  HBV	  infection	  is	  more	  prevalent	  in	  Asians124.	  Other	  risk	  factors	  include	  drug	  and	  alcohol-­‐induced	  damage.	  In	  contemporary	  scientific	  literature,	  there	  has	  been	  much	  active	  research	  on	  the	  subject.	  A	  search	  on	  PubMed,	  using	  the	   command	   \(liver	   cancer[Title/Abstract])	   OR	   HCC[Title/Abstract])	   AND	  \2011"[Date	   -­‐	   Publication]"	   returned	   a	   staggering	   2900	   papers,	   a	   marked	  increment	  from	  2600	  in	  2010	  and	  2200	  in	  2009.	  But	  despite	  the	  large	  numbers	  of	  papers	  published	  yearly,	  recent	  large	  scale	  Systems	  Biology	  papers	  still	  report	  that	  little	  is	  known	  about	  the	  molecular	  basis	  of	  liver	  cancer	  progression,	  or	  the	  involvement	  of	  viral	  infection125,	  126.	  Currently,	   high-­‐throughput	   genomics	   technologies	   have	   sped	   up	   the	   rate	   at	  which	  cancer	  studies	  are	  performed.	  It	  is	  both	  cost	  and	  time	  feasible	  to	  sequence	  a	   complete	   transcriptome	   for	   an	   individual	   sample.	   However,	   understanding	  gene	  expression	  at	  the	  mRNA	  level	  is	  indirect	  and	  quite	  limiting.	  While	  there	  are	  approximately	   30k	   genes	   within	   the	   human	   genome,	   post-­‐translational	  modifications	  of	  translated	  genes	  (i.e.,	  proteins)	  can	  easily	  push	  the	  actual	  gene	  numbers	   beyond	   100k.	   Hence,	   proteomics-­‐-­‐-­‐the	   high-­‐throughput	   study	   of	  proteins-­‐-­‐-­‐is	  essential	  for	  a	  greater	  in-­‐depth	  analysis	  of	  the	  biological	  samples.	  As	  discussed	  earlier,	  proteomics	  suffers	  from	  several	  technical	  and	  analytical	  issues:	  These	   are	   primarily	   coverage	   and	   consistency.	   The	   following	   chapters	   will	  demonstrate	   how	   appropriate	   usage	   of	   network-­‐based	   strategies	   can	   help	  alleviate	  these	  problems.	  To	   avoid	   repetition,	  we	  describe	   the	  nature	   of	   the	   biological	   experiment	   setup	  and	   the	   MS	   peptide/protein	   identification	   and	   quantitation	   procedure	   below.	  This	   dataset	   is	   used	   as	   the	   reference	   study	   in	   all	   subsequent	   chapters,	   except	  chapter	  8.	  3.2 TISSUE	  SOURCE	  Liver	  tissues	  were	  obtained	  from	  12	  male	  patients	  diagnosed	  with	  HCC	  and	  suffered	  from	  cirrhosis	  with	  chronic	  HBV	  infection.	  There	  was	  no	  metastasis	  at	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the	  point	  of	  surgery.	  Tissues	  collected	  were	  grouped	  according	  to	  histology	  report;	  5	  had	  moderately	  differentiated	  HCC	  (mod)	  and	  7	  had	  poorly	  differentiated	  HCC	  (poor).	  Paired	  tissues	  were	  obtained	  from	  each	  patient,	  one	  from	  the	  adjacent	  non-­‐tumour	  region	  (normal)	  and	  the	  other	  from	  the	  tumour	  region	  of	  the	  resected	  liver.	  The	  tissues	  after	  resection	  were	  immediately	  snap-­‐frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐151ºC	  until	  use.	  Usage	  of	  these	  samples	  was	  approved	  by	  the	  National	  University	  Hospital	  Ethics	  committee127.	  	  3.3 TISSUE	  SAMPLE	  PREPARATION	  Human	  liver	  tissues	  were	  ground	  into	  a	  fine	  powder	  in	  liquid	  nitrogen	  and	  subsequently	  solubilized	  in	  a	  cocktail	  of	  7	  M	  urea,	  2	  M	  thiourea,	  4%	  (w/v)	  CHAPS,	  10	  mM	  Tris	  supplemented	  with	  1x	  HALT	  protease	  inhibitor	  cocktail,	  50	  µg/ml	  DNase	  I	  and	  50	  µg/ml	  RNase	  A.	  The	  lysates	  were	  then	  centrifuged	  at	  50,	  000	  g	  for	  2	  hr	  at	  15ºC	  to	  remove	  any	  insoluble	  cell	  debris.	  The	  supernatant	  was	  stored	  at	  -­‐80ºC.	  All	  protein	  estimations	  were	  carried	  out	  using	  the	  Coomassie	  Plus	  Protein	  Assay	  Reagent	  kit	  with	  minor	  modifications.	  Bovine	  serum	  albumin	  provided	  in	  the	  kit	  was	  used	  as	  the	  standard128.	  3.4 QUANTITATIVE	  PROTEOMICS	  USING	  ITRAQ	  Protein	  lysates	  from	  either	  the	  non-­‐tumour	  or	  tumour	  were	  first	  precipitated	  using	  the	  2-­‐D	  Clean-­‐Up	  kit.	  The	  protein	  pellets	  were	  subsequently	  resuspended	  in	  either	  dissolution	  buffer	  (500mM	  triethylammonium	  bicarbonate	  and	  0.1%	  (w/v)	  SDS)	  for	  iTRAQ	  labeling.	  iTRAQ	  labeling	  and	  processing	  of	  the	  samples	  were	  carried	  out	  as	  described	  by	  the	  protocol	  with	  minor	  modifications	  and	  using	  the	  reagents	  provided	  from	  Applied	  Biosystems.	  100µg	  of	  protein	  from	  each	  sample	  was	  reduced	  with	  50mM	  of	  TCEP	  at	  6ºC	  for	  1	  hr,	  and	  subsequently	  alkylated	  with	  200mM	  of	  methyl	  methanethiosulfonate	  (MMTS)	  for	  10	  min	  at	  room	  temperature.	  Each	  sample	  was	  diluted	  to	  achieve	  a	  final	  concentration	  of	  0.05%	  (w/v)	  SDS	  prior	  to	  trypsinization	  at	  37ºC	  for	  16	  hr.	  Following	  this,	  each	  tryptic	  digest	  was	  labeled	  for	  1	  hr	  with	  one	  of	  the	  four	  isobaric	  amine-­‐reactive	  tags.	  The	  labeling	  was	  carried	  out	  at	  random	  ensuring	  that	  2	  pairs	  of	  patient	  tissues	  were	  labeled	  as	  follows:	  Channel	  114	  (non-­‐tumour);	  Channel	  115	  (tumour);	  Channel	  116	  (non-­‐tumour);	  and	  Channel	  117	  (tumour	  samples).	  These	  four	  iTRAQ-­‐labelled	  samples	  were	  then	  pooled	  and	  passed	  through	  a	  strong	  cation	  exchange	  cartridge	  as	  recommended	  by	  the	  manufacturer	  (Applied	  Biosystems).	  This	  eluate	  was	  further	  desalted	  using	  a	  Sep-­‐Pak	  cartridge	  (Millipore),	  lypholised	  and	  reconstituted	  in	  appropriate	  buffers	  for	  2-­‐D	  LC129.	  3.5 TWO-­‐DIMENSIONAL	  LIQUID	  CHROMATOGRAPHY	  SEPARATION	  OF	  LABELED	  PEPTIDES	  iTRAQ-­‐labeled	  peptide	  mixtures	  was	  further	  separated	  using	  an	  UltimateTM	  dual-­‐gradient	  LC	  system	  (Dionex-­‐LC	  Packings)	  with	  a	  ProbotTM	  MALDI	  spotting	  device.	  A	  two-­‐dimensional	  LC	  separation	  was	  performed	  as	  follows:	  the	  labeled	  peptide	  mixture	  was	  first	  dissolved	  in	  2%	  (v/v)	  acetonitrile	  (ACN)	  containing	  0.05%	  (v/v)	  TFA	  and	  injected	  into	  a	  0.3	  ×	  150	  mm	  strong	  cation-­‐exchange	  (SCX)	  column	  (FUS-­‐15-­‐CP,	  Poros	  10S;	  Dionex-­‐LC	  Packings)	  for	  the	  first	  dimensional	  separation.	  The	  mobile	  phase	  A	  was	  5mM	  KH2PO4	  buffer,	  pH	  3,	  5%	  ACN	  and	  mobile	  phase	  B	  5mM	  KH2PO4	  buffer,	  pH	  3,	  5%	  ACN	  +	  500	  mM	  KCl	  respectively.	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The	  flow	  rate	  was	  6	  µl/min.	  A	  total	  of	  9	  fractions	  were	  obtained	  using	  step	  gradients	  of	  mobile	  phase	  B:	  unbound,	  0-­‐5,	  5-­‐10,	  10-­‐15,	  15-­‐20,	  20-­‐30,	  30-­‐40,	  40-­‐50,	  50-­‐100%	  of	  B.	  The	  eluting	  fractions	  were	  captured	  alternatively	  onto	  two	  0.3	  
×	  1-­‐mm	  trap	  column,	  washed	  with	  0.05%	  TFA	  and	  followed	  by	  gradient	  elution	  in	  a	  0.2	  ×	  50-­‐mm	  reverse-­‐phase	  column	  (Monolithic	  PS-­‐DVB;	  Dionex-­‐LC	  Packings).	  The	  mobile	  phase	  used	  for	  this	  second-­‐dimensional	  separation	  was	  2%	  ACN	  with	  0.05%	  TFA	  (A)	  and	  80%	  ACN	  with	  0.04%	  TFA	  (B).	  The	  gradient	  elution	  step	  was	  0-­‐60%	  B	  in	  15	  min	  at	  a	  flow	  rate	  of	  2.7	  µl/min.	  The	  LC	  fractions	  were	  mixed	  directly	  with	  MALDI	  matrix	  solution	  (7mg/ml	  CHCA	  and	  130	  µg/ml	  ammonium	  citrate	  in	  75%	  ACN)	  at	  a	  flow	  rate	  of	  5.4	  µl/min	  via	  a	  25-­‐nl	  mixing	  tee	  (Upchurch	  Scientific)	  before	  they	  were	  spotted	  onto	  a	  192-­‐well	  stainless	  steel	  MALDI	  target	  plate	  (Applied	  Biosystems)	  using	  a	  Probot	  Micro	  Precision	  Fraction	  collector	  (Dionex-­‐LC	  Packings),	  at	  a	  speed	  of	  5	  sec	  per	  well.	  50	  fmol	  of	  ACTH	  (18-­‐39)	  peptide	  (m/z	  =	  2465.199)	  was	  spiked	  into	  each	  well	  as	  internal	  standard130.	  3.6 MASS	  SPECTROMETRY	  ANALYSIS	  AND	  DATABASE	  SEARCH	  The	  samples	  on	  the	  MALDI	  target	  plates	  were	  analyzed	  using	  a	  4700	  Proteomics	  Analyzer	  mass	  spectrometer	  (AB	  SCIEX)	  with	  MALDI	  source	  and	  TOF/TOF	  optics.	  MS/MS	  analyses	  were	  performed	  using	  nitrogen	  at	  collision	  energy	  of	  1	  kV	  and	  a	  collision	  gas	  pressure	  of	  1	  ×	  10-­‐6	  Torr.	  The	  GPS	  ExplorerTM	  software	  Ver.	  3.6	  (AB	  SCIEX)	  was	  used	  to	  create	  and	  search	  files	  with	  the	  MASCOT	  search	  engine	  (version	  2.1;	  Matrix	  Science)	  for	  peptide	  and	  protein	  identifications.	  The	  International	  Protein	  Index	  (IPI)	  human	  database	  (Version	  3.31)	  was	  used	  for	  the	  search	  and	  this	  was	  restricted	  to	  tryptic	  peptides.One	  thousand	  shots	  were	  accumulated	  for	  each	  MS	  spectrum.	  For	  MS/MS,	  6,000	  shots	  were	  combined	  for	  each	  precursor	  ion	  with	  signal	  to	  noise	  (S/N)	  ratio	  greater	  or	  equal	  to	  100.	  For	  precursors	  with	  S/N	  ratio	  between	  50	  and	  100,	  10,000	  shots	  were	  acquired.	  The	  resolution	  used	  to	  select	  the	  parent	  ion	  was	  200.	  No	  smoothing	  was	  applied	  before	  peak	  detection	  for	  both	  MS	  and	  MS/MS,	  and	  the	  peaks	  were	  deisotoped.	  For	  MS/MS,	  only	  the	  peaks	  from	  60	  Da	  to	  20	  Da	  below	  each	  precursor	  mass,	  and	  with	  S/N	  greater	  than	  or	  equal	  to	  10	  were	  selected.	  Peak	  density	  was	  limited	  to	  30	  peaks	  per	  200	  Da,	  and	  the	  maximum	  number	  of	  peaks	  was	  set	  to	  125.	  Cysteine	  methanethiolation,	  N-­‐terminal	  iTRAQ	  labeling,	  and	  iTRAQ	  labeled-­‐lysine	  were	  selected	  as	  fixed	  modifications	  while	  methionine	  oxidation	  was	  considered	  as	  a	  variable	  modification.	  One	  missed	  cleavage	  was	  allowed.	  Precursor	  error	  tolerance	  was	  set	  to	  100	  ppm	  while	  MS/MS	  fragment	  error	  tolerance	  was	  set	  to	  0.4	  Da.	  Maximum	  peptide	  rank	  was	  set	  to	  2.	  iTRAQ	  quantification	  was	  performed	  using	  the	  GPS	  ExplorerTM	  software	  and	  normalized	  among	  samples130.	  For	  MS/MS,	  only	  the	  peaks	  from	  50	  Da	  to	  20	  Da	  below	  each	  precursor	  mass,	  and	  the	  minimum	  S/N	  filter	  was	  designated	  at	  10.	  The	  mass	  exclusion	  tolerance	  was	  3	  Da	  around	  115.5	  m/z.	  Peak	  density	  was	  limited	  to	  50	  peaks	  per	  200	  Da,	  and	  the	  maximum	  number	  of	  peaks	  was	  set	  to	  80.	  iTRAQ	  ratios	  were	  calculated	  based	  on	  the	  areas	  of	  the	  iTRAQ	  reporter	  fragment	  peaks	  (114,	  115,	  116	  and	  117),	  and	  the	  ratios	  calculation	  included	  only	  peptides	  identified	  with	  C.I.	  %	  above	  cutoff	  thresholds	  as	  described	  below.	  The	  average	  iTRAQ	  ratio	  and	  standard	  deviation	  (S.D.)	  were	  determined	  using	  the	  GPS	  ExplorerTM	  software	  (Ver.	  3.6).	  In	  order	  to	  verify	  the	  identified	  proteins	  and	  degree	  of	  quantification,	  the	  same	  set	  of	  spectra	  were	  run	  on	  a	  different	  database	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search	  algorithm,	  the	  Paragon	  algorithm	  in	  Protein	  Pilot	  4	  software	  (AB	  SCIEX).	  Autobias	  correction	  was	  applied	  and	  the	  Unused	  ProtScore	  was	  >	  1.3	  (C.I.%	  >	  95%).	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4 OVERCOMING	  THE	  COVERAGE	  ISSUE	  USING	  CLUSTER	  DISCOVERY:	  	  PROTEOMICS	  EXPANSION	  PIPELINE	  (PEP)	  
Brief	  summary	  and	  key	  points	  
• 70-­‐80%	  of	  proteins	  share	  at	  least	  one	  biological	  process	  or	  function	  with	  their	   interaction	   partners	   in	   PPINs	   and	   GINs.	   A	   protein	   is	   also	   often	  observed	   to	   participate	   in	   a	   biological	   process	   or	   function	   that	   is	   over-­‐represented	   in	   its	   interaction	  partners.	  More	  generally,	  proteins	   that	  are	  connected	  or	  proximal	  within	  a	  biological	  network	  often	  form	  a	  functional	  unit.	   On	   the	   basis	   of	   these	   observations,	   many	   algorithms	   have	   been	  developed	  for	  predicting	  protein	  complexes	  and	  functional	  modules	  from	  PPINs	  and	  GINs.	  
• We	  developed	  a	  method	  that	  uses	  a	  powerful	  protein	  complex	  prediction	  algorithm	   and	   termed	   it	   Proteomics	   Expansion	   Pipeline	   (PEP).	   PEP	   first	  identifies	  the	  group	  of	  high-­‐confidence	  proteins	  from	  the	  proteomic	  screen.	  It	   then	  maps	   these	  proteins	   to	  nodes	   in	   a	   large	   integrated	  PPIN.	  Next,	   it	  generates	   an	   expanded	   subnet	   by	   taking	   the	   immediate	   neighbours	   of	  these	   seeds	   in	   the	   PPIN.	   The	   subnet	   is	   then	   clustered	   using	   CFinder	   97,	  which	  overlaps	  closely	  related	  cliques.	  Each	  cluster	   is	   then	  ranked	  based	  on	   the	   average	   expression	   value	   of	   the	   proteins	   it	   contains.	   Proteins	   (in	  high-­‐ranking	   clusters)	   not	   found	   in	   the	   proteomics	   screen	   are	   then	  screened	  against	  the	  original	  mass	  spectra	  for	  evidence	  of	  existence.	  
• A	  notable	   aspect	   of	   PEP	   is	   the	   PPIN	   that	   it	   uses.	   The	   PPIN	   is	   one	   of	   the	  most	  comprehensive	  to	  date	  (at	  time	  of	  writing).	  While	  combining	  PPINs	  improves	  coverage	  of	  the	  protein	  interactome,	  it	  may	  also	  compound	  the	  noise	   present	   in	   them.	   PEP	   uses	   the	   iterated	   Czekanowski-­‐Dice	   distance	  (CD-­‐distance)	   technique	   to	   eliminate	   potential	   noise	   edges	   from	   the	  integrated	   PPIN.	   While	   this	   method	   eliminates	   about	   50%	   of	   the	   edges	  from	  the	  integrated	  PPIN,	  it	  doubles	  the	  level	  of	  functional	  and	  localization	  coherence	  in	  the	  remaining	  edges	  in	  the	  PPIN.	  
• In	   the	   original	   MS	   dataset,	   over	   500	   proteins	   were	   detected	   from	   the	  tumors	  of	  12	  male	  patients,	  but	  PEP	  analysis	  identified	  an	  additional	  1000	  proteins.	  Through	  this	  integrative	  effort	  of	  network	  cleaning,	  community	  finding	   methods	   and	   network	   analysis,	   several	   biologically	   interesting	  clusters	  implicated	  in	  HCC	  were	  uncovered.	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4.1 INTRODUCTION	  Mass	  spectrometry	  (MS)-­‐based	  proteomics	  is	  currently	  the	  most	  powerful	  tool	  for	  systems-­‐wide	  analysis	  of	  protein	  expression	  changes1.	  Part	  of	  the	  current	  interest	  in	  proteomics	  is	  to	  profile	  and	  decipher	  the	  complexities	  of	  disease	  pathogenesis,	  such	  as	  in	  cancer,	  as	  well	  as	  to	  identify	  new	  therapeutic	  targets.	  Yet,	  comprehensive	  proteome	  characterization	  is	  not	  yet	  achievable.	  Firstly	  the	  complexity	  of	  biological	  samples	  and	  the	  wide	  dynamic	  range	  of	  proteins	  limit	  the	  number	  of	  proteins	  that	  can	  be	  detected	  per	  unit	  time	  by	  MS.	  Furthermore,	  in	  shotgun	  proteomics	  where	  proteins	  are	  digested	  into	  peptides,	  the	  number	  of	  analytes	  entering	  the	  mass	  spectrometer	  increases	  tremendously,	  compounding	  the	  sampling	  problem.	  Secondly,	  technological	  limitations	  such	  as	  in	  sequencing	  speed	  and	  dynamic	  range	  of	  measurement	  often	  preclude	  the	  detection	  of	  low	  abundant	  proteins.	  For	  instance,	  while	  the	  dynamic	  range	  of	  serum	  is	  an	  estimated	  ten	  orders	  of	  magnitude,	  the	  dynamic	  range	  of	  detection	  of	  most	  mass	  spectrometers	  is	  in	  the	  range	  of	  1000	  to	  10000	  30.	  For	  these	  reasons,	  there	  remains	  a	  gap	  in	  the	  sensitivity	  of	  detection	  and	  quantification	  of	  proteins	  in	  complex	  biological	  samples	  by	  MS.	  Despite	  this,	  much	  progress	  has	  been	  made	  in	  advancing	  knowledge	  of	  cancer	  through	  the	  use	  of	  proteomics	  131.	  HCC	  is	  the	  third	  most	  common	  cause	  of	  cancer-­‐related	  mortality	  132	  (See	  chapter	  3).	  It	  is	  usually	  distinguished	  against	  other	  forms	  of	  cancers	  in	  that	  its	  etiology	  is	  primarily	  due	  to	  tissue	  damage.	  Risk	  factors	  of	  HCC	  includes	  (i)	  chronic	  infection	  via	  hepatitis	  B	  or	  C	  virus	  (HBV	  or	  HCV)	  ,	  (ii)	  germline	  mutations,	  (iii)	  cirrhosis,	  (iv)	  alcoholic	  liver	  disease	  (v)	  hemochromatosis	  and	  (vi)	  other	  liver	  diseases	  133.	  	  Such	  diverse	  etiologies	  imply	  high	  variability	  in	  the	  initiation	  mechanisms	  leading	  to	  HCC.	  HCC	  can	  be	  categorized	  histologically	  into	  three	  progressive	  stages:	  well–,	  moderately-­‐	  and	  poorly-­‐	  differentiated.	  While	  histological	  distinguishing	  aids	  stratification,	  it	  is	  worth	  noting	  that	  HCC	  differentiation	  is	  notoriously	  heterogeneous	  –-­‐-­‐	  it	  is	  difficult	  to	  divide	  borderline	  cases,	  histological	  criteria	  variability	  exists	  and	  they	  do	  not	  necessarily	  correlate	  well	  with	  clinical	  outcome	  such	  as	  prognosis	  and	  survival.	  Hence	  the	  ability	  to	  comprehensively	  characterize	  and	  quantify	  the	  changes	  in	  protein	  expression	  at	  the	  molecular	  level	  may	  better	  distinguish	  HCC	  progression,	  enhance	  our	  understanding	  of	  cancer	  pathogenesis	  and	  also	  yield	  molecular	  targets	  for	  the	  treatment	  	  	  of	  HCC	  and	  other	  cancer	  types.	  	  With	  the	  human	  HCC	  iTRAQ	  dataset	  as	  a	  reference,	  we	  propose	  a	  set	  of	  complementary	  methods	  that	  can	  help	  to	  overcome	  incomplete	  data	  coverage	  and	  inconsistency,	  and	  present	  functional	  information	  by	  combining	  iTRAQ	  data	  with	  network	  and	  pathway	  information.	  The	  mapping	  of	  genomic	  data	  onto	  biological	  networks	  is	  not	  a	  novel	  concept	  but	  is	  worth	  exploring	  and	  developing	  further134.	  In	  Ramakrishnan	  et	  al,	  it	  was	  demonstrated	  that	  the	  use	  of	  gene	  interaction	  network	  information	  can	  meaningfully	  expand	  the	  repertoire	  of	  proteins	  returned	  via	  MS	  analysis134.	  In	  microarray	  screens,	  genomic	  expression	  combined	  with	  network	  analysis	  can	  yield	  important	  information	  on	  how	  expression	  variation	  relates	  to	  differences	  between	  observed	  states67.	  As	  closely	  connected	  genes	  tend	  to	  be	  involved	  in	  similar	  functions,	  network	  annotation	  can	  complement	  clusters	  obtained	  via	  fold	  change	  analysis105.	  Microarray	  and	  deep	  sequencing	  methods	  tended	  to	  provide	  a	  much	  larger	  information	  pool	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relative	  to	  proteomic	  platforms.	  In	  addition,	  the	  general	  reproducibility	  is	  more	  amendable	  to	  statistical	  analyses.	  However,	  these	  methods	  are	  less	  able	  to	  provide	  information	  at	  the	  functional	  level.	  Alternatively,	  the	  smaller	  information	  yield	  and	  general	  inconsistency	  in	  iTRAQ	  screens	  impedes	  analysis.	  The	  former	  increases	  false	  negatives	  that	  are	  not	  taken	  into	  consideration	  during	  analysis.	  As	  a	  result	  many	  important	  pathways	  and	  components	  are	  missed.	  We	  show	  here	  that	  recovering	  shared	  components	  or	  closely	  associated	  neighbors	  can	  attenuate	  this	  problem.	  The	  consistency	  issue	  is	  harder	  to	  solve.	  Because	  the	  various	  protein	  (data)	  points	  are	  not	  all	  accounted	  for,	  it	  is	  difficult	  to	  establish	  if	  a	  protein	  is	  indeed	  differential.	  For	  example,	  if	  only	  one	  out	  of	  six	  samples	  reports	  a	  protein	  as	  being	  differential	  and	  there	  is	  no	  reading	  in	  the	  other	  ﬁve,	  it	  is	  harder	  to	  establish	  if	  the	  protein	  is	  truly	  important.	  It	  is	  possible	  to	  increase	  the	  confidence	  by	  increasing	  sample	  size,	  but	  not	  always	  feasible.	  Alternatively,	  it	  is	  not	  unreasonable	  to	  hypothesize	  that	  lowly	  supported	  differential	  proteins	  could	  become	  important	  if	  they	  are	  linked	  to	  high	  confidence	  differential	  proteins	  in	  the	  network,	  indicating	  that	  they	  share	  similar	  properties	  or	  a	  deregulation	  in	  any	  of	  them	  could	  be	  phenotypically	  equivalent.	  A	  scoring	  function	  that	  takes	  into	  account	  low	  and	  high	  confidence	  proteins	  in	  a	  cluster	  can	  help	  recover	  important	  information	  that	  may	  be	  lost	  due	  to	  over-­‐stringent	  filtering.	  Here,	  we	  look	  to	  two	  elements	  of	  biological	  networks	  that	  can	  be	  applied	  towards	  improving	  MS	  analysis.	  These	  are	  the	  clusters/cliques,	  and	  the	  chains	  (or	  biological	  pathways).	  	  Clusters	  in	  networks	  are	  functionally	  related	  components	  in	  a	  Protein-­‐Protein	  Interaction	  Network	  (PPIN)	  as	  they	  correspond	  to	  protein	  complexes	  or	  tightly	  inter–connected	  subcomponents	  in	  biological	  pathways100,	  135.	  	  A	  cluster	  may	  be	  a	  clique	  (a	  completely	  connected	  sub	  graph),	  or	  composed	  of	  several	  overlapping	  cliques.	  It	  is	  unlikely	  many	  clusters	  are	  strictly	  cliques	  since	  they	  are	  unlikely	  to	  be	  strictly	  mathematically	  defined	  anyway.	  To	  find	  interesting	  clusters	  in	  the	  mapped	  network,	  clique	  percolation	  is	  a	  useful	  method	  for	  detecting	  overlapping	  cliques	  given	  a	  defined	  core	  size97.	  Other	  suitable	  cluster	  finding	  methods	  include	  the	  Girvan-­‐Newman	  algorithm98,	  CMC100,	  MCODE74,	  and	  MCL99.	  Because	  clusters	  are	  strongly	  connected	  internally,	  those	  that	  contain	  a	  high	  proportion	  of	  detected	  differential	  proteins	  can	  yield	  novel	  testable	  targets.	  They	  also	  allow	  discovery	  of	  closely	  associated	  differential	  proteins.	  A	  second	  advantage	  of	  using	  cluster	  information	  is	  recovery	  of	  interesting	  associations	  between	  proteins	  that	  are	  lost	  due	  to	  using	  a	  threshold.	  A	  biological	  pathway,	  also	  referred	  to	  as	  a	  chain,	  is	  composed	  of	  several	  biological	  molecules	  known	  to	  be	  involved	  in	  a	  specific	  biological	  system.	  This	  can	  be	  metabolic,	  signaling,	  etc.	  Chains	  are	  better	  defined	  biologically	  than	  clusters	  due	  to	  curation	  and	  established	  literature	  sources.	  For	  the	  same	  reason,	  chain	  information	  is	  also	  relatively	  scarce.	  Despite	  the	  fact	  that	  chains	  are	  better	  annotated,	  surprisingly,	  the	  components	  within	  a	  chain	  are	  not	  always	  agreed	  on	  across	  various	  data	  sources.	  Chain	  analysis	  is	  also	  generally	  not	  straightforward	  due	  to	  difficulties	  in	  extracting	  information	  from	  data	  repositories	  such	  as	  the	  Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes	  (KEGG),	  or	  costs	  incurred	  from	  subscribing	  to	  commercial	  databases	  such	  as	  Ingenuity	  Pathway	  Analysis	  (IPA).	  Furthermore,	  it	  is	  known	  that	  despite	  being	  better	  annotated	  than	  protein	  complexes,	  pathway	  agreement	  across	  various	  databases	  such	  as	  KEGG	  and	  IPA	  
	   44	  
is	  also	  generally	  low52.	  	  In	  addition,	  their	  overlaps	  are	  also	  low.	  To	  improve	  the	  coverage	  of	  pathway	  information,	  my	  collaborators	  and	  I	  further	  developed	  an	  integrated	  Pathway	  database,	  PathwayAPI52	  so	  that	  robust	  data	  evaluation	  could	  be	  performed.	  	  Combining	  network	  cleaning	  with	  community	  finding	  methods,	  we	  uncovered	  several	  biologically	  interesting	  clusters,	  one	  of	  which	  consists	  of	  a	  heavily	  targeted	  protein	  kinase	  (which	  is	  found	  in	  most	  poor	  patients	  and	  is	  also	  strongly	  differentially	  expressed)	  and	  surrounded	  by	  an	  array	  of	  DNA	  repair	  enzymes,	  each	  of	  which	  is	  found	  in	  fewer	  than	  half	  the	  patients.	  	  The	  reference	  HCC	  data	  was	  also	  comprised	  of	  two	  biological	  stages	  (moderate	  and	  poor).	  To	  better	  understand	  how	  these	  two	  stages	  could	  be	  understood	  in	  terms	  of	  pathway	  progression,	  we	  developed	  a	  method	  of	  tracing	  links	  based	  on	  average	  path	  lengths	  from	  pathways	  found	  in	  both	  (mod	  and	  poor)	  to	  poor	  only.	  	  This	  method	  differs	  from	  previous	  approaches	  as	  firstly,	  we	  based	  our	  analysis	  on	  an	  integrated	  gene	  interaction	  network	  that	  has	  been	  evaluated	  for	  functional	  coherence.	  Secondly,	  we	  performed	  a	  similar	  analysis	  on	  an	  integrated	  and	  curated	  biological	  pathway	  database	  consisting	  of	  the	  widely	  used	  KEGG,	  WikiPathways	  as	  well	  as	  IPA.	  Thirdly,	  by	  combining	  both	  pathway	  and	  functional	  interaction	  analyses,	  it	  is	  possible	  to	  derive	  a	  more	  comprehensive	  understanding	  of	  the	  experimental	  data.	  Finally,	  it	  is	  observed	  that	  expansion	  of	  the	  data	  to	  incorporate	  highly	  connected	  neighbours	  is	  crucial	  in	  overcoming	  data	  sparseness	  in	  MS.	  Detecting	  HCC–associated	  molecular	  changes	  could	  help	  manage	  HCC–staging,	  improve	  surveillance	  and	  also	  in	  development	  of	  stage-­‐speciﬁc	  therapeutic	  intervention	  or	  biomarker	  discovery.	  4.2 METHODS	  	  4.2.1 ESTABLISHMENT	  OF	  DIFFERENTIAL	  CANDIDATES	  	  Proteins	  identified	  and	  quantified	  by	  iTRAQ	  formed	  the	  basis	  of	  our	  seed	  selection.	  For	  each	  patient,	  a	  ratio	  was	  obtained	  for	  each	  protein	  by	  self-­‐comparison	  to	  non-­‐tumorigenic	  liver	  tissue.	  The	  definition	  of	  a	  differential	  protein	  required	  passing	  two	  levels.	  Firstly,	  the	  protein	  should	  meet	  the	  expression	  threshold	  of	  1.25	  and	  0.8	  (reciprocal	  of	  1.25)	  for	  over-­‐expressed	  and	  under-­‐expressed	  proteins	  respectively.	  We	  chose	  a	  slightly	  lower	  cut-­‐off	  as	  this	  would	  help	  bolster	  sensitivity.	  Traditionally,	  the	  significant	  cut-­‐off	  threshold	  proposed	  was	  based	  on	  the	  standard	  deviation	  (S.D.)	  of	  all	  the	  ratios	  of	  the	  respective	  labeled	  peptides	  and	  this	  would	  theoretically	  be	  1.3/0.77	  (based	  on	  1	  
±	  2	  S.D.)130.	  Secondly,	  the	  other	  requirement	  is	  that	  the	  protein	  has	  to	  be	  consistently	  detected	  in	  at	  least	  3/5	  of	  patients	  for	  the	  moderately	  differentiated	  samples	  and	  5/7	  patients	  for	  the	  poorly	  differentiated	  tumors.	  Of	  note,	  there	  were	  cases	  where	  proteins	  met	  the	  expression	  threshold	  but	  did	  not	  meet	  the	  second	  requirement	  and	  thus	  were	  removed	  (Supplementary	  Figure	  1).	  Taken	  together,	  proteins	  that	  meet	  the	  requirements	  in	  both	  filters	  (expression	  change	  and	  patient	  support)	  were	  maintained	  as	  seeds	  for	  neighbors	  and	  cluster	  analysis.	  4.2.2 PROTEIN-­‐PROTEIN	  INTERACTION	  NETWORK	  (PPIN)	  CLEANING	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n 	  where	  S	  is	  the	  calculated	  score,	  E	  is	  the	  expression	  value	  for	  a	  detected	  protein	  (if	  protein	  is	  under	  expressed,	  then	  the	  reciprocal	  score	  is	  used).	  
	  
FIGURE	  2	  SCHEMATIC	  OF	  INTEGRATED	  ANALYSIS	  PIPELINE.	  	  
THE	  ANALYSIS	  PIPELINE	  CAN	  BE	  BROADLY	  DIVIDED	  INTO	  TWO	  MAJOR	  COMPONENTS.	  ON	  THE	  LEFT	  BLOCK,	  MS	  
PROTEIN	   LIST	   IS	   FIRST	   FILTERED	   FOR	   SEED	  PROTEINS.	   THE	   EXPANSION	   STEP	   IS	  DONE	   IN	  RELATION	  TO	  THE	  
CLEANED	   PROTEIN-­‐PROTEIN	   INTERACTION	   NETWORK	   OR	   PPIN	   (FOR	   INFORMATION	   ON	   HOW	   THIS	   IS	   DONE,	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PLEASE	  REFER	  TO	  MATERIALS	  AND	  METHODS).	   CLIQUE	  ANALYSIS	   IS	   THEN	  PERFORMED	  TO	  OBTAIN	  TIGHTLY	  
CONNECTED	  CLUSTERS.	  THE	  CLUSTERS	  ARE	  THEN	  SCORED	  AND	  RANKED.	  FOR	  PATHWAY	  ANALYSIS,	  WE	  USED	  AN	  
INTEGRATED	  PATHWAY	  DATABASE	  DEVELOPED	  IN-­‐HOUSE	  (PATHWAY	  API).	  SIMILARLY,	  THE	  MS	  PROTEIN	  LIST	  
IS	  EXPANDED	  BY	  LOCATING	  SHARED	  NEIGHBOURS	  IN	  THE	  LIST	  OF	  PATHWAYS.	  PATHWAYS	  SIGNIFICANT	  IN	  MOD	  
AND	  POOR	  RESPECTIVELY	  WERE	  IDENTIFIED.	  THE	  SHORTEST	  PATH	  DISTANCES	  BETWEEN	  THE	  MOD	  TO	  POOR	  
PATHWAYS	  WERE	  THEN	   IDENTIFIED	  ON	  AN	   INTEGRATED	  GENE	  NETWORK	  COMBINING	  BOTH	  PATHWAY	  AND	  
PPIN	   INFORMATION.	  FINALLY,	  THE	  SET	  OF	  SIGNIFICANT	  PATHWAYS	  CAN	  BE	  COMPARED	  TO	  THE	  SIGNIFICANT	  


























⎟ 	  where	  N	   is	   the	  number	  of	  proteins	   in	  the	  pathway	  network;	  x	   is	   the	  number	  of	  proteins	  in	  the	  poor	  or	  mod	  list;	  m	  is	  the	  number	  of	  proteins	  in	  current	  pathway;	  
k	   is	   the	   number	   of	   same	   proteins	   between	   the	   poor	   or	  mod	   gene	   list	   and	   the	  pathway.	  	  We	  tracked	  the	  progression	  of	  moderate	  into	  poor	  stage	  by	  first	  taking	  into	  account	  all	  significant	  pathways	  that	  are	  common	  to	  both	  mod	  and	  poor	  stage.	  We	  then	  considered	  pathways	  that	  are	  found	  only	  in	  mod,	  and	  in	  poor	  stage	  and	  calculated	  the	  minimum	  and	  average	  distance	  needed	  to	  go	  from	  one	  pathway	  to	  another	  using	  the	  Floyd-­‐Warshall	  algorithm142.	  Distance	  d,	  is	  defined	  as	  the	  number	  of	  steps	  (in	  terms	  of	  biological	  molecules)	  needed	  to	  reach	  one	  pathway	  from	  another.	  A	  distance	  of	  0	  implies	  shared	  common	  node(s).	  Average	  distance	  is	  the	  average	  number	  of	  steps	  from	  one	  pathway	  to	  another.	  That	  is,	  for	  each	  node	  Nx	  in	  ﬁrst	  pathway,	  Ny	  in	  second	  pathway,	  find	  the	  minimum	  distance	  from	  
Nx	  to	  Ny,	  then	  averaged	  over	  all	  combinations	  of	  Nx,	  Ny.	  4.3 RESULTS	  AND	  DISCUSSION	  4.3.1 RESULT	  CORRELATION	  BETWEEN	  MASCOT	  AND	  PARAGON	  	  Combining	  multiple	  search	  engines	  has	  the	  dual	  advantages	  of	  checking	  reproducibility	  and	  providing	  complementary	  data	  from	  the	  same	  raw	  results143.	  To	  leverage	  the	  different	  search	  algorithms	  we	  performed	  a	  search	  using	  Paragon	  (on	  ProteinPilot)	  and	  Mascot.	  	  Using	  a	  cut-­‐off	  of	  5%	  protein	  “local”	  FDR	  on	  Paragon,	  we	  found	  that	  the	  agreement,	  in	  terms	  of	  common	  protein	  identifications,	  between	  Mascot	  and	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Paragon	  was	  good	  (Table	  3).	  Interestingly,	  it	  also	  appeared	  that	  Paragon	  consistently	  returned	  more	  protein	  hits	  (Table	  3).	  That	  many,	  if	  not	  most,	  of	  the	  Mascot	  hits	  were	  also	  found	  in	  the	  Paragon	  list	  showed	  that	  despite	  differences	  in	  database	  search	  algorithm	  methods,	  proteins,	  especially	  those	  of	  high	  confidence	  identifications	  (see	  below)	  were	  repeatedly	  identified.	  This	  is	  plausible	  in	  that	  multiple	  search	  engines	  adds	  to	  the	  confidence	  of	  original	  protein	  identifications	  by	  working	  through	  different	  algorithms	  and	  assigning	  previously-­‐unassigned	  high	  quality	  MS/MS	  spectrum	  to	  peptides144.	  To	  further	  determine	  the	  degree	  of	  similarity	  in	  both	  Mascot	  and	  Paragon,	  we	  performed	  correlation	  analysis	  on	  the	  intersection	  for	  proteins	  from	  all	  12	  patients	  of	  their	  list	  Rank	  and	  list	  Ratio	  scores	  (Supplementary	  Figure	  2).	  Our	  results	  indicated	  that	  for	  proteins	  agreed	  on	  by	  both	  Mascot	  and	  Paragon,	  there	  is	  a	  clear	  positive	  correlation	  for	  both	  ranks	  and	  ratio.	  	  
TABLE	  3	  OVERLAPS	  BETWEEN	  MASCOT	  AND	  PARAGON	  PROTEIN	  HITS	  FOR	  ALL	  SAMPLES.	  
 
Patient 





199 197 28 63 
131 246 16 120 
215 499 33 250 
196 247 16 119 
200 198 28 62 
207 498 33 251 
126 531 30 287 
155 531 30 287 
203 586 41 180 
120 586 41 180 
157 696 34 376 
187 697 36 375 	  As	  Paragon	  was	  returning	  many	  more	  protein	  hits,	  it	  is	  of	  interest	  to	  establish	  if	  these	  additional	  Paragon	  unique	  proteins	  were	  of	  lower	  confidence.	  	  We	  performed	  a	  one-­‐sided	  Wilcoxon	  Ranked	  Sum	  test	  on	  Paragon-­‐only	  proteins	  and	  compared	  it	  to	  the	  distribution	  of	  ranks	  in	  Paragon.	  	  It	  was	  found	  that	  the	  distribution	  of	  ranks	  in	  the	  Paragon-­‐only	  list	  was	  always	  significantly	  greater	  than	  that	  in	  the	  full	  data	  set.	  In	  11	  of	  12	  patient,	  the	  values	  were	  close	  to	  zero	  (<	  2.2e-­‐16)	  with	  only	  one	  patient	  giving	  a	  value	  of	  0.00064.	  This	  confirms	  that	  the	  Paragon-­‐only	  list	  is	  of	  lower	  confidence	  than	  the	  intersection	  set.	  Hence,	  only	  proteins	  that	  are	  supported	  by	  both	  Mascot	  and	  Paragon	  were	  retained	  for	  establishment	  of	  differential	  candidates.	  4.3.2 EXPANSION	  BY	  FIRST-­‐DEGREE	  NEIGHBORS	  IMPROVES	  COVERAGE	  SIGNIFICANTLY	  From	  the	  original	  dataset	  of	  approximately	  500	  proteins	  detected	  from	  iTRAQ	  2DLC-­‐MS/MS	  we	  were	  able	  to	  expand	  to	  approximately	  1500	  proteins,	  an	  additional	  1000	  proteins,	  through	  the	  use	  of	  our	  bioinformatics	  pipeline	  (Figure	  3).	  Proteins	  classified	  as	  “differential”	  given	  the	  expression	  ratio	  threshold	  and	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patient	  count	  criteria	  are	  used	  as	  “seeds”	  for	  first-­‐degree	  neighbor	  expansion.	  A	  first-­‐degree	  neighbor	  is	  a	  protein	  that	  has	  a	  direct	  connection	  or	  interaction	  with	  a	  seed.	  Second-­‐degree	  neighbors,	  that	  is,	  proteins	  that	  are	  linked	  to	  seeds	  via	  a	  single	  intermediary,	  were	  also	  considered	  but	  due	  to	  the	  wide	  dispersal	  of	  the	  proteins	  in	  the	  network,	  resulted	  in	  covering	  most	  of	  the	  reference	  network.	  Hence,	  only	  first	  degree	  clique	  analysis	  results	  were	  retained.	  	  
	  
FIGURE	  3	  EXPANSION	  OF	  CANDIDATE	  PROTEINS	  FROM	  MOD	  AND	  POOR.	  	  
MS-­‐DETECTED	  PROTEINS	  FROM	  MOD	  AND	  POOR	  STAGES	  SHOW	  SMALLER,	  SPARSER	  NETWORKS	  AND	  THERE	  ARE	  
TOO	  FEW	  TARGETS	  FOR	  CLUSTERING	  ANALYSIS.	  NOTE	  THAT	  MOD	  IS	  A	  SUBSET	  OF	  POOR,	  HENCE	  ONLY	  PROTEINS	  
FROM	   THE	   POOR	   STAGE	   WERE	   EXPANDED.	   EXPANSION	   OF	   FIRST	   ORDER	   CANDIDATES	   HELPS	   TO	   CREATE	   A	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coverage	  but	  may	  give	  rise	  to	  compounded	  errors.	  Functional	  evaluation	  of	  edges	  in	  a	  PPIN	  is	  therefore	  an	  important	  ﬁrst	  step.	  We	  used	  the	  algorithm	  CMC	  to	  reduce	  the	  PPIN	  to	  only	  high	  confidence	  edges	  based	  on	  CD	  distance	  (Czekanowski-­‐Dice	  Distance)	  100.	  We	  also	  introduced	  a	  GO	  term	  coherence	  cut-­‐off	  as	  a	  second	  filter.	  	  Although	  in	  the	  cleaning	  process,	  about	  half	  of	  edges	  were	  lost,	  it	  corresponded	  to	  a	  3-­‐4	  fold	  enrichment	  for	  GO	  term	  coherence.	  While	  integration	  of	  several	  PPINs	  improved	  coverage,	  data	  quality	  is	  also	  important.	  We	  demonstrated	  here	  that	  by	  coupling	  integration	  to	  our	  data	  cleaning	  algorithm,	  there	  is	  an	  appreciable	  improvement	  (3	  to	  5	  times)	  in	  data	  quality.	  
	  
	  
FIGURE	  4	  NETWORK	  OF	  DIFFERENTIAL	  CANDIDATE	  PROTEINS	  IN	  MOD	  AND	  POOR.	  	  
NETWORK	   OF	   POOR	   PROTEINS	   SHOWS	   THE	   EMERGENCE	   OF	   A	   GIANT	   CONNECTED-­‐COMPONENT	   (GRAY	   AND	  
YELLOW	  NODES)	   BY	   OVERLAYING	   DIFFERENTIAL	   PROTEINS	   ONTO	  HPRD.	   SINCE	  MODS	   ARE	   A	   NEAR	   PERFECT	  
SUBSET	   OF	   POOR	   WE	   OVERLAID	   THE	   FORMER	   ONTO	   THIS	   NETWORK	   (YELLOW	   NODES)	   AND	   FOUND	   THAT	  
WHILE	  THERE	  APPEARED	  TO	  BE	  SOME	  POCKETS	  WHERE	  MOD	  PROTEINS	  TENDED	  TO	  AGGREGATE,	  WE	  FOUND	  
THAT	  OVERALL,	  POOR	  AND	  MOD	  PROTEINS	  ARE	  INTERSPERSED.	  
	  	   Mod and Poor Poor only 
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For	  brevity,	  we	  limit	  our	  discussion	  to	  the	  larger	  clusters,	  i.e.,	  overlapping	  cliques	  with	  a	  core	  comprised	  at	  least	  5	  to	  8	  proteins.	  Some	  smaller	  clusters	  might	  be	  meaningful	  and	  could	  be	  isolated	  through	  scoring	  function,	  but	  these	  were	  few	  and	  usually	  were	  subsets	  of	  a	  larger	  cluster.	  Moreover,	  larger	  clusters	  provided	  an	  initial	  list	  of	  higher	  confidence	  proteins	  that	  could	  aid	  in	  understanding	  the	  biological	  significance	  of	  the	  data.	  To	  build	  the	  clusters,	  all	  poor	  stage	  proteins	  found	  to	  be	  differential,	  and	  their	  first-­‐degree	  neighbors,	  were	  used	  (mod	  differential	  proteins	  are	  a	  subset	  of	  the	  poor	  differential	  proteins;	  Figure	  4).	  The	  top-­‐ranked	  clusters	  were	  found	  associated	  with	  expected	  functions	  such	  as	  stress,	  DNA	  damage,	  apoptosis	  and	  differentiation	  (Figure	  5A).	  One	  interesting	  cluster	  is	  the	  PRKDC	  cluster	  which	  comprised	  of	  six	  members,	  PRKDC,	  XRCC6,	  PCNA,	  XRCC5,	  WRN	  and	  PARP1	  (Figure	  5B,	  top	  left).	  XRCC5/6,	  and	  PCNA	  and	  PARP1	  are	  repair	  factors,	  while	  WRN	  is	  a	  nuclear	  protein	  that	  could	  be	  involved	  in	  maintaining	  genomic	  stability.	  PRKDC	  is	  a	  protein	  kinase	  that	  is	  capable	  of	  targeting	  p53,	  and	  found	  to	  be	  diﬀerential	  in	  a	  majority	  of	  poor	  patients	  (5	  out	  of	  7).	  It	  was	  interesting	  to	  note	  that	  the	  repair	  factors	  were	  all	  low	  count,	  between	  1	  to	  2	  patients	  each.	  It	  might	  be	  that	  mutations	  of	  these	  repair	  factors	  are	  crucial	  in	  affecting	  the	  functionality	  of	  this	  group	  of	  functionally	  close	  knitted	  proteins.	  In	  particular,	  these	  repair	  factors	  all	  appear	  to	  interact	  with	  PRKDC.	  Checking	  the	  cluster	  against	  a	  reference	  microarray	  database	  (Cancer	  Gene	  Expression	  Database146)	  	  indicated	  that	  the	  low	  count	  repair	  factors	  have	  been	  previously	  reported	  to	  be	  diﬀerentially	  expressed	  in	  earlier	  screens.	  This	  lends	  further	  support	  that	  the	  cluster	  identification	  can	  identify	  meaningful	  biological	  relationships	  and	  establish	  a	  functional	  context	  for	  our	  data.	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FIGURE	  5	  TOP	  6	  	  PEP	  CLUSTERS.	  	  
(A)	  IN	  THE	  CONTEXT	  OF	  THE	  NETWORK,	  FROM	  THE	  TOP	  DOWN	  VIEW,	  THE	  TOP	  SIX	  CLUSTERS	  (YELLOW	  NODES)	  
ARE	   SHOWN	  TO	  BE	  RELATED	  TO	  EACH	  OTHER.	  HIGHLIGHTED	   IN	  RED	  ARE	  THE	  LINKS	  OF	  CLUSTERS	  TO	  EACH	  
OTHER	  AND	  TO	  THE	  NETWORK.	  (B)	  THE	  CLUSTERS	  ARE	  THE	  TOP	  SIX	  RANKED	  CLUSTERS	  OBTAINED	  IN	  THE	  HCC	  
POOR	   STAGE.	   EACH	  CLUSTER	   CONSISTS	  OF	  BOTH	  MS-­‐DETECTED	  AND	  UNDETECTED	  PROTEINS.	   THE	  GO	  TERM	  
ANALYSIS	   REVEALS	   THAT	   MANY	   OF	   THE	   CLUSTERS	   ARE	   INVOLVED	   IN	   CANCER	   CAUSING	   EVENTS	   SUCH	   AS	  
APOPTOSIS	   AND	   CELL	   GROWTH.	   CALCULATION	   OF	   SCORES	   IN	   BOTH	   THE	   MOD	   AND	   POOR	   STAGE,	   AND	  
COMPARING	  THEIR	  RATIO	  ALLOWS	   IDENTIFICATION	  OF	  THE	  CLUSTERS	  MOST	   INVOLVED	   IN	  THE	  TRANSITION	  
EVENT.	  Only	  XRCC5	  was	  found	  to	  be	  differentially	  expressed	  by	  comparing	  the	  PRKDC	  cluster	  to	  the	  patient	  data	  in	  the	  mod	  stage.	  Taking	  the	  ratio	  between	  the	  scores	  in	  this	  cluster	  for	  both	  mod	  and	  poor	  revealed	  this	  cluster	  to	  have	  the	  greatest	  
A 
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score	  jump	  (that	  is,	  in	  poor,	  the	  score	  in	  poor	  is	  approximately	  10	  times	  greater	  than	  the	  mod	  stage).	  This	  cluster	  therefore	  appears	  to	  be	  important	  in	  the	  transition	  between	  mod	  and	  poor	  stage	  (Table	  4).	  The	  exact	  functional	  significance	  and	  its	  possible	  role	  in	  triggering	  liver	  cancer	  progression	  to	  the	  poor	  stage	  require	  further	  wet-­‐lab	  validation.	  	  
TABLE	   4	   CLUSTERS	  WITH	   HIGHEST	   SCORE	   JUMP	   RATIO.	   P_C	   –	   POOR	   COUNT,	  M_C	   –	  MOD	   COUNT,	   P_S	   –	   POOR	  
SCORE,	  M_S	  –	  MOD	  SCORE.	  
Clique p_C m_C p_S m_S Ratio Members 
K=6_0 5 1 3.74 0.38 9.7  PRKDC XRCC6 XRCC5 WRN PARP1 PCNA  
K=5_1 5 1 2.8 0.28 9.7  PRKDC TP53 XRCC6 XRCC5 WRN NCOA6 PARP1 
PCNA  
K=5_3 1 1 2.34 1.35 1.72  CHUK IKBKB MAP3K14 MAP3K7 PEBP1  
K=5_5 2 2 2.17 2.03 1.06  YWHAE YWHAZ CDC25A RAF1 MAP3K5  
K=6_5 4 3 2.16 1.09 1.97  ABL1 BCR CDKN1B YWHAB YWHAE YWHAG YWHAH 
SRC  
K=5_1 1 1 1.95 1.13 1.72  RAF1 MAP2K1 PRKCZ PRKCD PEBP1 MAPK1  
K=5_3 1 1 1.59 1.66 0.96  YWHAZ EGFR KRT18 CBL PRKCA  
K=5_4 3 1 1.4 1.03 1.34  YWHAH YWHAZ CDC42 PARD6A PRKCI PARD3 
PRKCG PARD6B  
K=5_2 1 1 1.1 0.28 3.82  TP53 PIAS4 SMAD3 SMAD2 KPNB1  	  We	  also	  found	  TP53	  in	  several	  high	  ranking	  clusters.	  TP53	  is	  well	  established	  in	  cancer	  but	  was	  not	  detected	  in	  the	  iTRAQ	  screen.	  TP53	  is	  a	  small	  protein	  of	  low	  abundance	  and	  detection	  of	  low	  abundant	  proteins	  by	  MS-­‐based	  proteomics	  has	  limited	  success.	  To	  this	  end,	  innovative	  protocols	  have	  emerged	  to	  improve	  the	  detection	  of	  low	  abundant	  proteins	  such	  as	  extensive	  fraction	  by	  MuDPIT147	  and	  targeted	  proteomics	  by	  MRM148.	  However,	  extensive	  time	  and	  resources	  are	  required	  before	  detecting	  such	  low	  abundant	  proteins	  is	  possible.	  As	  an	  alternative,	  our	  pipeline	  offers	  the	  prospect	  of	  detecting	  such	  proteins.	  4.3.4 RECOVERY	  OF	  CLIQUE	  PROTEINS	  FROM	  MS	  SPECTRA	  Based	  on	  the	  cliques	  isolated	  for	  analysis,	  we	  found	  a	  total	  of	  160	  unique	  proteins	  of	  interest.	  These	  were	  formed	  from	  14	  participating	  seed	  proteins.	  We	  combined	  Mascot-­‐	  and	  Paragon-­‐only	  proteins	  into	  an	  excess	  list	  and	  identified	  23	  of	  these	  in	  the	  cliques.	  However,	  this	  subset	  of	  23	  proteins	  did	  not	  possess	  any	  enrichment	  for	  ranks	  or	  ratio	  scores	  (Wilcoxon	  ranked	  sum	  test,	  P	  =	  0.512).	  	  Some	  MS	  spectra	  may	  match	  to	  a	  particular	  protein,	  but	  because	  their	  scores	  were	  below	  the	  defined	  cutoff	  threshold	  they	  may	  not	  be	  reported	  initially	  in	  the	  first	  round	  of	  data	  analysis.	  	  Our	  bioinformatics	  pipeline	  by	  improving	  the	  coverage	  of	  protein	  communities	  could	  have	  highlighted	  these	  proteins.	  In	  an	  iterative	  approach,	  we	  are	  empowered	  now	  to	  return	  to	  the	  original	  MS/MS	  spectra	  to	  look	  for	  evidence	  to	  support	  the	  existence	  of	  these	  recovered	  clique	  proteins.	  	  There	  are	  a	  few	  reasons	  for	  not	  reporting	  these	  proteins	  in	  the	  initial	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round	  of	  data	  analysis	  –	  1)	  they	  did	  not	  satisfy	  the	  two	  unique	  peptides	  requirement,	  that	  is	  protein	  identification	  by	  a	  single	  peptide,	  2)	  they	  were	  identified	  by	  short	  peptides	  and/or	  3)	  they	  were	  not	  consistently	  found	  in	  the	  patients.	  To	  this	  end,	  we	  selected	  several	  proteins	  (ACTR2,	  CDC42,	  GNB2L1,	  KIF5B,	  PPP2R1A,	  PKACA	  and	  TOP1)	  from	  the	  top	  34	  cliques/chains	  and	  not	  detected	  by	  Paragon,	  and	  manually	  examined	  their	  GPS	  and	  Mascot	  search	  results	  and	  also	  their	  MS/MS-­‐to-­‐peptide	  assignments	  to	  verify	  the	  legitimacy	  of	  the	  predictions.	  Assessment	  of	  MS/MS	  spectra	  of	  their	  top	  ranked	  peptides	  revealed	  accurate	  y	  and	  b	  ion	  assignments	  and	  were	  of	  good	  quality	  (Expectation	  value	  <	  0.05)	  supporting	  and	  verifying	  the	  in	  silico	  expansion	  (Supplementary	  Figure	  3);	  with	  the	  exception	  of	  KIF5B	  whose	  top	  scoring	  peptide	  had	  an	  Expectation	  value	  of	  >	  0.05.	  PKACA	  could	  not	  be	  found	  in	  any	  of	  the	  12	  patients,	  possibly	  due	  to	  the	  Mascot	  peptide	  significance	  P-­‐value	  >	  0.05.	  Proteins	  of	  low	  copy	  numbers	  and	  high	  cellular	  turnover	  such	  as	  transcription	  factors	  and	  protein	  kinases	  however	  still	  cannot	  be	  found	  through	  retrospective	  assessment	  of	  original	  MS/MS	  data	  and	  highlighted	  the	  utility	  of	  our	  bioinformatics	  pipeline	  in	  circumventing	  such	  challenging	  MS	  tasks.	  4.3.5 CHAINED-­‐BASED	  ANALYSIS	  SUPPORTS	  CLUSTER-­‐BASED	  ANALYSIS	  BUT	  REVEALS	  MANY	  MORE	  FUNCTIONAL	  RELATIONSHIPS	  Cluster	  based	  analysis	  showed	  that	  the	  DNA	  damage	  cluster	  was	  most	  pertinent	  in	  the	  poor	  stage	  relative	  to	  the	  mod	  stage,	  exhibiting	  the	  largest	  jump	  in	  score	  ratio.	  Ranking	  the	  top	  scoring	  pathways	  in	  the	  poor	  stage	  showed	  that	  the	  top	  ranking	  pathways	  included	  mostly	  detoxiﬁcation	  and	  metabolic	  pathways.	  It	  would	  appear	  therefore	  chain	  and	  cluster–based	  analysis	  yielded	  different	  results.	  A	  closer	  check	  against	  the	  top	  clusters	  GO	  terms	  against	  significant	  pathways	  in	  poor	  revealed	  that	  it	  was	  not	  so.	  The	  top	  PRKDC	  cluster	  was	  mapped	  to	  stress	  responses	  (P	  =	  3.09E-­‐11).	  Significant	  pathways	  in	  poor	  include	  Oxidative	  stress,	  FAS	  pathway	  and	  Stress	  induction	  of	  HSP	  regulation,	  and	  ER	  stress	  responses.	  The	  PEBP1	  cluster,	  also	  highly	  ranked	  in	  our	  list,	  comprising	  members	  PEBP1,	  AKT1,	  ESR1,	  HSP90AA1,	  CHUK,HSP90AB1,	  HSPA8,MAP3K7,	  CASP8,	  MAP3K8,	  SRC,	  TBK1,	  MAP3K14,	  IKBKB,	  IKBKG	  and	  NFKB2	  corresponded	  to	  the	  term	  “nuclear	  receptor”.	  Interestingly,	  this	  set	  of	  proteins	  is	  also	  implicated	  in	  stress	  responses	  and	  immune	  response	  to	  infection.	  This	  is	  of	  particular	  relevance	  since	  the	  liver	  cancer	  subtype	  being	  considered	  is	  hepatitis	  induced.	  We	  also	  uncovered	  apoptosis-­‐associated	  clusters,	  which	  matched	  to	  apoptotic	  pathways	  in	  the	  poor	  stage	  (RAF1,MAP3K5,YWHAZ,CDC25A,YWHAE	  and	  	  ABL1,	  BCR,	  YWHAB,	  YWHAH,	  SRC,YWHAE	  and	  YWHAG).	  Proteins	  involved	  with	  focal	  adhesions,	  cell-­‐cell	  junctions	  and	  adherens	  which	  were	  strongly	  represented	  in	  the	  PARD	  cluster	  (CDC42,	  RAC1,	  YWHAH,	  PRKCI,	  YWHAZ,	  PARD3,	  PRKCG,	  PARD6A	  and	  PARD6B)	  were	  also	  found	  in	  the	  poor	  list.	  	  The	  good	  correspondence	  between	  top	  cluster	  GO	  annotation	  and	  signiﬁcant	  pathways	  suggested	  that	  the	  results	  were	  congruent.	  However,	  the	  chains	  revealed	  that	  cluster	  analysis	  has	  several	  limitations	  in	  understanding	  the	  functional	  and	  biological	  differences	  between	  the	  two	  stages.	  Because	  cluster	  analysis	  does	  not	  consider	  the	  functional	  biological	  units	  a	  priori,	  it	  is	  limited	  by	  the	  size	  cut-­‐oﬀ	  for	  the	  clusters.	  Moreover,	  if	  many	  of	  the	  relationships	  do	  not	  exist	  in	  at	  least	  a	  clique	  of	  size	  3,	  it	  would	  not	  be	  detectable.	  Chain	  analysis,	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however,	  was	  not	  as	  useful	  in	  yielding	  novel	  target	  proteins,	  or	  unveiling	  new	  interactions,	  as	  they	  are	  already	  well	  studied	  to	  begin	  with.	  	  4.3.6 CHAIN	  BASED	  ANALYSIS	  REVEALS	  CANCER	  PROGRESSION	  MAINLY	  OCCURS	  IN	  MOD	  STAGE	  WHILE	  POOR	  STAGE	  EXHIBITS	  MOST	  DAMAGE-­‐SPECIFIC	  EFFECTS	  	  HCC	  progression	  can	  be	  categorized	  into	  three	  stages	  –	  (i)	  well-­‐differentiated,	  where	  HCC	  cells	  resemble	  hepatocytes,	  are	  hypovascularised	  and	  considered	  the	  early	  form	  of	  HCC,	  (ii)	  poorly	  differentiated,	  which	  is	  characterized	  by	  diffused	  growth	  suggesting	  advanced	  HCC	  progression	  and	  (iii)	  moderate	  HCC,	  which	  is	  an	  intermediate	  stage	  between	  the	  two.	  We	  compared	  pathways	  that	  are	  shared	  in	  both	  mod	  and	  poor,	  and	  ranked	  them	  by	  their	  scores	  to	  obtain	  a	  list	  of	  pathways	  most	  affected	  in	  the	  mod	  stage,	  and	  poor	  stage	  respectively.	  For	  pathways	  that	  are	  significantly	  common	  (P	  ≤	  0.05)	  in	  both	  mod	  and	  poor,	  deregulation	  of	  the	  cytoskeleton,	  cell-­‐cell	  interactions	  and	  immune	  responses	  are	  strongly	  represented.	  In	  the	  mod	  stage	  only	  pathway	  list	  (Table	  5),	  there	  appears	  to	  be	  strong	  enrichment	  for	  immune-­‐specific	  responses.	  These	  include	  pathways	  involved	  in	  antigen	  presentation	  and	  processing,	  T-­‐cell	  receptor	  signaling,	  and	  proteins	  involved	  with	  InterLeukin-­‐2/4	  and	  interferon	  pathways.	  Differential	  proteins	  found	  in	  these	  pathways	  may	  be	  able	  to	  provide	  suitable	  marker	  candidates	  for	  early	  detection	  for	  patients	  that	  have	  yet	  to	  develop	  to	  mod	  stage.	  HCC	  is	  a	  complex,	  multistep	  process	  that	  commonly	  develops	  against	  a	  cirrhotic	  background	  (largest	  risk	  factor)	  that	  arises	  from	  chronic	  liver	  inflammation.	  HBV	  and	  HCV	  infection	  are	  known	  etiological	  factors	  to	  HCC,	  accounting	  for	  approximately	  80%	  of	  all	  HCC	  cases128.	  	  Patients	  who	  are	  seropositive	  with	  chronic	  HBV	  infection	  are	  5	  to	  15-­‐fold	  more	  likely	  to	  develop	  HCC149.	  HBV	  and	  HCV	  infections	  induce	  liver	  inflammation	  by	  continuous	  cycle	  of	  hepatocyte	  death	  and	  their	  regeneration.	  This	  leads	  to	  the	  development	  of	  chronic	  hepatitis,	  liver	  ﬁbrosis	  and	  cirrhosis,	  eventually	  leading	  to	  HCC.	  In	  particular	  HCV	  RNA	  and	  core	  proteins	  have	  been	  implicated	  in	  T-­‐cell	  activation150	  and	  evade	  immune-­‐mediated	  cell	  death	  by	  interactions	  with	  Interferon-­‐α151.	  HCV	  core	  proteins	  have	  also	  been	  shown	  to	  interact	  with	  MAPK	  signaling	  to	  modulate	  cell	  proliferation.	  Our	  results	  that	  inflammation-­‐associated	  pathways	  were	  overrepresented	  were	  in	  line	  with	  the	  conjecture	  that	  chronic	  inflammation	  drives	  hepatocytes	  to	  a	  malignant	  phenotype	  into	  the	  mod	  stage.	  Major	  signaling	  pathways	  activated	  during	  HCC	  progression	  include	  Insulin/IGF-­‐1/IRS-­‐1/MAPK	  and	  Wnt/Frizzled/beta-­‐catenin	  signaling152.	  
TABLE	  5	  PATHWAYS	  UNIQUE	  TO	  MOD	  STAGE.	  
Mod Only Pathway  
Antigen processing and presentation - Homo sapiens (human)  
Cell adhesion molecules (CAMs) - Homo sapiens (human)  
FGF Signaling  
Id Signaling Pathway  
IL-2 Signaling  
IL-4 Signaling  
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Insulin Recpetor Signaling  
Interferon type I  
mTOR signaling pathway - Homo sapiens (human)  
Natural killer cell mediated cytotoxicity - Homo sapiens (human)  
Neurotrophin/TRK Signaling  
Peptidoglycan biosynthesis - Homo sapiens (human)  
T-cell receptor Signaling  
Triacylglyceride Synthesis  
Vitamin B6 metabolism - Homo sapiens (human)  	  
TABLE	  6	  PATHWAYS	  UNIQUE	  TO	  POOR	  STAGE.	  
Poor Only pathway  
Alkaloid biosynthesis II - Homo sapiens (human)  
C21-Steroid hormone metabolism - Homo sapiens (human)  
Cell Cycle-G2M DNA Damage Checkpoint Regulation  
D-Arginine and D-ornithine metabolism - Homo sapiens (human)  
Eicosanoid Synthesis  
Ether lipid metabolism - Homo sapiens (human)  
G1 to S cell cycle control  
Glucocorticoid & Mineralcorticoid Metabolism  
Glycerophospholipid metabolism - Homo sapiens (human)  
Glycogen Metabolism  
Jak-STAT signaling pathway - Homo sapiens (human)  
Monoterpenoid biosynthesis - Homo sapiens (human)  
Nuclear Receptors  
Pantothenate and CoA biosynthesis - Homo sapiens (human)  
Riboflavin metabolism - Homo sapiens (human)  
Selenium metabolism/Selenoproteins  
Steroid Biosynthesis  	  Our	  analysis	  found	  the	  enrichment	  of	  MAPK	  and	  Wnt	  signaling	  pathways	  in	  both	  mod	  and	  poor,	  confirming	  evidence	  that	  aberrant	  signaling	  of	  these	  two	  important	  signaling	  cascades	  help	  shape	  cancer	  transformation.	  Inflammation	  induces	  oxidative	  stress	  and	  the	  latter	  is	  another	  important	  factor	  contributing	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towards	  HCC.	  We	  did	  not	  ﬁnd	  oxidative	  stress	  in	  the	  top	  20;	  however	  it	  ranked	  67	  (P	  =	  1.27E-­‐10)	  in	  mod	  and	  87	  in	  poor	  (P	  =	  2.20E-­‐13;	  data	  not	  shown).	  Signaling	  pathways	  such	  as	  mTOR,	  insulin	  and	  MAPK	  are	  known	  to	  contribute	  to	  cancer	  metabolic	  transformation.	  In	  poor	  only	  pathways,	  there	  was	  enrichment	  in	  metabolic	  pathways	  (Table	  6).	  Histologically,	  HCC	  is	  classified	  as	  poor	  when	  specimens	  are	  noted	  to	  be	  highly	  vascularised	  and	  suggest	  advanced	  HCC	  progression.	  To	  the	  extent	  that	  several	  metabolic	  processes	  were	  over-­‐represented,	  we	  reasoned	  that	  the	  observed	  perturbation	  in	  metabolic	  pathways	  represented	  a	  gross	  effect	  on	  the	  transformed	  liver	  cells	  beyond	  a	  “threshold	  of	  no	  return”.	  In	  addition,	  they	  may	  confer	  an	  advantage	  that	  promotes	  the	  survivability	  of	  tumor	  cells153.	  This	  metabolic	  transformation	  creates	  a	  phenotype	  for	  sustained	  tumor	  growth	  and	  survival,	  cell-­‐death	  signals	  resistance	  as	  characterized	  by	  the	  histological	  features	  of	  poorly	  diﬀerentiated	  HCC.	  Increased	  amino	  acid	  synthesis,	  lipid	  metabolism	  and	  synthesis	  were	  found	  enriched	  in	  poor.	  In	  conjunction	  with	  perturbations	  in	  G1	  to	  S	  cell	  cycle	  control	  (and	  G2M	  DNA	  damage	  checkpoint	  regulation;	  Table	  6),	  these	  observations	  suggest	  that	  amino	  acids	  and	  lipids	  synthesis	  are	  modulated	  for	  the	  actively	  dividing	  tumor	  cells.	  Interestingly,	  eicosanoids	  are	  known	  to	  promote	  secretion	  of	  angiogenic	  factors.	  Angiogenesis	  and	  vasculogenesis	  implement	  the	  formation	  of	  the	  vascular	  network	  characteristic	  of	  poorly	  diﬀerentiated	  HCC.	  Eicosanoids	  such	  as	  prostaglandins	  and	  leukotrienes	  modulate	  angiogenesis	  at	  diﬀerent	  levels154	  and	  our	  data	  are	  congruent	  with	  this	  observation.	  	  	  4.3.7 CHAIN	  DISTANCES	  IN	  MOD	  AND	  POOR	  REVEALS	  KEY	  ROLES	  IN	  IL-­‐2	  SIGNALING	  AND	  MONOTERPENOID	  BIOSYNTHESIS	  RESPECTIVELY	  	  In	  mod,	  the	  integrated	  network	  revealed	  that	  IL-­‐2	  signaling	  pathway	  appeared	  closely	  associated	  with	  many	  growth-­‐signaling	  pathways	  such	  as	  TGF-­‐β,	  PDGF,	  EGF	  and	  hepatocyte	  growth	  factor	  signaling.	  It	  is	  also	  closely	  associated	  to	  cancer	  associated	  signaling	  pathways	  such	  as	  Jak-­‐Stat,	  as	  well	  as	  the	  stress-­‐signaling	  pathway,	  SAPK/JNK.	  This	  suggests	  that	  the	  mod	  specific	  IL-­‐2	  pathway	  is	  important,	  and	  possibly	  quite	  involved	  in	  cancer	  progression.	  In	  poor,	  it	  appears	  that	  many	  of	  the	  metabolic	  process	  such	  as	  arachidonic	  acid,	  linoleic	  acid,	  as	  well	  as	  anti-­‐toxicity	  processes	  such	  as	  drug	  metabolism	  (CYP-­‐P450),	  tetrachloroethane	  degradation,	  and	  styrene	  degradation	  are	  closely	  associated	  with	  the	  monoterpenoid	  synthesis	  pathway.	  The	  latter	  does	  not	  appear	  to	  be	  significantly	  involved	  in	  cancer.	  However,	  this	  pathway,	  and	  its	  constituent	  proteins	  may	  be	  closely	  related	  to	  many	  of	  the	  damage-­‐associated	  events	  observed	  in	  poor.	  We	  also	  observed	  a	  close	  connection	  between	  p53	  signaling	  (significantly	  present	  in	  both	  mod	  P	  =	  4.32E-­‐05	  and	  poor	  P	  =	  9.24E-­‐08)	  and	  the	  Cell	  Cycle-­‐G2M	  DNA	  Damage	  Checkpoint	  Regulation,	  which	  was	  significantly	  enriched	  in	  the	  poor	  stage	  (P	  =	  0.017).	  4.4 REMARKS	  The	  integration	  of	  networks	  and	  pathways	  with	  proteomic	  data	  generated	  from	  iTRAQ	  2DLC-­‐MS/MS	  enhanced	  our	  understanding	  of	  the	  functional	  relationships	  of	  proteome	  changes	  during	  HCC	  progression.	  Using	  our	  developed	  pipeline	  on	  HCC	  samples,	  we	  were	  able	  to	  expand	  the	  proteomic	  data	  to	  recover	  common	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neighbors.	  This	  in	  turn	  made	  it	  possible	  to	  expand	  the	  set	  of	  deregulated	  biological	  pathways.	  By	  applying	  both	  cliques	  and	  chains	  analyses	  our	  results	  suggest	  that	  HCC	  late	  stage	  is	  characterized	  by	  heavy	  metabolic	  defects	  which	  may	  be	  related	  to	  the	  large	  scale	  tissue	  damage	  characteristic	  of	  HCC.	  It	  also	  implies	  that	  intervention	  at	  the	  moderate	  stage	  is	  important	  in	  preventing	  further	  irreversible	  damage.	  	  This	  offers	  the	  opportunity	  to	  better	  characterize	  tumor	  proteomes	  of	  a	  small	  sample	  set	  and	  can	  be	  used	  for	  informed	  clinical	  decision-­‐making	  for	  individual	  cases.	  We	  also	  examined	  the	  possibility	  of	  integrating	  the	  outputs	  of	  several	  database	  search	  algorithms	  in	  enhancing	  the	  protein	  list	  for	  analysis.	  Although	  we	  found	  that	  the	  protein	  set	  in	  Mascot	  was	  largely	  covered	  by	  the	  Paragon,	  the	  large	  excess	  list	  in	  Paragon	  turned	  out	  to	  be	  of	  lower	  confidence.	  Given	  that	  the	  overlaps	  between	  Mascot	  and	  Paragon	  were	  strongly	  linearly	  correlated,	  it	  indicated	  that	  despite	  different	  approaches,	  they	  generally	  give	  rise	  to	  similar	  results.	  In	  future	  work,	  it	  may	  be	  worth	  exploring	  combining	  the	  results	  of	  even	  more	  database	  search	  algorithms	  to	  improve	  the	  confidence	  level	  of	  the	  protein	  set	  despite	  the	  time	  consuming	  searches.	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5 IMPROVING	  COVERAGE	  VIA	  AN	  ASSOCIATION-­‐BASED	  METHOD:	  	  MAXLINK	  
Brief	  summary	  and	  key	  points	  
• PPINs	  have	   a	   fairly	   high	   level	   of	   false	   positives	   and	   false	  negatives.	   This	  has	   an	   impact	   on	   the	   sensitivity	   of	   clique	   finding	   and	   other	   protein	  complex	   prediction	   algorithms	  mentioned	   earlier.	   For	   example,	   a	   single	  missing	  edge	  in	  the	  PPIN	  is	  sufficient	  to	  exclude	  a	  protein	  from	  a	  clique	  in	  clique	  finding.	  
• To	   achieve	   greater	   sensitivity,	   rather	   than	   requiring	   an	   entire	   protein	  complex	  to	  be	  predicted	  before	  testing	  for	  enrichment	  in	  high-­‐confidence	  proteins,	  one	  can	  test	  for	  a	  more	  relaxed	  condition.	  In	  particular,	  one	  can	  instead	  test	  whether	  a	  protein	  is	  likely	  to	  be	  part	  of	  the	  same	  complex	  with	  a	   group	   of	   already	   known	   high-­‐confidence	   proteins,	   without	   requiring	  knowing	  what	  the	  other	  proteins	  in	  the	  complex	  are.	  
• Maxlink	   is	   a	   method	   for	   identifying	   cancer	   genes.	   It	   first	   requires	   the	  identification	   of	   a	   set	   of	   high-­‐confidence	   seeds.	   It	   then	   generates,	   scores	  and	   ranks	   a	   list	   of	   new	   candidates	   based	   on	   the	   number	   of	   links	   in	  FunCoup	  (which	  is	  a	  PPIN	  database)	  to	  the	  seed	  set.	  The	  more	  the	  number	  of	  connections	  to	  seeds,	  and	  the	  fewer	  the	  number	  of	  connections	  to	  non-­‐seeds,	  the	  higher	  the	  score.	  This	  approach	  is	  justified	  because	  a	  protein	  is	  often	   observed	   to	   participate	   in	   the	   same	   biological	   process,	   biological	  function,	   or	   protein	   complex	   that	   is	   over-­‐represented	   in	   its	   interaction	  partners.	   Moreover,	   proteins	   in	   the	   same	   complex	   are	   thought	   to	   have	  more	   interactions	   between	   themselves	   than	   with	   proteins	   outside	   the	  complex.	  
• We	  applied	  Maxlink	  to	  our	  HCC	  dataset.	  	  There	  are	  two	  insights	  from	  this	  analysis.	   First,	   the	   process	   of	   network	   cleaning	  provides	   a	   list	   of	   higher	  quality	   linked	   proteins,	  which	   are	   highly	   enriched	   for	   similar	   biological	  process	   Gene	   Ontology	   terms.	   Linked	   proteins	   are	   also	   enriched	   for	  known	   cancer	   genes	   and	   are	   linked	   to	   many	   well-­‐established	   cancer	  processes	   such	   as	   apoptosis	   and	   immune	   response.	   Secondly,	  we	   found	  that	  there	  is	  an	  increased	  propensity	  for	  known	  cancer	  genes	  to	  be	  found	  amongst	   highly	   linked	   proteins.	   Three	   highly-­‐linked	   proteins	   were	  identified	  that	  may	  play	  an	   important	  role	   in	  driving	  HCC	  progression—the	   G-­‐protein	   coupled	   receptor	   signaling	   proteins,	   ARRB1/2	   and	   the	  structural	   protein	   beta-­‐actin,	   ACTB.	   Interestingly,	   both	   ARRB	   proteins	  evaded	   detection	   in	   the	   iTRAQ	   screen.	   ACTB	   was	   not	   detected	   in	   the	  original	   dataset	   derived	   from	   Mascot	   but	   was	   found	   to	   be	   strongly	  supported	   when	   we	   re-­‐ran	   analysis	   using	   another	   protein	   detection	  database	  (Paragon).	  
• This	   form	   of	   network-­‐based	   analysis	   complements	   cluster-­‐based	  approaches	  such	  as	  CEA	  and	  PEP,	  and	  can	  provide	  a	  larger	  list	  of	  proteins	  on	   which	   to	   perform	   functional	   analysis,	   as	   well	   as	   for	   biomarker	  identification.	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5.1 INTRODUCTION	  In	   Chapter	   4,	   I	   proposed	   a	   powerful	   complex	   prediction	   algorithm	   termed	   the	  Proteomics	  Expansion	  Pipeline	  (PEP)	  69.	  The	  PEP	  approach	  is	  largely	  focused	  on	  cluster	   discovery	   and	   analysis,	   as	  well	   as	   recovery	   of	   low	   abundance	   and	   low	  confidence	  proteins.	  However,	  there	  are	  other	  network-­‐based	  approaches	  which	  can	  be	  applied	  on	  the	  cleaned	  PPIN.	  This	  may	  produce	  results	  that	  can	  augment	  our	   existing	   findings.	  More	   interestingly,	   it	  may	   reveal	   insights	   that	   have	   been	  missed.	  One	  approach	  is	  Maxlink,	   introduced	  by	  Ostlund	  et	  al.	  71.	   It	   is	  a	  method	  for	   identifying	  novel	  cancer	  genes	  based	  on	  a	  given	  set	  of	   identified	  oncogenes.	  Maxlink	   first	   requires	   a	   set	   of	   oncogenes	   (seeds)	   to	   be	   identified	   based	   on	  literature	  search	  and	  the	  Cancer	  Gene	  Census	  155.	  It	  then	  produces	  a	  ranked	  list	  of	  new	  candidate	  genes	  based	  on	  the	  number	  of	  links	  they	  have	  in	  the	  FunCoup	  PPIN	  database	  156	  to	  the	  seed	  set.	  The	  higher	  the	  number	  of	  connections	  to	  seeds,	  with	   concomitant	   disconnections	   to	   non-­‐seeds,	   the	   higher	   the	   rank.	   This	  approach	   relies	   on	   two	   reasonable	   hypotheses.	   The	   first	   hypothesis	   is	   that	   a	  protein	  should	  participate	  in	  the	  same	  biological	  processes,	  biological	  functions,	  or	   protein	   complexes	   that	   are	   over-­‐represented	   among	   its	   interaction	  partners157,	   158.	   The	   second	   hypothesis	   is	   that	   proteins	   in	   the	   same	   complex	  should	  have	  more	   interactions	  between	   themselves	   than	  with	  proteins	  outside	  the	  complex	  159.	  Maxlink	  has	  not	  yet	  been	  explicitly	  tested	  on	  proteomics	  data.	   In	  this	  work,	  we	  apply	  a	  Maxlink-­‐type	  approach	  on	  the	  HCC	  proteomics	  data	  (Chapter	  3).	  5.2 METHODS	  5.2.1 SELECTION	  OF	  SEED	  PROTEINS	  A	  seed	   is	  defined	  as	  meeting	   the	   following	  requirements:	  Support	  by	  at	   least	  4	  poor	   patients,	   and	   with	   a	   combined	   differential	   score	   ≥	   1.2.	   The	   combined	  differential	  score	  is	  calculated	  as	  the	  average	  score	  of	  the	  protein	  ratios	  (tumour	  over	  self-­‐non-­‐tumour).	  If	  the	  ratio	  is	  below	  1	  (under-­‐expressed),	  the	  reciprocal	  is	  used.	  5.2.2 NETWORK	  INTEGRATION	  AND	  CLEANING	  An	  integrated	  PPIN	  was	  built	  consisting	  of	  data	  from	  HPRD	  56,	  BioGRID	  54,	  IntAct	  57,	  and	  DIP	  55,	  137,	  138,	  as	  well	  as	  data	  from	  literature	  107,	  108.	  The	  various	  IDs	  were	  mapped	  using	  BioMart	  to	  gene	  names.	  This	  network	  was	  then	  filtered	  using	  the	  iterated	  CD-­‐distance	  method	  from	  CMC	  100,	  and	  the	  top	  90%	  of	  the	  highest	  non-­‐zero	   scoring	   edges	   are	   kept.	   The	   resultant	   combined	   network	   displayed	   the	  properties	   of	   a	   typical	   PPIN	   such	   as	   a	   power-­‐law	   distribution	   of	   the	   degrees,	  disassortativity	   (hubs	   less	   likely	   to	   be	   linked	   to	   each	   other)	   and	   small-­‐world	  (small	  diameter)	  (data	  not	  shown).	  5.2.3 IDENTIFICATION	  OF	  LINKED	  PROTEINS	  Let	  the	  network	  G	  be	  comprised	  of	  nodes	  V	  and	  edges	  E.	  From	  the	  set	  of	  seeds	  X	  ⊆	  V	  ,	  the	  set	  of	  non-­‐seeds	  Y	  is	  derived	  (Y	  =	  V	  −	  X).	  The	  set	  of	  linked	  proteins	  L	  are	  those	  proteins	  in	  Y	  that	  have	  at	  least	  1	  connection	  to	  proteins	  in	  X.	  That	  is,	  L	  =	  {y	  ∈	  Y	  |	  1	  ≤	  |{x	  ∈	  X	  |	  (x,	  y)	  ∈	  E}|}.	  5.2.4 GENE-­‐ONTOLOGY	  (GO)-­‐BASED	  CHARACTERIZATION	  AND	  COHERENCE	  MEASUREMENT	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Annotation	   and	   the	   GO	   tree	   (ver	   1.2	   OBO)	   files	   for	   Homo	   Sapiens	   were	  downloaded	  from	  geneontology.org	  (dated	  23	  April	  2011).	  UniProtKB	  accessions	  were	  mapped	   to	   Ensembl	   Gene	   IDs	   and	   gene	   names	   via	   Biomart.	   Informative	  biological	  process	  terms	  were	  extracted	  from	  the	  GO	  OBO	  file;	  as	  in	  Zhou	  et	  al.	  160,	  a	   term	   is	   considered	   informative	   if	   it	   is	   annotated	   to	   at	   least	   30	   genes	   and	  no	  direct	   descendant	   of	   the	   term	   is	   annotated	   to	   at	   least	   30	   genes.	   Significance	  testing	   for	   each	   cluster	   was	   performed	   using	   the	   hypergeometric	   test	   with	  Bonferroni	  correction	  (p	  ≤	  0.05).	  To	   evaluate	   the	   quality	   of	   linked	   proteins	   derived	   from	   the	   cleaned	   and	  uncleaned	   integrated	   network,	  we	  measured	  Gene	  Ontology	  Biological	   Process	  (BP),	  Cellular	  Component	  (CC)	  and	  Molecular	  Function	  (MF)	  term	  coherence	  for	  every	  edge	  –-­‐-­‐	  i.e.,	  a	  seed	  protein	  connected	  to	  a	  linked	  protein	  –-­‐-­‐	  derived	  from	  the	   cleaned	   and	   uncleaned	   network.	   Edge	   coherence	   is	   calculated	   by	   counting	  the	  number	  of	   shared	  GO	   terms	   in	   each	   category	   for	   every	  GO-­‐annotated	   edge	  divided	  by	  the	  total	  number	  of	  considered	  edges.	  5.3 RESULTS	  5.3.1 IDENTIFICATION	  OF	  LINKED	  PROTEINS	  AND	  THE	  IMPORTANT	  EFFECTS	  OF	  NETWORK	  CLEANING	  The	  overall	  pipeline	  and	  concepts	  are	  shown	  and	  summarized	   in	  Figure	  6.	  235	  seeds	   were	   returned	   from	   the	   dataset.	   From	   the	   cleaned	   dataset,	   288	   linked	  proteins	  were	  found	  to	  share	  at	  least	  one	  other	  connection	  with	  a	  seed.	  From	  the	  uncleaned	  dataset,	  902	  linked	  proteins	  were	  returned.	  
	  
FIGURE	  6	  MAXLINK	  OVERVIEW.	  	  
(A)	  OVERVIEW	  OF	  ANALYTICAL	  PIPELINE.	   TWO	   SETS	  OF	  NETWORKS	  ARE	  USED;	   A	   CLEANED	  AND	  UNCLEANED	  
NETWORK,	   TO	   DISCOVER	   LINKED	   PROTEINS	   UNDETECTED	   BY	   THE	   MS	   SCREEN.	   THE	   RESULTS	   ARE	   THEN	  
COMPARED	   USING	   GO	   COHERENCE	   MEASUREMENTS	   AND	   RANKS	   CORRELATION	   ANALYSIS.	   THE	   SET	   OF	  
INTERESTING	   LINKED	   PROTEINS	   ARE	   THEN	   FUNCTIONALLY	   ANNOTATED	   USING	   GO	   TERMS.	   (B)	   A	   CLEANED	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NETWORKS	   ARE	   TOO	   COMPLEX	   TO	   VISUALISE.	   (C)	   AN	   EXAMPLE	   OF	   A	   MAXLINKED	   PROTEIN	   (BLUE).	   A	  
MAXLINKED	   PROTEIN	   IS	   ONE	   THAT	   IS	   HIGHLY	   CONNECTED	   TO	   DETECTED	   DIFFERENTIALLY	   EXPRESSED	  
PROTEINS	  We	   then	   built	   two	   sets	   of	   derived	   networks	   from	   cleaned	   and	   uncleaned	  networks,	   obtaining	   edges	   formed	   between	   seed	   and	   linked	   proteins	   (seed	   +	  linked)	   from	  the	  reference	   integrated	  PPIN,	  and	  checked	  the	  extent	  of	  GO	  term	  sharing.	   It	   is	   observed	   that	   the	   cleaned	   network	   boasts	   much	   higher	   quality	  edges	  where	  the	  joined	  nodes	  tend	  to	  have	  deep	  sharing	  of	  GO	  terms.	  Hence,	  the	  linked	   proteins	   derived	   from	   the	   cleaned	   network	   are	   likely	   to	   be	   more	  biologically	  relevant.	  The	  improvement	  in	  quality	  as	  a	  result	  of	  the	  cleaning	  step	  is	  observed	  to	  be	  at	  least	  two	  fold;	  see	  Table	  7.	  
TABLE	  7	  GO	  TERM	  COHERENCE	  OF	  LINKED	  PROTEINS	  DERIVED	  FROM	  CLEANED	  AND	  UNCLEANED	  NETWORKS.	  
	  To	  see	  whether	  the	  improvement	  in	  the	  three	  GO	  categories	  (biological	  process	  –	  BP,	  Molecular	  Function	  –	  MF	  and	  Cellular	  Localisation	  –	  CC)	  is	  greater	  than	  the	  network	   generally,	   we	   calculated	   the	   log	   odds	   ratio,	   i.e.,	   seed+linked	   from	  cleaned	   network/	   seed+linked	   from	   uncleaned	   network	   divided	   over	   total	  cleaned/total	   uncleaned	  network.	   Interestingly,	   there	  was	   a	  1.5X	   enhancement	  for	  BP	  terms	  whereas	  there	  were	  no	  improvements	  for	  MF	  (1.02X)	  and	  CC	  terms	  (1.02X).	   This	   indicates	   that	   the	   cleaned	   seed+linked	   protein	   network	   is	   highly	  enriched	   for	   proteins	   in	   shared	   biological	   processes.	   The	   significant	  enhancement	   of	   GO	   term	   coherence	   in	   the	   cleaned	   network	   indicates	   that	   the	  cleaning	   step	   is	   important.	   It	   also	   improves	   analytical	   results	   in	   combination	  with	  the	  Maxlink	  approach.	  There	  appears	  to	  be	  a	  strong	  linear	  correlation	  between	  the	  ranks	  of	  the	  linked	  proteins	  (sorted	  in	  descending	  order	  by	  the	  number	  of	  connections	  to	  seeds)	  in	  the	  cleaned	  and	  uncleaned	  networks;	  Figure	  7.	  This	  is	  evident	  from	  the	  string	  of	  points	   forming	   a	   near	   perfect	   diagonal	   and	   is	   not	   particularly	   surprising.	  However,	  it	  can	  also	  be	  seen	  that	  a	  large	  number	  of	  points	  are	  ranked	  below	  the	  diagonal.	   This	   means	   that	   they	   are	   ranked	   relatively	   higher	   than	   they	   would	  actually	  be	  after	  the	  cleaning	  step.	  It	  also	  means	  that	  the	  cleaned	  linked	  proteins	  are	   enriched	   for	   linked	   proteins	   with	   high	   ranks	   from	   the	   poor	   network.	  Although	   this	   is	   less	  direct	  evidence	   than	  measuring	  GO	  coherence	  as	  above,	   it	  does	  demonstrate	  the	  efficacy	  and	  relevance	  of	  the	  cleaning	  procedure.	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FIGURE	  7	  RANKS	  CORRELATIONS	  BETWEEN	  CLEANED	  AND	  UNCLEANED	  NETWORKS.	  	  
THERE	  IS	  A	  STRONG	  LINEAR	  RANKS	  CORRELATION	  BETWEEN	  THE	  LINKED	  PROTEINS	  FOUND	  IN	  THE	  CLEANED	  
AND	  UNCLEANED	  NETWORKS.	  THE	  TRENDLINE	   IS	  APPROXIMATED	  WITH	  A	  GRADIENT	  OF	  2	  AND	  Y-­‐INTERCEPT	  
OF	  55	  (ADJUSTED	  R-­‐SQUARED	  =	  0.39,	  P	  ≤	  2.2E	  −	  16)	  We	  then	  turned	  to	  informative	  GO	  term	  enrichment	  for	  the	  linked	  proteins	  in	  the	  cleaned	  network.	  This	  produced	  87	  significant	  GO	  BP	  terms	  (for	  288	  proteins).	  To	   find	   out	   whether	   these	   terms	   are	   closely	   associated	   in	   the	   GO	   tree,	   we	  calculated	  the	  shortest-­‐path	  lengths	  between	  all	  terms,	  and	  returned	  the	  average	  path	  length.	  A	  null	  distribution	  is	  then	  generated	  by	  picking	  a	  number	  of	  proteins	  equal	   to	   the	   linked	   proteins	   from	   the	   reference	   network,	   calculating	   the	  significant	   informative	   GO	   terms,	   and	   calculating	   the	   average	   GO	   term	   path	  length.	   This	   is	   repeated	   1000	   times.	   For	   linked	   proteins,	   we	   find	   that	   the	   GO	  terms	  are	  significantly	  more	  closely	  associated	  (Z-­‐score	  =	  −3.98,	  p	  =	  0.000034).	  5.3.2 PROPERTIES	  OF	  THE	  MOST	  HIGHLY	  LINKED	  PROTEINS:	  ACTB	  AND	  THE	  ARRB1/2	  The	  list	  of	  most	  highly	  connected	  proteins	  to	  seeds	  is	  shown	  in	  Table	  8	  below.	  In	  the	  cleaned	  dataset,	  34	  proteins	  share	  at	   least	  3	  connections	   to	   the	  seeds.	  This	  set	  includes	  known	  oncogenes	  such	  as	  NFKB2,	  RAF1,	  REL,	  TP53	  and	  VHL.	  
TABLE	  8	  LIST	  OF	  MOST	  HIGHLY	  CONNECTED	  PROTEINS	  TO	  THE	  SEED	  SET	  (SORTED	  IN	  DESCENDING	  ORDER).	  




























	   63	  
	  	  Of	   these	  34	  highly	   linked	  proteins,	  ARRB1/2	  and	  ACTB	  were	   found	   to	  be	  most	  connected	  to	  the	  seeds.	  Interestingly,	  these	  3	  proteins	  were	  not	  found	  in	  the	  set	  of	   detected	   non-­‐seed	   proteins	   either.	   Hence,	   it	   is	   possible	   that	   these	   proteins	  were	  not	  picked	  up	  by	  MS.	  To	  verify	  this,	  we	  turned	  to	  another	  MS-­‐protein	  identification	  algorithm,	  Paragon.	  In	  PEP	  69,	  we	  found	  that	  there	  was	  good	  correlation	  between	  the	  reported	  ranks	  and	   ratios	   of	   Mascot	   and	   Paragon.	   However,	   Paragon	   reported	   many	   more	  proteins	  than	  Mascot	  even	  although	  these	  extra	  proteins	  were	  found	  to	  originate	  from	   lower	   quality	   MS/MS	   spectra.	   We	   generated	   a	   Paragon	   excess	   list	  comprising	   the	  read	  outs	   from	  all	  12	  patients	  not	   found	   in	  Mascot.	  Here,	  ACTB	  was	   found	   to	   be	   supported	   in	   all	   12	   patients.	   It	   was	   also	   found	   to	   be	   very	  confidently	  predicted	  in	  Paragon	  with	  a	  normalized	  average	  rank	  of	  0.028	  (out	  of	  1).	  The	  omission	  of	  ACTB	  in	  the	  set	  of	  detected	  proteins	  could	  be	  due	  to	  a	  variety	  of	   factors	   –	   e.g.,	   Mascot’s	   filtering	   parameters,	   incomplete	   coverage	   in	   its	  database	   or	   differences	   in	   peptide	   matching	   algorithms	   34.	   ARBB1	   and	   2,	  however,	  were	  not	  found	  to	  be	  predicted	  in	  Paragon.	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The	  inter-­‐connections	  of	  linked	  proteins	  to	  the	  seeds	  are	  shown	  in	  Figure	  8.	  This	  network	  appears	  to	  be	  quite	  sparse,	  and	  is	  probably	  not	  suitable	  for	  performing	  cluster	   analysis.	   ARRB1	   and	   ARRB2	   share	   many	   seeds	   (Figure	   8	   inset).	   This	  includes	   HSPA8,	   HNRNPM,	   HSPA5,	   TUBA1C,	   HNRNPH1,	   FLNA,	   CLTC,	   S100A9,	  NCL	  and	  ANXA2.	  This	  set	  of	  proteins	  appear	  to	  be	  important	  in	  vesicle-­‐mediated	  transport	   (p	   =	   0.0016),	   as	   well	   as	   actin	   cytoskeleton	   reorganization	   (p	   =	  0.00885).	  
	  
FIGURE	  8	  NETWORK	  INTER-­‐CONNECTIONS	  BETWEEN	  ARRB1,2	  AND	  ACTB.	  
BACKGROUND:	   THE	   INTER-­‐CONNECTIONS	   OF	   LINKED	   PROTEINS	   TO	   THE	   SEEDS;	   INSET:	  THE	   CONNECTIONS	  
BETWEEN	   ARBB1,2	   AND	   ACTB.	   BACKGROUND:	   THE	   NETWORK	   COMPRISING	   SEEDS	   AND	   LINKED	   PROTEINS	   IS	  
TOPOLOGICALLY	   SPARSE.	   INSET:	   HERE,	   PROTEINS	   LINKED	   ONLY	   TO	   ARRB1	   AND	   2	   ARE	   LABELLED	   YELLOW;	  
ARRB1	  AND	  ACTB	  IN	  LIGHT	  BLUE;	  CONNECTIONS	  TO	  ALL	  3	  IN	  PURPLE;	  PROTEINS	  NOT	  SHARED	  ARE	  IN	  PINK	  (SEE	  
ONLINE	  VERSION	  FOR	  COLOURS)	  The	  subnet	   formed	  by	  ARRB1/2	  and	  ACTB	  (Figure	  8	   inset)	  shows	  that	  ACTB	  is	  less	  strongly	  connected	  to	  ARRB1/2.	  Here,	  proteins	  linked	  only	  to	  ARRB1	  and	  2	  are	  colored	  yellow;	  ARRB1	  and	  ACTB	  in	   light	  blue;	  all	  3	   in	  purple;	  proteins	  not	  shared	  are	  in	  pink.	  GO	  term	  analysis	  of	  the	  20	  connected	  seeds	  does	  not	  reveal	  any	  term	  typically	  associated	  with	  cancers.	  Instead,	  many	  of	  the	  terms	  are	  more	  akin	  to	   functionalities	  associated	  with	  the	   liver,	  e.g.,	  vesicle-­‐mediated	  transport	  and	  transport.	  However,	  stress	  responses	  and	  wound	  healing	  is	  represented	  by	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half	   of	   the	   proteins,	   and	   it	   does	   agree	   with	   our	   previous	   observations	   where	  many	  of	  the	  significant	  clusters	  were	  also	  enriched	  for	  stress	  responses.	  ARRB1/2	   are	   signaling	   proteins	   of	   G	   protein-­‐coupled	   receptors	   (GPCRs).	   They	  are	   known	   to	   play	   an	   important	   role	   in	   tumor	   tissue	   invasion	   and	  metastasis.	  Rosano	  et	  al.	  161	   	  showed	  that	  in	  ovarian	  cancer,	  silencing	  of	  both	  ARRB1	  and	  2	  inhibited	   endothelin-­‐A	   (ET(A)R)	   receptor-­‐driven	   silencing,	   resulting	   in	   SRC	  suppression,	   mitogen-­‐activated	   protein	   kinase	   (MAPK),	   AKT	   activation,	   EGFR	  transactivation	  and,	  most	  importantly,	  complete	  inhibition	  of	  ET-­‐1-­‐induced	  beta-­‐catenin/TCF	  transcriptional	  activity	  and	  cell	  invasion.	  In	  colorectal	  cancer,	  it	  was	  reported	   that	   the	   association	   of	   ARRB1	  with	   SRC	   is	   critical	   for	   carcinoma	   cell	  migration	   as	   well	   as	   metastatic	   spread	   of	   cancer	   to	   liver	   in	   vivo162.	   This	  association	   is	   stimulated	   by	   the	   expression	   of	   prostagladin	   E,	   and	  may	   act	   by	  activation	  of	  the	  EGFR	  controlled	  pathways.	  Like	  Rosano	  et	  al.	  161,	  this	  study	  also	  implied	  a	  functional	  role	  for	  ARRB1	  as	  an	  important	  mediator	  of	  tumor	  invasion	  and	   metastasis.	   Interestingly,	   to	   our	   best	   knowledge,	   ARRB1/2	   has	   not	   been	  reported	  as	  a	  crucial	  factor	  in	  driving	  oncogenic	  progression	  in	  HCC	  from	  mod	  to	  poor.	  However,	  the	  fact	  that	  it	  is	  linked	  to	  the	  most	  number	  of	  our	  MS-­‐detected	  deregulated	   proteins,	   coupled	   to	   its	   enrichment	   in	   other	   metastatic	   tumours,	  suggests	  a	  potentially	  important	  role	  in	  driving	  HCC	  progression.	  Actins	  are	  highly	  conserved	  proteins	  that	  are	  involved	  in	  cell	  motility,	  structure,	  and	   integrity.	   ACTB	   or	   beta-­‐action	   is	   a	   major	   constituent	   of	   the	   contractile	  apparatus	   and	   one	   of	   two	   non-­‐muscle	   cytoskeletal	   actins.	   Because	   it	   is	   a	  housekeeping	  protein,	  it	  is	  commonly	  used	  for	  normalization	  in	  gene	  expression	  studies.	  However,	  here,	  we	  found	  that	  ACTB	  is	  connected	  to	  a	  disproportionate	  number	  of	  deregulated	  proteins	  in	  the	  cleaned	  network	  (as	  well	  as	  in	  uncleaned),	  and	   could	   possibly	   be	   involved	   in	   driving	   HCC	   progression.	   Indeed,	   several	  studies	  have	  shown	  that	  ACTB	  is	  differentially	  expressed	  in	  cancer.	  This	  includes	  differential	   expression	   of	   ACTB	   in	   N1S1	   rat	   hepatoma	   163,	   colon	  carcinoma/colorectal	   cancer	   (CRC)	   164,	   and	   blood	   cancers	   such	   as	   Chronic	  Myelogenous	   Leukemia	   (CML),	   Chronic	   Lymphocytic	   Leukemia	   (CLL),	   Acute	  Myelogenous	   Leukemia	   (AML)	   165.	   In	   human	   colon	   adenocarcinoma	   166,	  hepatoma	  167	  	  and	  melanoma	  168,	  there	  is	  a	  tendency	  for	  ACTB	  to	  be	  deregulated	  in	  cells	  with	  greater	  metastatic	  capacity.	  Of	   the	   34	   most	   highly	   linked	   proteins,	   there	   is	   enrichment	   for	   significant	   GO	  terms	   commonly	   associated	   with	   cancer.	   For	   example,	   apoptosis	   and	  programmed	  cell	  death	  (n	  =	  16,	  p	  =	  5.19e	  −	  09),	  activation	  of	  immune	  responses	  (n	  =	  7,	  p=6.15e−08),	   response	   to	  stress	   (n=18,p=1.40e−06),	  positive	   regulation	  of	  NF-­‐kappaB	  transcription	   factor	  activity	  (n	  =	  5,	  p	  =	  4.30e	  −	  05),	  and	  negative	  regulation	   of	   cell	   proliferation	   (n	   =	   8,	   p	   =	   7.33e	   −	   05).	   Comparing	   the	   highly	  linked	   proteins	   (at	   least	   3	   connections	   to	   seeds)	   and	   lower	   linked	   proteins	  against	   the	   Cancer	   Gene	   Census	   (Futreal	   et	   al.,	   2004),	   we	   found	   1.86X	   more	  enrichment	   for	   known	   cancer	   genes	   among	   the	   highly	   linked	   proteins.	   This	  reinforces	   the	   notion	   that	   increased	   connectivity	   to	   seed	   proteins	   is	   likely	   to	  imply	  potential	  oncogenic	  function.	  5.4 DISCUSSIONS	  5.4.1 HOW	  MAXLINK	  COMPLEMENTS	  PEP	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Both	  Maxlink	  71	  and	  PEP	  69	  addresses	  to	  an	  extent	  incomplete	  coverage	  issues	  in	  proteomics.	   However,	   they	   do	   this	   differently.	   Maxlink	   identifies	   additional	  proteins	   based	   on	   the	   number	   of	   connections	   to	   seed	   proteins	   whereas	   PEP	  identifies	   significantly	   differentially	   expressed	   sub	   modules	   formed	   by	   the	  neighbours	   of	   the	   seeds.	   Functional	   analysis	   reveals	   a	   common	   enrichment	   of	  terms	   such	   as	   apoptosis	   and	   stress	   responses.	   However,	   Maxlink	   picked	   up	  immune	  responses	  which	  we	  did	  not	  observe	  in	  PEP.	  One	  likely	  possibility	  is	  that	  these	  proteins	  are	  poorly	  connected	  in	  the	  reference	  PPIN	  and	  therefore	  did	  not	  qualify	   as	   clusters.	   Since	   Maxlink	   only	   considers	   proteins	   connected	   to	   seeds	  regardless	  of	  their	  inter-­‐connectivity,	  it	  provides	  an	  additional	  dimension	  to	  the	  results	   from	   cluster	   analysis.	   The	   Maxlink	   approach	   is	   also	   dependent	   on	   the	  quality	   of	   the	   reference	   network.	  We	   show	   in	   this	   chapter	   that	   the	   process	   of	  network	  cleaning	  greatly	  reduces	  the	  number	  of	  linked	  proteins	  from	  902	  to	  288	  but	  the	  latter	  set	  is	  enriched	  for	  coherent	  terms	  as	  well	  as	  highly	  ranked	  linked	  proteins	  in	  the	  former.	  However,	   both	   methods	   are	   not	   able	   to	   deal	   adequately	   with	   the	   consistency	  issue	  in	  proteomics	  –	  viz.,	  the	  unrepeatability	  of	  results	  from	  the	  same	  samples.	  Furthermore,	  the	  dependence	  on	  identifying	  seeds	  from	  the	  iTRAQ	  screen	  filters	  off	   a	   large	   amount	   of	   the	   limited	   available	   information,	   because	   only	   proteins	  supported	   by	   the	   majority	   of	   samples	   and	   clearly	   differentially	   expressed	   are	  primarily	  considered.	  Hence,	   there	   is	   still	   avenue	   for	   further	   development	   of	  methods	   that	   can	   deal	  with	  these	  shortfalls.	  5.4.2 THE	  ROLE	  OF	  ARRB1/2	  PROTEINS	  AND	  ACTB	  IN	  DRIVING	  HCC	  PROGRESSION	  It	   is	   interesting	   that	   the	  most	   linked	  proteins	   in	  HCC	  to	  seeds	   turned	  out	   to	  be	  non-­‐classical	   oncogenes.	   This	   reinforces	   the	   notion	   of	   how	   complex	   cancer	   is,	  and	  how	  limited	  current	  knowledge	  is.	  There	  is	  limited	  literature	  evidence	  on	  the	  roles	  of	  ARRB1/2	  and	  even	  beta-­‐actin	   in	  driving	  metastasis.	  Although	  much	  of	  the	   reported	   literature	   documents	   other	   cancer	   types,	   especially	   more	  aggressive	   cancers,	   it	   is	   possible	   that	   deregulation	   of	   these	   proteins	   can	   also	  have	  similar	  effects	  in	  driving	  HCC	  progression.	  Furthermore,	  although	  found	  in	  more	  aggressive	  tumors,	  GO	  term	  analysis	  of	  the	  shared	  neighbors	  by	   these	  3	  proteins	   revealed	  no	  significant	   cancer	  associated	  term,	  aside	  from	  wound	  healing	  and	  stress	  response.	  This	  could	  be	  also	  be	  due	  to	  the	   limited	   annotations	   in	  GO,	   as	  well	   as	  due	   to	   the	   limited	   scope	   in	   analyzing	  only	  PPIN	  information.	  ARRB1/2	  proteins	  are	  GPCR	  signaling	  proteins	  and	  may	  drive	   invasiveness	   and	  metastasis	   via	   several	   different	   pathways	   ranging	   from	  ET(A)R,	  SRC	  and	  EGFR,	  AKT	  and	  MAPK	  161,	  162.	  The	   role	   of	   beta-­‐actin	   is	   more	   interesting	   given	   that	   it	   is	   a	   well-­‐known	  housekeeping	  protein	  with	  widespread	  expression.	  It	  is	  typically	  used,	  alongside	  GADPH,	   as	   a	   marker	   for	   normalization	   of	   gene	   expression	   experiments.	   Its	  functional	  role	  in	  cancer	  is	  not	  particularly	  well-­‐characterized	  despite	  literature	  evidence	  indicating	  its	  deregulation	  in	  more	  aggressive	  cancer	  types	  166,	  167,	  169.	  In	   our	   derived	   network,	   we	   noted	   that	   ARRB1/2’s	   shared	   neighbors	   were	  enriched	  for	  the	  GO	  term,	  actin	  cytoskeleton	  reorganization	  (p	  =	  0.00885).	  This	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6 A	  NOVEL	  FEATURE-­‐BASED	  METHOD	  CAPABLE	  OF	  OVERCOMING	  BOTH	  CONSISTENCY	  AND	  COVERAGE	  ISSUES	  -­‐-­‐-­‐	  PROTEOMICS	  SIGNATURE	  PROFILING	  (PSP)	  	  
Brief	  summary	  and	  key	  points	  
• Traditional	   proteomics	   analysis	   is	   plagued	   by	   the	   use	   of	   arbitrary	  thresholds	  resulting	  in	  large	  loss	  of	  information.	  We	  propose	  here	  a	  novel	  method	  in	  proteomics	  that	  utilizes	  all	  detected	  proteins.	  We	  demonstrate	  its	  efficacy	  in	  a	  proteomics	  screen	  of	  5	  and	  7	  liver	  cancer	  patients	  in	  the	  moderate	  and	  late	  stage.	  
• Using	   biological	   complexes	   as	   a	   cluster	   vector,	   and	   augmenting	   it	   with	  sub-­‐modules	   obtained	   from	   partitioning	   an	   integrated	   and	   cleaned	  protein-­‐protein	  interaction	  network,	  we	  calculate	  a	  Proteomics	  Signature	  Profile	   (PSP)	   for	   each	   patient	   based	   on	   the	   hit	   rates	   of	   their	   reported	  proteins,	   in	   the	   absence	   of	   fold	   change	   thresholds,	   against	   the	   cluster	  vector.	  Using	  this,	  we	  demonstrate	  that	  moderate-­‐	  and	  late-­‐stage	  patients	  segregate	   with	   high	   confidence.	   We	   also	   discover	   a	   moderate-­‐stage	  patient	   who	   displayed	   a	   proteomics	   profile	   similar	   to	   other	   poor-­‐stage	  patients.	  	  
• We	   identified	   significant	   clusters	   using	   a	   modified	   version	   of	   the	   SNet	  approach.	   Comparing	   our	   results	   against	   the	   Proteomics	   Expansion	  Pipeline	   (PEP)	   on	  which	   the	   same	  patient	   data	  was	   analyzed,	  we	   found	  good	   correlation.	   Building	   on	   this	   finding,	   we	   report	   significantly	   more	  clusters	   (176	   clusters	   here	   compared	   to	   70	   in	   PEP),	   demonstrating	   the	  sensitivity	   of	   this	   approach.	   Gene	   Ontology	   (GO)	   terms	   analysis	   also	  reveals	   that	   the	   significant	   clusters	   are	   functionally	   congruent	  with	   the	  liver	  cancer	  phenotype.	  
• PSP	  is	  a	  powerful	  and	  sensitive	  method	  for	  analyzing	  proteomics	  profiles	  even	  when	  sample	  sizes	  are	  small.	  It	  does	  not	  rely	  on	  the	  ratio	  scores	  but,	  rather	   on	  whether	   a	  protein	   is	   detected	  or	  not.	  Although	   consistency	  of	  individual	   proteins	   between	   patients	   is	   low,	   we	   found	   the	   reported	  proteins	  tend	  to	  hit	  clusters	  in	  a	  meaningful	  and	  informative	  manner.	  By	  extracting	  this	  information	  in	  the	  form	  of	  a	  Proteomics	  Signature	  Profile,	  we	   confirm	   that	   this	   information	   is	   conserved	   and	   can	   be	   used	   for	   1/	  clustering	   of	   patient	   samples,	   2/	   identification	   of	   significant	   clusters	  based	  on	   real	   biological	   complexes,	   and	  3/	   overcoming	   consistency	   and	  coverage	  issues	  prevalent	  in	  proteomics	  data	  sets.	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6.1 INTRODUCTION	  Proteomics	  profiling	   in	  cancer	   is	  a	  very	  useful	   tool	   for	  detecting	  key	  players	   in	  oncogenic	  progression.	  Although	  high-­‐throughput	  methods	  such	  as	  microarrays	  and	   RNA	   sequencing	   have	   been	   very	   useful	   in	   enhancing	   our	   molecular	  understanding,	   they	   only	   measure	   RNA	   level,	   not	   protein	   level.	   Thus,	   the	  evidences	  provided	   are	   indirect.	  On	   the	  other	  hand,	   as	   discussed	   earlier,	   there	  are	  many	  difficulties	  associated	  with	  high-­‐throughput	  direct	  protein	  analysis	  or	  proteomics.	  The	  traditional	  post-­‐MS	  analysis	  approach	  is	  to	  select	  and	  study	  only	  those	   proteins	   that	   are	   found	   in	   most	   of	   the	   samples,	   as	   well	   as	   having	   a	  consistently	   over-­‐	   or	   under-­‐expressed	   ratio.	   This	   approach	   is	   referred	   to	   as	  thresholding	  and	  was	  utilised	  in	  earlier	  analyses	  as	  observed	  in	  PEP	  (Chapter	  4)	  and	  Maxlink	  (Chapter	  5).	  Since	   the	  use	   of	   thresholds	   increases	   stringency	  by	   imposing	   expressional	   and	  sample-­‐support	   constraints,	   it	   is	   expected	   that	   this	   procedure	   improves	   data	  quality,	   and	   the	   investigator	   can	   therefore	   concentrate	   on	   analyzing	   a	   smaller	  subset	  of	  proteins.	  However,	  there	  are	  three	  major	  problems	  associated	  with	  the	  thresholding	  approach.	  Firstly,	  it	  is	  an	  arbitrary	  filtering	  step	  with	  no	  fixed	  rules	  on	   the	   parameters.	   Secondly,	   the	   use	   of	   thresholds	   disregards	   most	   of	   the	  generated	   data.	   This	   is	   especially	   wasteful	   given	   already	   low	   levels	   of	  consistency	   between	   different	   samples.	   Furthermore,	   noticeably	   high	   or	   low	  protein	   expression	   does	   not	   necessarily	   imply	   importance	   or	   causality	   in	   the	  phenotype	   -­‐-­‐-­‐in	   particular,	   a	   mutated	   protein	   that	   drives	   other	   proteins	   to	  change	  their	  levels	  may	  not	  itself	  report	  any	  change	  in	  expression	  or	  miss	  being	  detected.	  Thirdly,	  for	  those	  proteins	  that	  do	  meet	  a	  specified	  threshold,	  there	  is	  a	  tendency	   to	   try	   to	   determine	   if	   the	   protein	   is	   over	   or	   under	   expressed	   by	  averaging	  the	  reported	  ratios.	  Where	  patient	  sample	  size	  is	  small,	   the	  averaged	  ratio	  reveals	   little	   information	  about	  the	  expression	  behavior	  of	  the	  proteins	   in	  the	   cancer	   population	   at	   large.	   The	   other	   point	   of	   contention	   with	   regards	   to	  averaging	  is	  that	  many	  proteins	  report	  “swing”	  ratios-­‐-­‐-­‐that	  is,	  a	  mixture	  of	  both	  high	  and	  low	  ratios	  between	  samples.	  	  Since	   proteins	   do	   not	  work	   singly	   but	   in	   groups	   as	   complexes	   or	   submodules,	  clusters	   could	   be	   built	   based	   on	   the	   first-­‐degree	   neighbours	   of	   highly	  differentially	  expressed	  proteins	   (seeds),	  and	  ranked	  as	   in	  PEP	  (Chapter	  4).	  By	  building	   clusters	   around	   seeds,	   PEP	   allows	   recovery	   of	   lower	   confidence	  proteins	   -­‐-­‐-­‐	   i.e.,	   proteins	   supported	  by	  only	   a	   few	  patients	   or	   the	  proteins	   that	  have	  ratios	  around	  1.	  It	  also	  allows	  recovery	  of	  proteins	  not	  immediately	  evident	  from	  the	  mass	  spectra	  or	  filtered	  during	  the	  data	  analysis.	  The	  method	  is	  further	  augmented	  by	  hypergeometric	  test	  of	  the	  seeds	  to	  discover	  significant	  pathways	  derived	  from	  the	  integrated	  database,	  PathwayAPI	  52	  as	  well	  as	  transition	  tracing	  between	  early-­‐	  and	  late-­‐stage	  cancer	  69.	  However,	  PEP	  lacks	  sensitivity	  owing	  to	  the	  requirement	   that	  clusters	  must	   first	  contain	  a	  seed.	   It	   is	  also	  dependent	  on	  the	  quality	  of	  the	  reference	  protein-­‐protein	  interaction	  network	  (PPIN).	  Finally,	  while	   PEP	   addresses	   the	   coverage	   issue	   in	   proteomics	   partially,	   it	   does	   not	  resolve	  consistency	  issues	  between	  samples.	  In	   this	   chapter,	   we	   take	   a	   radical	   departure	   from	   conventional	   analysis	  approaches	   utilizing	   biological	   networks.	   We	   hypothesized	   that	   meaningful	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information	  is	  embedded	  in	  the	  total	  set	  of	  expressed	  proteins	  in	  every	  patient	  if	  appropriately	  contextualized.	  As	  such,	   it	   is	  possible	   to	  do	  away	  with	   the	  use	  of	  thresholds	  on	  the	  detected	  proteins	  and	  maximally	  utilize	  available	  experimental	  evidence.	  	  Protein	   complexes	   can	   be	   regarded	   as	   units	   of	   biological	   function	   and	   are	  suitable	   for	   contextualizing	   proteomics	   data.	   A	   given	   set	   of	   complexes	   can	   be	  represented	  as	  an	  unranked	  “cluster	  vector”	  against	  which	  we	  can	  measure	  the	  hit	  rate	  of	  a	  patient’s	  reported	  proteins.	  For	  each	  patient	  and	  each	  cluster,	  the	  hit	  rate	  =	  max	  (Np/N),	  where	  Np	  is	   the	  number	  of	  proteins	   in	  that	  specific	  patient	  found	  in	  that	  cluster,	  and	  N	  is	  the	  total	  number	  of	  proteins	  found	  in	  that	  cluster.	  The	  patient’s	  Proteomics	  Signature	  Profile,	  or	  PSP,	  is	  therefore	  simply	  a	  vector	  of	  hit	   rates	  checked	  against	   the	  cluster	  vector.	  Since	  a	  patient’s	  PSP	   is	  a	  vector	  of	  fixed	  length	  m,	  a	  set	  of	  n	  PSPs	  can	  be	  represented	  as	  a	  matrix	  of	  dimension	  (n	  x	  m)	  on	  which	  statistical	  and	  mathematical	  analysis	  can	  be	  performed.	  The	  PSP	  can	  be	  used	   in	   two	  ways	  as	   illustrated	   in	   this	   thesis.	   	  Firstly,	   it	  can	  be	  used	   to	   understand	   the	   relationship	   between	   samples	   or	   patients.	   This	   is	  important	   because,	   normally,	   the	   samples	   are	   first	   staged	   according	   to	   clinical	  and	   pathological	   criteria	   rather	   than	   by	   their	   molecular	   profiles.	  Histopathological	   classifications	   may	   be	   subjective	   and	   may	   give	   rise	   to	  misclassifications.	  With	  PSP,	  proteomic	  data	  can	  be	  clustered	  and	  analyzed	  in	  a	  manner	  analogous	  to	  microarray	  data.	  This	  allows	  a	  confidence	  check	  to	  ensure	  the	  molecular	   signatures	   also	   concur	  with	   the	  histopathology.	  The	   second	  way	  PSP	  can	  be	  used	  is	  to	  determine	  the	  significance	  of	  each	  cluster	  within	  the	  cluster	  vector.	  This	  allows	  for	  selection	  of	  critical	  gene	  targets	  for	  functional	  studies	  and	  biomarker	   development.	   To	   this	   end,	   we	   adopted	   and	   modified	   the	   SNet	  algorithm	   (previously	   developed	   for	   gene	   expression	   studies),	  which	   has	   been	  shown	  to	  be	  extremely	  robust	  in	  detecting	  significant	  subnets	  95.	  The	  significant	  clusters	  can	  then	  be	  scored	  and	  ranked	  using	  “clusters	  scores”	  derived	  from	  the	  reported	  expression	  ratios.	  	  To	  illustrate	  the	  efficacy	  of	  our	  approach,	  we	  applied	  PSP	  to	  the	  liver	  cancer	  data	  (Chapter	   3);	   the	   pipeline	   is	   summarized	   below	   in	   Figure	   9.	   If	   the	   information	  embedded	  within	  the	  matrix	  is	   indeed	  meaningful,	   it	  should	  properly	  segregate	  patients	  according	  to	  the	  cancer	  stage.	  The	  returned	  significant	  clusters	  based	  on	  feature	   selection	   should	   also	   make	   biological	   sense	   and	   support	   what	   is	  currently	   known	   about	   liver	   cancer.	   Finally,	   because	   thresholding	   was	   not	  performed	   to	   filter	   off	   any	   reported	   proteins,	   PSP	   is	   expected	   to	   be	   more	  sensitive,	   therefore	   capturing	   a	   wider	   array	   of	   biological	   information.	   To	  illustrate	  how	  PSP	  compares	  with	  a	  more	  conventional	  network-­‐based	  approach,	  the	  best	  matched	  clusters	  from	  PEP	  and	  PSP	  were	  compared69.	  As	  a	  supplement,	  we	  also	  propose	  and	  show	  how	  cluster	  mining	  from	  a	  PPIN	  can	  meaningfully	  expand	  the	  cluster	  vector.	  This	  is	  important	  because	  the	  current	  set	  of	   known	   complexes	   is	   incomplete.	   Furthermore,	   more	   biological	   information	  can	  be	  extracted	  by	  taking	  advantage	  of	  network-­‐based	  information.	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FIGURE	  9	  THE	  PROTEOMICS	  SIGNATURE	  PROFILING	  (PSP)	  PIPELINE.	  	  
THE	   PIPELINE	   CONSISTS	   OF	   INCORPORATING	   DATA	   FROM	   COMPLEX,	   PPI	   AND	   GO.	   PROTEIN	   LISTS	   FROM	  
INDIVIDUAL	  PATIENTS	  ARE	  CONVERTED	  INTO	  A	  PROTEOMICS	  SIGNATURE	  PROFILE	  (PSP)	  BASED	  ON	  A	  VECTOR	  
OF	  COMPLEXES	  GENERATED	  FROM	  CORUM	  AND	  GRAPHLET-­‐DERIVED	  CLUSTERS.	  THE	  PSP	  CAN	  THEN	  BE	  USED	  
FOR	   PERFORMING	   SAMPLE	   CLUSTERING	   FOR	   ASSESSING	   THE	   PATIENT	   SAMPLES	   AND	   DETERMINING	  
SIGNIFICANT	   CLUSTERS.	   GO	   TERMS	   ARE	   USED	   TO	   EVALUATE	   FUNCTIONAL	   SIGNIFICANCE	   AND	   COHERENCE.	  
(ABBREVIATIONS:	   GDV	   –	   GRAPHLET	   DEGREE	   VECTOR,	   GDS	   –	   GRAPHLET	   DEGREE	   SIMILARITY	   SCORES).	   FOR	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For	  each	  cluster	  C	  in	  the	  cluster	  vector,	  we	  can	  produce	  two	  lists	  HA=	  <H_CA1,	  …,	  H_CAm>	  and	  HB=	  <H_CB1,	  …,	  H_CBn>,	  where	  A	  and	  B	  correspond	  to	  the	  mod	  and	  poor	  stages.	  The	  t-­‐statistic	  score	  between	  the	  lists	  HA	  and	  HB	  is	  then	  computed	  by	  the	  standard	  formula:	  	  












(m −1)SHA2 + (n −1)SHB2
m+ n − 2 	  
If	   this	   t-­‐statistic	   is	   significant,	   then	   the	   cluster	   C	   is	   differentially	   expressed	  between	  mod	   and	   poor	   stage.	   As	   the	   t-­‐statistic	   may	   not	   necessarily	   follow	   an	  approximately	   normal	   distribution,	   weighted	   randomization	   via	   class	   label	  swapping	  was	  performed	  between	  members	  of	  moderate	  and	  poor	  10,000	  times	  to	  produce	  the	  null	  distribution.	  If	  the	  t-­‐statistic	  value	  is	  negative,	  the	  empirical	  p-­‐value	   is	   determined	   by	   the	   percentage	   of	   null-­‐distribution	   t-­‐scores	   that	   are	  smaller	   than	   the	   actual	   t-­‐statistic	   value.	   If	   the	   t-­‐statistic	   value	   is	   positive,	   the	  empirical	   p-­‐value	   is	   determined	  by	   the	  percentage	  of	   null-­‐distribution	   t-­‐scores	  that	  are	  larger	  than	  the	  actual	  t-­‐statistic	  value.	  Examples	  of	  the	  null-­‐distribution	  t-­‐scores	  for	  4	  clusters	  are	  shown	  in	  Supplementary	  Figure	  4.	  6.2.4 CLUSTER	  SCORE	  For	  those	  clusters	  regarded	  as	  significant	  (p	  ≤0.05),	  we	  calculate	  a	  score	  for	  the	  mod	   and	   poor	   stage	   respectively	   using	   the	   reported	   iTRAQ	   protein	   ratios.	  Suppose	  we	  have	  a	  complex	  comprised	  of	  proteins	  A,	  B,	  C,	  D.	  A	  is	  supported	  by	  4	  mod	  stage	  patients	  with	  ratio	  (1.1,	  0.8,	  1,	  1.2),	  B	  is	  supported	  by	  1	  patient	  with	  ratio	  of	  5	  while	  C	  and	  D	  are	  not	  supported.	  If	  the	  ratio	  is	  lower	  than	  1,	  we	  convert	  it	  by	  taking	  its	  reciprocal.	  To	  find	  out	  how	  big	  is	  this	  ratio,	  we	  take	  difference	  =	  ratio	  –	  1.	  The	  score	  S,	  would	  thus	  be	  Σ(0.1,	  1/0.8	  -­‐	  1,	  0,	  0.2)/	  4.	  	  However,	  with	  this	  scoring	  approach,	  complexes	  with	  more	  proteins	  tend	  to	  be	  ranked	  high.	  For	  example,	  a	  complex	  with	  10	  proteins	  (A1,	  …,	  A10)	  and	  patient_i	  has	   high	   ratio	   value	   on	   Ai	   and	   low	   ratio	   value	   on	   the	   other	   9	   proteins;	   this	  complex	  will	  get	  a	  higher	  score	   than	  a	  complex	  of	   size	  4	  with	  all	  patients	  have	  medium	   ratio	   value	   	   on	   all	   4	   proteins	   in	   this	   complex.	   To	   improve	   the	   scoring	  function	   for	   such	   instances,	   we	   propose	   dividing	   S	   by	   the	   number	   of	   unique	  proteins	  that	  were	  reported	  in	  the	  patient.	  For	  example,	  in	  complex	  (A,	  B,	  C,	  D),	  2	  patients	  report	  A	  -­‐	  and	  their	  scores	  are	  1.1,	  1.2	  while	  1	  patient	  report	  B	  and	  his	  score	   is	   5.	   The	   cluster	   score	   is	   therefore	   (0.1	   +	   0.2	   +	   4)/2	   (note	   that	   the	  denominator	  is	  not	  4).	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6.2.5 GENE	  ONTOLOGY	  AND	  CLUSTER	  FUNCTIONAL	  ANNOTATION	  GO	   provides	   a	   controlled	   vocabulary	   for	   assessing	   cluster	   function	   and	  coherence177.	  The	  annotation	  files	  and	  GO	  tree	  (ver.	  1.2)	  files	  for	  Homo	  Sapiens	  were	   downloaded	   from	   http://www.geneontology.org/	   (dated	   23	   April	   2011).	  UniProtKB	  accessions	  were	  mapped	  to	  Ensembl	  Gene	  IDs	  via	  Biomart.	  Informative	   biological	   process	   terms	  were	   extracted	   from	   the	   GO	  OBO	   file	   104.	  Significance	   testing	   for	   each	   cluster	   was	   performed	   using	   the	   hypergeometric	  test	  with	  Bonferroni	  correction	  (p	  ≤	  0.05).	  	  6.2.6 CLUSTERING	  OF	  PATIENT	  PROTEOMIC	  SIGNATURE	  PROFILES	  The	  patient	  proteomic	  signature	  profiles	  can	  be	  used	  to	  examine	  the	  consistency	  and	  confidence	  of	  the	  derived	  relationships	  between	  samples.	  	  Hierarchical	   clustering	   was	   used	   to	   understand	   links	   between	   samples.	  Euclidean	   distance	   was	   used	   to	   generate	   distance	   matrix	   based	   on	   an	   m	   x	   n	  matrix	   (where	   m	   are	   the	   samples,	   and	   n	   is	   the	   patient	   proteomic	   signature	  profile).	  Ward’s	  178	  was	  used	  to	  evaluate	  distance	  between	  groups	  derived	  from	  the	  distance	  matrix.	  	  To	   gain	   confidence	   on	   the	   structure	   of	   the	   tree,	   we	   used	   the	   R	   bootstrap	  resampling	  package	  pvclust.	  For	  each	  cluster	  in	  hierarchical	  clustering,	  p-­‐values	  (between	   0	   and	   1)	   are	   calculated	   via	  multiscale	   bootstrap	   resampling.	   pvclust	  provides	  two	  types	  of	  p-­‐values:	  AU	  (Approximately	  Unbiased)	  and	  BP	  (Bootstrap	  	  Probability).	   AU,	   which	   is	   computed	   by	   multiscale	   bootstrap	   resampling,	   is	   a	  better	   approximation	   to	   unbiased	   p-­‐value	   than	   BP	   value	   computed	   by	   normal	  bootstrap	  resampling.	  6.2.7 REFERENCE	  PPI	  NETWORK	  As	  a	  supplement	  to	  CORUM,	  we	  used	  a	  reference	  protein	  interaction	  network	  as	  compiled	  by	  Bossi	  and	  Lerner	  109	  to	  mine	  for	  additional	  clusters.	  Briefly,	  human	  protein	  interactions	  were	  extracted	  from	  21	  different	  databases.	  To	  improve	  the	  confidence	   of	   an	   edge,	   each	   had	   to	   be	   supported	   by	   at	   least	   one	   direct	  experimental	  source	  confirming	  the	  physical	  interaction.	  The	  complete	  network	  consists	  of	  80	  922	  interactions	  between	  10	  229	  human	  proteins.	  6.2.8 CALCULATION	  OF	  GRAPHLET	  DEGREE	  SIMILARITIES	  FROM	  THE	  GDVS	  The	  Graphlet	  degree	  vector	  (GDV)	  is	  a	  generalization	  of	  the	  degree	  property,	  i.e.,	  the	   number	   of	   connections	   of	   any	   node	   in	   a	   network	   179.	   Graphlets	   are	   all	   the	  possible	   combinations	   for	   subgraphs	   size	  2	   to	  5.	  However,	   some	  positions	   in	  a	  graphlet	  are	   topologically	  equivalent.	  For	  example,	   the	   three	  points	   in	  a	   closed	  triangle.	  	  To	  eliminate	  redundancy,	  the	  notion	  of	  graphlet	  orbit	  is	  introduced.	  That	  is,	  if	  the	  node	  of	  interest	  is	  involved	  in	  a	  graphlet	  position	  of	  topological	  equivalence	  (e.g.	  one	   point	   of	   a	   closed	   triangle),	   it	   only	   counts	   once.	   As	   there	   are	   73	   graphlet	  orbits	  from	  size	  2	  to	  5,	  this	  can	  be	  represented	  as	  a	  vector	  of	  length	  73,	  with	  each	  position	  indicating	  the	  number	  of	  counts	  the	  node	  of	  interest	  is	  found	  in	  an	  orbit.	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The	  distance	  for	  orbit	  i	  between	  two	  nodes	  u	  and	  v	  is	  computed	  as:	  
€ 
Di(u,v) = wi




















Since	  the	  distance	  is	  a	  value	  between	  0	  and	  1,	  the	  similarity	  can	  be	  calculated	  as:	  
S(u,v)	  =	  1	  –	  D(u,v)	  If	  two	  nodes	  have	  very	  similar	  connection	  patterns	  between	  them,	  it	  is	  plausible	  they	   are	   involved	   in	   similar	   processes.	   This	   is	   checked	   using	   functional	  coherence	  measures	  as	  shown	  in	  the	  next	  chapter.	  6.2.9 CLUSTER	  GENERATION	  AND	  FUNCTIONAL	  EVALUATION	  USING	  LOC-­‐SCORES	  GDV	   similarity	   scores	   are	   calculated	   for	   all	   connected	   nodes	   in	   the	   reference	  PPIN.	   Since	   a	   high	   GDV	   similarity	   score	   between	   two	   adjoined	   nodes	   implies	  same	   cluster	   membership,	   we	   partitioned	   the	   network	   into	   clusters	   based	   on	  establishing	  a	   range	  of	   thresholds	   from	  0.8	   to	  0.9.	  That	   is,	   at	   threshold	  0.8,	  we	  keep	   edges	   in	   the	   PPIN	   with	   a	   score	   of	   at	   least	   0.8,	   and	   keep	   connected	  components	  of	  size	  4	  and	  above	  as	  clusters.	  A	   cluster	   needs	   to	   be	   biologically	   relevant.	   To	   evaluate	   if	   the	   clusters	   have	  “reason”	  to	  exist,	  we	  measured	  their	  localization	  coherence.	  Cellular	  component	  terms	   from	   Gene	   Ontology	   177	   were	   extracted	   and	   filtered	   for	   informative	   GO	  localization	  terms	  (that	  is,	  this	  term	  is	  annotated	  to	  at	  least	  30	  proteins	  and	  none	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of	  its	  descendant	  terms	  are	  annotated	  to	  at	  least	  30	  proteins)	  160.	  We	  let	  L={L1,	  L2,…,	  Lk}	  be	  a	  set	  of	  localization	  groups,	  where	  each	  group	  contains	  a	  set	  of	  co-­‐localized	   proteins.	   The	   co-­‐localisation	   score	   of	   a	   complex	   is	   defined	   as	   the	  maximal	   fraction	   of	   proteins	   in	   this	   complex	   that	   are	   in	   the	   same	   localization	  group	  among	  those	  proteins	  with	  localization	  annotations	  100.	  It	  is	  a	  measure	  of	  functional	  coherence	  based	  on	  whether	  the	  members	  in	  a	  cluster	  tend	  to	  localize	  to	  the	  same	  functional	  complex	  or	  subcellular	  component	  104.	  The	  co-­‐localization	  score	   of	   a	   set	   of	   complexes	   loc_score	   (C	   )	   is	   defined	   as	   the	   weighted	   average	  score	  over	  all	  complexes	  c	  ∈	  C:	  By	   using	   different	   levels	   of	   similarity	   scores	   (from	   0.6	   to	   0.95),	   the	   PPIN	   is	  fragmented	  into	  clusters	  where	  we	  monitored	  the	  effect	  on	  the	  localization	  score	  (loc_score)	  (Supplementary	  Figure	  6).	  Although	  the	  best	  loc_score	  is	  observed	  at	  similarity	  score	  of	  0.95,	  the	  number	  of	  graphlet-­‐derived	  clusters	  (minimum	  size	  4)	   is	   far	   too	   few.	  We	   chose	   to	   use	   a	   similarity	   score	   cut	   off	   of	   0.85	  where	   the	  number	  of	  returned	  clusters	  did	  not	  drop	  too	  drastically	  and	  where	  the	  loc_score	  was	   acceptably	   high	   (Supplementary	   Figure	   6).	   73	   graphlet-­‐derived	   clusters	  were	  obtained.	  6.3 RESULTS	  	  6.3.1 PSP	  CLUSTERING	  REVEALS	  STRONG	  ASSOCIATIONS	  WITHIN	  PHENOTYPE	  CLASSES	  Despite	  high	  variability	  and	  low	  consistency	  in	  reported	  proteins	  for	  each	  patient	  (Supplementary	  Figure	  7),	  we	  find	  that	  meaningful	  information	  can	  be	  extracted	  by	  contextualizing	  the	  reported	  proteins	  in	  each	  patient	  using	  the	  PSP	  approach.	  	  	  PSP	   was	   performed	   using	   the	   identified	   proteins	   from	   Mascot	   and	   Paragon	  respectively.	   In	  both	   cases,	   Paragon	   and	  Mascot	   generated	   tree	   structures	   that	  are	   similar.	   This	   indicates	   that	   PSP	   produces	   results	   that	   are	   stable.	   Also,	  Paragon	   consistently	   outperforms	   Mascot	   (Figure	   10)	   due	   to	   its	   higher	  sensitivity	   69.	   Since	   hierarchical	   clustering	   of	   patient	   PSPs	   is	   an	   unsupervised	  method	   (i.e.,	   no	   class	   label	   of	   patients	  was	   used),	   there	   can	   be	   no	   over-­‐fitting	  with	  regards	  to	  class	  label	  of	  the	  patients.	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FIGURE	  10	  COMPARISON	  OF	  BOOTSTRAPPED	  HCL	  TREES	  GENERATED	  VIA	  PVCLUST.	  	  
VALUES	   ON	   THE	   EDGES	   OF	   THE	   CLUSTERING	   ARE	  P-­‐VALUES	   (%).	  RED	  VALUES	   ARE	  AU	  P-­‐VALUES,	   AND	  
GREEN	  VALUES	   ARE	  BP	  VALUES	   AS	   EXPLAINED	   EARLY	   UNDER	   METHODS.	   CLUSTERS	   WITH	  AU	  LARGER	   THAN	  
95%	   ARE	   HIGHLIGHTED	   BY	   RED	   BOXES	   AND	   ARE	   VERY	   STRONGLY	   SUPPORT	   BY	   THE	   DATA.	   WITH	   ONLY	   73	  
GRAPHLET-­‐DERIVED	   CLUSTERS,	   THIS	   DID	   NOT	   PROVIDE	   SUFFICIENT	   DIMENSIONS	   FOR	   CLEARLY	   RESOLVING	  
THE	   MOD	   AND	   POOR	   PATIENTS	   (LEFT	   COLUMN)	   ALTHOUGH	   PARAGON	   FARED	   MUCH	   BETTER	   BECAUSE	   OF	  
BETTER	  HIT	  RATES.	  THE	  RIGHT	  COLUMN	  SHOWS	  THAT	  WITH	  THE	  USE	  OF	  A	  MUCH	  LARGER	  SET	  OF	  DIMENSIONS	  
OR	   CLUSTERS,	   IN	   THIS	   CASE,	   DERIVED	   FROM	   CORUM,	   THE	   TREES	   ARE	   VIRTUALLY	   IDENTICAL	  DESPITE	   THAT	  
PARAGON	  REPORTS	  A	  CONSIDERABLY	  LARGER	  NUMBER	  OF	  PROTEINS.	  IT	  IS	  ALSO	  NOTEWORTHY	  IN	  ALL	  CASES;	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the	   other	   mod	   patients	   reported	   on	   average	   ~300	   proteins.	   Analysis	   of	   the	  histopathology	  data	  (reported	   in	  2002)	  did	  not	  reveal	  any	  useful	  or	   interesting	  information	   on	   mod	   patient	   #203.	   Unfortunately,	   due	   to	   confidentiality	  agreements,	   it	   was	   impossible	   to	   follow	   up	   on	   whether	   mod	   patient	   #203	  subsequently	  developed	  poor-­‐stage	  cancer.	  6.3.2 SIGNIFICANT	  CLUSTERS	  ARE	  FUNCTIONALLY	  CONGRUENT;	  EXPRESSIONALLY	  SILENT	  CLUSTERS	  MAY	  ALSO	  PLAY	  KEY	  ROLES	  Using	   a	   modified	   SNet	   approach	   (we	   do	   not	   arbitrarily	   filter	   for	   the	   top	  expressed	   proteins)95,	   we	   identified	   159	   CORUM	   complexes	   as	   significant	   (p-­‐value	  ≤0.05).	  To	  guide	  functional	  analysis,	  i.e.,	  whether	  a	  cluster	  has	  a	  propensity	  to	  show	  obvious	  expressional	  changes,	  expression	  information	  is	  incorporated	  to	  score	  and	  rank	  the	  significant	  clusters	  (see	  “cluster	  score”	  under	  Methods).	  Since	  the	   clusters	   are	   scored	   in	   a	   similar	   manner	   in	   PEP2,	   this	   facilitates	  correspondence	   analysis	   to	   check	   if	   the	   best	  matched	   clusters	   score	   and	   rank	  similarly.	  	  Among	   the	   top	   ranking	   clusters	   in	   PSP	   (Table	   9),	   which	   also	   corresponded	  closely	  to	  the	  top	  reported	  clusters	  in	  PEP,	  is	  a	  cluster	  comprising	  XRCC5,	  XRCC6,	  WRN,	  PARP1	  and	  PRKDC2.	  This	  correspondence	  further	  supports	  that	  this	  group	  of	  proteins	  are	  likely	  key	  drivers	  for	  HCC	  progression.	  	  
TABLE	  9	  TOP	  RANKED	  PSP	  CLUSTERS.	  
Cluster_ID p_val mod_score poor_score cluster_name 
5179 0.000300541 0.513951977 3.159758312 
NCOA6-DNA-PK-Ku-PARP1 
complex 
5235 0.000300541 0.513951977 3.159758312 
WRN-Ku70-Ku80-PARP1 
complex 
1193 0.000300541 0.513951977 3.159758312 Rap1 complex 
159 0 0 2.810927655 
Condensin I-PARP-1-XRCC1 
complex 
2657 0.008815869 0 2.55616281 
ESR1-CDK7-CCNH-MNAT1-
MTA1-HDAC2 complex 
3067 0.00911641 0 2.55616281 
RNA polymerase II complex, 
incomplete (CDK8 complex), 
chromatin structure 
modifying 
1226 0.013323983 0.715352108 2.420592827 H2AX complex I 
5176 0 0.513951977 2.339059313 
MGC1-DNA-PKcs-Ku 
complex 
1189 0 0.513951977 2.339059313 
DNA double-strand break 
end-joining complex 
5251 0 0.513951977 2.339059313 Ku-ORC complex 
2766 0 0.513951977 2.339059313 TERF2-RAP1 complex 	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We	   also	   ranked	   the	   most	   commonly	   occurring	   GO	   BP	   terms	   among	   all	   159	  significant	  clusters	  (Table	  10).	  The	  results	  are	  congruent	  with	  expectations.	  The	  top	  ranking	  term	  is	  “viral	  reproduction”,	  which	  is	  in	  line	  with	  the	  fact	  that	  all	  12	  patients	  are	  Hepatitis	  B	   infected.	  The	  subsequent	  ranking	   terms	  corresponding	  to	  cellular	  reproduction	   -­‐-­‐-­‐	  e.g.	  mitotic	  cycle,	  S	  phase,	  etc.	   -­‐-­‐-­‐	   is	   in	   line	  with	   the	  unregulated	   division	   of	   cancer	   cells.	   Interestingly,	   “base-­‐excision	   repair”,	  “telomere	   maintenance”	   and	   “apoptosis”	   also	   come	   among	   the	   top-­‐ranking	  terms.	  	  The	   loss	   of	   repair	   mechanisms	   gives	   rise	   to	   mutations	   that	   fuel	   cancer	  progression	   while	   telomeres	   and	   control	   over	   cell	   death	   or	   apoptosis	   are	  essential	  for	  cellular	  immortality	  and	  continued	  division.	  These	  findings	  indicate	  that	  even	  without	  artificially	  filtering	  the	  proteins	  by	  the	  expression	  ratios	  or	  by	  consensus	   from	   at	   least	   half	   of	   the	   patients,	   the	   threshold-­‐free	   PSP	   approach	  produced	  significant	  clusters	  that	  were	  functionally	  congruent	  with	  GO	  BP	  terms	  expected	  in	  cancer.	  
TABLE	  10	  TOP	  RANKED	  GO	  BP	  TERMS	  FOUND	  IN	  SIGNIFICANT	  PSP	  CLUSTERS.	  
GO ID Description No. of clusters 
GO:0016032 viral reproduction 36 
GO:0000398 nuclear mRNA splicing, via spliceosome 34 
GO:0000278 mitotic cell cycle 28 
GO:0000084 S phase of mitotic cell cycle 28 
GO:0006366 Transcription from RNA polymerase II promoter 26 
GO:0006283 Transcription-coupled nucleotide-excision repair 22 
GO:0006369 Termination of RNA polymerase II transcription 22 
GO:0006284 base-excision repair 21 
GO:0000086 G2/M transition of mitotic cell cycle 21 
GO:0000079 regulation of cyclin-dependent protein kinase activity 20 
GO:0010833 Telomere maintenance via telomere lengthening 20 
GO:0033044 regulation of chromosome organization 19 
GO:0006200 ATP catabolic process 18 
GO:0042475 Odontogenesis of dentine-containing tooth 18 
GO:0034138 toll-like receptor 3 signaling pathway 17 
GO:0006915 Apoptosis 17 
GO:0006271 DNA strand elongation involved in DNA replication 17 
GO:0031145 
anaphase-promoting complex-dependent proteasomal 
ubiquitin-dependent protein catabolic process 17 
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GO:0006261 DNA-dependent DNA replication 17 
GO:0048015 phosphatidylinositol-mediated signaling 16 
GO:0006986 Response to unfolded protein 16 
GO:0000077 DNA damage checkpoint 16 
GO:0008063 Toll signaling pathway 16 
GO:0043488 regulation of mRNA stability 16 
GO:0006338 chromatin remodeling 16 
GO:0002756 MyD88-independent toll-like receptor signaling pathway 16 
GO:0000216 M/G1 transition of mitotic cell cycle 16 
GO:0071103 DNA conformation change 16 
GO:0000724 double-strand break repair via homologous recombination 16 
GO:0034142 toll-like receptor 4 signaling pathway 16 
GO:0010212 Response to ionizing radiation 16 
GO:0051301 cell division 15 
GO:0006333 chromatin assembly or disassembly 15 
GO:0071445 cellular response to protein stimulus 15 
GO:0002755 MyD88-dependent toll-like receptor signaling pathway 14 
GO:0043487 regulation of RNA stability 14 	  There	  were	  24	  clusters	  for	  which	  the	  mod	  and	  poor	  cluster	  scores	  are	  both	  zero,	  i.e.,	   the	  reported	  protein	  ratios	   for	  patients	   in	  both	  groups	  had	  no	  change	  from	  the	   normal	   state.	   This	   means	   the	   cluster	   score	   is	   zero	   in	   both	   mod	   and	   poor	  samples	   for	   these	   clusters.	   However,	   each	   of	   these	   clusters	   is	   still	   significant	  because	   proteins	   in	   them	   tend	   to	   occur	  mostly	   in	  mod	   group	   and	   not	   in	   poor	  group	  (or	  vice	  versa).	  We	   took	   the	   view	   that	   significantly	   differing	   patterns	   of	   expression	   are	  important	  even	  if	  the	  proteins	  are	  not	  necessarily	  driven	  to	  excessively	  higher	  or	  lower	  levels.	  Not	  all	  mutations	  function	  in	  such	  a	  manner.	  On	  the	  other	  hand,	  it	  can	   also	   be	   argued	   that	   coverage	   issues	   due	   to	   small	   sample	   size	   may	   also	  introduce	  many	  false	  positives,	  in	  which	  case,	  it	  may	  be	  more	  feasible	  to	  focus	  on	  complexes	   with	   either	   high	   poor	   scores,	   low	   moderate	   scores,	   or	   a	   high	  poor/moderate	  score	  ratio.	  Given	  that	  this	  group	  may	  be	  potentially	  interesting,	  we	  describe	  two	  significant	  complexes	  therein	  with	  the	  lowest	  p-­‐values,	  the	  Wave2	  complex	  and	  the	  Bloc1-­‐Bloc2	  complex.	  The	  Wave2	  complex	  plays	  a	  role	  in	  controlling	  cellular	  movement	  and	  is	  implicated	  in	  metastasis	  of	  liver	  cells	  to	  the	  colon.	  Bloc1-­‐Bloc2	  functions	  in	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secretion	   and	   lysosomal	   functions.	   While	   this	   is	   an	   associated	   function	   of	   the	  liver,	  whether	  it	  plays	  a	  key	  role	  in	  liver	  cancer	  is	  not	  clear.	  6.3.3 COMPARISONS	  WITH	  PROTEOMICS	  EXPANSION	  PIPELINE	  (PEP)	  APPROACH	  In	  PEP,	  we	  obtained	  a	  smaller	  number	  of	  clusters	  at	  70.	  This	  is	  hardly	  surprising	  because	  in	  PEP,	  clusters	  were	  built	  around	  seed	  proteins,	  i.e.,	  proteins	  which	  are	  supported	   by	  more	   than	   half	   of	   patients,	   and	  which	   exhibit	   fold	   change	   ratios	  above	   1.3	   and	   below	   0.75	   69.	   With	   such	   thresholds	   in	   place,	   (Supplementary	  Figure	  4),	  fewer	  proteins	  can	  meet	  such	  a	  stringent	  requirement.	  	  To	  understand	  how	  well	  results	  match	  between	  PEP	  and	  PSP,	  we	  pre-­‐sorted	  the	  files	  in	  similar	  order	  (that	  is,	  in	  descending	  order	  of	  poor	  cluster	  scores,	  followed	  by	  mod	  cluster	  scores).	  	  Since	  the	  complexes	  will	  not	  match	  completely,	  we	  find	  the	  best	  similarity	  (max	  Jaccard	  score	  or	  J	  score)	  of	  at	  least	  10%	  similarity	  for	  each	  PSP	  complex	  to	  PEP	  complex.	   The	   reason	   is	   because	   PEP	   clusters	   are	   built	   using	   the	   clique	  percolation	  method	  where	  similar	  or	  overlapping	  groups	  are	  merged	  and	  hence	  are	  more	  likely	  to	  be	  unique.	  PEP	  ranks	  and	  PSP	  ranks	  obeyed	  a	   linear	  correlation	   (pval	  =	  0.00058)	  and	   the	  adjusted	  fit	  is	  acceptable	  (Adjusted	  R-­‐squared	  =	  0.5)	  (Figure	  11).	  This	  imperfect	  correlation	   is	   not	   unexpected	   given	   how	   methodologically	   different	   the	   two	  methods	  are.	  	  
	  
FIGURE	  11	  RANKS	  CORRELATION	  BETWEEN	  PEP	  AND	  PSP.	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Although	  PEP	  and	  PSP	  clusters	  were	  derived	  from	  very	  different	  methods,	  it	  can	  be	  seen	  that	  their	  results	  correlate	  well.	  To	  reduce	  the	  level	  of	  noise,	  we	  required	  a	  Jaccard	  score	  of	  at	  least	  0.1	  (10%	  similarity).	  Table	   11	   shows	   the	   best-­‐matched	   PEP	   clusters	   ranked	   by	   the	   J	   score.	   As	  mentioned	  earlier,	  the	  third	  best	  cluster	  reported	  in	  PSP	  corresponds	  closely	  to	  PEP’s	  DNA	  damage	  cluster	  comprising	  of	  XRCC6,	  PCNA,	  PRKDC,	  WRN,	  XRCC5	  and	  PARP1.	   As	   previously	   reported,	   XRCC5/6,	   and	   PCNA	   and	   PARP1	   are	   repair	  factors,	  while	  WRN	   is	   a	   nuclear	   protein	   that	   could	   be	   involved	   in	  maintaining	  genomic	  stability.	  PRKDC	  is	  a	  protein	  kinase	  that	  is	  capable	  of	  targeting	  p53	  (and	  we	  did	  find	  p53	  in	  a	  larger	  but	  lower	  scoring	  variant	  of	  this	  cluster),	  and	  this	  was	  found	   to	  be	  differentially	  expressed	   in	  a	  majority	  of	  poor	  patients	   (5	  out	  of	  7).	  The	  repair	  factors	  were	  all	   low	  count,	  between	  1	  to	  2	  patients	  each.	  In	  PEP,	  we	  proved	  that	  even	  if	  patients	  report	  different	  proteins,	  they	  are	  likely	  to	  be	  linked	  directly	  to	  a	  seed,	  or	  situated	  in	  the	  same	  community	  as	  a	  seed	  and	  thus	  can	  be	  recovered	   by	   clustering	   the	   expanded	   neighborhood	   around	   the	   seed.	   In	   PSP,	  this	  was	  taken	  to	  a	  higher	  level	  where	  we	  did	  not	  consider	  seeds,	  but	  we	  found	  that	  patients	  expressed	  proteins	  that	  tend	  to	  be	  localized	  to	  certain	  complexes	  or	  sub-­‐modules	  anyway	  (similar	  contexts).	  	  
TABLE	  11	  BEST	  MATCHING	  PEP	  CLUSTERS	  TO	  PSP	  CLUSTERS.	  
PEP rank PSP rank J score Members (as in PEP) 
41 104 0.4 
 DHX9 SMN1 DDX20 GEMIN4 SMN2 SNRPB 
SIP1  
23 17 0.333333333  COL1A2 CD36 ITGB3 ITGA2B  
9 1 0.25  XRCC6 PCNA PRKDC WRN XRCC5 PARP1  
20 134 0.25  PRKDC XPA RPA1 RPA2  
11 20 0.222222222  ACTR2 ACTR3 ARPC4 ARPC5  
40 147 0.222222222  PRKCD RAF1 MAPK1 PRKCZ PEBP1 MAP2K1  
16 1 0.2 
 XRCC6 PCNA PRKDC TP53 WRN NCOA6 XRCC5 
PARP1  
34 74 0.1875  MAP3K14 CHUK MAP3K7 PEBP1 IKBKB  
4 33 0.142857143  FUS PTBP1 SFPQ ZMYM2  
5 88 0.142857143  YWHAB HSP90AB1 IKBKB MAP3K3  
22 30 0.142857143  CANX ITGA6 ITGB1 CD82  
43 137 0.133333333  GSN AR CASP3 PXN BCAR1 FYN  
1 77 0.125  YWHAQ HSPA1A HSPA8 YWHAG  
2 0 0.125  TP53 NPM1 NCL PARP1  
12 77 0.125  SET APEX1 GZMA HMGB2  
13 23 0.125  RAN RCC1 XPO1 RANBP3  
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52 162 0.125  PRKCD EP300 CREBBP KLF5  
57 147 0.125  PRKACA RAF1 BAD BCL2  
61 74 0.117647059  AKT1 IRS1 PRKCQ CHUK IKBKB  
27 147 0.111111111  YWHAZ RAF1 CDC25A MAP3K5 YWHAE  
31 77 0.111111111  HSPA1A BAG1 STUB1 HSPA8 HSF1  
65 147 0.111111111  RAF1 AR HSP90AA1 MAPK1 NR3C1  	  Other	   top	   ranking	   clusters	   in	   PEP	   were	   also	   found	   highly	   ranked	   in	   PSP.	   For	  example,	   clusters	   comprising	   ACTR2,	   ACTR3,	   ARPC4	   and	   ARPC5;	   RAN,	   RCC1,	  XPO1	  and	  RANBP3;	  FUS,	  PTBP1,	  SFPQ	  and	  ZMYM2	  were	  all	  found	  in	  the	  top	  30	  ranks	  of	  their	  corresponding	  PSP	  best	  match.	  6.3.4 USING	  PSP	  WITH	  PREDICTED	  CLUSTERS	  FROM	  PPIN	  It	  was	  unsurprising	  that	  the	  CORUM-­‐derived	  cluster	  vector	  performs	  better	  than	  the	  use	  of	   graphlet-­‐derived	   clusters	   (73	   clusters)	   alone	   as	   the	   former	   contains	  many	   more	   clusters	   (523	   complexes).	   As	   the	   number	   of	   graphlet-­‐derived	  clusters	   is	  only	  73,	   it	   lacks	  sufficient	   information	  on	   its	  own	   to	  properly	  group	  our	   cancer	   patients.	   Indeed,	   it	   was	   found	   that	   it	   was	   less	   powerful	   (lower	   AU	  scores)	  in	  resolving	  poor	  and	  moderate	  patients	  although	  the	  tree	  structure	  was	  	  on	  the	  whole	  still	  stable	  (Figure	  10	  left	  column).	  To	  investigate	  if	  there	  are	  significant	  overlaps	  between	  the	  information	  captured	  in	   CORUM	   and	   the	   graphlet-­‐derived	   clusters,	   we	   checked	   the	   Jaccard	   distance	  between	   all	   clusters	   in	   both	   groups.	   The	   Jaccard	   distance	   is	   a	   measure	   of	  similarity	  between	  two	  groups	  by	  comparing	  their	  intersection	  divided	  over	  the	  union.	  At	  Jaccard	  threshold	  0.9,	  that	  is,	  at	  least	  90%	  similarity,	  only	  one	  graphlet-­‐derived	  cluster	  was	  dropped.	  When	  we	  relaxed	  the	  Jaccard	  threshold	  to	  0.6,	  we	  still	   kept	   about	   69	   out	   of	   75	   graphlet-­‐derived	   clusters.	   This	   suggests	   that	   the	  graphlet-­‐derived	   clusters	   are	   quite	   distinct	   from	   the	   CORUM	   complexes	   and	  encapsulate	  a	  different	  set	  of	  information	  that	  is	  potentially	  interesting.	  	  17	  out	  of	  72	  graphlet-­‐derived	  clusters	  were	  identified	  as	  significant	  (24%).	  This	  is	  comparable	  to	  30%	  from	  CORUM	  complexes.	  This	  suggests	  that	  there	  might	  be	  a	  slight	  bias	  to	  hit	  only	  real	  complexes.	  Hence	   we	   merged	   the	   72	   graphlet-­‐derived	   clusters	   (based	   on	   0.9	   Jaccard	  distance	  threshold)	  and	  the	  523	  CORUM	  complexes	  to	  be	  compared	  against	  the	  Paragon	  dataset	   in	   the	   final	   and	   functional	   analysis.	  We	   find	   that	   the	  HCL	   tree	  generated	   from	   the	   merger	   (Supplementary	   Figure	   5)	   is	   identical	   to	   that	   of	  Paragon	   with	   CORUM	   clusters	   (Figure	   10	   bottom	   right).	   However,	   the	  approximately	   unbiased	   (AU)	   p-­‐value	   dropped	   slightly.	   This	   is	   not	   surprising	  since	  the	  larger	  number	  of	  dimensions	  may	  give	  rise	  to	  more	  noise	  but,	  in	  turn,	  increase	   the	   number	   of	   potential	   clusters	   that	   could	   be	   implicated	   in	   cancer.	  CORUM	  complexes,	  while	  extensive,	  are	  likely	  to	  contain	  gaps	  in	  information	  that	  could	   be	   supplemented	   by	   the	   graphlet-­‐derived	   clusters.	   Hence,	   for	   functional	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downstream	  analysis,	  we	  used	  Paragon	  with	  the	  cluster	  vector	  comprising	  both	  CORUM	  complexes	  and	  graphlet-­‐derived	  clusters.	  In	   any	   case,	   PSP	   can	   confidently	   resolve	   the	   patient	   groups	   even	   in	   the	   event	  where	  very	  few	  dimensions	  are	  available	  (using	  only	  graphlet-­‐derived	  clusters)	  although	   it	   would	   be	   preferable	   in	   such	   a	   situation	   to	   use	   a	   database	   search	  algorithm	  that	  returns	  more	  protein	  hits	  such	  as	  Paragon.	  This	  suggests	  that	  PSP	  can	   be	   used	   in	   instances	   where	   only	   a	   reference	   PPI	   network	   and	   very	   little	  complex	  information	  are	  available.	  6.4 DISCUSSIONS	  In	   this	   study,	   we	   have	   described	   a	   novel	   in	   silico	   method	   to	   functionally	  characterize	  proteome-­‐wide	  data	   related	   to	  HCC	  progression	  by	  doing	  without	  predefined	   data	   thresholds	   on	   the	   reported	   protein	   list.	   Early	   thresholding	   of	  MS-­‐generated	   proteomic	   data	   may	   result	   in	   a	   decreased	   volume	   of	   crucial	  information	   for	   statistical	   and	   biological	   interpretation.	   To	   yield	   potentially	  useful	   interpretations,	   we	   avoided	   the	   use	   of	   analysis	   thresholds	   at	   this	   level,	  instead,	  opting	  to	  generate	  a	  PSP	  using	  our	  cluster	  vector.	  	  Importantly,	  since	  PSP	  does	  not	  rely	  on	  fold	  change	  ratios	  and	  patient	  selection	  a	  priori,	   and	   utilizes	   several	   lines	   of	   evidence	   including	   protein	   complexes	   and	  biological	  networks,	  we	  implicated	  deregulated	  DNA	  repair	  and	  immune-­‐evasion	  as	  two	  important	  mechanisms	  in	  the	  transition	  of	  moderate-­‐stage	  HCC	  to	  poor-­‐stage	  HCC	  characterized	  by	  poor	  survival	  prognosis	  in	  our	  patient	  set.	  	  Although	  we	  are	  not	  able	  to	  follow	  up	  on	  mod	  patient	  #203,	  the	  results	  from	  PSP	  revealed	   fundamental	   weaknesses	   in	   relying	   solely	   on	   histopathological	  classifications.	   Compared	   to	   clinical	   staging,	   e.g.	   TNM	   Classification	   and	  Barcelona-­‐Clinic	   Liver	   Cancer	   (BCLC)	   staging	   which	   is	   often	   hampered	   by	  surgeon-­‐to-­‐surgeon	   subjectivity,	   heterogeneity	   of	   HCC	   (including	   borderline	  cases)	   and	   poor	   qualification,	   molecular	   signatures	   are	   objective,	   specific	   to	  cancer	   types	   and	   our	   results	   here	   demonstrate	   that	   PSP	   can	   deliver	  unprecedented	  characterization	  of	  HCC	  tumors	  at	  a	  medically	  relevant	  level.	  Although	   mod	   patient	   #203	   may	   be	   an	   anomaly,	   PSP	   results	   are	   stable	   even	  when	   performed	   using	   different	   protein	   prediction	   algorithms	   or	   when	   using	  predicted	  clusters	  and	  real	  protein	  complexes.	  Furthermore,	  with	  the	  exception	  of	  mod	  patient	  #203	  and	  given	  that	  clustering	  approaches	  do	  make	  errors	  due	  to	  incomplete	  information,	  its	  performance	  is	  acceptable	  for	  classifying	  patients	  by	  their	  molecular	  signatures.	  	  6.4.1 THE	  USE	  OF	  BOTH	  CORUM	  AND	  GRAPHLET-­‐DERIVED	  CLUSTERS	  IN	  THE	  CLUSTER	  VECTOR	  The	   drop	   in	   p-­‐value	   for	   the	   cluster	   vector	   comprising	   CORUM	   and	   graphlet-­‐derived	   clusters	   is	   not	   unexpected.	   Given	   the	   larger	   number	   of	   dimensions	  included,	   the	   more	   likely	   that	   some	   dimensions	   might	   be	   noise/irrelevant	  despite	  controlling	   for	  biological	  coherence	  of	   the	  graphlet-­‐derived	  clusters	  via	  the	  loc_score.	  Hence,	  it	  may	  be	  by	  sheer	  chance	  that	  some	  patients	  (of	  different	  phenotypes)	   scored	   identically	   on	   these	   irrelevant	   dimensions,	   contributing	   to	  the	   slight	   fall	   in	   p-­‐value.	   It	   does	   however	   justify	   the	   use	   of	   our	   SNet-­‐based	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approach	   for	   feature	  selection,	   such	   that	  analysis	   is	   focused	  only	  on	  significant	  clusters.	  A	  second	  point	  is	  that	  graphlet-­‐derived	  clusters	  are	  very	  different	  from	  CORUM	  complexes.	  As	  reported,	  at	  the	  minimum	  Jaccard	  score	  of	  0.9,	  only	  one	  graphlet-­‐derived	   cluster	   was	   dropped.	   This	   did	   not	   change	   significantly	   as	   the	   Jaccard	  score	   threshold	  was	   lowered	   to	  0.6.	  Hence,	   it	   is	  more	   likely	   it	   is	   that	   graphlet-­‐derived	   clusters	   capture	   different	   biological	   information	   from	   CORUM	   clusters	  and	  are	  therefore	  potentially	  interesting.	  6.4.2 FUNDAMENTAL	  DIFFERENCES	  BETWEEN	  PSP	  AND	  PEP	  AND	  HOW	  THEY	  COMPLEMENT	  EACH	  OTHER	  We	   showed	   that	   the	   ranked	   results	   from	   PSP	   correlated	   well	   with	   PEP	   even	  though	  they	  are	  quite	  different	  techniques.	  	  PEP	  is	  dependent	  on	  the	  quality	  of	  the	  reference	  PPIN	  but	  produces	  clusters	  that	  are	  generally	  larger	  and	  more	  likely	  to	  contain	  novel	  interactions.	  It	  requires	  the	  initial	  definition	  of	   seeds,	  which	  means	   that	   it	   begins	  with	   a	   large	   loss	  of	  data,	  which	  is	  attenuated	  by	  the	  expansion	  and	  clustering	  phase.	  PSP	   only	   considers	   whether	   a	   protein	   is	   detected	   or	   not,	   and	   uses	   this	  information	  to	  first	  establish	  a	  vector	  of	  hit	  rates	  to	  define	  the	  patient’s	  signature	  profile.	  The	  vector	   is	   limited	  on	   current	  knowledge	  of	   complexes,	   in	  which	   the	  exact	   binding	   configuration	   needs	   not	   be	   well	   defined.	   Although	   there	   is	  substantially	  more	  knowledge	  on	  human	  complexes,	  it	  is	  by	  no	  means	  complete.	  To	   boost	   the	   information	   contained	   in	   the	   cluster	   vector,	   CORUM	   can	   be	  supplemented	   via	   the	   partitioning	   the	   reference	   network	   into	   biologically	  coherent	  sub-­‐modules.	  	  We	   opted	   to	   use	   the	   graphlets	   approach	   because	   it	   has	   been	   shown	   to	   be	  effective	   in	   identifying	   clusters	   based	   on	   topological	   similarity	   179.	   Although	   it	  gives	   rise	   to	   a	   small	   number	   of	   topologically	   coherent	   subnets,	   which	  may	   or	  may	  not	  be	  real,	  we	  found	  that	  there	  was	  only	  a	  slight	  propensity	  to	  report	  real	  complexes	   as	   significant.	   In	   the	   current	   literature,	   there	   exists	   a	   multitude	   of	  clustering	  algorithms	   that	   could	  also	  be	  utilized	   to	  generate	  a	  more	  exhaustive	  list	   of	   predicted	   clusters.	   However,	   in	   this	   instance,	   using	   one	   clustering	  approach	  is	  sufficient	  to	  demonstrate	  the	  potential	  of	  this	  approach	  in	  enriching	  PSP’s	  cluster	  vector.	  The	   top-­‐ranked	   clusters	   in	   both	   PEP	   and	   PSP	   are	   well	   matched	   given	   the	  surprisingly	   good	   correlations	  between	   the	   ranks	  of	   similar	   clusters.	  However,	  we	  also	  note	  that	  the	  complexes	  in	  PEP	  and	  PSP	  have	  a	  generally	  modest	  overlap.	  The	   best	  match	   is	   only	   about	   Jaccard	   score	   0.4.	   Since	   PSP	   reports	   known	   and	  generated	  complexes	  whereas	  PEP	  identifies	  novel	  clusters	  based	  around	  seeds,	  matched	   clusters	  based	  on	   similarity	   should	   therefore	  be	   analyzed	   closely	   in	   a	  complementary	   manner.	   This	   should	   be	   a	   good	   way	   to	   discover	   previously	  unreported	   or	   novel	   cluster	   members	   that	   make	   for	   interesting	   biological	  interpretations.	  6.4.3 WHY	  THE	  PSP	  APPROACH	  IS	  MORE	  POWERFUL	  AND	  SENSITIVE.	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PSP	  is	  a	  very	  powerful	  technique	  because	  firstly,	  it	  is	  not	  constrained	  by	  the	  use	  of	   thresholds	   on	   the	   reported	   protein	   list,	   which	   is	   arbitrarily	   defined	   by	   the	  analyst.	  Instead,	  it	  uses	  all	  the	  information	  provided	  from	  the	  proteomics	  screen.	  It	  also	  does	  not	  use	  the	  average	  expression	  ratios	  of	  any	  given	  protein	  because	  that	  is	  likely	  misleading	  in	  a	  small	  sample	  set,	  especially	  for	  proteins	  supported	  by	  only	  two	  to	  three	  patients,	  or	  if	  the	  protein	  expression	  levels	  swing	  from	  low	  to	  high	  in	  different	  patients.	  	  Secondly,	   it	   is	   less	   reliant	   on	   the	   reference	   network	   in	  which	   noise	   levels	   and	  false	  negative	  levels	  are	  not	  known.	  Instead,	  it	  uses	  biologically	  rich	  data	  sources	  such	   as	   complexes.	   It	   is	   also	   expandable	   to	   incorporate	   information	   from	  network	   partitions	   as	  we	   did	  with	   the	   derivation	   of	   graphlet-­‐derived	   clusters.	  Although	  we	   found	   that	   the	   sole	   use	   of	   graphlet-­‐derived	   clusters	   gave	   poorer	  results,	   it	   was	   likely	   due	   to	   the	   small	   number	   of	   clusters	   and	   hence	   lesser	  resolving	   dimensions.	   The	   results	   are	   improved	   by	   using	   a	   more	   sensitive	  protein	  search	  algorithm	  such	  as	  Paragon.	  The	  third	  important	  advantage	  of	  PSP	  is	   that	   by	   generating	   the	   signature	   profiles	   for	   each	   patient,	   it	   allows	   the	  generation	  of	  a	  matrix	  on	  which	  systematic	  analysis	  can	  be	  applied.	  As	  seen	  here,	  we	   showed	   that	   the	  poor	   and	  mod	  patients	   segregate	  well.	  We	  also	  discover	   a	  single	   mod-­‐stage	   patient	   who	   is	   anomalous,	   and	   would	   skew	   the	   analytical	  results	   by	   virtue	   of	   the	   small	   sample	   size.	   PSP’s	   signature-­‐based	  methodology	  will	  be	  able	  to	  detect	  this.	  We	  have	  also	  developed	  a	  feature	  selection	  method	  on	  which	   to	   identify	   clusters	   that	   are	   significantly	   different	   in	   the	   moderate	   and	  poor	  phase.	  6.4.4 POSSIBLE	  LIMITATIONS	  OF	  PSP	  PSP	  is	  dependent	  on	  the	  quality	  and	  quantity	  of	  the	  cluster	  vector.	  As	  seen	  under	  Results,	   PSP	   performs	   relatively	   poorly	   in	   its	   ability	   to	   resolve	   moderate	   and	  poor	  patients	  using	  only	  the	  73	  graphlet-­‐derived	  clusters	  although	  performance	  is	  greatly	   improved	  by	  using	  Paragon	   instead	  of	  Mascot,	   the	  obvious	  difference	  being	  that	  Paragon	  is	  more	  sensitive.	  Our	  previous	  analysis	  showed	  that	  Paragon	  and	   Mascot	   correlated	   well	   in	   both	   ranks	   and	   reported	   ratios	   for	   the	   same	  proteins	   69.	   In	   addition,	   most	   Mascot	   proteins	   are	   also	   found	   in	   Paragon.	   The	  extra	   proteins	   reported	   in	   Paragon,	   however,	   are	   of	   lower	   confidence.	   That	   is,	  their	  ranks	  are	  significantly	  lower	  than	  expected	  by	  chance	  69.	  	  On	   the	   other	   hand,	   although	   we	   used	   523	   CORUM	   complexes,	   there	   might	   be	  some	  redundancy.	  Some	  CORUM	  complexes	  are	  quite	  similar,	  with	  high	  overlaps	  with	   each	   other	   (results	   not	   shown).	   However,	  we	   elected	   not	   to	  merge	   these	  given	   that	   the	  merged	   clusters	  would	   be	   arbitrary	   and	   not	   reflective	   of	   a	   true	  biological	   unit.	   A	   second	   problem	  with	   CORUM	   complexes	   is	   that	   they	   do	   not	  encompass	   the	   entire	   protein	   network.	   Although	   we	   demonstrate	   how	   to	  improve	   this	   shortcoming	   by	   supplementing	   the	   cluster	   vector	   with	   graphlet-­‐derived	   clusters,	   the	   “representative”	   cluster	   vector,	   encompassing	   maximal	  biological	  information,	  is	  probably	  not	  attainable.	  We	  do	  know	  that	  the	  cluster	  vector	  derived	  using	  CORUM	  complexes	  gives	  very	  significant	  resolution	  in	  segregating	  mod	  and	  poor	  patients.	  Despite	  veering	  far	  from	  conventional	  methods,	  it	  produced	  results	  that	  are	  congruent	  with	  what	  is	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known	  about	  liver	  cancer,	  and	  correlates	  very	  well	  with	  PEP,	  which	  is	  closer	  to	  current	  conventional	  approaches.	  Since	  we	  did	  not	  use	  any	  kind	  of	  thresholds	  to	  filter	  proteins	  in	  PSP,	  the	  effects	  of	  false-­‐positive	   proteins	   are	   a	   legitimate	   concern.	   This	   is	   especially	   so	   on	   big	  protein	   complexes,	   	   because	  a	  big	   complex	  encompasses	  more	  proteins	  and	   so	  has	   a	   higher	   likelihood	   to	   be	   hit	   by	   false-­‐positive	   proteins.	   However,	   this	   is	  mitigated	  as	  elaborated	  below:	  Let	   the	   false	   positive	   rate	   be	   r,	   where	   0<	   r	   <	   1.	   For	   some	   complex	   C,	   let	   the	  number	   of	   proteins	   be	   defined	   as	   n	   (where	   4	   ≤	   n).	   y	   denotes	   the	   number	   of	  predicted	   proteins	   (classified	   as	   positive,	   Np).	   x	   is	   the	   actual	   number	   of	   real	  proteins	   (True	   positives).	   We	   let	   u	   and	   v	   be	   the	   actual	   hit-­‐rate	   (sans	   false	  positives)	  in	  phenotype	  A	  and	  B	  respectively,	  and	  h	  the	  observed	  hit-­‐rate.	  Using	  phenotype	  A	  to	  explain,	  the	  hit	  rate	  for	  some	  complex	  i,	  under	  phenotype	  A	  is	  h:	  H_CAi	  =	  y/n	  The	  false	  positive	  rate	  can	  be	  expressed	  as:	  𝑟 = 𝑦 − 𝑥𝑛 − 𝑥	  And	  the	  actual	  hit	  rate,	  u	  is	  given	  by:	   𝑢 = 𝑥𝑛	  The	  false	  positive	  rate	  can	  be	  rewritten	  as:	  
𝑟 = 𝑦 − 𝑢𝑛𝑛 − 𝑢𝑛   = 1𝑛 𝑦 − 𝑢𝑛1− 𝑢 = ℎ 11− 𝑢 − 𝑢1− 𝑢	  The	  expected	  value	  of	  the	  hit-­‐rate,	  h	  can	  be	  derived	  from	  the	  above	  as:	  ℎ = 𝑟 +    𝑢1− 𝑢 1− 𝑢 =   𝑢 1− 𝑟 +   𝑟	  	  In	  phenotype	  B,	  the	  corresponding	  hit	  rate	  (H_CBi	  =)	  would	  be:	  ℎ =   𝑣 1− 𝑟 +   𝑟	    The	  t-­‐score	  generated	  by	  comparing	  phenotype	  A	  and	  B	  should	  be	  independent	  of	  r.	  To	  show	  this,	  first	  consider	  the	  estimator	  of	  the	  common	  standard	  variation	  between	  A	  and	  B:	  
SHA,HB =
(m −1)SHA2 + (n −1)SHB2
m+ n − 2 	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SHA,HB =
(m−1)var[(1− r)u+ r]+ (n−1)var[(1− r)v+ r]2
m+ n− 2 	  
SHA,HB =
(m−1)(1− r)2 var(u)+ (n−1)(1− r)2 var(v)
m+ n− 2 	  
SHA,HB = (1− r)Su,v 	  The	  t-­‐score	  is	  given	  as:	  










E[(1− r)u+ r]−E[(1− r)v+ r]
(1− r)Su,v 1n +
1
m 	  
t _ score = (1− r)E(u)+ r − (1− r)E(v)− r











Hence,	   the	   t-­‐score	   is	   independent	  of	   the	   false	  positive	   rate,	   r.	   The	   empirical	   p-­‐values	  are	  based	  on	  the	  distribution	  of	  t-­‐scores.	  Since	  t-­‐score	  is	  independent	  of	  r,	  it	  should	  follow	  that	  the	  p-­‐value	  is	  also	  independent.	  	  Although	   theoretically,	  pathways	  could	  also	  be	  used	  as	   cluster	  vectors	   for	  PSP,	  there	   might	   be	   many	   limitations.	   We	   expect	   PSP	   to	   work	   well	   with	   small	  pathways	  but	  for	  pathways	  that	  are	  too	  large,	  the	  extra	  proteins	  would	  confound	  the	   significance	   testing.	   For	   example,	   in	   gene	   expression	   analysis,	   GSEA	   often	  indicates	   a	   pathway	   as	   insignificant.	   Yet,	   when	   a	   subnet	   identified	   using	   SNet	  from	   the	   same	   pathways	   is	   fed	   to	   GSEA,	   the	   results	   become	   significant.	   One	  possible	   way	   to	   get	   around	   this	   is	   to	   extract	   likely	   subnets	   from	   pathways;	  however,	  there	  is	  no	  straightforward	  way	  to	  perform	  this.	  In	  the	  next	  chapter,	  we	  propose	  a	  simple	  yet	  effective	  way	  of	  managing	  this	  problem.	  	  6.5 REMARKS	  We	   introduce	   a	   novel	   contextualization	   proteomics	   approach	   that	   does	   away	  with	   thresholding	   at	   the	  protein	   list	   level	   and	   apply	   it	   to	   a	   case	   study	  on	   liver	  cancer.	  We	  compared	   the	   results	   to	  our	  analytical	  pipeline	  PEP	  and	   found	   that	  the	   results	   correlated	  well.	   Unlike	   PEP	   and	   other	   network-­‐based	  method,	   PSP	  can	   deal	   with	   both	   coverage	   and	   consistency	   issues	   in	   proteomics.	   GO	   term	  analysis	  also	  indicates	  that	  the	  threshold-­‐free	  approach	  select	  clusters	  that	  play	  integral	   roles	   in	   cancer.	   The	   PSP	   approach	   revealed	   many	   more	   potential	  clusters	  than	  PEP	  and	  is	  not	  constrained	  by	  any	  prior	  arbitrary	  filtering	  which	  is	  a	  common	  first	  step	  in	  conventional	  analytical	  approaches.	  As	  PSP	  only	  considers	  whether	  a	  protein	  is	  present	  or	  not	  in	  a	  sample,	  it	  should	  also	  mean	  that	  it	  could	  be	  generalized	  for	  multi-­‐phase	  comparisons,	  e.g.,	  mixing	  data	  from	  different	  cancers	  and	  establishing	  which	  clusters	  are	  differential.	  This	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is	  likely	  to	  be	  useful	  for	  discovering	  cancer-­‐type-­‐specific	  complexes	  from	  which	  biomarkers	  could	  be	  derived	  and	  developed.	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7 EXPANDING	  THE	  UTILITY	  OF	  PSP	  USING	  PATHWAY-­‐DERIVED	  SUBNETS	  (PDS),	  FALSE	  POSITIVE	  ANALYSIS	  AND	  ADVANCED	  ONTOLOGIES	  
Brief	  summary	  and	  key	  points	  
• PSP,	   as	   described	   in	   the	   previous	   chapter,	   is	   a	   powerful	   and	   sensitive	  method	   for	   analyzing	   proteomics	   profiles	   even	   when	   sample	   sizes	   are	  small.	  It	  does	  not	  rely	  on	  the	  ratio	  scores	  but,	  rather,	  whether	  a	  protein	  is	  detected	  or	  not.	  	  
• While	   complexes	   (both	   real	   and	   predicted)	   provided	   a	   biologically-­‐rich	  feature	   set	   for	   PSP,	   it	   is	   limiting	   in	   that	   protein	   networks	   are	   only	   one	  aspect	   of	   biological	   function.	   Pathways	   correspond	   closely	   to	   biological	  processes	  such	  as	  metabolic	  reactions,	  as	  well	  as	  signaling	  and	  regulatory	  networks.	   The	   information	   contained	   therein	   is	   highly	   curated,	   and	   has	  been	  extensively	  studied.	  	  
• A	   pathway	   is	   identifiable	   with	   a	   defined	   set	   of	   biological	   functions.	   As	  such,	  they	  are	  commonly	  used	  in	  performing	  biological	  interpretations	  of	  biological	  data.	  There	  are	   two	  major	  problems	  with	  analysis.	  The	   first	   is	  the	  requirement	  for	  a	  threshold	  to	  establish	  the	  set	  of	  seeds.	  The	  second	  issue	   is	   the	   size	   and	   topology	   of	   the	   pathway	   itself.	   Pathways	   are	   not	  necessarily	  comprehensive	  and	  the	  size	  varies	  considerably.	  Suppose	  that	  only	   a	   small	   portion	  of	   a	   large	  pathway;	   the	  overlapping	  method	  would	  fail.	  	  
• We	   use	   proteins	   found	   in	   more	   than	   half	   of	   mod	   and	   poor	   patients	  respectively	   to	   build	   connected	   components	   from	   pathway	   data.	   These	  connected	  components,	  which	  we	  term	  Pathway-­‐Derived	  Subnets	  (PDSs)	  are	   much	   fewer	   in	   number	   than	   complexes	   (87)	   but	   are	   sufficiently	  informative	   that	   they	   can	   reproduce	   the	   same	   results	   in	   PSP	   (including	  the	  anomalous	  patient).	  	  
• Comparative	   analysis	   revealed	   that	   the	   integrated	   pathway	   database,	  PathwayAPI	  performed	  best.	  KEGG	   came	   in	   second	  while	  WikiPathways	  and	  IPA	  came	  in	  far	  behind.	  This	  reveals	  the	  extent	  of	  a	  lack	  of	  consistency	  and	  coverage	  among	  the	  major	  pathway	  databases.	  	  	  
• To	   understand	   whether	   there	   is	   any	   interplay	   between	   identified	  significant	  complexes	  and	  PDSs,	  we	   found	  that	  PDSs	  and	  complexes	  that	  co-­‐locate	  onto	  the	  same	  pathway	  had	  high	  expression	  correlation.	  There	  is	   an	   exception	   however,	   where	   cancer-­‐associated	   complexes	   “DNA	  synthesome”	  and	  “TNF	  alpha/NK-­‐kappa-­‐B	  sig	  complex	  5”	  colocates	  with	  a	  PDS	   on	   the	   pathway	   “purine	   metabolism”.	   Here,	   there	   was	   an	   extreme	  jump	   in	   terms	   of	   expression	   scores	   from	   mod	   to	   poor	   stage.	   We	  hypothesize	   that	   this	   interplay	   might	   be	   a	   novel	   molecular	   switch	  significant	  in	  cancer	  progression.	  	  
• Current	   functional	   analysis	   are	   heavily	   dependent	   on	   the	   use	   of	  ontologies,	   specifically,	   Gene	   Ontology.	   However,	   this	   is	   developed	   for	  more	  general	  purposes.	  Analytical	  resolution	  can	  be	  achieved	   further	  by	  developing	   focused	   thematic	   ontologies.	   Examples	   include	   cancer-­‐associated	  GO	  terms	  or	  lipid	  GO	  terms.	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7.1 INTRODUCTION	  In	   Chapter	   6,	   we	   demonstrated	   how	   Proteomics	   Signature	   Profiling	   (PSP)	   is	   a	  novel	  method	  for	  overcoming	  small	  sample	  size,	  consistency	  and	  coverage	  issues	  in	  proteomics	  180.	  Utilizing	  real	  and	  predicted	  protein	  complexes,	  it	  is	  possible	  to	  strongly	   recover	   patient	   subclasses	   in	   agreement	  with	   histopathology.	   Feature	  selection	  also	  identified	  liver	  cancer-­‐associated	  complexes	  involved	  in	  apoptosis,	  cell	  cycle	  regulation,	  etc.	  	  It	   is	   remarkable	   this	   is	   achievable	   in	   spite	   of	   little	   inter-­‐patient	   agreement.	   To	  highlight	   this,	   in	   mod-­‐stage	   patients,	   only	   25	   out	   of	   over	   800	   proteins	   are	  common	  to	  all	  5	  patients.	  Of	  these	  25,	  all	  are	  also	  reported	  in	  poor-­‐stage	  patients	  with	   relatively	   high	   counts	   (≥4	   out	   of	   7	   patients)	   with	   the	   exception	   of	  HSP90AA2	  and	  TRAP1	  (≤2	  out	  of	  7	  patients).	   In	  poor	   stage,	  only	  3	  out	  of	  over	  1000	  proteins	  are	  common	  to	  all	  7.	  Of	  these,	  2	  (CLU	  and	  CSTB)	  are	  reported	  in	  mod-­‐stage	  patients.	  LYZ	  or	  lysozyme,	  is	  the	  only	  detected	  protein	  common	  to	  all	  7	   poor	   patients	   and	   not	   found	   in	   mod-­‐stage	   patients.	   The	   large	   disparities	  between	   reported	   proteins	   meant	   that	   it	   was	   difficult	   to	   select	   potential	  biomarkers,	  and	  also	  not	  possible	  to	  generate	  meaningful	  hierarchical	  clustering	  based	  on	  detected	  proteins.	  Supplementary	  Figure	  9	  highlights	  the	  extent	  of	  poor	  analytical	   resolution	   if	  hierarchical	   clustering	   is	  performed	  on	   the	  data	  as	   it	   is;	  the	  underlying	  patient	  classes	  cannot	  be	  recovered.	  In	  this	  chapter,	  four	  critical	  follow	  up	  points	  are	  addressed:	  	  	  Firstly,	   whether	   pathways	   can	   also	   be	   used	   with	   the	   PSP	   approach.	   While	  complexes	   provided	   a	   biologically-­‐rich	   feature	   set,	   it	   is	   limited.	   Pathways	   are	  also	  suitable	  networks	  on	  which	  PSP	  could	  be	  utilized	  but	  has	  several	  caveats.	  1/	  Size	  and	   topology:	   Individual	  pathways	  vary	  considerably	   in	  size.	  Suppose	   that	  only	   a	   small	   portion	   of	   a	   large	   pathway	   is	   involved,	   standard	   statistical	   tests	  would	  fail.	  2/	  Coverage	  and	  consistency	  issues:	  Current	  pathway	  databases	  have	  very	   poor	   agreement	   even	   on	   the	  most	  well-­‐studied	   pathways.	   The	   integrated	  pathway	   database,	   PathwayAPI	   52,	   utilizes	   a	   novel	   pathway	  merging	   approach	  based	  on	  pathway	  name	  matches	  (Longest	  Common	  Substring	  matching;	  LCS)	  52.	  However,	   the	   value	   of	   this	   integration	   has	   never	   been	   demonstrated	   in	   a	  functional	  study	  (this	  is	  explored	  further	  in	  this	  chapter).	  Furthermore,	  it	  is	  not	  known	   how	   using	   individual	   pathway	   databases-­‐-­‐-­‐e.g.,	   KEGG	   or	   IPA-­‐-­‐-­‐would	  affect	  or	  skew	  analysis.	  	  Secondly,	   as	   pathways	   are	   large	   biological	   entities	   with	   specialized	   processes,	  significant	  PSP-­‐derived	  complexes	  and	  PDSs	  that	  co-­‐locate	  on	  the	  same	  biological	  pathways,	   might	   engage	   in	   novel	   interplays	   that	   may	   account	   for	   cancer	  progression.	  This	  is	  worth	  examining	  further.	  Thirdly,	  the	  actual	  false	  positive	  rate	  needs	  to	  be	  better	  understood,	  as	  it	  was	  not	  studied	  in	  the	  original	  paper.	  As	  PSP	  uses	  all	  detected	  proteins,	  the	  possibility	  of	  high	  false	  positive	  rates	  could	  be	  a	  concern.	  While	  we	  demonstrated	  theoretically	  in	  Chapter	  6	  why	  false	  positives	  are	  negated,	  we	  did	  not	  show	  in	  actual	  terms	  its	  severity	  or	  negligibility.	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The	   fourth	   aim	   of	   this	   study	   is	   to	   demonstrate	   PSP’s	   generalizability	   and	   to	  enhance	  its	  analytical	  resolution	  using	  specialized	  ontologies.	  On	  the	  latter,	  many	  functional	  studies	  are	  reliant	  on,	  but	  also	  limited	  by,	  the	  analytical	  resolution	  of	  Gene	   Ontology	   (GO).	   GO	  was	   developed	   for	   general	   purposes	   and,	   on	   its	   own,	  might	   not	   yield	   specialized/advanced	   insights	   especially	   when	   a	   specific	  biological	   context-­‐-­‐-­‐e.g.,	   cancer-­‐-­‐-­‐is	   being	   considered.	   Here,	   a	   lipid-­‐specific	  ontology	   based	   on	   GO	   for	   uncovering	   novel	   lipid-­‐associated	   complexes	  implicated	   in	   liver	   cancer	   progression.	   Given	   that	   energy	  metabolism	   is	   now	  a	  novel	  cancer	  hallmark181,	  identifying	  novel	  lipid	  associated	  complexes	  can	  focus	  attention	   on	   this	   particular	   class	   of	   aberrations	   (of	   the	   set	   of	   differential	  complexes/clusters),	  as	  well	  as	  pin-­‐point	  the	  search	  for	  novel	  lipid	  markers.	  On	  generalisability,	  it	  was	  demonstrated	  that	  PSP	  also	  works	  in	  a	  non-­‐small-­‐cell	  lung	  carcinoma	  (NSCLC)	  dataset	  comparing	  two	  subtypes,	  adenocarcinoma	  (ADC)	  and	  squamous	  cell	  carcinoma	  (SCC).	  	  7.2 METHODS	  7.2.1 DATA	  SOURCES	  7.2.1.1 PATIENT	  SAMPLE	  PREPARATION	  AND	  PROTEOMICS	  PROFILING	  Patient	  sample	  preparation	  has	  already	  been	  described	  in	  Chapter	  3.	  7.2.1.2 PATHWAYAPI	  For	   the	   reference	   pathway	   database,	   we	   utilized	   Pathway	   API52	   ,	   which	  comprised	  data	  from	  three	  major	  pathway	  repositories:	  the	  Kyoto	  Encyclopedia	  of	   Genes	   and	   Genomes	   (KEGG)	   182,	   WikiPathways	   183	   and	   Ingenuity	   Pathways	  (IPA)	   (www.ingenuity.com).	   It	   contains	   a	   total	   of	   299	   gene	   pathways,	   21,314	  genes	  and	  60,900	  gene	  pairs.	  	  7.2.2 IDENTIFYING	  PROTEINS	  FOR	  CANDIDACY	  IN	  THE	  PDSS	  As	  a	  whole	  pathway	  can	  be	  quite	  large,	  analytical	  resolution	  can	  be	  enhanced	  by	  considering	   only	   the	   relevant	   subnets.	   A	   PDS	   is	   a	   pathway-­‐derived	   and	  biologically	  coherent	  subnet.	  To	  determine	  a	  PDS,	  detected	  proteins	  found	  in	  at	  least	   half	   of	   the	   patients	   in	  mod	   and	   poor	   stage	   respectively	  were	  mapped	   to	  each	   pathway.	   Expression	   filters	   (i.e.,	   the	   protein	   expression	   levels)	   were	   not	  used	   as	   they	   produced	   very	   sparse	   and	   small	   subnets.	   Unmapped	   pathway	  proteins	   are	   removed,	   causing	   the	   pathway	   to	   fragment	   into	   connected	  components	  or	  subnets.	  	  Subnets	  of	  minimum	  size	  4	  were	  extracted	  for	  analysis	  as	   PDSs.	   The	   minimum	   size	   requirement	   reduces	   effects	   of	   large	   hit	   rate	  fluctuations.	  The	  derived	  PDSs	  are	  treated	  as	  a	  cluster	  vector	  of	  features.	  7.2.3 CLUSTERING	  AND	  FEATURE	  SELECTION	  As	   in	   Chapter	   6,	   the	   feature	   selection	   and	   class	   identification	   procedures	   are	  similar,	  except	  that	  PDSs	  are	  used	  in	  placed	  of	  the	  complexes.	  	  7.2.4 FALSE	  POSITIVE	  ANALYSIS	  FOR	  PDS	  AND	  PSP	  To	  determine	  whether	  the	  hit-­‐rate	  based	  methods	  (PSP	  and	  PDS)	  were	  reporting	  a	   large	   number	   of	   false	   positives,	   poor-­‐stage	   patients	   (being	   the	   larger	   group)	  were	   divided	   into	   groups	   A	   and	   B	   randomly	   10,000	   times.	   A	   t-­‐score,	   and	  accompanying	  p-­‐value	  were	  calculated	  in	  the	  typical	  PSP	  procedure.	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7.2.5 GENE	  ONTOLOGY	  FILTERING	  AND	  CLUSTER	  FUNCTIONAL	  ANNOTATION	  GO	   provides	   a	   controlled	   vocabulary	   for	   assessing	   cluster	   function	   and	  coherence.	   The	   annotation	   files	   and	   GO	   tree	   files	   (ver.	   1.2)	   for	   Homo	   sapiens,	  dated	   23	   April	   2011,	   were	   downloaded	   from	   http://www.	   geneontology.org.	  UniProtKB	  accessions	  were	  mapped	  to	  Ensembl	  Gene	  IDs	  via	  Biomart.	  To	  refine	  analysis,	  informative	  biological	  process	  terms	  (term	  that	  is	  annotated	  to	  at	  least	  30	  proteins	  and	  has	  no	  child	  term	  having	  more	  than	  30	  annotated	  proteins)	  were	  extracted	   from	   the	   GO	   OBO	   file	   160.	   Significance	   testing	   was	   performed	   using	  hypergeometric	  test	  with	  Bonferroni	  correction	  (p	  ≤	  5%).	  7.2.6 IDENTIFICATION	  OF	  NOVEL	  LIPID-­‐ASSOCIATED	  COMPLEXES	  IMPLICATED	  IN	  LIVER	  CANCER	  The	   Lipid	   Ontology	   curation	   rules	   are	   briefly	   explained	   here:	   For	   MF	   and	   CC	  terms,	  they	  are	  based	  on	  indirect	  lipid-­‐term	  and	  functional	  associations.	  For	  BP	  terms,	   two	   principles,	   criticality	   and	   generality	   are	   applied.	   The	   former	   is	  concerned	   with	   identification	   of	   lipid-­‐related	   key	   events,	   for	   which	   no	  alternative	   steps	   are	   possible,	   while	   the	   latter	   only	   holds	   if	   the	   association	   is	  generalizable	  across	  various	  tissues	  or	  species.	  	  The	  lipid	  association	  of	  a	  complex	  is	  the	  hit	  rate	  (a/n)	  where	  a	  is	  the	  number	  of	  proteins	  (in	  the	  complex)	  annotated	  to	  at	  least	  one	  lipid-­‐related	  GO	  term,	  and	  n	  is	   the	   size	   of	   the	   complex.	   We	   calculate	   the	   p-­‐value	   using	   a	   Functional	   Class	  Scoring	   (FCS)-­‐like	   procedure	   184	   	   where	   for	   each	   real	   cluster,	   we	   generate	  random	  clusters	  of	  size	  n	  10,000	  times,	  and	  calculate	  a	  randomized	  lipid	  content	  in	  a	  similar	  manner.	  The	  p-­‐value	  is	  the	  number	  of	  times	  a	  random	  lipid	  content	  for	   a	   randomized	   complex	   is	   bigger	   than	   the	  original	   complex	  divided	  by	   total	  number	  of	  randomizations.	  Determination	   of	   a	   complex’s	   novelty	   is	   done	   manually	   by	   searching	   for	   the	  presence	  of	  lipid-­‐associated	  annotations	  or	  references	  in	  the	  literature.	  A	  harder	  task,	   however,	   is	   identifying	   which	   lipids	   are	   associated	   with	   the	   protein	  complex.	  This	  is	  non-­‐trivial	  as	  there	  are	  over	  2,000	  species	  of	  lipids,	  many	  with	  unknown	  functions	  or	  poor	  annotations.	  	  7.3 RESULTS	  AND	  DISCUSSIONS	  7.3.1 SIGNIFICANT	  PDSS	  ARE	  INVOLVED	  WITH	  CANCER-­‐ASSOCIATED	  FUNCTIONALITIES	  A	  PDS	  is	  a	  pathway-­‐derived	  and	  biologically	  coherent	  feature	  determined	  by	  the	  proteomics	  data.	   It	   is	  a	  connected	  subnet	  within	  a	  biological	  pathway,	  which	   is	  more	  likely	  to	  function	  together	  based	  on	  the	  expression	  data	  (See	  methods	  for	  details).	  There	  are	  a	  number	  of	  prior	  works	  on	  extracting	  subnets	   from	  (large)	  interaction	   databases,	   e.g.,	   	   Ideker	   et	   al	   185	   and	   Rajagopalan	   and	   Agarwal	   186.	  While	  it	  may	  also	  be	  possible	  to	  adapt	  these	  other	  subnet	  methods	  for	  extracting	  PDSs,	   we	   feel	   it	   is	   probably	   best	   left	   to	   a	   separate	   (preferably,	   independently	  conducted)	  comparative	  study.	  Here,	  we	   focus	   instead	  on	  a	  proof-­‐of-­‐concept	   to	  demonstrate	   that	   subnets	   extracted	   from	   pathways	   also	   work	   with	   the	   PSP	  approach.	  	  From	  PathwayAPI,	  87	  PDSs	  are	  derived	  from	  the	  non-­‐merged	  pathways	  (derived	  from	   75	   different	   pathways),	   of	   which	   23	   belong	   to	   pathways	   merge-­‐able	   in	  PathwayAPI	  via	  LCS.	  The	  PDSs	  are	  of	  reasonable	  sizes,	  with	  about	  70%	  of	  size	  10	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and	  above	  (Supplementary	  Figure	  10).	  There	  does	  not	  appear	  to	  be	  a	  bias	  for	  any	  particular	  pathway,	  with	  most	  contributing	  just	  one	  and	  some,	  two	  PDSs.	  To	  observe	  any	  shared	  functional	  themes,	  significant	  GO	  terms	  for	  each	  of	  these	  PDSs	  are	  identified.	  We	  are	  also	  interested	  in	  the	  proportional	  representation	  of	  the	  significant	  GO	  terms	  across	  all	  significant	  PDSs.	  Unsurprisingly,	  many	  of	  the	  PDSs	  are	  associated	  with	  metabolism;	  Figure	  12C.	  However,	  we	  also	  observed	  a	  good	  number	  of	   significant	  PDSs	   involved	   in	  deregulated	  metabolism,	  unstable	  DNA,	   cellular	   proliferation	   and	   self-­‐sufficiency	   in	   growth	   signals,	   inflammation	  and	   immunity,	   angiogenesis,	   metastasis	   and	   invasiveness,	   and	   avoiding	   cell	  death.	  	  
	  
FIGURE	  12	  PSP-­‐PDS	  RESULTS	  OVERVIEW.	  
A:	   DETECTED	   PROTEINS	   IN	   MOD-­‐	   AND	   POOR-­‐STAGE	   HCC	   PATIENTS	   ARE	   USED	   TO	   BUILD	   PDSS	   (PATHWAY-­‐
DERIVED	  SUBNETS)	  FROM	  AN	  INTEGRATED	  PATHWAY	  DATABASE	  (PATHWAYAPI).	  THESE	  PDSS	  ARE	  USED	  FOR	  
CALCULATING	  HIT	  RATES	  FOR	  EACH	  PATIENT	  TO	  GENERATE	  A	  PSP.	  THE	  SET	  OF	  PSPS	  ARE	  USED	  FOR	  SAMPLE	  
CLASS	  ANALYSIS	  AS	  WELL	  AS	  SIGNIFICANT	  FEATURE	   IDENTIFICATION.	  B:	  SAMPLE	  CLASS	  ANALYSIS	  PDSS	  HAVE	  
SUFFICIENT	   RESOLUTION	   TO	   SEGREGATE	   MOD-­‐	   AND	   POOR-­‐STAGE	   PATIENTS	   WITH	   HIGH	   CONFIDENCE.	   C:	  
SIGNIFICANT	  GO	  TERM	  DISTRIBUTION	  A	   LARGE	  NUMBER	  OF	   SIGNIFICANT	  GO	  TERMS	  ARE	  ASSOCIATED	  WITH	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RESPONSES	   ARE	   ALSO	   UNCOVERED.	   THIS	   IS	   CONSISTENT	   WITH	   EARLIER	   OBSERVATIONS	   BASED	   ON	   THIS	  
DATASET.	  7.3.2 EFFECTS	  OF	  PATHWAY	  MERGING	  ON	  PSP/PDS	  PERFORMANCE	  	  While	  Soh	  et	  al	  52	  showed	  that	  pathway	  merging	  via	  string	  name	  matching	  (LCS)	  is	  a	  more	  robust	  approach	  than	  one	  based	  on	  gene	  and	  gene	  interaction	  overlaps,	  	  the	  effect	  of	  this	  merging	  method	  is	  not	  known	  in	  any	  sort	  of	  functional	  analysis.	  We	  would	  like	  to	  understand	  how	  this	  integration	  affects	  analysis.	  	  Extracting	  subnets	   from	  merged	  PathwayAPI	  data	  returned	  82	  PDSs.	  The	  small	  drop	  of	  5	  PDSs	  (from	  87)	  suggests	  that	  merging	  the	  pathways	  (based	  on	  the	  LCS	  approach)	   did	   not	   make	   any	   major	   change	   to	   the	   overall	   results.	   But	   since	  slightly	   fewer	   PDSs	   are	   produced	   for	   merged	   pathways,	   they	  must	   have	   been	  merged	   into	   the	   other	   PDSs.	   Suppose	   PDSx	   (among	   the	   5	   absorbed	   PDSs)	   got	  merged	  with	  PDSy	  (among	  the	  remaining	  PDSs)	  in	  some	  merged	  pathway	  P.	  This	  must	   mean	   that	   PDSx	   and	   PDSy	   hit	   two	   different	   parts	   of	   P	   that	   were	   not	  contiguous	  in	  the	  un-­‐merged	  source	  pathways	  Px	  and	  Py	  of	  P.	  But	  Px	  and	  Py	  got	  connected	  in	  P	  after	  merging.	  Clustering	  of	  the	  87	  PDSs	  from	  non-­‐merged	  PathwayAPI	  did	  reveal	  they	  are	  also	  capable	   of	   segregating	   the	   patients	   into	   their	   respective	   subclasses	   with	   high	  confidence	  (AU	  score	  =	  100)	  (Figure	  12B).	  The	  red	  and	  green	  numbers	  refer	  to	  the	   	   AU	   (Approximately	   Unbiased)	   and	   BP	   (Bootstrap	   Probability)	   p-­‐values	  (between	  0	  and	  100)	  respectively.	  Higher	  values	  denote	  higher	  confidence.	  Red	  squares	   indicate	   largest	   possible	   clusters	   where	   the	   AU	   p-­‐value	   is	   above	   95.	  Additionally,	  mod	  patient	  203,	  which	  was	  previously	  found	  to	  be	  anomalous,	  was	  once	  again	  found	  in	  the	  poor-­‐stage	  cluster.	  	  Clustering	   the	   82	   PDSs	   from	   merged	   PathwayAPI	   recovered	   the	   same	   tree	  topology.	   However,	   the	   AU	   score	   dipped	   slightly	   to	   99.	   While	   the	   PDSs	   and	  significant	  biological	  complexes	  from	  PSP	  are	  vastly	  different,	  the	  topology	  of	  the	  clustering	   tree	   is	   essentially	   similar,	  with	   strong	   segregation	   of	   both	  mod	   and	  poor	  class	  patients;	  Supplementary	  Figure	  11.	  These	   results	   suggest	   that	   the	   LCS	   merging	   procedure	   in	   PathwayAPI	   does	  maintain	   the	   integrity	   of	   pathway	   information.	   But	   beyond	   this	   automated	  approach,	  more	  needs	  be	  done,	  e.g.,	  manual/expert	  curation	  to	  ensure	  functional	  congruity	   and	   data	   quality.	   After	   all,	   pathways	   are	   very	   intricately	   joined,	   and	  contain	   many	   common	   members/edges	   (which	   also	   causes	   the	   problem	   with	  data	   integration	   in	  pathway	  databases).	  To	   illustrate	   this	  point,	   a	  network	  was	  built	  based	  on	  taking	  a	  naïve	  union	  of	  all	  existing	  pathways	  in	  PathwayAPI.	  There	  were	   no	   isolated	   components	   in	   this	   highly	   inter-­‐connected	   system	  making	   it	  difficult	   to	   disambiguate	   the	   various	   constituent	   pathways.	   More	   importantly,	  attempting	  to	  extract	  PDSs	  from	  this	  results	  in	  one	  super	  component	  of	  size	  350,	  and	  3	  components	  of	  sizes	  4,	  4	  and	  6.	  This	  lack	  of	  informative	  network	  features	  confounds	  the	  PSP	  profiling	  approach.	  7.3.3 COMPARATIVE	  ANALYSIS	  BETWEEN	  PATHWAYAPI	  AND	  ITS	  CONSTITUENT	  DATABASES	  PathwayAPI	   (both	   merged	   based	   on	   the	   LCS	   approach	   and	   non-­‐merged)	  outperforms	   its	   constituent	   databases,	   demonstrating	   the	   value	   of	   integration	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(Supplementary	  Figure	  11).	  Of	  the	  constituent	  databases,	  KEGG	  performs	  slightly	  worse	   than	   PathwayAPI	   but	   the	   topology	   of	   the	   tree	   is	   similar.	  Wiki	   performs	  second	   best:	   it	   keeps	   the	   general	   order	   of	   the	   patients	   but	   does	   not	   have	  sufficient	   information	   to	   reach	   significance	   in	   separating	   the	   patient	   classes	  (threshold	  AU	  score	  ≥	  95).	  IPA	  is	  generally	  similar	  to	  Wiki	  as	  well,	  but	  the	  mod	  203	  and	  poor	  120	  branch	  is	  translocated	  to	  the	  mod	  group	  instead.	  	  In	  any	  case,	  the	  two	  trees	  (IPA	  and	  Wiki)	  are	  of	  lower	  confidence	  than	  KEGG’s,	  as	  well	   as	   those	   based	   on	  PathwayAPI	   and	   real/predicted	   complexes.	   The	   reason	  for	  this	  is	  due	  to	  the	  number	  of	  features	  (PDSs	  and	  significant	  PDSs)	  contributed	  by	  each	  database.	  Altogether,	  58	  out	  of	  87	  PDSs	  reached	  significance	  at	  p	  ≤	  5%,	  indicating	   they	   are	   strongly	   discriminative	   between	  mod	   and	   poor	   stages.	   The	  high	   proportion	   of	   significant	   PDSs	   is	   because	   they	   are	   already	   pre-­‐pruned	   to	  just	  the	  pathway	  regions	  where	  variation	  between	  mod	  and	  poor	  is	  expected	  to	  occur.	  	  On	  the	  individual	  pathway	  databases,	  KEGG	  contributes	  43	  significant	  PDSs	  out	  of	  65	  derived	  from	  172	  pathways	  in	  KEGG,	  Wiki	  6	  significant	  PDSs	  out	  of	  11	  (82	  pathways),	  and	  IPA	  9	  significant	  PDSs	  out	  of	  11	  (45	  pathways)	  respectively	  (to	  make	  a	  total	  of	  58	  significant	  out	  of	  87	  total	  PDSs	  (299	  pathways)	  in	  PathwayAPI.	  Due	  to	  the	  smaller	  number	  of	  resolving	  features	  (PDSs),	  it	  is	  not	  surprising	  that	  Wiki	  and	  IPA	  perform	  more	  poorly	  in	  their	  ability	  to	  resolve	  the	  patient	  samples	  properly.	  	  Given	   this	   result,	   we	   cannot	   over-­‐generalize	   on	   the	   respective	   quality	   of	   the	  individual	  databases.	  But	  the	  key	  implication	  here	  is	  that	  one	  should	  never	  defer	  to	   the	   results	   from	   one	   database	   solely.	   Obviously,	   coverage	   discrepancies	  between	  different	  databases	  can	  result	  in	  variations	  of	  analytical	  outcomes.	  It	  is	  thus	  best	  to	  refer	  to	  an	  integrated	  data	  resource.	  7.3.4 SIGNIFICANT	  PDSS	  AND	  COMPLEXES	  ARE	  ENRICHED	  FOR	  CO-­‐LOCATION	  ON	  PATHWAYS	  We	  use	  the	  term	  “involved”	  to	  suggest	  that	  a	  pathway	  is	   implicated	   in	  HCC	  if	   it	  gave	  rise	  to	  a	  significant	  PDS.	  	  There	  are	  a	  total	  of	  159	  significant	  PSP	  complexes	  (i.e.,	  biological	  complexes	  that	  are	  significantly	  differential	  between	  mod	  and	  poor	  stage).	  The	  significant	  PDSs	  originate	   from	   58	   different	   “involved”	   pathways.	   The	   number	   of	   non-­‐involved	  pathways	   is	   therefore	  241	  (299	  -­‐	  58).	  On	  the	  other	  hand,	  20%	  (12	  /	  58)	  of	   the	  involved	  pathways	  overlap	  with	  a	  significant	  complex	  while	  11%	  (27	  /	  241)	  of	  the	   non-­‐involved	   pathways	   overlap	   with	   a	   significant	   complex.	   Hence,	   an	  involved	  pathway	   is	  ~	  2x	   (20/11)	  more	   likely	   than	  a	  non-­‐involved	  pathway	   to	  overlap	  a	  significant	  complex.	  Also,	  none	  of	  the	  364	  (523	  -­‐	  159)	  non-­‐significant	  complexes	  overlap	  with	  any	  of	  the	  75	   involved	  pathways,	  while	  10	  non-­‐significant	  complexes	  overlap	  some	  of	  the	  241	  non-­‐involved	  pathways.	  The	  propensity	  for	  significant	  complexes	  to	  co-­‐localize	  onto	  the	  same	  pathway	  with	  a	  significant	  PDS	  is	  therefore	  notably	  high.	  To	   show	   that	   the	   co-­‐localization	   effect	   is	   not	   due	   to	   the	   effect	   of	   the	   same	  proteins	   being	   found	   on	   both	   the	   PSP	   complexes	   and	   PDSs,	   we	   looked	   at	   the	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distribution	  of	  overlaps	  between	  PDS	  and	  PSP	  complexes	  co-­‐located	  on	  the	  same	  pathway.	   In	   70%	   of	   cases,	   the	   Jaccard	   Score	   (i.e.,	   intersection	   over	   union)	   is	  much	  smaller	  than	  0.2,	  indicating	  that	  this	  was	  not	  due	  to	  the	  effect	  of	  the	  shared	  proteins.	  7.3.5 A	  NOVEL	  MOLECULAR	  SWITCH	  IMPLICATED	  IN	  HCC	  PROGRESSION	  The	   co-­‐locating	   PDSs	   and	   PSP	   complexes	   (onto	   the	   same	   pathway)	   should	  function	   in	   a	   coordinate	   manner	   (i.e.,	   their	   corresponding	   cluster	  scores/expression	   values	   should	   correlate);	   and	   generally,	   this	   is	   true.	   The	  cluster	   score	   correlations	   between	   co-­‐located	   PDS	   and	   PSP	   complexes	   were	  examined	   for	  both	  mod	  and	  poor	   stage;	  Figure	  13.	  Although	   the	   cluster	   scores	  are	   clearly	   correlated,	   this	   effect	   is	   more	   pronounced	   in	   the	   poor	   stage	   (P	   =	  0.0014,	   R-­‐square	   =	   0.47).	   In	   the	   mod	   stage,	   the	   correlation	   is	   skewed	   by	   the	  presence	   of	   two	   outliers	   which	   are	   relatively	   high	   scoring	   in	   PDS	   but	   low	   for	  complex.	   Removing	   the	   two	   outliers	   improved	   the	   p-­‐value	   to	   1.5e-­‐05	   from	  0.0077	  and	   the	  regression	   fit	   (R-­‐square)	   to	  0.76	   from	  0.34.	   In	  poor	  stage,	  both	  corresponding	  PDS	  and	  complexes	  are	  consistently	  high.	  
	  
	  
FIGURE	   13	   CO-­‐LOCALISATION	   AND	   EXPRESSION	   PROFILE	   OF	   PDSS	   AND	   COMPLEXES	   (DNA	   SYNTHESOME	   AND	  
TNF-­‐ALPHA/NF-­‐KAPPA	  B	  SIGNALING	  COMPLEX	  5)	  ON	  THE	  PURINE	  METABOLISM	  PATHWAY.	  	  
A:	  THE	  PURINE	  METABOLIC	  PATHWAY	  IS	  SHOWN	  AS	  AN	  UNDIRECTED	  GRAPH.	  SIGNIFICANT	  PSP	  CLUSTERS	  ARE	  
HIGHLIGHTED	   IN	   GREEN	   WHILE	   SIGNIFICANT	   PDS	   IS	   SHOWN	   IN	   PURPLE.	   B	   AND	   C:	   REGRESSION	   PLOTS	   FOR	  
EXPRESSION	  SCORES	  OF	  PROTEIN	  COMPLEXES	  AND	  PDSS	  CO-­‐LOCATED	  ON	  THE	  SAME	  BIOLOGICAL	  PATHWAY	  IN	  
MOD	  AND	  POOR	  STAGE	  RESPECTIVELY.	  ENVELOPED	  IN	  A	  CHECKED	  CIRCLE	  ARE	  TWO	  COMPLEX	  OUTLIERS	  THAT	  
ARE	   LOW	   EXPRESSING	   IN	   THE	   MOD	   STAGE	   RELATIVE	   TO	   THE	   CO-­‐LOCATING	   PDS	   BUT	   SWUNG	   TO	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negated:	   It	   is	  high	   in	  both	  PDS	  and	   complex.	   It	   is	  possible	   that	   this	   is	   a	   switch	  mechanism	  that	  may	  be	  involved	  in	  the	  progression	  from	  mod	  to	  poor	  stage.	  The	  major	  site	  of	  purine	  synthesis	  is	  in	  the	  liver.	  Interestingly,	  it	  is	  known	  early	  on	  that	  enzymes	  involved	  in	  purine	  metabolism	  play	  a	  role	  in	  cancer.	  In	  fact,	  an	  enzymic	  imbalance,	  specific	  only	  to	  liver	  cancer,	  was	  known	  as	  early	  as	  1983	  187.	  However,	  the	  mechanistic	  details	  are	  only	  recently	  being	  uncovered.	  Pang	  et	  al.	  188	   recently	   showed	   that	   defects	   in	   purine	   metabolism	   leads	   to	   substantial	  incorporation	   of	   xanthine	   and	   hypoxanthine	   into	   DNA.	   This	   in	   turn	   induces	  mutations,	  a	  key	  driver	  for	  oncogenic	  progression.	  We	  decide	   to	   investigate	   further	   by	   analyzing	   the	   functions	   of	   the	   co-­‐localized	  complexes:	   “DNA	   synthesome	   complex”	   and	   “TNF-­‐alpha/NF-­‐kappa	   B	   signaling	  complex	   5”.	   The	   former	   is	   involved	   in	   fat	   signaling	   (GO:0048015	  phosphatidylinositol-­‐mediated	   signaling,	   P	   =	   0.003),	   cellular	   immortality	  (GO:0010833	  telomere	  maintenance	  via	  telomere	  lengthening,	  P	  =	  4.9e-­‐32),	  DNA	  repair	  (GO:0000724	  double-­‐	  strand	  break	  repair	  via	  homologous	  recombination,	  P	   =	   0.048;	   GO:0006284	   base-­‐excision	   repair,	   P	   =	   3.4e-­‐10;	   GO:0006283	  transcription-­‐coupled	   nucleotide-­‐excision	   repair,	   P=5.0e-­‐19)	   and	   cellular	  proliferation	  (GO:0000082	  G1/S	  transition	  of	  mitotic	  cell	  cycle,	  P=1.7e-­‐12).	  The	  latter	   is	   involved	   in	   stress/immune	   responses	   (GO:0045087	   innate	   immune	  response,	   P=1.7e-­‐07;	   GO:0043123	   positive	   regulation	   of	   I-­‐kappaB	   kinase/NF-­‐kappaB	   cascade,	   P	   =	   2.4e-­‐06),	   DNA	   repair	   (GO:0006283	   transcription-­‐coupled	  nucleotide-­‐excision	  repair,	  P	  =	  0.002),	  cell	  death	  (GO:0006916	  anti-­‐apoptosis,	  P	  =	  0.005)	   and	   cellular	  proliferation	   (GO:0000082	  G1/S	   transition	  of	  mitotic	   cell	  cycle,	   P	   =	   0.02;	   GO:0016032	   viral	   reproduction,	   P=	   0.01).	   It	   is	   clear	   that	   both	  complexes	  are	  involved	  in	  cancer-­‐associated	  functions,	  in	  particular,	  DNA	  repair.	  The	  associated	  PDS	  appears	  to	  work	  primarily	  on	  metabolic	  and	  purine-­‐related	  functions,	   including	   GO:0009161	   ribonucleoside	   monophosphate	   metabolic	  process	  (P	  =	  0.0001)	  and	  GO:0006144	  purine	  base	  metabolic	  process	  (P	  =	  7.9e-­‐09).	   However,	   it	   is	   also	   related	   to	   differentiation	   (GO:0002761	   regulation	   of	  myeloid	   leukocyte	  differentiation,	  P	  =	  0.03)	  although	  myeloid	  differentiation	   is	  typically	  associated	  with	  leukemia,	  not	  liver	  cancer.	  Since	   the	   expression	   level	   of	   the	  PDS	   is	   both	  high	   in	  mod	   and	  poor	   stage,	   it	   is	  possible	  that	  this	  is	  an	  early	  requirement	  for	  oncogenic	  transformation.	  Indeed,	  upsetting	   nitrogenous	   base	   balances	   can	   lead	   to	   increased	   chance	   of	   error	   in	  DNA	  replications.	  Our	  identified	  PDS	  suggests	  that	  this	  is	  the	  region	  of	  the	  purine	  metabolism	   pathway	   most	   differentially	   affected.	   But	   in	   order	   for	   oncogenic	  progression	   to	  occur	  or	   speed	  up	   (for	   transition	   from	  mod-­‐	   to	  poor-­‐stage	   liver	  cancer),	  it	  is	  logical,	  and	  indeed	  as	  we	  find,	  to	  target	  protein	  complexes	  that	  are	  involved	   in	   rectifying	  mistakes	   in	   DNA	   replication	   or	   effecting	   DNA	   repair.	   To	  further	  implicate	  these	  two	  out	  of	  several	  other	  candidate	  DNA	  repair	  complexes,	  they	  are	  closely	  associated	  with	  the	  pathway	  as	  well.	  In	  light	  of	  these	  results,	  the	  biological	   relationship	  between	   the	  purine	  metabolism	  PDS	   and	   the	   associated	  PSP	   complexes	   are	   currently	   being	   explored	   experimentally	   (but	   beyond	   the	  scope	  of	  this	  thesis).	  7.3.6 PSP	  IS	  A	  POWERFUL	  AND	  PRECISE	  METHOD	  WITH	  REASONABLY	  LOW	  FALSE	  POSITIVE	  RATES	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There	  are	  523	  biological	  complexes	  found	  in	  CORUM	  (size	  ≥4)	  used	  in	  PSP.	  At	  p	  ≤	  5%,	  approximately	  523	  *	  5%	   ≈	  27	  false	  positives	  are	  expected.	  Similarly,	  there	  are	  87	  PDSs,	  and	  thus	  at	  p	  ≤	  5%,	  approximately	  87	  *	  5%	  ≈	  5	  false	  positives	  are	  expected.	   In	   order	   to	   check	   the	   empirical	   false	   positive	   rates	   against	   these	  theoretical	   estimates,	   we	   used	   the	   7	   poor-­‐stage	   patients,	   randomly	   assigned	  them	  into	  two	  groups,	  and	  applied	  PSP	  analysis.	  Since	  both	  groups	  were	  actually	  poor-­‐stage	  patients,	  all	  significant	  complexes	  /	  PDSs	  resulting	  from	  this	  analysis	  should	  be	  considered	  false	  positives.	  	  Figure	  14	  shows	  the	  distribution	  of	  false	  positives	  across	  10,000	  randomizations	  for	   the	   poor-­‐stage	   patients.	   In	   each	   round,	   the	   set	   of	   significant	   complexes	   or	  PDSs	   (false	   positives)	   are	   reported	   at	   p	   ≤	   5%	   (with	   Benjamini-­‐Hochberg	  correction).	   Figure	   2A	   and	   2B	   shows	   the	   false	   positives	   reported	   for	   CORUM	  (mean	  ≈	  80,	  median	  =	  40,	  mode	  =	  6)	  and	  PathwayAPI	  (mean	  ≈	  18,	  median	  =	  12,	  mode	   =	   3)	   respectively.	   The	   red	   bars	   show	   the	   absolute	   false	   positive	   counts	  while	  the	  purple	  bars	  are	  normalised	  to	  1.	  The	  first	  two	  peaks	  in	  Fig	  2A	  and	  2B	  are	   within	   expectation	   and	   indicate	   a	   low	   false	   positive	   rate.	   However,	   the	  overall	  distribution	  of	  peaks,	  as	  well	  as	  the	  mean	  number	  of	  significant	  clusters	  over	  10,000	  randomizations	  is	  slightly	  higher	  than	  expected.	  This	  is	  likely	  due	  to	  the	  presence	  of	  internal	  clusters	  among	  the	  poor-­‐stage	  patients	  as	  well	  as	  small	  sample	  size;	  Supplementary	  Figure	  9.	  
	  
FIGURE	  14	  FALSE	  POSITIVE	  DISTRIBUTION	  FOR	  PSP	  (A)	  AND	  PDS	  (B).	  	  
LEFT	   GRAPH	   (RED)	   SHOWS	   ABSOLUTE	   COUNT	   DISTRIBUTION	   OF	   FALSE	   POSITIVE	   FEATURES	   WHILE	   RIGHT	  
(PURPLE)	  IS	  THE	  DISTRIBUTION	  OF	  PROPORTION	  (FALSE	  POSITIVE	  FEATURES/TOTAL	  NUMBER	  OF	  FEATURES).	  
AT	   5%	   SIGNIFICANCE,	   THE	   LEFT	   SHIFT	   OF	   PEAKS	   IS	   WITHIN	   EXPECTATION.	   HOWEVER,	   THE	   FREQUENCY	  
DISTRIBUTIONS	   IS	   STILL	   RATHER	   HIGH,	   IMPLYING	   INTERNAL	   CLUSTERING	   AMONG	   POOR	   PATIENTS.	   THIS	   IS	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The	   liver	   is	   a	   major	   metabolic	   center,	   and	   a	   primary	   regulation	   site	   of	   lipids.	  Current	  evidence	  suggests	  that	  lipids	  are	  not	  mere	  energy-­‐providing	  metabolites	  but	   can	   effect	   profound	   changes	   via	   various	   signaling	   pathways.	   This	   is	   not	  limited	  to	  cholesterol-­‐based	  signaling	  molecules,	  which	  are	  better	  known.	  There	  are	  over	  2,000	   species	  of	   lipids,	  most	  of	  which	  have	  poor	   characterization	  and	  not	   easily	   analyzable	   189.	   Lipid	   deregulation	   is	   also	   commonly	   associated	  with	  liver	  cancer	  190.	  Many	  proteins	  are	  annotated	  to	  specific	   functionalities	  based	  on	  GO	  annotation	  rules	  but	  the	  lipid	  associations	  are	  not	  well	  known	  or	  sufficiently	  comprehensive.	  	  To	   overcome	   this	   and	   to	   maximize	   compatibility	   with	   current	   annotation	  standards,	  we	  developed	  a	  set	  of	  gold-­‐standard	  lipid-­‐related	  terms	  based	  on	  GO	  terms.	   This	   list	   consists	   of	   1463	   lipid-­‐associated	   GO	   terms	   in	   the	   Biological	  Processing	   category	   (BP	   terms),	   924	   GO	   terms	   in	   the	   Cellular	   Component	  category	  (CC	  terms)	  and	  1736	  GO	  terms	  in	  the	  Molecular	  Function	  category	  (MF	  terms).	  	  For	   BP,	   out	   of	   a	   total	   of	   177	   PSP	   predicted/real	   complexes,	   21	   reached	  significance.	   Of	   these	   21,	   5	   are	   predicted	   clusters.	   Therefore,	   about	   12%	   of	  significant	   PSP	   complexes	   are	   lipid	   associated.	   About	   half	   of	   these	   are	   not	  previously	  known	   to	  be	   lipid	  associated.	  A	   list	  of	   these	  novel/potentially	  novel	  BP	  lipid-­‐associated	  real	  complexes	  is	  reported	  in	  Table	  12.	  	  
TABLE	   12	   LIST	   OF	   POTENTIALLY	   NOVEL	   AND	   NOVEL	   LIPID	   ASSOCIATED	   COMPLEXES	   IMPLICATED	   IN	   LIVER	  
CANCER	  	  *PN	  –	  potentially	  novel,	  N	  –	  novel.	  
Novelty	  
CORUM	  
ID	   Complex	  name	   Function	  
Lipid	  
involvement	  
PN	  	   1096	   	  SNX	  and	  PDGF	  receptor	  complex	  
reported	   to	   be	   involved	   in	   transport	   and	  
transmembrane	  signal	  transduction	  
	  lipid	  involvement	  
yes	  
PN	  	   1104	   Transferrin	  receptor	  complex	  
reported	   involved	   in	   transport	   and	   receptor	  
mediated	  endocytosis	  
	  lipid	   association	  
yes	  
PN	  	   563	   	  Complex	  V;	  F1F0	  ATPase	  
energy	   production,	   mitochondrial	   processes,	  
particularly	  in	  heart	  muscle	  
	  lipid	  involvement	  
yes	  
PN	  	   654	   	  BLOC1-­‐BLOC2	  complex	   transport	  and	  targeting	  
	  lipid	  involvement	  
potentially	  novel	  
PN	  	   142	  
	  CD147-­‐gamma-­‐secretase	   complex	  
(APH-­‐1a,	  PS-­‐1,	  PEN-­‐2,	  NCT	  variant)	   signaling,	  protein	  fate	  
	  lipid	  involvement	  
yes	  
PN	  	   652	   	  AP3-­‐Bloc1-­‐complex	   transport	  
	  lipid	  involvement	  
yes	  
PN	  	   657	  
	  Retromer	  complex	  (SNX1,	  SNX2,	  VPS35,	  
VPS29,	  VPS26A)	   protein	  targeting	  and	  transport	  
	  lipid	  involvement	  
yes	  
PN	  	   2837	   	  Profilin	  1	  complex	  
cytoskeleton	   organisation,	   endocytosis,	  
potential	  metastasis	  involvement	  
	  lipid	  involvement	  
yes	  
PN	  	   1060	  
	  Retromer	  complex	  (SNX1,	  SNX2,	  VPS35,	  
VPS29,	  VPS26B)	   transport	  
	  lipid	   association	  
yes	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N	  	   280	  
HMGB1-­‐HMGB2-­‐HSC70-­‐ERP60-­‐GAPDH	  
complex	  
DNA	   repair,	  nucleic	  acid	  binding,	   response	   to	  
stress	  and	  DNA	  damage	  stimulus);high	  cancer	  
association	  
	  lipid	  involvement	  
not	   immediately	  
decipherable	  
N	  	   312	   	  Cell	  cycle	  kinase	  complex	  CDK4l	   cell	  cycle	  control,	  cancer	  association	  yes	  
	  lipid	  involvement	  
not	   immediately	  
decipherable	  
N	  	   247	  
	  RalBP1-­‐CCNB1-­‐AP2A-­‐NUMB-­‐EPN1	  
complex	   cell	  cycle	  control,	  endocytosis	  
	  lipid	  involvement	  
not	   immediately	  
decipherable	  
N	  	   5230	  
	  CHUK-­‐NFKB2-­‐REL-­‐IKBKG-­‐SPAG9-­‐NFKB1-­‐
NFKBIE-­‐COPB2-­‐TNIP1-­‐NFKBIA-­‐RELA-­‐
TNIP2	  complex	   Signaling,	  cancer	  association	  yes	  
	  lipid	  involvement	  
not	   immediately	  
decipherable	  
N	  	   311	   	  Cell	  cycle	  kinase	  complex	  CDK2	   cell	  cycle	  control,	  cancer	  association	  yes	  
	  lipid	  involvement	  
not	   immediately	  
decipherable	  
N	  	   5423	   	  HSP70-­‐BAG5-­‐PARK2	  complex	   protein	  folding	  and	  stabilisation	  
	  lipid	  involvement	  
not	   immediately	  
decipherable	  
N	  	   2390	   	  CD98-­‐LAT2-­‐ITGB1	  complex	  
cell	   adhesion,	   may	   define	   cell	   polarity	   which	  
in	  turn	  has	  to	  do	  with	  invasiveness	  
	  lipid	  involvement	  
not	   immediately	  
decipherable	  	  Among	  the	  novel	  lipid-­‐associated	  complexes,	  the	  HMGB1-­‐HMGB2-­‐HSC70-­‐ERP60-­‐GAPDH	  complex	  is	  of	  particular	  interest.	  This	  complex	  was	  isolated	  from	  human	  leukemia	  cells	  deficient	   in	  components	  of	   the	  mismatch	  repair	  system	  (Nalm6)	  and	  functions	  by	  detecting	  changes	  in	  DNA	  structure	  caused	  by	  incorporation	  of	  non-­‐natural	  nucleosides	  and	  is	  a	  determinant	  of	  cell	  sensitivity	  to	  DNA	  modifying	  chemotherapy191.	  Disruption	  of	  DNA-­‐repair	  mechanisms	  is	  important	  in	  driving	  liver	   cancer	   progression	   from	   early	   to	   late	   stage192.	   Moreover,	   this	   cluster	  exhibited	  a	  2.5	  fold	  increase	  in	  expressional	  level.	  Its	  lipid	  involvement	  appears	  to	   be	   dispersed	   however:	   It	   is	   involved	   in	   both	   Golgi-­‐mediated	   transport	   and	  phosphoinositide-­‐mediated	  signaling.	  Also	  interesting	  are	  that	  the	  HMG	  family	  of	  proteins	  are	  associated	  with	  malignant	  neoplasias	  193,	  in	  particular,	  HMGB1	  was	  identified	  as	  a	  potential	  cancer	  therapeutic	  target	  194.	  	  To	   understand	   if	   the	   other	   lipid	   GO	   categories	   also	   report	   similar	   results,	   a	  similar	   analysis	   was	   repeated	   for	   CC	   and	   MF	   terms,	   reporting	   30	   and	   20	  significant	   complexes	   respectively.	   Figure	   15	   shows	   the	   overlaps	   between	   the	  significant	   lipid-­‐associated	   complexes	   derived	   from	   each	   GO	   category.	   For	   MF	  and	  BP,	  more	   than	  half	   of	   the	   complexes	   are	   shared	  with	   the	  other	   categories.	  For	  CC,	   this	   is	  slightly	   less	  than	  half.	  8	  significant	  complexes	  are	  common	  to	  all	  three	   categories.	   These	   include	   Retromer	   complex	   (comprising	   SNX1,	   SNX2,	  VPS35,	  VPS29,	  VPS26B;	  involved	  in	  transport),	  SNX	  complex	  (comprising	  SNX1,	  1a,	   2,4,	   PDGF	   receptor;	   transport	   and	   signaling),	   SNX	   complex	   (comprising	  SNX1a,	   SNX2,	   SNX4,	   TFRC;	   transport),	   RalBP1-­‐CCNB1-­‐AP2A-­‐NUMB-­‐EPN1	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complex	   (cell	   cycle),	   and	   Retromer	   complex	   (comprising	   NX1,	   SNX2,	   VPS35,	  VPS29,	  VPS26A;	  transport).	  The	  remaining	  3	  clusters	  are	  predicted.	  Although	   BP	   is	   commonly	   used	   for	   functional	   annotation	   and	   analysis,	   the	  limited	  overlaps	  between	  the	  3	  categories	  suggest	  that	  it	   is	  prudent	  to	  examine	  all	  three	  GO	  categories	  when	  determining	  lipid	  associations.	  	  
	  
FIGURE	  15	  OVERLAPS	  BETWEEN	  SIGNIFICANT	  COMPLEXES	   IDENTIFIED	  VIA	  LIPID-­‐ASSOCIATED	  GO	  BP,	   CC	  AND	  
MF	  TERMS.	  	  
THE	  OVERLAPS	  BETWEEN	  SIGNIFICANT	  LIPID-­‐ASSOCIATED	  CLUSTERS	  IDENTIFIED	  VIA	  LIPID-­‐ASSOCIATED	  GO	  BP,	  
CC	  AND	  MF	  TERMS	  ARE	  EXPRESSED	  AS	  A	  VENN	  DIAGRAM.	  FOR	  ALL	  3	  CATEGORIES,	  ABOUT	  AT	  LEAST	  HALF	  OF	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However,	   there	   is	  variability,	   though	   limited,	   in	   terms	  of	   identified	  proteins	   for	  each	   sample	   (n	   =	   30).	   On	   average,	   there	   are	   about	   3000	   identified	   proteins	   in	  total,	  which	  is	  3	  times	  more	  than	  the	  HCC	  dataset.	  	  Figure	  16A	  shows	  that	  the	  underlying	  patient	  subclasses	  can	  be	  recovered	  with	  high	   confidence	   using	   complexes.	   The	   estimated	   number	   of	   false	   positives	  (average	  =	  19.93,	  median	  =15,	  mode	  =12)	  for	  this	  was	  also	  within	  the	  expected	  limit-­‐-­‐-­‐523	  complexes	  *	  5%	    ≈	  27	   false	  positives	  are	  expected;	  Figure	  16B.	  The	  left	   histogram	   shows	   the	   absolute	   (Abs)	   count	   of	   significant	   clusters	   per	  randomization.	   The	   right	   histogram	   is	   the	   number	   of	   significant	   clusters	  normalized	  by	  the	  total	  number	  of	  randomizations	  (ratio	  sig	  clusters).	  Figure	  16C	  shows	  the	  extent	  of	  protein	  support	  across	  all	  30	  samples	  analyzed.	  Most	  proteins	  are	  supported	  by	  few	  of	  the	  samples.	  But	  unlike	  the	  original	  HCC	  dataset	  studied	  in	  PSP,	  the	  extent	  of	  variability	  is	  much	  reduced	  here.	  
	  
FIGURE	  16	  GENERALISABILITY	  TESTS	  USING	  NSCLC	  DATASET.	  	  	  
A:	  THE	  UNDERLYING	  PATIENT	  SUBCLASSES	  CAN	  BE	  RECOVERED	  WITH	  HIGH	  CONFIDENCE	  USING	  COMPLEXES.	  B:	  
THE	  LEFT	  HISTOGRAM	  SHOWS	  THE	  ABSOLUTE	  (ABS)	  COUNT	  OF	  SIGNIFICANT	  CLUSTERS	  PER	  RANDOMISATION.	  
THE	  RIGHT	  HISTOGRAM	  IS	  THE	  NUMBER	  OF	  SIGNIFICANT	  CLUSTERS	  NORMALISED	  BY	  THE	  TOTAL	  NUMBER	  OF	  
RANDOMISATIONS	  (RATIO	  SIG	  CLUSTERS).	  C:	  PROTEIN	  SUPPORT	  OVER	  30	  SAMPLES.	  MOST	  PROTEINS	  ARE	  ONLY	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Current	   proteomics	   assays	   also	   saw	   the	   rise	   of	   extensive	   set	   ups	   allowing	  reporting	   of	   more	   than	   10,000	   proteins	   in	   samples196,	   197.	   However,	   these	  datasets	  are	   incompatible	  with	   the	  PSP	  approach	  as	   the	  premise	  of	   these	   is	  on	  deep	   proteome	   investigation	   of	   single	   cell	   lines	  within	   a	   single	   pooled	   sample	  whereas	  PSP	  examines	  variability	  between	  samples.	  	  7.4 REMARKS	  PSP	  is	  a	  powerful	  and	  precise	  method,	  with	  acceptable	  false	  positive	  rates.	  This	  is	  confirmed	  in	  the	  use	  of	  both	  biological	  complexes	  as	  well	  as	  PDSs.	  	  	  The	  PDSs	  are	  informative,	  being	  able	  to	  properly	  recover	  the	  patient	  classes	  as	  well	   as	   selecting	   significant	   features	   whose	   enriched	   GO	   terms	   are	   consistent	  with	  the	  liver	  cancer	  phenotype.	  	  Pathway	   analysis	   based	   on	   integrated	   data	   is	   evidently	   superior	   due	   to	  consistency	  and	  coverage	  issues	  among	  databases.	  KEGG	  performs	  well	  with	  our	  data	   but	   the	   added	   PDSs	   from	   WikiPathways	   and	   IPA	   improved	   analytical	  resolution.	  	  By	  analyzing	  the	  inter-­‐play	  between	  co-­‐localized	  significant	  PDSs	  and	  complexes,	  we	   find	   very	   good	   expression	   correlation	   implying	   coordinate	   responses	   and	  activity.	   We	   also	   uncovered	   an	   interesting	   relationship	   for	   two	   DNA	   repair	  complexes	  with	  the	  “purine	  metabolism”	  pathway.	  This	  co-­‐	  localization	  appears	  to	  be	  involved	  in	  mod-­‐to-­‐poor-­‐stage	  liver	  cancer	  transition	  and	  warrants	  further	  biological	   exploration.	   Finally,	   we	   also	   demonstrate	   how	   analytical	   resolution	  can	   be	   enhanced	   via	   the	   use	   of	   specialized	   ontologies.	   Specifically,	   we	   have	  identified	   several	   novel	   lipid-­‐associated	   complexes	   from	   the	   set	   of	   significant	  PSP	  complexes.	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8 RECOVERY	  PERFORMANCE	  OF	  THE	  VARIOUS	  NETWORK-­‐BASED	  STRATEGIES	  
Brief	  summary	  and	  key	  points	  
• Despite	   its	   prominence	   for	   characterization	   of	   complex	   mixtures,	   LC-­‐MS/MS	  frequently	  fails	  to	  identify	  many	  proteins.	  Network-­‐based	  analysis	  methods-­‐-­‐-­‐based	   on	   Protein-­‐Protein	   Interaction	   Networks	   (	   PPINs),	  biological	   pathways,	   and	   protein	   complexes-­‐-­‐-­‐are	   useful	   for	   recovering	  non-­‐detected	   proteins,	   thereby	   enhancing	   analytical	   resolution.	   But	  network-­‐based	  analysis	  methods	  do	  come	  in	  varied	  flavours	  for	  which	  the	  respective	  efficacies	  are	  largely	  unknown.	  	  
• We	  compare	  the	  recovery	  performance	  and	  functional	  insights	  from	  three	  distinct	  instances	  of	  PPIN-­‐based	  approaches-­‐-­‐-­‐viz.,	  Proteomics	  Expansion	  Pipeline	   (PEP),	   Functional	   Class	   Scoring	   (FCS)	   and	   Maxlink-­‐-­‐-­‐in	   a	   test	  scenario	   of	   valproic	   acid	   (VPA)-­‐treated	   mouse.	   We	   find	   that	   the	   most	  comprehensive	   functional	   insights,	   as	  well	   as	   best	   non-­‐detected	   protein	  recovery	   performance,	   are	   derived	   from	   FCS	   utilizing	   real	   biological	  complexes.	  This	  outstrips	  other	  network-­‐based	  methods	  such	  as	  Maxlink	  or	  Proteomics	  Expansion	  Pipeline	  (PEP).	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8.1 INTRODUCTION	  Proteomics	   profiling	   is	   essential	   for	   direct	   analysis	   of	   the	   molecular	   players	  (proteins)	   partaking	   in	   biological	   processes.	   But	   it	   is	   limited	   by	   coverage,	  consistency	   and	   generally	   small	   sample	   size	   issues180.	   Although	   these	   can	   be	  remedied	  by	  extensive	  experimental	  procedures,	  e.g.	  subcellular	  fractionation198	  or	   high	   resolution	   setups199,	   such	   brute	   force	   methods	   are	   time	   consuming,	  expensive	   and	   non-­‐scalable.	   Network-­‐based	   methods,	   as	   demonstrated	   in	  sections	   4	   to	   7,	   capture	   relationships	   between	   functionally	   related	   proteins,	  therefore	  allowing	  recovery	  of	  proteins	  that	  are	  undetected	  but	  likely	  to	  be	  in	  the	  sample.	   In	   this	   way,	   they	   offer	   a	   fast	   and	   cost-­‐effective	   solution	   to	   limited	  coverage	   and	   reproducibility.	   This	   has	   direct	   implications	   for	   important	  biological	  studies	  including	  cancer200.	  However,	  they	  do	  come	  in	  different	  forms	  which	  may	  produce	  different	  outcomes.	  Therefore,	  a	  comparative	  functional	  and	  performance	  (recovery)	  analysis	   is	  necessary.	  We	  test	  and	  evaluate	  three	  types	  of	   Protein-­‐Protein	   Interaction	   Network	   (PPIN)-­‐based	   methods-­‐-­‐-­‐a	   cluster	  discovery-­‐based	   approach,	   PEP	   (Described	   in	   Chapter	   4);	   a	   feature-­‐based	  approach,	  Functional	  Class	  Scoring	  (FCS),	  which	  has	  similarities	  to	  PSP	  described	  in	  Chapters	  6	  and	  7;	  and	  an	  association-­‐based	  approach,	  Maxlink	  (Described	   in	  Chapter	   5)	   -­‐-­‐-­‐	   using	   proteomics	   data	   derived	   from	   valproic	   acid	   (VPA)-­‐treated	  mice.	  	  Using	  networks,	  more	  accurate	  identification	  of	  present	  proteins	  (recovery)	  can	  be	   attained	  by	   identifying	   cliques	   or	   clusters	   closely	   associated	  with	   identified	  proteins.	  This	   forms	  the	  methodological	  basis	   for	  methods	  e.g.	  PEP	  (Section	  4).	  For	  example,	  protein	  relations	  can	  be	  described	  by	  a	  graph	  where	  pairs	  of	  nodes	  symbolizing	  proteins	  are	  connected	  by	  an	  edge.	  The	  edge	  can	  represent	  protein	  co-­‐expression	   assembled	   from	   previous	   knowledge	   and	   experiments,	   physical	  binding	   or	   genetic	   interaction.	  Within	   this	   graph,	   cliques	   (sets	   of	   nodes	  where	  every	  pair	  of	  nodes	  are	  connected)	  and	  highly	  connected	  clusters	  (sets	  of	  nodes	  where	   a	   high	   percentage	   of	   node	   pairs	   are	   connected)	   are	   indicative	   of	  modularity	  (e.g.	  a	  protein	  complex).	  Once	  these	  cliques	  or	  clusters	  are	  identified,	  they	  can	  be	  used	  for	  post	  processing	  on	  the	  identified	  proteins;	  the	  identification	  in	   a	   sample	   of	   many	   proteins	   A1,	   …,	   An	   from	   a	   network-­‐identified	   clique201	  provides	   reasonable	   evidence	   that	   a	   protein	   C,	   which	   is	   in	   the	   same	   clique	   as	  proteins	   A1,	   …,	   An,	   should	   also	   be	   present	   in	   the	   sample.	   “Cluster	   discovery”	  approaches	   define	   clusters	   by	   protein	   identifications	   but	   this	   is	   potentially	  unstable	  as	  it	  is	  particularly	  subject	  to	  network	  completeness	  and	  nature	  of	  the	  cluster	  prediction	  algorithm.	  	  In	   contrast,	   “Feature-­‐based	   approaches”	   define	   the	   clusters	   a	   priori	   and	   are	  immutable.	   To	  disambiguate,	  we	   term	   such	   clusters	   “features”.	  One	   example	   is	  FCS	   (Functional	   Class	   Scoring)184.	   Here,	   overlaps	   (hit-­‐rates)	   are	   obtained	   by	  comparing	   the	   identified	  protein	   list	   against	   features	   such	  as	  predicted	  and/or	  real	   biological	   complexes.	   A	   key	   advantage	   of	   FCS	   is	   that	   a	   p-­‐value	   can	   be	  determined	  using	  class-­‐label	  randomization	  methods.	  This	  empirically	  generated	  p-­‐value	   is	   important:	  Venet	  et	  al202	  demonstrated	   that	  distribution	  of	  values	   in	  real	  data	   is	  acutely	  different	   from	   theoretical	  distributions	  and	  hence,	  p-­‐values	  derived	  from	  the	  latter	  have	  little	  relevance	  or	  bearing.	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The	  third	  class	  of	  methods	  is	  “association	  based”.	  From	  a	  set	  of	  high-­‐confidence	  seeds,	   new	   candidates	   are	   identified	   and	   ranked	   based	   on	   the	   number	   of	  network	  links	  to	  seeds.	  An	  example	  is	  Maxlink,	  developed	  by	  Ostlund	  et	  al71,	  for	  identifying	   novel	   cancer	   genes.	   This	   method	   is	   more	   relaxed	   than	   “cluster	  discovery”	   approaches	   and	   does	   not	   depend	   on	   the	   choice	   of	   clustering	  algorithm.	  	  Cluster-­‐based	   methods	   are	   the	   most	   commonly	   used	   type	   of	   tool	   in	   network	  analysis.	   Although	   more	   relaxed,	   association-­‐based	   methods	   are	   seldom	   used.	  Feature-­‐based	  methods	  (e.g.	  PSP	  in	  Chapter	  6)	  are	  the	  newest	  class	  of	  methods	  developed	   for	   proteomic	   analysis.	   Although	   radically	   different	   from	   more	  conventional	  analyses,	  this	  class	  of	  methods	  is	  the	  only	  type	  able	  to	  resolve	  both	  the	   consistency	   and	   coverage	   issue	   with	   low	   false	   positive	   rates203,	   204.	   An	  evaluation	   of	   the	   pros	   and	   cons	   of	   each	   method	   is	   given	   in	   Table	   15	   and	  elaborated	  under	  Results	  and	  Discussions.	  	  To	  the	  best	  of	  our	  knowledge,	  there	  is	  no	  current	  gold	  standard	  dataset	  for	  which	  all	  the	  proteins	  within	  a	  dataset	  are	  known.	  While	  this	  does	  somewhat	  limit	  the	  robustness	   of	   performing	   evaluation	   studies	   on	   network-­‐based	   methods,	   it	   is	  possible	  to	  gain	  insight	  based	  on	  specific	  experimental	  data.	  Here,	  we	  study	  these	  methods	  by	  applying	  them	  on	  mass	  spectrometry-­‐based	  proteomics	  data	  derived	  from	  valproic	  acid	  (VPA)-­‐treated	  mice	  using	  two	  protein	  search	  criteria.	  VPA	  is	  used	  medically	  as	  an	  anticonvulsant	  and	  a	  mood	  stabilizer,	  but	  also	  has	  positive	  effects	  on	  learning	  and	  memory205.	  It	  has	  a	  role	  in	  epigenetic	  remodeling	  through	  its	  histone	  deacetylase	   inhibitor	  activity	  and	  has	  a	   tangible	   impact	  on	  neuronal	  differentiation206.	   VPA	   prompts	   the	   differentiation	   of	   hippocampal	   neural	  progenitor	   cells	   into	   neurons,	   but	   also	   prevents	   differentiation	   into	  oligodendrocytes	  and	  astrocytes207.	  In	  a	  screen	  of	  several	  psychoactive	  drugs	  in	  rats,	   it	   has	   been	   shown	   that	   only	   VPA	   exerted	   clear	   definable	   increase	   in	  acetylation208.	   Studies	   in	   rats	   showed	   that	   HDAC	   inhibitor	   treatments,	   such	   as	  VPA	  and	  trichostatin	  A	  (TSA),	  increased	  visual	  evoked	  potentials	  and	  recovered	  their	   visual	   acuity	   after	   long-­‐term	   monocular	   deprivation	   209,	   210	   Recently,	   we	  found	  that	  VPA	  also	  exerts	  its	  effect	  via	  miRNA	  complex	  regulation,	  in	  particular	  the	  BAF/npBAF	  and	  histone	  deacetylases	  (HDAC)	  complexes211.	  Figure	  18	  shows	  a	  proposed	  model	  for	  VPA	  activity.	  Treatment	   of	   wild-­‐type	   adult	   mice	   with	   VPA	   over	   a	   2-­‐day	   period	   re-­‐adjusts	  miRNA,	  gene	  and	  protein	  levels	  in	  the	  brain.	  At	  structural	  and	  phenotypic	  levels,	  VPA-­‐treated	   mice	   showed	   an	   increase	   in	   dendritic	   branching	   and	   spine	  morphology	  and	  also	   improved	  visual	  acuity.	  As	   the	  biological	  mechanisms	  are	  not	  well	  understood	  for	  this	  phenotypic	  response,	  the	  first	  part	  of	  this	  work	  uses	  the	  afore	  mentioned	  network-­‐based	  methods	  for	  functional	  analysis.	  The	  second	  part	   comparatively	   analyzes	   the	   relative	   performances	   (recovery)	   of	   the	  methods.	  8.2 METHODS	  8.2.1 ANIMALS	  Adult	  C57BL/6	  mice	  of	  either	  sex	  were	  used	  by	  my	  collaborators	  in	  Dr	  Judy	  Sng’s	  group.	  Animals	  were	  maintained	  on	  a	  12	  hr	   light/dark	  cycle	  and	  had	  access	   to	  food	   and	   water	   ad	   libitum.	   All	   animal	   protocols	   have	   been	   approved	   by	   the	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Institutional	  Animal	  Care	  and	  Use	  Committee	  (IACUC)	  in	  the	  Agency	  for	  Science,	  Technology	   and	   Research,	   A*STAR.	   Visual	   cortex	   tissue	   was	   excised	   under	   a	  dissecting	  microscope	  and	  used	  for	  protein,	  RNA	  extraction	  and	  iTRAQ	  assays.	  8.2.2 DRUG	  ADMINISTRATION	  Valproic	   acid	   (VPA;	   200mgkg-­‐1,	   i.p;	   Sigma-­‐Aldrich)	   was	   dissolved	   in	   sterile	  saline.	   The	   same	   volume	   of	   vehicle	   solution	  was	   injected	   into	   control	   animals.	  VPA	   or	   vehicle	   solution	   (Veh)	   was	   injected	   every	   12	   hours	   into	   wild	   type	  postnatal	   day-­‐56	   adult	   mice.	   The	   mice	   were	   sacrificed	   after	   2	   days	   of	   drug	  administration	  for	  gene	  expression	  array	  and	  proteomics	  iTRAQ	  profiling.	  8.2.3 RNA	  EXTRACTION	  Total	  RNA	  was	   isolated	   from	  visual	   cortex	  using	  RNase	  Easy	  kit	   (Qiagen).	   	   For	  every	  qPCR	  experiment,	   independent	  pairs	  of	  visual	  cortex	  from	  3-­‐4	  mice	  were	  used	   as	   biological	   replicates:	   Veh-­‐	   and	   VPA-­‐treated.	   For	   every	   microarray	  experiment,	   independent	   pairs	   of	   visual	   cortex	   from	   4	   mice	   were	   used	   as	  biological	  replicates:	  Veh-­‐	  and	  VPA-­‐treated.	  8.2.4 GENE	  EXPRESSION	  ARRAY	  PROFILING	  The	  quality	  of	  the	  total	  RNA	  was	  verified	  by	  an	  Agilent	  2100	  Bioanalyzer	  profile.	  From	   each	   sample,	   10	   µg	   of	   total	   RNA	   was	   labeled,	   hybridized	   to	   Affymetrix	  Murine	   Genome	   430	   GeneChips	   according	   to	   the	   Affymetrix	   protocols	   and	  scanned	  at	  the	  Biopolis	  Shared	  Facilities,	  A*STAR.	  	  All	  analyses	  were	  performed	  using	   standard	   statistics-­‐based	   Affymetrix	   GeneChip	   Software;	   statistical	  algorithms	  were	  implemented	  using	  Affymetrix	  Microarray	  Suite	  version	  5.0.	  8.2.5 PROTEOMICS	  BIOLOGICAL	  SAMPLE	  PREPARATION	  Frozen	  visual	  cortical	  samples	  were	  lyzed	  at	  4	  °C	  with	  ice-­‐cold	  lyses	  buffer	  [2%	  SDS;	   0.5	   M	   triethylammonium	   bicarbonate	   (TEAB)	   with	   Complete	   Protease	  Inhibitor	   Cocktail	   (COMPLETE,	   Roche,	   Mannheim,	   Germany)	   and	   phosphatase	  inhibitor	   cocktail	   (PhosSTOP,	  Roche)]	  by	   intermittent	  vortexing	  and	   sonication	  (amplitude,	   23%;	   Pulse:	   5	   s/	   5	   s	   for	   5	   min)	   using	   a	   Vibra	   Cell	   high	   intensity	  ultrasonic	   processor	   (Jencon,	   Leighton	   Buzzard,	   UK).	   The	   lysates	   were	  centrifuged	  at	  20	  000	  x	  g	  for	  30	  min	  at	  4	  °C.	  The	  supernatant	  was	  collected	  and	  stored	  in	  aliquots	  at	  -­‐80	  °C	  (longer	  term)	  or	  at	  -­‐20	  °C	  (shorter	  duration).	  Protein	  quantification	  was	  done	  using	  Bicinchoninic	  Acid	  Protein	  Assay	  kit.	  8.2.6 IN-­‐GEL	  TRYPTIC	  DIGESTION	  AND	  ISOBARIC	  LABELING	  The	   samples	  were	   subjected	   to	   denaturing	   polyacrylamide	   gel	   electrophoresis	  (PAGE)	   for	   the	   purpose	   of	   removing	   the	   non-­‐protein	   interfering	   substances.	  Briefly,	  500	  µg	  of	  protein	  from	  each	  condition	  were	  run	  on	  an	  8%	  stacking–25%	  separating	  gel.	  Proteins	  which	  migrated	  into	  the	  8%	  layer	  were	  retarded	  by	  the	  25%	  layer,	  thus	  concentrating	  them	  in	  a	  narrow	  strip	  at	  the	  end	  of	  the	  stacking	  gel.	   The	   diced	   gel	   bands	   were	   then	   reduced	   (5	   mM	   tris-­‐(2-­‐carboxyethyl)	  phosphine,	   60	   °C,	   1	   h)	   and	   alkylated	   (10	  mM	  methyl	  methanethiosulfonate	   in	  isopropanol,	  room	  temperature,	  15	  min)	  before	  being	  digested	  with	  10	  ng/µl	  of	  sequencing-­‐grade	   modified	   trypsin	   (Promega,	   Madison,	   WI)	   for	   overnight	   at	  37	   °C.	   The	  peptides	  were	   extracted	  with	   50%	  ACN	  and	   vacuum	   centrifuged	   to	  dryness.	   The	   dried	   peptides	  were	   reconstituted	   into	   0.5	  M	   TEAB	   and	   ethanol,	  and	  labeled	  with	  respective	  isobaric	  tags	  of	  4-­‐plex	  iTRAQ	  Reagent	  Multi-­‐Plex	  kit	  (Applied	  Biosystems,	  Foster	  City,	  CA)	  as	  follows:	  sham,	  114;	  2+0,	  115;	  2+4,	  116;	  
	   110	  
2+24,	  117.	  	  The	  labeled	  samples	  were	  combined	  after	  2	  h	  and	  dried	  in	  a	  vacuum	  centrifuge.	  8.2.7 STRONG	  CATION	  EXCHANGE	  (SCX)	  CHROMATOGRAPHY	  The	  dried	  iTRAQ-­‐labeled	  peptide	  was	  reconstituted	  in	  Buffer	  A	  (10	  mM	  KH2PO4;	  25%	  ACN;	   pH	   2.85)	   and	   fractionated	   using	   a	   PolySULFOETHYL	   A	   SCX	   column	  (200	  ×	  4.6	  mm;	  5	  µm;	  200	  Å)	  (PolyLC,	  Columbia)	  as	  mentioned	  previously	  on	  a	  Prominence	  HPLC	  system	  (Shimadzu,	  Japan)	  in	  a	  50	  min	  gradient	  with	  Buffer	  B	  (10	   mM	   KH2PO4,	   25%	   ACN,	   500	   mM	   KCl	   (pH	   3.0)).	   Eluted	   fractions	   were	  collected	   in	   every	   1	  min,	   and	   then	   pooled	   into	   25	   fractions,	   depending	   on	   the	  peak	  intensities,	  before	  drying	  them	  in	  a	  vacuum	  centrifuge.	  The	  dried	  fractions	  were	   desalted	   through	   C18	   Sep-­‐Pak	   Vac	   reverse	   phase	   cartridges	   (Waters,	  Milford,	  MA)	  and	  stored	  at	  -­‐20	  °C	  till	  MS	  analysis.	  8.2.8 LC-­‐MS/MS	  ANALYSIS	  USING	  QSTAR	  The	  iTRAQ-­‐labeled	  desalted	  peptides	  were	  reconstituted	  with	  0.1%	  formic	  acid	  (FA)	  for	  MS	  analysis.	  Each	  sample	  was	  analyzed	  three	  times	  using	  a	  QSTAR	  Elite	  Hybrid	  MS	  (Applied	  Biosystems/MDS-­‐SCIEX),	  coupled	  to	  an	  online	  HPLC	  system	  (Shimadzu,	  Japan).	  For	  each	  analysis,	  30	  µl	  of	  peptide	  solution	  was	  injected	  and	  separated	  on	  a	  home-­‐packed	  nanobored	  C18	  column	  with	  a	  picofrit	  nanospray	  tip	   (75	  µm	   ID	  ×	  15	  cm,	  5	  µm	  particles)	   (New	  Objectives,	  Wubrun,	  MA).	  Mobile	  phase	   A	   (0.1%	   FA	   in	   2%	   ACN)	   and	   B	   (0.1%	   FA	   in	   100%	   ACN)	   were	   used	   to	  establish	   a	   90	   min	   HPLC	   gradient	   with	   an	   effective	   flow	   rate	   of	   0.2	   µl/min,	  obtained	   from	   a	   constant	   flow	   of	   30	   µl/min	   using	   a	   splitter.	   The	   mass	  spectrometer	   was	   set	   to	   perform	   data	   acquisition	   in	   the	   positive	   ion	   mode.	  Precursors	  with	  a	  mass	  range	  of	  300–2000	  m/z	  and	  calculated	  charge	  of	  +2	  to	  +4	  were	  selected	  for	  fragmentation.	  The	  three	  most	  abundant	  peptide	  ions	  above	  a	  5	   count	   threshold	   were	   selected	   for	   each	   MS/MS	   spectrum.	   The	   selected	  precursor	  ion	  was	  dynamically	  excluded	  for	  30	  s	  with	  a	  30	  mDa	  mass	  tolerance.	  Smart	  information-­‐dependent	  acquisition	  was	  activated	  with	  automatic	  collision	  energy	   and	   automatic	  MS/MS	   accumulation.	   The	   fragment	   intensity	  multiplier	  was	  set	   to	  20	  and	  maximum	  accumulation	   time	  was	  2	  s.	  The	  peak	  areas	  of	   the	  iTRAQ	  reporter	  ions	  reflect	  the	  relative	  abundance	  of	  the	  proteins	  in	  the	  samples.	  8.2.9 MASS	  SPECTROMETRIC	  RAW	  DATA	  ANALYSIS	  The	  spectral	  data	  acquisition	  was	  performed	  using	  the	  Analyst	  QS	  2.0	  software	  (Applied	   Biosystems/MDS	   SCIEX).	   ProteinPilot	   Software	   2.01	   (Applied	  Biosystems,	   Foster	   City,	   CA)	   was	   used	   for	   peak	   list	   generation,	   protein	  identification	  and	  quantification	  against	  the	  International	  Protein	  Index	  	  (IPI)	  rat	  database	   (version	   3.40;	   79354	   sequences;	   41861410	   residues)212.	   Although	  deprecated,	  the	  IPI	  database	  still	  provides	  a	  relatively	  high-­‐quality	  search	  which	  can	   be	   compared	   against	   a	  more	   current	   and	   larger	   database.	   A	   concatenated	  target-­‐decoy	  database	   search	   strategy	  was	   also	   employed	   to	   estimate	   the	   false	  discovery	  rate	  (FDR)213.	  FDR	  was	  calculated	  as	  the	  percentage	  of	  decoy	  matches	  divided	  by	  the	  total	  matches	  (i.e.,	  #decoy	  /	  (#decoy	  +	  #target)).	  The	  user-­‐defined	  parameters	  of	  the	  software	  were	  configured	  as	  follows:	  (i)	  Sample	  Type,	  iTRAQ	  4-­‐plex	  (Peptide	  Labeled);	  (ii)	  Cysteine	  alkylation,	  MMTS;	  (iii)	  Digestion,	  Trypsin;	  (iv)	   Instrument,	   QSTAR	  Elite	   ESI;	   (v)	   Special	   factors,	   None;	   (vi)	   Species,	   None;	  (vii)	   Specify	   Processing,	   Quantitate;	   (viii)	   ID	   Focus,	   biological	   modifications,	  amino	   acid	   substitutions;	   (ix)	  Database,	   concatenated	   ‘target’	   	   and	   ‘decoy’	   (the	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corresponding	   reverse	   sequences);	   (x)	   Search	   effort,	   thorough	   214.	   For	   iTRAQ	  quantitation,	   the	   peptide	   for	   quantification	   was	   automatically	   selected	   by	   Pro	  Group	   algorithm	   to	   calculate	   the	   reporter	   peak	   area,	   error	   factor	   (EF)	   and	   p-­‐value.	  The	  resulting	  data	  set	  was	  auto	  bias-­‐corrected	  to	  get	  rid	  of	  any	  variations	  imparted	  due	  to	  the	  unequal	  mixing	  during	  combining	  different	  labeled	  samples.	  	  The	   Paragon	   algorithm34	   was	   used	   for	   the	   peptide	   identification	   which	   was	  further	   processed	   by	   the	   Pro	   Group	   algorithm	   where	   isoform-­‐specific	  quantification	   was	   adopted	   to	   trace	   the	   differences	   between	   expressions	   of	  various	   isoforms.	  The	  Proteinpilot	  software	  employed	  iTRAQ	  reporter	   ion	  peak	  area	  for	  quantification.	  Details	  of	  the	  quantification	  algorithm	  can	  be	  found	  in	  the	  supplier’s	  manual.	  The	  resulting	  dataset	  was	  auto	  bias-­‐corrected	  to	  get	  rid	  of	  any	  variations	   imparted	   due	   to	   the	   unequal	   mixing	   during	   combining	   different	  labeled	   samples.	   Subsequently	   background	   correction	   was	   also	   performed	   to	  eliminate	  any	  background	  ion	  signal	  due	  to	  non-­‐target	  peptides,	  co-­‐eluting	  with	  the	   target	   peptide.	   396	   proteins	   were	   identified	   but	   of	   these,	   only	   291	   have	  determined	  quantification	  ratios.	  A	  second	  round	  of	  peptide/protein	  identification	  was	  performed	  by	  scanning	  the	  MS	   against	   the	   UniProtkb	   database	   (con_Xuni_mouse_12032010;	   sequences	  125176;	   67,329,692	   residues)	   using	   ProteinPilot	   (Paragon)	   (v2.01).	   Similar	  search	  parameters	  were	  usd	  as	  before	  with	  false	  discovery	  rates	  deployed	  using	  target-­‐decoy	  database	  search	  and	  set	  to	  <	  1%	  FDR.	  789	  proteins	  were	  identified.	  This	   is	   a	   superset	   of	   the	   originally	   identified	   proteins	   identified	   by	   matching	  against	   IPI.	   The	   498	   (=	   789	   –	   291)	   additional	   proteins	   are	   used	   for	   recovery	  analysis	  of	  the	  individual	  network-­‐based	  methods.	  They	  are	  referred	  to	  as	  the	  set	  D	  in	  Recovery	  performance	  of	  network-­‐based	  methods.	  8.2.10 MOUSE	  PPIN	  CONSTRUCTION	  Since	  mouse	  PPIN	  data	  is	  incomplete	  and	  sparse,	  I	  built	  an	  expanded	  network	  by	  merging	   data	   from	   two	   data	   sources,	   MppDB215	   and	   IntNetDB216.	   MppDB	   is	   a	  mouse	  protein-­‐protein	  interaction	  (PPI)	  database	  and	  we	  used	  the	  reference	  set	  of	  mouse	  PPI	  data	  collected	  over	  five	  PPI	  databases:	  DIP,	  BIND,	  MIPS,	  MINT	  and	  IntAct.	  This	  network	  is	  rather	  sparse,	  with	  limited	  information.	  The	  Human	  PPI	  (IntNetDB)	  network	  however	  is	  much	  more	  extensive	  and	  well-­‐studied.	  We	  thus	  used	   IntNetDB	  to	  map	   interologs	   from	  human	  PPIN	  to	  mouse,	  and	  merged	  this	  with	   the	   MppDB	   dataset.	   IntNetDB	   is	   comprised	   of	   both	   human	   PPI	   data	   and	  predicted	   PPI	   based	   on	   several	   model	   organisms	   including	   mouse.	   Functional	  homogeneity/coherence	   is	   evaluated	   by	   the	   smallest	   shared	   biological	   process	  (SSBP)	  score,	  which	  is	  calculated	  in	  three	  steps:	  (1)	  find	  all	  the	  GO	  terms	  shared	  by	  each	  pair	  of	  genes,	  (2)	  find	  the	  number	  of	  other	  genes	  also	  sharing	  these	  GO	  terms,	  and	  (3)	  get	  the	  GO	  term	  with	  the	  smallest	  gene	  count216.	  While	  the	  SSBP	  to	  some	  extent	  addresses	  issue	  of	  reliability	  by	  using	  information	  from	  GO,	  it	  is	  not	  clear	   that	   the	  SSBP	  of	   interologs	  (in	  mouse)	  would	  necessarily	  have	  high	  SSBP.	  This	  is	  a	  caveat	  that	  needs	  be	  noted	  as	  a	  limitation	  of	  our	  analysis.	  	  The	  resultant	  combined	  network	  (IntNetDB	  +	  MppDB)	  consists	  of	  10307	  nodes	  and	  124866	  edges.	  	  8.2.11 CLUSTER	  PREDICTION	  ALGORITHM	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n 	  Where	  S	  is	  the	  calculated	  score,	  E	  is	  the	  expression	  value	  for	  a	  detected	  protein	  (if	  protein	  is	  under	  expressed,	  then	  the	  reciprocal	  score	  is	  used).	  For	   more	   information	   on	   the	   PEP	   method,	   refer	   to	   the	   pipeline	   diagram	   	   in	  Chapter	  4	  (Figure	  1).	  	  8.2.14 MAXLINK	  As	  before,	  we	  let	  the	  network	  G	  be	  comprised	  of	  nodes	  V	  and	  edges	  E.	  From	  the	  set	   of	   seeds	   X	  ∈	   V	   (expression	   ratio	   ≥	   1.2	   or	   ≤	   0.8),	   the	   set	   of	   non-­‐seeds	   Y	   is	  derived	  (Y	  =	  V	  −	  X).	  The	  set	  of	  linked	  proteins	  L	  are	  those	  proteins	  in	  Y	  that	  have	  at	  least	  2	  connections	  to	  proteins	  in	  X.	  That	  is,	  L={y∈Y	  |2≤	  |{x∈X	  |	  (x,y)	  ∈E}|}.	  	  8.2.15 PRECISION-­‐RECALL	  ANALYSIS	  To	   evaluate	  whether	   higher	   ranked	   complexes	   are	  more	   reliable	   in	   recovering	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proteins	   and	  whether	   they	   recover	  more	   proteins,	   significant	   complexes	   from	  FCS	  are	  ranked	  by	  p-­‐value	  in	  ascending	  order.	  Proteins	  are	  ranked	  based	  on	  the	  best	  complex	  they	  are	  in	  and	  inherit	  the	  corresponding	  p-­‐value.	  For	  each	  level	  n	  (p-­‐value	  <	  n),	   the	  precision	  and	  recall	  are	  calculated	  based	  on	   the	  recovery	   for	  that	  level.	  	  We	  let	  U	  be	  the	  set	  of	  proteins	  at	  some	  level	  n	  where	  p-­‐value	  <	  n,	  V	  is	  the	  set	  of	  detected	   proteins.	   Precision	   is	   calculated	   as	   U∩V/U	   and	   recall	   is	   calculated	   as	  U∩V/V.	  	  8.3 RESULTS	  AND	  DISCUSSIONS	  The	   overall	   analyses	   are	   as	   follows:	   1/	   	   a	   first	   pass	   proteomic	   analysis	   was	  performed	  to	  gauge	   the	  quality	  of	   information	  as	  well	  as	   their	  relevance	   to	   the	  observed	  phenotype.	  2/	  we	  subsequently	  built	  on	  this	  by	  examining	  the	  results	  from	  PEP,	  Maxlink	  and	  FCS	  in	  a	  concurrent	  manner	  (Figure	  17	  summarizes	  each	  method).	   This	   involves	   first	   using	   FCS	   to	   build	   an	   initial	   model,	   followed	   by	  augmentation	  with	   PEP	   complexes,	   and	   lastly	   checking	   for	   testable	   candidates	  using	   Maxlink.	   Details	   are	   given	   below.	   3/	   To	   understand	   how	   congruent	   or	  varied	  the	  network	  based	  methods	  are,	  we	  first	  checked	  the	  extent	  of	  functional	  term	   variation	   between	   the	   3	   methods,	   the	   extent	   of	   protein	   overlap	   and	  recovery	   performance.	   4/	   Since	   FCS	   performed	   best	   (precision	   and	   recall),	  we	  subsequently	  built	  a	  precision-­‐recall	  graph	  to	  check	  whether	  the	  distribution	  of	  real	  proteins	  is	  concentrated	  in	  the	  region	  where	  the	  p-­‐value	  is	  highly	  significant.	  	  5/	  Finally,	  we	  end	  with	  a	  critical	  evaluation	  on	  the	  pros	  and	  cons	  of	  each	  method.	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FIGURE	  17	  SCHEMATIC	  OF	  THE	  3	  NETWORK-­‐BASED	  METHODS.	  	  
A:	   FCS.	   THE	  HIT-­‐RATE	  OF	   EACH	   COMPLEX	   (REAL/PREDICTED)	   IS	  MEASURED	  AGAINST	  THE	  MS	  PROTEIN	   LIST.	  
RANDOMIZATION	   VIA	   CLASS-­‐LABEL	   SWOPPING	   IS	   USED	   TO	   GENERATE	   P-­‐VALUE.	   B)	   PEP.	  MS	   PROTEIN	   LIST	   IS	  
FIRST	   FILTERED	   FOR	   SEED	   PROTEINS.	   THE	   EXPANSION	   STEP	   IS	   DONE	   IN	   RELATION	   TO	   THE	   PPIN.	   CLIQUE	  
ANALYSIS	  IS	  THEN	  PERFORMED	  TO	  OBTAIN	  TIGHTLY	  CONNECTED	  CLUSTERS.	  THE	  CLUSTERS	  ARE	  THEN	  SCORED	  
AND	  RANKED.	  C:	  MAXLINK.	  MS	  PROTEIN	  LIST	  IS	  FIRST	  FILTERED	  FOR	  SEED	  PROTEINS.	  CONNECTIONS	  OF	  EVERY	  
NODE	   IN	   THE	  NETWORK	  TO	  THESE	   SEEDS	  ARE	   COUNTED	  AND	  RANKED.	   (ABBREVIATIONS:	   FCS	   –	   FUNCTIONAL	  
CLASS	   SCORING,	   MS	   –	   MASS	   SPECTROMETRY,	   PEP	   –	   PROTEOMICS	   EXPANSION	   PIPELINE,	   PPIN	   –	   PROTEIN-­‐
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using	   gene	   lists	   is	   not	   very	   informative.	   It	   is	   not	   known	   how	   these	   proteins	  interact	   with	   each	   other	   in	   order	   to	   achieve	   the	   observed	   phenotype.	   The	  enriched	   GO	   terms	   may	   not	   be	   stable	   if	   additional	   proteins	   were	   uncovered.	  Networks	   offer	   the	   possibility	   of	   contextualizing	   the	   protein	   lists	   both	   for	  functional	  analysis	  and	  recovery.	  	  8.3.2 INTEGRATIVE	  FUNCTIONAL	  ANALYSIS	  BASED	  ON	  FCS,	  PEP	  AND	  MAXLINK	  -­‐-­‐-­‐	  A	  PLAUSIBLE	  APPROACH	  Although	   network-­‐based	   methods	   are	   powerful,	   it	   is	   time	   consuming	   to	  exhaustively	  analyze	  and	  validate	   the	  network-­‐identified	  proteins	  of	  any	  single	  method.	  Moreover,	  integration	  of	  outputs	  can	  be	  difficult.	  Instead,	  we	  propose	  a	  simple	  approach	   involving	   these	   three	  methods	  by	  drawing	  on	   their	   individual	  strengths	  to	  bolster	  functional	  analysis;	  see	  Figure	  20.	  	  
Building	   an	   initial	   model	   with	   FCS	   (CORUM)	   -­‐-­‐-­‐	   FCS	   (using	   biological	  complexes	  from	  CORUM176)	  utilizes	  informative	  biological	  features	  with	  defined	  functions	   and	   stable	   components.	   Significant	   complexes	   (Figure	   20)	   can	   be	  implicated	   by	   building	   on	   and	   expanding	   the	   proposed	  model	   for	   VPA	   activity	  (Figure	  18).	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FIGURE	  18	  THE	  PROPOSED	  BIOLOGICAL	  ACTION	  OF	  VPA	  TREATMENT	  	  
VPA	  ACTIVATES	  HDAC,	  WHICH	  IN	  TURN	  EPIGENETICALLY	  TURNS	  ON	  THE	  EXPRESSION	  OF	  GENES	  INVOLVED	  IN	  
SYNAPSE	   FORMATION,	   NERVE	  GROWTH	  ACTIVATION	  AND	   CYTOSKELETAL	  REORGANIZATION.	   THE	   COMBINED	  
EFFECTS	  OF	  THESE	  THREE	  ACTIVITIES	  RESULT	   IN	  THE	  PHENOTYPIC	  OBSERVATION	  OF	   INCREASED	  DENDRITIC	  
GROWTH.	   	   THIS	   IN	   TURN	   CONTRIBUTES	   TO	   SYNAPTIC	   PLASTICITY	   AND	   ENHANCED	   VISUAL	   ACUITY.	  
(ABBREVIATIONS:	  HDAC	  –	  HISTONE	  DEACETYLASE	  ,	  VPA	  –	  VALPROIC	  ACID).	  Human	  complexes	  were	  used	  because	  they	  are	  more	  extensive211.	  Moreover	  we	  have	   prior	   insight	   as	   similar	   genomics	   analysis	   of	   the	   same	  biological	   samples	  using	   Affymetrix	   430	   2.0	   chips	   (mouse)	  was	   performed211.	   Also,	   the	   reference	  mouse	  network	  (on	  which	  the	  Maxlink	  and	  PEP	  are	  performed)	  comprises	  many	  human	  network	  elements	  via	  homology	  transfer.	  Expectedly,	  a	  large	  number	  of	  epigenetically	  related	  complexes	  were	  significant	  (HDAC-­‐related,	  SWI/SNF	  and	  LARC)	  (p	  ≤	  0.05).	  Epigenetic	  modifications	  can	  lead	  to	   the	  activation	  of	  other	  genes,	  but	   this	  requires	  activation	  of	  gene	  expression	  machinery	   including	   the	   spliceosome,	   CDC5L	   and	   nop56p	   complexes.	   This	  further	   leads	   to	   the	   significant	   activation	   of	   complexes	   involved	  with	   synaptic	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formation	  (Polycystin-­‐1),	  cytoskeletal	  reorganization	  (Profilin	  1,	  Emerin,	  Arp2/3	  and	  beta-­‐AR	  receptosome),	  as	  well	  as	  neuronal	  development	  (BAF	  218	  and	  MeCP2	  219).	  	  
Augmenting	  with	   PEP	   complexes	   -­‐-­‐-­‐	  The	  primary	   limitation	  of	  using	  existing	  biological	   complexes	   is	   non-­‐exhaustive	   representation.	   For	   instance,	   if	  complexes	   involved	   in	   neuronal	   differentiation	   are	   non-­‐represented176,	   then	  these	  functionalities	  will	  not	  be	  reflected.	  Hence,	  FCS-­‐based	  model	  can	  be	  further	  enhanced	  and/or	  augmented	  with	  predicted	  complexes	  from	  PEP	  and	  FCS	  (using	  predicted	  complexes).	  	  Figure	  20	  shows	  two	   instances	  of	   top	  predicted	  complexes	   in	  PEP	  with	  related	  functionalities	   not	   found	   among	   real	   protein	   complexes.	   In	   particular,	   the	   PEP	  clusters	   (YWHAB,	  NR1,	  NR2b,	  ACTB	  and	  TJP1)	  as	  well	  as	   (YWHAB,	  RAF1,	  NR1,	  NR2b,	  PRKCE,	  SRC	  and	  YWHAG)	  further	  add	  value	  to	  the	  analysis.	  This	  group	  of	  proteins	   is	   involved	   in	   a	   variety	  of	   functions	   related	   to	  neuronal	  plasticity	   and	  development.	  These	  include	  detection	  of	  stimulus	  involved	  in	  sensory	  perception,	  negative	   regulation	   of	   neuron	   apoptosis,	   synaptic	   transmission,	   axonogenesis,	  regulation	   of	   synaptic	   plasticity,	   neuromuscular	   process	   and	   adult	   locomotory	  behavior.	   But	  more	   relevantly,	   it	   implicates	   additional	   terms	   such	   as	   learning,	  memory,	   regulation	   of	   dendrite	   development	   and	   associative	   learning.	   In	  particular,	  NR1	  and	  NR2B	  are	  important	  in	  visual/ocular	  dominance	  plasticity220,	  221;	  see	  Supplementary	  Table	  2	  for	  details	  and	  associated	  p-­‐values.	  	  
	  
FIGURE	  19	  COMBINED	  ANALYSIS	  -­‐-­‐-­‐	  A	  PLAUSIBLE	  APPROACH.	  	  
BASED	  ON	  OUR	  PROPOSED	  BIOLOGICAL	  MODEL,	  WE	  CAN	  GROUP	  SIGNIFICANT	  FCS	  COMPLEXES	  (AS	  THEY	  HAVE	  
WELL-­‐DEFINED	  FUNCTIONS	  AND	  ARE	  REAL)	  ACCORDINGLY.	  THIS	  PROVIDES	  A	   FUNCTIONAL	  MODEL	   IN	  WHICH	  
WE	   SUGGEST	   HOW	   COMPLEXES	   ACT	   IN	   CONCERT	   TO	   AFFECT	   THE	   PHENOTYPE	   AS	   OPPOSED	   TO	   JUST	   SINGLE	  
GENES.	  WE	  CAN	  FURTHER	  AUGMENT	  THE	  MODEL	  WITH	   INFORMATION	  FROM	  CLUSTER-­‐DISCOVERY	  METHODS	  
LIKE	  PEP.	  SHOWN	  ARE	  TWO	  PREDICTED	  PEP	  CLUSTERS	  WITH	  HIGHLY	  RELEVANT	  FUNCTIONAL	  TERMS	  BUT	  NO	  
CORRESPONDENCE	  WITH	  THE	  FCS	  ANALYSIS.	   THIS	  ALLOWS	  ENRICHMENT	  AND	  EXPANSION	  OF	  THE	  ANALYSIS.	  
MAXLINK	   ALLOWS	   IDENTIFICATION	   OF	   NOVEL	   PROTEINS	   THAT	   DO	   NOT	   NECESSARILY	   EXIST	   WITHIN	   THE	  
CONTEXT	  OF	  A	  CLUSTER.	  OF	  THE	  TOP	  MAXLINK	  PROTEINS,	  YWHAZ,	  ALSO	  KNOWN	  AS	  14-­‐3-­‐3,	  IS	  INVOLVED	  IN	  A	  
WIDE	   VARIETY	   OF	   FUNCTIONS	   AS	   A	   TRANSCRIPTION	   FACTOR	   AND	   PROMISCUOUS	   BINDER.	   THIS	   IS	   IN	  
AGREEMENT	   WITH	   OUR	   OBSERVATIONS	   THAT	   VPA	   TREATMENT	   RESULTS	   IN	   A	   RESHIFTING	   OF	   THE	   GENE	  
EXPRESSION	  MECHINARY	  (ABBREVIATIONS:	  FCS	  –	  FUNCTIONAL	  CLASS	  SCORING,	  MS	  –	  MASS	  SPECTROMETRY,	  PEP	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Also	   consistent	   with	   the	   FCS	   (CORUM)176	   results	   are	   that	   several	   of	   the	   PEP	  predicted	  clusters	  are	  involved	  in	  transcriptional/translational	  processes	  as	  well	  as	   in	  epigenetic	  remodeling	  processes;	  see	  Supplementary	  Table	  2.	  An	  example	  of	   the	   former	   is	   (LMNB1,	   CDK1	   and	   PLEC),	   which	   is	   involved	   in	   multiple	  functions	   including	   cell	   cycle,	   cell	   aging	   processes,	   and	   DNA	   conformational	  change.	  On	   the	   latter,	   a	   cluster	   comprised	  of	  HDAC2222,	  with	  HSPA8,	  MORF4l1,	  COQ6,	   SIN3A	   and	   PHF20	   is	   involved	   in	   negative	   regulation	   of	   cell	   projection	  organization	  and	  chromatin	  remodeling.	  	  These	   are	   particularly	   interesting	   as	   epigenetic	   regulation	   (via	   chromatin	  remodeling)	   may	   play	   an	   important	   role	   in	   effecting	   synaptic	   plasticity.	  Moreover,	   this	   predicted	   complex	   is	   novel	   and	   has	   no	   counterpart	   in	   CORUM.	  Aside	   from	   SIN3A,	   which	   is	   known	   to	   be	   associated	   with	   HDAC1/2	   in	   some	  complexes	  such	  as	  the	  MeCP2-­‐SIN3A-­‐HDAC	  complex,	  the	  remaining	  components	  are	  unique,	  and	  intricately	  associated	  via	  protein-­‐protein	  interactions.	  
Augmenting	  with	  FCS	  (predicted	  complexes)	  -­‐-­‐-­‐	  As	  the	  constructed	  network	  is	  large	   (10307	   proteins,	   124866	   interactions),	   choice	   of	   clustering	   algorithm	   is	  important.	  SPICi	  was	  selected	  due	  to	  its	  ability	  to	  quickly	  predict	  complexes	  from	  large	   networks217.	   It	   was	   also	   shown	   to	   be	   good	   at	   recovering	   biologically	  relevant	  complexes	  and	  sub	  modules217.	  701	  complexes	  (size	  3	  and	  above)	  were	  predicted	  with	  an	  average	  size	  of	  6.55.	  74	  of	  these	  complexes	  were	  found	  to	  be	  significant	  at	  p-­‐value	  ≤	  0.05.	  	  On	  neuronal	  development,	  the	  complex	  comprising	  CDC42,	  ARHGEF2,	  MYBBP1A,	  PRKCI,	   PPP2CB,	   CYFIP1,	   SMARCA4,	  USP9X,	   YWHAG,	   YWHAH,	   YWHAZ,	   PNMA2,	  USP7,	  PPP2R1A,	  YWHAB,	  KCTD20,	  DOCK7,	  1110012J17RIK,	  PNMA1	  and	  CYFIP2	  is	  heavily	   involved	   in	  neuronal	  development	  processes	   (Neurogenesis,	  nervous	  system	   development	   and	   neuron	   differentiation).	   Interestingly,	   this	   group	   of	  proteins	   is	   also	   intricately	   involved	   with	   apoptosis.	   But	   that	   should	   not	   be	  surprising,	   considering	   that	  apoptosis	   is	   also	   required	   for	   system	  development	  and	  formation.	  On	  cytoskeletal	  reorganization,	  the	  top	  cluster	  consisting	  of	  ACTN1,	  ADD1,	  CAP1,	  CAPZA1,	   CAPZB,	   PPP1R12A,	  WDR1,	   CORO1C,	   ARPC3,	   ARPC4,	   2900064A13RIK,	  ACTR3,	   ARPC2	   and	   CORO7	   is	   relevant	   since	   it	   is	   involved	   in	   cytoskeletal	  reorganization	   and	   neuronal	   growth	   cones	   necessary	   for	   visual	   cortical	   area	  maturation	  which	   is	   reportedly	   important223.	   In	   our	   observation,	   valproic	   acid	  also	  induces	  dendritic	  spine	  growth224	  and	  the	  regulation	  of	  dendritic	  spines	  are	  determined	   by	   actin-­‐signaling	   pathways225	   	   and	   may	   contribute	   to	   long-­‐term	  synaptic	  plasticity226.	   In	  fact,	  structural	  rearrangements	  have	  been	  shown	  to	  be	  effective	  in	  promoting	  plasticity	  in	  adult	  age227.	  The	  third	  top	  clusters	  comprising	  GRM3,	  CACNA1A,	  DNM1,	  GABRB3,	  GAD1,	  GDI1,	  GNB2l1,	   GRIA2,	   GRIK2,	   NR1,	   NR2b,	   RPH3A,	   SLC1A3,	   SPNA2,	   STX1A,	   STXBP1,	  SYN2,	   SYNGR1,	   SYT1,	   TEX2,	   PI4KA,	   SLC6A1,	   ABAT,	   GABBR1	   and	   NOVA1	   is	  involved	   in	   synaptic	   transmission	   processes.	   We	   note	   that	   some	   of	   the	  components	  here	  are	  also	  found	  in	  the	  PEP	  clusters	  e.g.	  NR1	  and	  NR2b	  (Figure	  4).	  This	   cluster	   is	   particularly	   interesting	   as	   γ-­‐Aminobutyric	   acid	   (GABA)ergic,	  N-­‐methyl-­‐d-­‐aspartate	   (NMDA),	   and	   cholinergic	   receptors	   are	   thought	   to	   be	  involved	  in	  visual	  cortex	  plasticity	  in	  animal	  studies228.	  It	  is	  widely	  believed	  that	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NMDA	   receptor-­‐dependent	   forms	   of	   synaptic	   modification,	   such	   as	   long-­‐term	  potentiation	   (LTP)	   and	   long-­‐term	   depression	   (LTD),	   are	   essential	   for	  developmental	  plasticity	  in	  the	  visual	  cortex.	  These	  changes	  can	  be	  theoretically	  accounted	   for	  by	  mechanisms	  of	   LTD	  and	  LTP	  assuming	   that	   the	  properties	  of	  synaptic	   plasticity	   are	   “metaplastic”	   to	   keep	   synaptic	   strengths	  within	   a	   useful	  dynamic	  range229.	  This	  metaplasticity	  results	  from	  activity-­‐dependent	  regulation	  of	   NMDAR	   subunit	   composition.	   Since	   both	   the	   channel	   properties	   and	   the	  intracellular	  binding	  partners	  of	  NMDARs	  rely	  on	  the	  NR2	  subunit	  present	  in	  the	  heteromer,	   experience-­‐dependent	   changes	   in	  NR2A/2B	  and	   ratio	  230	   that	   alters	  the	  receptor	  function	  and	  LTP	  threshold	  231.	  	  Another	   interesting	   component	   of	   this	   cluster	   is	   that	   GABAergic	   circuitry	  proteins	  (GAD1,	  GABRB3,	  GABBR1)	  are	  also	  implicated.	  We	  do	  know	  that	  the	  use	  of	  related-­‐benzodiazepines,	  such	  as	  diazepam,	  that	  can	  initiate	  closure	  of	  visual	  cortical	   plasticity	   prematurely	   by	   enhancing	   GABA–mediated	   transmission	  acting	   through	   GABAA	   receptors	   to	   elicit	   its	   effects232.	   However,	   administering	  diazepam	  during	   adulthood	   doesn’t	   elicit	   the	   reactivation	   of	   plasticity	   seen	   233	  when	  administering	  VPA	  and	  recovery	  of	  amblyopia	   is	  observed	  209.	   	  Thus,	   it	   is	  plausible	   that	  VPA	  mediates	   its	   effects	   on	  mainly	   through	   the	  HDAC	   inhibition	  and	   to	   an	   extent,	   different	   GABA	   receptor	   subtype	   and	   decreasing	   GABA	  inhibition.	  The	  TNR,	  SDCBP2,	  NFASC	  cluster	  is	  focused	  on	  synapse	  organization.	  	  	  
Seeking	  individually	  testable	  targets	  with	  Maxlink	  -­‐-­‐-­‐	  Given	  limited	  time	  and	  resources,	  Maxlink	  can	  be	  a	  useful	  means	  of	   experimental	  prioritization.	  There	  are	   two	  ways	   this	   can	   be	   achieved:	   Firstly,	   a	   highly	   linked	   protein	   could	   be	   a	  coordinator	   of	   various	   complexes	   that	   are	   up	   regulated.	   Because	   these	  complexes	   are	   related	  by	  being	   located	   in	   a	  highly	   concentrated	   area	  of	   seeds,	  these	  particular	  complexes	  may	  be	  worth	  testing	  first.	  The	  highly	  linked	  protein,	  YWHAZ	  fits	  this	  description	  where	  it	  is	  a	  promiscuous	  binder	  and	  also	  capable	  of	  acting	   as	   a	   transcription	   factor,	   able	   to	   control	   several	   different	  functionalities/complexes.	  YWHAZ	  (Maxlink	  rank	  1)	   is	  a	  member	  of	   the	  14-­‐3-­‐3	  family	   of	   proteins,	   which	   mediate	   signal	   transduction	   by	   binding	   to	  phosphoserine-­‐containing	  proteins.	  14-­‐3-­‐3	  proteins	  are	  positively	  correlated	  to	  critical	   period	   plasticity221.	   A	   coordinative	   protein	   may	   not	   necessarily	   be	  located	  within	  a	  densely	  connected	  region	  itself	  and	  hence	  may	  be	  missed	  by	  the	  “cluster	  discovery”	  methods.	  	  A	  second	  way	  Maxlink-­‐ed	  proteins	  can	  be	  used	  for	  experimental	  prioritization	  is	  to	   check	   whether	   they	   are	   found	   in	   a	   variety	   of	   significant	   and	   functionally	  relevant	  FCS	  (real/predicted)	  or	  PEP	  complexes.	  For	  example,	  SRC	  (Maxlink	  rank	  2)	   is	   uncovered	   in	   a	   novel	   PEP	   complex	   that	   also	   plays	   an	   important	   role	   in	  memory	   and	   forebrain	   development	   (Figure	   4).	   Furthermore,	   its	   high	  connectivity	  to	  seeds	  denotes	  importance.	  
Understanding	  GO	   term	  variations	   between	   the	   3	  methods	   -­‐-­‐-­‐	  To	  compare	  the	  results	  from	  a	  functional	  and	  more	  general	  perspective,	  Table	  13	  summarizes	  the	   significant	   GO	   terms	   for	   each	   of	   the	   observed	   phenotypic	   traits.	   Despite	  overall	   agreements,	   there	   are	   slight	   differences	   in	   represented	   functionalities	  and	  associated	  significance	  values.	   It	   is	  unsurprising	   that	   these	  variations	  exist	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due	  to	  differences	  in	  recovery	  overlaps.	  But	  they	  could	  potentially	  lead	  to	  partial	  or	  incomplete	  analysis.	  	  
TABLE	  13	  COMPARATIVE	  GO	  TERM	  ANALYSIS	  OF	  THE	  3	  METHODS	  
	   PPIN	  Based	  Methods	  
	   FCS	  (real)	   FCS	  (predicted)	   PEP	   Maxlink	  
Cytoskeletal	  Re-­‐
organization	  
negative	  regulation	  of	  
cytoskeleton	  organization	  
negative	  regulation	  of	  
cytoskeleton	  organization	  
regulation	  of	  microtubule	  
polymerization	  or	  
depolymerization	  
negative	  regulation	  of	  
cytoskeleton	  organization	  
positive	  regulation	  of	  
cytoskeleton	  organization	  
cytoskeleton	  organization	  
positive	  regulation	  of	  
cytoskeleton	  organization	  
cytoskeleton	  organization	  
regulation	  of	  actin	  
filament	  polymerization	  





actin	  filament	  organization	   actin	  filament	  organization	   	  	  
actin	  cytoskeleton	  
organization	  
regulation	  of	  actin	  
filament	  polymerization	  
regulation	  of	  actin	  
filament	  polymerization	  













nerve	  growth	  factor	  
receptor	  signaling	  pathway	  
transmission	  of	  nerve	  
impulse	  
nerve	  growth	  factor	  
receptor	  signaling	  pathway	  
transmission	  of	  nerve	  
impulse	  






















of	  a	  tube	  
neuron	  projection	  
morphogenesis	  
negative	  regulation	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histone	  H3	  acetylation	   	  	   	  	   histone	  modification	  
histone	  methylation	   	  	   	  	   	  	  
	   	   	   	   	  
	   Legend	   	   	   	   	   	   	   	  
	   	  	   	  	   	  	   	   	   	   	   	  
	   0.001<	   0.01<	   0.05<	   	   	   	   	   	  
	  8.3.3 OVERLAPS	  ANALYSIS	  The	  Venn	  diagrams	  in	  Figure	  19	  illustrate	  the	  degree	  of	  overlaps	  between	  the	  3	  network-­‐based	   methods	   (reported	   and	   recovered).	   Two	   sets	   of	   analyses	   here	  utilizing	  different	  versions	  of	  FCS	  (predicted	  complexes	  –	  green,	  real	  complexes	  -­‐	  purple)	  were	  performed.	  Using	  real	  complexes	  did	  recover	  more	  proteins.	  On	  the	  other	   hand,	   utilizing	   predicted	   complexes	   for	   FCS	   only	   slightly	   decreased	   the	  number	   of	   proteins	   reported.	   But	   on	   the	   whole,	   the	   results	   did	   not	   differ	  significantly.	  
FIGURE	  20	  OVERLAPS	  BETWEEN	  THE	  THREE	  NETWORK-­‐BASED	  METHODS	  	  
ANALYSIS	  WAS	  REPEATED	  TWICE	  WITH	  FCS	  UTILIZING	  PREDICTED	  COMPLEXES	  (GREEN)	  AND	  REAL	  COMPLEXES	  
(PURPLE).	  INTERESTINGLY,	  THE	  RESULTS	  IN	  BOTH	  CASES	  ARE	  RATHER	  CONSISTENT.	  ALSO,	  IN	  BOTH	  CASES,	  THE	  
OVERLAPS	  BETWEEN	  MAXLINK	  AND	  PEP	  WAS	  DEEPER	  THAN	  WITH	  FCS.	  THE	  LATTER	  ALSO	  REPORTS	  THE	  MOST	  
NUMBER	  OF	   ADDITIONAL	   PROTEINS	   NOT	   PICKED	  UP	   BY	   THE	  OTHER	   TWO	  METHODS	   (ABBREVIATIONS:	   FCS	   –	  
FUNCTIONAL	   CLASS	   SCORING,	   MS	   –	   MASS	   SPECTROMETRY,	   PEP	   –	   PROTEOMICS	   EXPANSION	   PIPELINE,	   PPIN	   –	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(585+180)	  proteins.	  Only	  47	  proteins	  are	  truly	  uniquely	  detected	  by	  Maxlink	  and	  not	  found	  by	  the	  other	  2	  methods.	  	  The	   consistent	  deep	  overlap	  between	  Maxlink	   and	  PEP	   is	  not	  unexpected.	  PEP	  and	   Maxlink	   relies	   on	   PPINs	   and	   associations	   with	   seeds	   (requirement	   for	  threshold	   definition).	   This	   is	   unlike	   FCS,	  which	   uses	   predicted/real	   complexes	  and	  no	  threshold.	  PEP	  essentially	  detects	  densely	  connected	  clusters	  of	  proteins	  whereas	  Maxlink	   is	   a	   direct	   link	   counting	  method.	   This	   accounts	   for	  why	   PEP	  recovers	  more	  proteins	  generally.	  	  FCS	   has	   653	   (real)	   and	   474	   (predicted)	   proteins	   uniquely	   detected	   by	   it.	  Although	  242	  (180+10+52)	  proteins	  are	  shared	  with	  the	  other	  two	  methods,	  in	  both	  cases	  FCS	  reports	  a	  very	  large	  number	  of	  additional	  proteins.	  This	  could	  be	  because	   there	   is	   a	   very	   large	   number	   of	   biological	   complexes	   that	   cannot	   be	  picked	  up/detected	   from	   the	  network.	  A	   second	   reason	   is	   that	   these	  biological	  complexes	  are	  larger,	  thereby	  implicating	  a	  larger	  number	  of	  additional	  proteins.	  	  8.3.4 RECOVERY	  PERFORMANCE	  OF	  NETWORK-­‐BASED	  METHODS	  To	   understand	   which	   of	   the	   3	   network-­‐based	   methods	   performs	   best	   in	  recovering	  additional	  proteins	  we	  performed	  a	  comparative	  examination.	  Let	  A	  be	   the	   set	   of	   identified	   proteins.	   For	   each	  network-­‐based	  method,	   let	   B	   be	   the	  total	   set	   of	   proteins	   reported.	   For	   PEP,	   it	   would	   be	   the	   proteins	   from	   all	   the	  predicted	  clusters.	  For	  Maxlink,	  it	  would	  be	  all	  the	  proteins	  interacting	  with	  the	  detected	   proteins.	   And	   for	   FCS,	   it	   would	   be	   all	   the	   proteins	   comprising	  significantly	  identified	  features	  (real	  or	  predicted	  complexes).	  For	  each	  method,	  the	  set	  of	  additional	  predicted	  proteins,	  C,	  is	  therefore	  (B	  –	  A).	  We	  let	  D	  be	  the	  set	  of	  additional	  proteins	  identified	  at	  less	  stringent	  identification	  thresholds	  (789	  –	  291	   =	   498).	   The	   recovery	   performance	   (precision)	   of	   each	   method	   can	   be	  expressed	   as	   a	   proportion,	   |(C∩D)|/|C|.	   That	   is,	   the	   proportion	   of	   predicted	  proteins	  that	  can	  be	  verified	  at	  a	  less	  stringent	  identification	  threshold.	  And	  the	  sensitivity/recall,	   i.e.	   proportion	   of	   additional	   proteins	   identified	   at	   the	   less	  stringent	   identification	   that	   are	   successfully	   predicted	   can	   be	   expressed	   as	  |C∩D|/|D|.	  Table	  14	  shows	  the	  recovery	  performance	  of	  each	  method.	  In	  terms	  of	  precision	  and	   recall	   (sensitivity),	   the	   contrast	   between	   using	   predicted	  complexes/network	   information	   and	   real	   biological	   complexes	   is	   stark	   -­‐-­‐-­‐	   FCS	  using	   real	   complexes	  greatly	  outperforms	   the	  other	  3	  network-­‐based	  methods.	  Among	   the	   prediction-­‐based	  methods,	   FCS	   (Predicted)	   performs	   best	   in	   recall	  followed	   by	   Maxlink	   and	   PEP.	   FCS	   (Predicted)	   and	   Maxlink	   have	   similar	  precisions	   whereas	   PEP’s	   is	   lower.	   Comparing	   seed-­‐based	   methods	   PEP	   and	  Maxlink,	   the	   lower	   precision	   of	   PEP	   suggests	   that	  many	   of	   the	   seeds	   could	   be	  network	   hubs.	   Therefore,	   more	   proteins	   were	   reported	   that	   might	   not	   be	  reported	  in	  D	  (see	  above).	  	  
TABLE	  14	  PROTEIN	  RECOVERY	  PERFORMANCE	  OF	  THE	  VARIOUS	  NETWORK-­‐BASED	  METHODS	  	  
Method	   Novel	  Suggested	  Proteins	   Recovered	  proteins	   Recall	   Precision	  
PEP	   1037	   158	   0.317	  	   0.152	  
	   123	  
Maxlink	   822	   226	   0.454	   0.275	  
FCS	  
(predicted)	  
638	   224	   0.450	   0.351	  
FCS	  
(complexes)	  
895	   477	   0.958	  	   0.533	  	  The	   relatively	   poor	   performance	   using	   pure	   networks	   may	   be	   due	   to	  undeterminable	  false	  positive/negative	  rates.	  This	  may	  be	  further	  compounded	  via	  the	  inclusion	  of	  network	  elements	  based	  on	  homologous	  mapping.	  	  The	  results	  here	  suggest	   that	  despite	   the	  contemporary	  popularity	  of	  network-­‐based	  analysis,	  conclusions	  drawn	  from	  network-­‐identified	  elements	  need	  to	  be	  considered	   carefully	   and	   with	   sufficient	   alternative	   backing	   evidences.	   Real	  biological	  complexes	  appear	  to	  capture	  far	  more	  relevant	  information	  that	  is	  not	  reflected	  in	  or	  extractable	  from	  contemporary	  biological	  networks.	  	  8.3.5 PRECISION-­‐RECALL	  ANALYSIS	  OF	  FCS	  (COMPLEXES)	  Given	  that	  real	  complexes	  are	  able	  to	  recover	  most	  of	  the	  detected	  proteins	  with	  a	  high	   level	  of	  precision,	  and	  since	  a	  p-­‐value	   is	   calculable,	  we	  are	   interested	   in	  finding	   out	  whether	   the	  majority	   of	   detected	   proteins	   are	   concentrated	   in	   the	  upper	  echelons	  of	  significant	  complexes.	  	  	  The	  precision-­‐recall/sensitivity	  graph	  (Figure	  21	  left)	  shows	  that	  when	  p-­‐value	  is	  very	  significant	  (close	  to	  0),	  sensitivity	  is	  relatively	  low	  but	  quickly	  maximized	  while	   precision	   remains	   optimal.	   	  When	   p-­‐value	   is	  ≤0.05	   (pink	   zone,	   Figure	   5	  left),	  precision	  and	  sensitivity	  are	  both	  maximized	  (as	  reported	  in	  Table	  2).	  This	  means	  that	  the	  significant	  complexes	  are	  able	  to	  recover	  the	  majority	  of	  detected	  proteins	  while	  minimizing	  false	  positives.	  The	  histogram	  (Figure	  21	  right)	  shows	  the	   distribution	   of	   p-­‐values	   for	   detected	   proteins	   and	   non-­‐detected	   proteins.	  Most	   detected	   proteins	   have	   a	   highly	   significant	   p-­‐value	   whereas	   undetected	  proteins	  have	  reported	  p-­‐values	  that	  are	  usually	  greater	  than	  0.05.	  	  	  
	  
FIGURE	  21	  SIGNIFICANT	  FCS	  COMPLEXES	  CAPTURES	  MOST	  DETECTED	  PROTEINS	  	  
(LEFT)	  PRECISION-­‐RECALL	  GRAPH	  SHOWING	  PRECISION	  AND	  RECALL	  IS	  MAXIMISED	  EARLY	  ON	  WHEN	  P	  ≤ 	  0.05	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DETECTED	  PROTEINS.	  DETECTED	  PROTEINS	  MOSTLY	  BELONG	  TO	  FCS-­‐SIGNIFICANT	  COMPLEXES	  WHERE	  P	  ≤ 	  0.05	  
WHILE	  UNDETECTED	  PROTEINS	  ARE	  MOSTLY	  IN	  THE	  NON-­‐SIGNIFICANT	  ZONE	  WHERE	  P	  >	  0.05.	  THIS	  ACCOUNTS	  
FOR	  THE	  EXTREME	  LEFT	  SHIFT	  IN	  THE	  PRECISION-­‐RECALL	  GRAPH.	  Since	  FCS	  was	  performed	  with	  the	  initial	  detected	  set	  of	  291	  proteins,	  its	  strong	  ability	  to	  correctly	  identify	  additional	  proteins	  (from	  the	  expanded	  set	  of	  789)	  at	  the	   significant	   level	   demonstrates	   the	   efficacy	   of	   this	   approach	   as	   a	   recovery	  method.	  The	  strong	  recovery	  of	  proteins	  using	  real	  complexes	  also	  augurs	  well	  for	  feature-­‐based	  methods	  such	  as	  Proteomics	  Signature	  Profiling	  (PSP)	  204.	  	  8.3.6 STRENGTHS	  AND	  WEAKNESS	  OF	  EACH	  METHOD	  Table	   15	   summarizes	   the	   pros	   and	   cons	   of	   each	   of	   the	   methods.	   The	   chief	  strengths	  of	   feature-­‐based	  network	  analysis	  methods	  such	  as	  FCS	  are	  that	   they	  are	   less	   dependent	   on	   the	   reference	   biological	   network	   (can	   utilize	   real	  biological	   data	   classes	   e.g.	   complexes),	   independent	   of	   the	   use	   of	   arbitrary	  thresholds	   on	   the	   data,	   and	   that	   the	   discovered	   features	   are	   essentially	  immutable	   (do	   not	   depend	   on	   the	   supplied	   proteomics	   data).	   As	   this	   form	   of	  analysis	   is	   more	   stable,	   it	   allows	   for	   more	   robust	   comparisons	   against	   other	  datasets	   e.g.	   comparing	   significant	   features	   instead	   of	   individual	   genes	   can	  greatly	  simplify	  analysis.	  There	  are	  two	  major	  downsides	  however.	  The	  minor	  is	  that	   it	   is	   computationally	   more	   expensive	   to	   generate	   a	   new	   empirical	  distribution	  for	  every	  feature	  being	  tested.	  Still,	  given	  that	  we	  should	  not	  expect	  the	   data	   to	   fit	   a	   theoretical	   distribution	   anyway,	   it	   is	   worthwhile.	   The	   major	  downside	  however,	   is	   that	  complex	  databases	  such	  as	  CORUM	  may	  not	  be	  very	  comprehensive	   (non-­‐exhaustive	   representation).	   Hence,	   if	   the	   real	   complex	  causing	   a	   phenotype	   is	   not	   represented	   in	   the	   database,	   it	   will	   be	   missed	  completely.	  	  
TABLE	  15	  PROS	  AND	  CONS	  OF	  EACH	  NETWORK-­‐BASED	  METHOD	  
PPIN	  Based	  Methods	   	  
PEP	   	   Maxlink	   	   FCS	   	  
+	  Pros	  +	   	   +	  Pros	  +	   	   +	  Pros	  +	   	  
Novel:	  Uses	  predicted	  
clusters	   	  
Relaxed:Uses	  linked	  
proteins	   	  
Strong	  biological	  relevance	  
	  
Uses	  an	  advanced	  cluster	  
finding	  algorithm	  
	  
Does	  not	  depend	  on	  any	  
clustering	  algorithm	   	  
low	  false	  positive	  rate	  
	  
Fast	   	   Fast	  
	  
Empirically	  determined	  p-­‐
values	   	  
	  	   	   	  	  
	  
Can	  use	  all	  detected	  
proteins	   	  
	  	   	   	  	   	   	  	   	  
	   	   	   	   	   	  
-­‐	  Cons	  -­‐	   	   -­‐	  Cons	  -­‐	   	   -­‐	  Cons	  -­‐	   	  
Higher	  false	  positive	  rate	  
	  
Higher	  false	  positive	  rate	  
	  
Requires	  sufficient	  data	  
hit-­‐rate	   	  
Depends	  on	  quality	  of	  
PPIN	   	  
Depends	  on	  quality	  of	  
PPIN	   	  
Depends	  on	  extensiveness	  
of	  complex	  data	   	  
Requires	  threshold	  
	  
Requires	  	  threshold	  
	  
Computationally	  expensive	  
to	  calculate	  p-­‐value	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  The	  key	  advantage	  of	  Maxlink	  is	  that	  it	  is	  a	  more	  relaxed	  method	  and	  can	  recover	  proteins	   that	   are	   not	   necessarily	   found	   within	   a	   densely	   connected	   cluster	   or	  clique.	  Maxlink	  can	  be	  truly	  powerful	   if	  many	  of	  the	  known	  proteins	  associated	  with	  the	  phenotype,	  and	  the	  underlying	  functional	  profile	  are	  known.	  In	  this	  way,	  not	   only	   would	   links	   to	   known	   associated	   proteins	   be	   important,	   but	   also	  penalties	  for	  non-­‐associated	  protein	  links	  can	  also	  be	  imposed	  in	  the	  discovery	  of	  novel	  associated	  proteins.	  	  The	  strength	  of	  PEP	  is	  that	  it	  uses	  the	  idea	  that	  many	  of	  the	  relevant	  activities	  in	  the	   network	   should	   be	   proximal	   to	   the	   location	   of	   differential	   proteins/seeds.	  Hence,	   by	   first	   identifying	   these	   anchor	   points,	   it	   should	   be	   possible	   to	  confidently	  recover	  and	  identify	  a	  good	  number	  of	  lower	  confidence	  proteins.	  	  A	  common	  disadvantage	  of	  Maxlink	  and	  PEP	  are	  they	  require	  the	  imposition	  of	  a	  threshold	   on	   the	   proteomics	   data,	   which	   is	   subjective.	   They	   are	   also	   highly	  susceptible	   to	   the	  quality	  of	   the	  reference	  PPIN,	  which	  may	  be	  beset	  with	   false	  positives.	  	  8.4 REMARKS	  Network-­‐based	  profiling	  is	  useful	  in	  enhancing	  analytical	  outcome	  of	  proteomics	  experiments.	  We	  have	  demonstrated	  here	  a	  plausible	  approach	  in	  comparing	  and	  combining	  the	  analytical	  results	  of	  a	   feature-­‐based	  approach	  (FCS)	  with	  cluster	  discovery	   approach	   (PEP)	   and	   association-­‐based	   approach	   (Maxlink).	   We	  expand	   our	   biological	   roadmap	   with	   significant	   FCS	   complexes,	   and	   then	  augment	   this	  with	   additional	   knowledge	   from	  novel	  predicted	   complexes	   from	  PEP.	   Selection	   for	   experimental	   validation	   as	   well	   as	   uncovering	   non-­‐cluster	  based	  associated	  proteins	  can	  be	  uncovered	  using	  Maxlink.	  	  We	  also	  report	  some	  novel	   VPA-­‐associated	   clusters	   that	   are	   biologically	   relevant	   to	   the	   observed	  phenotype.	  Recovery	  analysis	  suggests	  that	  FCS	  utilizing	  real	  complexes	  far	  outperforms	  any	  method	  predicated	  on	  biological	  networks	   (including	  FCS).	  While	   this	   suggests	  that	  network	  quality	  is	  far	  from	  optimal,	  it	  also	  denotes	  that	  any	  conclusions	  or	  insights	   drawn	   from	   biological	   networks	   needs	   to	   be	   rigorously	   backed	   with	  supporting	  biological	  information	  drawn	  elsewhere.	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9 LESSONS	  LEARNT	  AND	  FINAL	  REMARKS	  9.1 LESSONS	  LEARNT	  The	  work	  and	  results	  presented	  in	  this	  thesis	  represent	  only	  the	  beginning	  of	  our	  efforts	   to	   improve	   the	   quality	   and	   applicability	   of	   proteomics	   data	   towards	  systems	  biology	  and	  translational	  efforts.	  	  But	  before	  proceeding	  further,	  it	  is	  invaluable	  to	  recapitulate	  on	  the	  most	  critical	  lessons	  garnered	  through	  the	  pursuit	  of	  this	  work:	  	  Firstly,	  with	  regards	  to	  experimental	  planning	  and	  biology,	  the	  bulk	  of	  this	  work	  was	   based	   on	   the	   proteomics	   experiment	   comparing	   early	   and	   late	   stage	   liver	  cancer	  patients.	  The	  controls	  for	  each	  patient	  were	  based	  on	  self	  “normal”	  tissue	  obtained	  on	  a	  non-­‐tumorigenic	   region	  of	   the	   liver.	  This	  approach	   is	  potentially	  naïve	   and	   may	   introduce	   more	   confounding	   factors	   into	   the	   analysis.	   For	  example,	  the	  self-­‐regions	  may	  or	  may	  not	  be	  hepatitis-­‐B	  infected	  (inflammation),	  or	  already	  undergoing	  early	  tumorigenic	  development.	  More	  rigorous	  molecular	  and	  histological	  checks	  would	  at	  least	  confirm	  the	  molecular	  background	  of	  the	  control.	  Another	  possibility	  that	  could	  give	  rise	  to	  problems	  here	  is	  procedural	  -­‐-­‐-­‐	   the	   protein	   extraction	   may	   not	   be	   consistent,	   which	   in	   turn	   affects	   protein	  release	  in	  the	  lysis	  buffer.	  To	  understand	  how	  much	  variation	  is	  due	  to	  extraction,	  variation	   controls	   based	   on	   the	   extraction	   procedure	  with	   only	   tissue	   cultures	  can	  be	  used.	  	  Secondly,	   the	   proteomics	   experiment	   should	   have	   been	   better	   designed	   and	  evaluated	   before	   proceeding	  with	   the	   downstream	   analysis.	   Admittedly,	  much	  more	  could	  have	  been	  done	  if	  access	  to	  the	  raw	  spectrometric	  data	  was	  made.	  I	  noted	   that	   the	   large	  protein	   identification	  and	  quantitation	  variations	   could	  be	  indications	  of	  poor	  experiment	  workflow,	  technique	  and/or	  procedure.	  It	  could	  also	   stem	   from	   poor	   control	   (as	   in	   the	   paragraph	   above).	   For	   a	   disease	   as	  complex	  as	  cancer,	  understanding,	  account	   for	  and	   limiting	  technical	  variations	  would	   bring	   focus	   to	   the	   variation	   stemming	   from	   the	   biology	   itself	   (which	   is	  interesting	   and	   of	   value).	   A	   set	   of	   technical	   replicates	   should	   have	   been	  performed	   in	   order	   to	   achieve	   this	   goal.	   Another	   important	   point	   is	   when	  performing	   the	   recovery	   procedure	   via	   Mascot	   and	   Paragon,	   again,	   without	  access	   to	   the	   raw	  spectrometric	  data	  and	  being	  able	   to	   control	   the	  parameters	  personally,	   the	   value	   of	   this	   aspect	   of	   the	  work	   is	   limited.	  We	   observed	   great	  number	  variations	  between	  the	  two,	  which	  may	  be	  difficult	  to	  believe.	  Granted,	  these	   are	   commercial	   software	  with	   optimized	   parameters.	   However,	   in	   a	   fair	  evaluation,	   it	   is	   important	  that	  as	  many	  as	  possible	  common	  parameters	  be	  set	  similarly.	  I	  am	  currently	  working	  further	  in	  this	  direction	  using	  another	  dataset	  for	   which	   the	   raw	   spectra	   is	   available,	   and	   comparing	   the	   effects	   of	   using	  different	   search	   engines	   (X!Tandem,	   Sequest,	   OMSSA,	   etc)	   within	   a	   controlled	  framework.	  	  	  Thirdly,	   on	   shortfalls	   of	   the	   bioinformatics	   pipeline,	   I	   focused	   mostly	   on	   the	  downstream	   analysis	   of	   the	   protein	   list	   using	   networks.	   There	   are	   other	  bioinformatics	   issues	   that	   should	   have	   been	   given	   more	   consideration.	   E.g.	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dealing	   with	   the	   missing	   values,	   developing	   better	   ways	   of	   mining	   the	   raw	  spectra,	   and	   considering	   alternative	  means	   of	   analyzing	   good	   quality	   data	   (i.e.	  when	   and	   when	   not	   to	   use	   PSP).	   Missing	   value	   imputation	   is	   a	   blue	   ocean	  research	   area	  with	   limited	   efforts	   and/or	   success.	   Currently,	  missing	   values	   in	  proteomics	  can	  be	  grouped	  broadly	  into	  “missing	  completely	  at	  random”	  (MCAR)	  and	   “abundance	   dependent”	   (AD).	   Both	   scenarios	   are	   difficult	   to	   model	   and	  predict.	  Furthermore,	  without	  sufficient	  background	  information	  and	  replicates	  (as	  is	  usually	  the	  case	  with	  proteomics	  studies),	  it	  may	  be	  a	  long	  time	  before	  this	  is	   resolvable.	   As	   for	   mining	   the	   raw	   spectra,	   in	   the	   earlier	   paragraph,	   I’ve	  indicated	  the	  current	  development	  of	  an	  integrated	  pipeline	  comparing	  various	  search	   engines,	   to	   add	   to	   this,	   I’m	   looking	   into	   comparing	   the	   outputs	   against	  other	   search	   methods	   e.g.	   de	   novo	   identification	   algorithms.	   Finally,	   on	  alternative	   methods	   where	   PSP	   is	   not	   applicable	   (e.g.	   high	   quality	   SRM/MRM	  data),	   there	   are	   some	   ongoing	   efforts	   towards	   feature	   selection	   for	   very	   small	  sample	   sizes	   for	  which	  quantitation	   is	   consistent	  and	  accurate,	  which	   could	  be	  further	   combined	  with	  network-­‐based	  methods	   such	  as	  PEP	  and	  Maxlink.	  This	  method,	  PFSNet,	   is	  a	   further	  refinement	  of	  SNet,	  and	  addresses	   the	   issues	  with	  having	  to	  define	  a	  critical	  threshold	  (resolved	  via	  fuzzification	  of	  the	  expression	  scores)	   and	   also	   considers	   expression	   information	   from	   the	   control	   state	   (via	  paired-­‐test	  scores	  between	  control	  and	  disease)	  for	  establishment	  of	  the	  critical	  pathway	   subnets.	   This	   method	   works	   well	   on	   genomics	   data,	   but	   in	   order	   to	  bring	   this	   to	   proteomics,	   concerted	   efforts	   towards	   studying	   and	   controlling	  quantitation	  variation/accuracy	  is	  paramount.	  	  In	  all,	  most	  of	  the	  problems	  faced	  here	  could	  have	  been	  better	  overcome	  if	  there	  were	  better	   communication	  and	  data	   sharing	  between	   the	  experimentalist	   and	  bioinformatician.	   Experimental	   procedures	   could	   thus	   be	   optimized	   for	  downstream	   analysis	   and	   appropriate	   statistical	   checks	   set	   in	   place	   for	   every	  experimental	   milestone,	   thus	   ensuring	   the	   rigor	   and	   quality	   of	   the	   biological	  insights.	  9.2 FINAL	  REMARKS	  The	   use	   of	   biological	   networks	   is	   an	   extremely	   powerful	   tool	   for	   enhancing	  proteomics	   analysis.	   Although	   protein	   clusters	   and	   metabolic	   pathways	   are	  topologically	  different,	  they	  do	  yield	  complementary	  results	  that	  can	  augment	  the	  functional	   characterization	   of	   the	   proteome.	   This	   is	   evident	   from	   the	   results	   of	  PEP,	  PSP	  and	  PDS.	  	  As	  indicated	  in	  the	  earlier	  section,	  data	  quality	  is	  paramount	  in	  determining	  the	  resolution	  and	  power	  of	  analysis.	  Due	  to	  different	  coverage	  of	  various	  databases,	  it	  is	  advisable	  to	  use	  all	  available	  information	  for	  network	  construction.	  A	  caveat	  is	  that	  quality	  of	  information	  should	  also	  be	  checked.	  Using	  measures	  such	  as	  GO	  term	  coherence,	  or	  topology-­‐based	  edge	  scoring	  methods	  such	  as	  CD-­‐distance	  can	  perform	  this.	  	  	  	  Pathway	  databases	  are	  fragmented,	  and	  merging	  such	  information	  is	  harder	  than	  in	   PPINs.	   Although	   we	   addressed	   some	   of	   the	   inherent	   problems,	   more	   work	  remains	  to	  be	  done	  in	  ensuring	  higher	  quality	  data	  extraction	  and	  merging.	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  Another	  point	  to	  address	  is	  on	  expansion	  of	  the	  proteome.	  Given	  the	  fragmented	  nature	   of	   the	   recovered	   proteins,	   they	   usually	   give	   rise	   to	   a	   relatively	   sparse	  network.	   Shortest	   distance	   approaches,	   or	   identification	   of	   whether	   the	  differential	  protein	  belongs	  to	  a	  clique,	  followed	  by	  recovery	  of	  lower	  confidence	  proteins	   can	   help	   to	   alleviate	   the	   problem	   of	   data	   wastage.	   It	   can	   also	   better	  capture	  information	  on	  function	  based	  on	  clusters,	  rather	  than	  average	  function	  based	  solely	  on	  differential	  proteins.	  	  We	  have	  made	  good	  progress	  in	  tackling	  the	  problems	  exigent	  in	  proteomics	  and	  produced	  a	  suite	  of	  techniques,	  although	  each	  is	  not	  a	  perfect	  solution	  in	  itself.	  Of	  particular	   note	   is	   how	   we	   demonstrate	   that	   in	   spite	   of	   the	   inconsistencies	  between	  detected	  proteins,	  the	  context	  is	  conserved,	  be	  it	  complexes	  or	  pathways.	  A	  much	  more	   significant	   outcome,	   is	   that	   the	   PSP-­‐PDS	   approach	   demonstrates	  that	   the	   node/edge	   heterogeneity	   problem	   (i.e.,	   true	   biological	   networks	  consisting	   of	   many	   node	   types:	   proteins,	   miRNAs,	   RNAs,	   and	   edges:	   signaling,	  epigenetic,	  protein	   interactions),	   can	  be	   indirectly	  overcome	  by	   first	   identifying	  the	  relevant	  functional	  components.	  	  	  Finally,	  there	  is	  room	  for	  improvement	  for	  network-­‐based	  analysis.	  It	  is	  expected	  as	   the	   quality	   of	   reference	   networks	   improves,	   resultant	   analyses	   should	   also	  improve.	  Currently,	   inferences	  drawn	  from	  networks	  cannot	  compare	  as	  well	  as	  insight	  drawn	  using	  real	  biological	  entities	  such	  as	  complexes.	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  11 APPENDIX:	  SUPPLEMENTARY	  FIGURES	  
	  Supplementary	  Figure	  1	  -­‐	  Histogram	  of	  Frequency	  Distribution	  of	  Patient	  Counts.	  	  
Support for proteins given patient size is small with most proteins only having 
support from one to two patients. Therefore, even if a protein is defined as 
“differential” given a large change, the lack of patient support may cause it to 
be filtered. Dotted lines correspond to the minimum number of patients we 
kept for each of HCC phases. 	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  Supplementary	   Figure	   2	   -­‐	   Ranks	   and	   Ratio	   Correlation	   Analysis	   of	   Proteins	  Detected	  by	  Mascot	  and	  Paragon.	  	  
The intersection for proteins agreed on by both Mascot and Paragon from all 
12 patients were analyzed for their (A) list Rank and (B) list Ratio scores.  
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Supplementary	   Figure	   3	   -­‐	   Mascot	   and	   MS/MS	   fragmentation	   information	   of	  clique	  recovered	  proteins.	  	  
High quality MS/MS spectra and good Mascot information of Paragon-unique 
and clique recovered proteins retrospectively verified our in silico protein 
community expansion. While the Expectation value of KIF5B (D) is 
insignificant, its MS/MS spectrum demonstrated reasonably good ion 
assignment.  
	  Supplementary	   Figure	   4	   –	   Scores	   distributions	   of	   four	   randomly	   generated	  clusters.	  	  The	   x-­‐axis	   refers	   to	   the	   t-­‐scores	   of	   randomly	   generated	   components	   produced	  via	  class	  label	  permutations.	  The	  y-­‐axis	  is	  the	  frequency.	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Paragon with CORUM and graphlet clusters
Supplementary Figure 2
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  Supplementary	  Figure	  7	  –	  Peptide	   consistency	  and	   coverage	   for	  both	  mod	  and	  poor	  patients	  Most	   proteins	   are	   only	   reported	   once,	   and	   patients	   in	   the	   same	   stage	   do	   not	  share	  the	  majority	  of	  reported	  proteins.	  The	  x-­‐axis	  refers	  to	  proteins	  supported	  by	  n	  number	  of	  patients	  while	   the	   y-­‐axis	   is	   the	   frequency.	  The	  dotted	   line	   is	   a	  typical	   cut-­‐off	   for	   minimal	   number	   of	   required	   patient	   support.	   Note	   that	  following	   this	   requirement,	   a	   second	   cut-­‐off	   for	   over-­‐	   or	   under-­‐	   expression	  further	  decreases	  the	  number	  of	  proteins	  analyzed.	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  Supplementary	  Figure	  8	  –	  Overview	  of	  labeling	  workflow	  The	   quantification	   of	   proteins	   differentially	   abundant	   using	   4-­‐plex	   iTRAQ	  was	  expressed	   as	   the	   fold	   change	   in	   the	   tumour	   section	   against	   its	   adjacent	   non-­‐tumour	  section	  from	  the	  same	  HCC	  patient.	  NC,	  no	  change;	  NS,	  not	  significant;	  S,	  significant.	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Left:	  Histograms	  showing	  the	  lack	  of	  consistency	  in	  identified	  proteins	  between	  patients	   in	   the	   same	   cancer	   group	   (moderate	   and	   late).	   The	   hierarchical	  clustering	   tree	   on	   the	   right	   demonstrates	   the	   poor	   resolving	   power	   of	   the	  proteomics	   data	   due	   to	   lack	   of	   consistency,	   which	   justifies	   the	   need	   for	   novel	  approaches	  for	  tackling	  this	  issue.	  	  	  
	  Supplementary	  Figure	  10	  –	  PDS	  size	  distribution	  Size	   distribution	   of	   pathway	   subnets	   or	   PDSs	   extracted	   from	   non-­‐merged	  PathwayAPI	  using	   liver	  cancer	  proteomics	  data.	  Most	  PDSs	  are	  relatively	  small,	  and	  range	  from	  size	  5	  to	  10.	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CORUM + Predicted Complexes
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shown.	   Included	  also	   is	   the	  original	   clustering	   result	   from	  PSP	  using	  biological	  (CORUM)	  and	  predicted	  complexes.	  	  
	  Supplementary	  Figure	  12	  –	  VPA/VEH	  correlations	  Corresponding	   protein	   expression	   ratios	   between	   two	   biological	   replicates	  (117/114	  and	  116/114,	  where	  116	  and	  117	  are	  VPA-­‐treated	  samples	  and	  114	  is	  a	  control,	  VEH)	  are	  shown	  in	  a	  regression	  plot.	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Adjusted R-squared:0.822
p-value < 2.2e-16
